Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

ABSTRACT

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling.

This application claims benefit to U.S. Provisional applications 61/493,933 (filed Jun. 6, 2011), 61/501,133 (filed Jun. 24, 2011), and 61/537,998 (filed Sep. 22, 2011), the contents of each of which are hereby incorporated in their entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 22, 2012, is named A-1650-US-NP_SeqListing.txt and is 340 KB in size.

FIELD OF THE INVENTION

The present disclosure relates to nucleic acid molecules encoding antigen binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, including antigen binding proteins that induce FGF21-like signaling, as well as pharmaceutical compositions comprising antigen binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, including antigen binding proteins that induce FGF21-like signaling, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. Diagnostic methods using the antigen binding proteins are also provided.

BACKGROUND

Fibroblast Growth Factor 21 (FGF21) is a secreted polypeptide that belongs to a subfamily of Fibroblast Growth Factors (FGFs) that includes FGF19, FGF21, and FGF23 (Itoh et al., (2004) Trend Genet. 20:563-69). FGF21 is an atypical FGF in that it is heparin independent and functions as a hormone in the regulation of glucose, lipid, and energy metabolism.

It is highly expressed in liver and pancreas and is the only member of the FGF family to be primarily expressed in liver. Transgenic mice overexpressing FGF21 exhibit metabolic phenotypes of slow growth rate, low plasma glucose and triglyceride levels, and an absence of age-associated type 2 diabetes, islet hyperplasia, and obesity. Pharmacological administration of recombinant FGF21 protein in rodent and primate models results in normalized levels of plasma glucose, reduced triglyceride and cholesterol levels, and improved glucose tolerance and insulin sensitivity. In addition, FGF21 reduces body weight and body fat by increasing energy expenditure, physical activity, and metabolic rate. Experimental research provides support for the pharmacological administration of FGF21 for the treatment of type 2 diabetes, obesity, dyslipidemia, and other metabolic conditions or disorders in humans.

FGF21 is a liver derived endocrine hormone that stimulates glucose uptake in adipocytes and lipid homeostasis through the activation of its receptor. Interestingly, in addition to the canonical FGF receptor, the FGF21 receptor also comprises the membrane associated β-Klotho as an essential cofactor. Activation of the FGF21 receptor leads to multiple effects on a variety of metabolic parameters.

In mammals, FGFs mediate their action via a set of four FGF receptors, FGFR1-4, that in turn are expressed in multiple spliced variants, e.g., FGFR1c, FGFR2c, FGFR3c and FGFR4. Each FGF receptor contains an intracellular tyrosine kinase domain that is activated upon ligand binding, leading to downstream signaling pathways involving MAPKs (Erk1/2), RAFT, AKT1 and STATs. (Kharitonenkov et al., (2008) BioDrugs 22:37-44). Several reports suggested that the “c”-reporter splice variants of FGFR1-3 exhibit specific affinity to β-Klotho and could act as endogenous receptor for FGF21 (Kurosu et al., (2007) J. Biol. Chem. 282:26687-95); Ogawa et al., (2007) Proc. Natl. Acad. Sci. USA 104:7432-37); Kharitonenkov et al., (2008) J. Cell Physiol. 215:1-7). In the liver, which abundantly expresses both β-Klotho and FGFR4, FGF21 does not induce phosphorylation of MAPK albeit the strong binding of FGF21 to the β-Klotho-FGFR4 complex. In 3T3-L1 cells and white adipose tissue, FGFR1 is by far the most abundant receptor, and it is therefore most likely that FGF21's main functional receptors in this tissue are the β-Klotho/FGFR1c complexes.

The present disclosure provides a human (or humanized) antigen binding protein, such as a monoclonal antibody, that induces FGF21-like signaling, e.g., an agonistic antibody that mimics the function of FGF21. Such an antibody is a molecule with FGF21-like activity and selectivity but with added therapeutically desirable characteristics typical for an antibody such as protein stability, lack of immunogenicity, ease of production and long half-life in vivo.

SUMMARY

The instant disclosure provides antigen binding proteins that bind a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, including antigen binding proteins that induce FGF21-like signaling, as well as pharmaceutical compositions comprising antigen binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, including antigen binding proteins that induce FGF21-like signaling. In another aspect, also provided are expression vectors and host cells transformed or transfected with the expression vectors that comprise the aforementioned isolated nucleic acid molecules that encode the antigen binding proteins disclosed herein. Representative heavy and light chains are provided in Tables 1A and 1B; representative variable region heavy chain and light chain sequences are provided in Tables 2A and 2B; coding sequences for the variable region of the heavy and light chains are provided in Tables 2C and 2D; Tables 3A and 3B provide CDR regions of the disclosed variable heavy and light chains, and Tables 3C and 3D provide coding sequences for the disclosed CDRs.

In another aspect, also provided are methods of preparing antigen binding proteins that specifically or selectively bind a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c and comprise the step of preparing the antigen binding protein from a host cell that secretes the antigen binding protein.

Other embodiments provide a method of preventing or treating a condition in a subject in need of such treatment comprising administering a therapeutically effective amount of a pharmaceutical composition provided herein to a subject, wherein the condition is treatable by lowering blood glucose, insulin or serum lipid levels. In embodiments, the condition is type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease or metabolic syndrome.

These and other aspects are described in greater detail herein. Each of the aspects provided can encompass various embodiments provided herein. It is therefore anticipated that each of the embodiments involving one element or combinations of elements can be included in each aspect described, and all such combinations of the above aspects and embodiments are expressly considered. Other features, objects, and advantages of the disclosed antigen binding proteins and associated methods and compositions are apparent in the detailed description that follows.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 a-1 b is an alignment showing the sequence homology between human FGFR1c (GenBank Accession No P11362; SEQ ID NO: 4) and murine FGFR1c (GenBank Accession No NP_(—)034336; SEQ ID NO: 1832); various features are highlighted, including the signal peptide, transmembrane sequence, heparin binding region, and a consensus sequence (SEQ ID NO: 1833) is provided.

FIG. 2 a-2 c is an alignment showing the sequence homology between human 13-Klotho (GenBank Accession No NP_(—)783864; SEQ ID NO: 7) and murine β-Klotho (GenBank Accession No NP_(—)112457; SEQ ID NO: 10); various features are highlighted, including the transmembrane sequence and two glycosyl hydrolase domains, and a consensus sequence (SEQ ID NO: 1834) is provided.

FIG. 3 is a plot showing the representative data from Luciferase reporter activity screens of the antibodies disclosed herein with FGF21 and a reference antibody 16H7.1 as positive controls (insert); these hybridomas were generated by immunization with cell-bound receptor of 293T transfectants expressing full length human β-Klotho and an N-terminal truncated form of human FGFR1c encompassing amino acid residue #141 to #822 polypeptide of SEQ ID NO:4. X- and Y-axis in the plot are % FGF21 activity from two independent assays (n=1 and n=2) of the same set of hybridoma samples (gray circles) showing the consistency of the assays; several hybridoma samples were also included as negative controls (black circles);

FIG. 4 shows a schematic representation of the chimeras constructed in relation to present invention.

FIG. 5 shows the ability of the antigen binding proteins, as well as human FGF21, to activate chimeras in L6 cells.

FIGS. 6 a-e show the amino acid alignment of heavy and light chains of the antibodies compared to the corresponding germline V-gene sequence.

DETAILED DESCRIPTION

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present application are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 3^(rd) ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001) and subsequent editions, Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow & Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1988), which are incorporated herein by reference. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The terminology used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

It should be understood that the instant disclosure is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present disclosure.

Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages can mean ±5%, e.g., 1%, 2%, 3%, or 4%.

I. DEFINITIONS

As used herein, the terms “a” and “an” mean “one or more” unless specifically stated otherwise.

As used herein, an “antigen binding protein” is a protein comprising a portion that binds to an antigen or target and, optionally, a scaffold or framework portion that allows the antigen binding portion to adopt a conformation that promotes binding of the antigen binding protein to the antigen. Examples of antigen binding proteins include a human antibody, a humanized antibody; a chimeric antibody; a recombinant antibody; a single chain antibody; a diabody; a triabody; a tetrabody; a Fab fragment; a F(ab′)₂ fragment; an IgD antibody; an IgE antibody; an IgM antibody; an IgG1 antibody; an IgG2 antibody; an IgG3 antibody; or an IgG4 antibody, and fragments thereof. The antigen binding protein can comprise, for example, an alternative protein scaffold or artificial scaffold with grafted CDRs or CDR derivatives. Such scaffolds include, but are not limited to, antibody-derived scaffolds comprising mutations introduced to, for example, stabilize the three-dimensional structure of the antigen binding protein as well as wholly synthetic scaffolds comprising, for example, a biocompatible polymer. See, e.g., Korndorfer et al., (2003) Proteins: Structure, Function, and Bioinformatics, 53(1):121-129; Roque et al., (2004) Biotechnol. Prog. 20:639-654. In addition, peptide antibody mimetics (“PAMs”) can be used, as well as scaffolds based on antibody mimetics utilizing fibronectin components as a scaffold.

An antigen binding protein can have, for example, the structure of a naturally occurring immunoglobulin. An “immunoglobulin” is a tetrameric molecule. In a naturally occurring immunoglobulin, each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function. Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids. See generally, Fundamental Immunology 2^(nd) ed. Ch. 7 (Paul, W., ed., Raven Press, N.Y. (1989)), incorporated by reference in its entirety for all purposes. The variable regions of each light/heavy chain pair form the antibody binding site such that an intact immunoglobulin has two binding sites.

Naturally occurring immunoglobulin chains exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. From N-terminus to C-terminus, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain can be done in accordance with the definitions of Kabat et al., (1991) “Sequences of Proteins of Immunological Interest”, 5^(th) Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242. Although presented herein using the Kabat nomenclature system, as desired, the CDRs disclosed herein can also be redefined according an alternative nomenclature scheme, such as that of Chothia (see Chothia & Lesk, (1987) J. Mol. Biol. 196:901-917; Chothia et al., (1989) Nature 342:878-883 or Honegger & Pluckthun, (2001) J. Mol. Biol. 309:657-670).

In the context of the instant disclosure an antigen binding protein is said to “specifically bind” or “selectively bind” its target antigen when the dissociation constant (K_(D)) is ≦10⁻⁸ M. The antibody specifically binds antigen with “high affinity” when the K_(D) is ≦5×10⁻⁹ M, and with “very high affinity” when the K_(D) is ≦5×10⁻¹⁰ M. In one embodiment, the antibodies will bind to a complex comprising β-Klotho and an FGFR, including a complex comprising both human FGFR1c and human β-Klotho, with a K_(D) of between about 10⁻⁷ M and 10⁻¹² M, and in yet another embodiment the antibodies will bind with a K_(D)≦5×10⁻⁹.

An “antibody” refers to an intact immunoglobulin or to an antigen binding portion thereof that competes with the intact antibody for specific binding, unless otherwise specified. Antigen binding portions can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen binding portions include, inter alia, Fab, Fab′, F(ab′)₂, Fv, domain antibodies (dAbs), fragments including complementarity determining regions (CDRs), single-chain antibodies (scFv), chimeric antibodies, diabodies, triabodies, tetrabodies, and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide.

A Fab fragment is a monovalent fragment having the V_(L), V_(H), C_(L) and C_(H)1 domains; a F(ab′)₂ fragment is a bivalent fragment having two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment has the V_(H) and C_(H)1 domains; an Fv fragment has the V_(L) and V_(H) domains of a single arm of an antibody; and a dAb fragment has a V_(H) domain, a V_(L) domain, or an antigen-binding fragment of a V_(H) or V_(L) domain (U.S. Pat. Nos. 6,846,634, and 6,696,245; and US App. Pub. Nos. 05/0202512, 04/0202995, 04/0038291, 04/0009507, 03/0039958, Ward et al., Nature 341:544-546 (1989)).

A single-chain antibody (scFv) is an antibody in which a V_(L) and a V_(H) region are joined via a linker (e.g., a synthetic sequence of amino acid residues) to form a continuous protein chain wherein the linker is long enough to allow the protein chain to fold back on itself and form a monovalent antigen binding site (see, e.g., Bird et al., (1988) Science 242:423-26 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-83). Diabodies are bivalent antibodies comprising two polypeptide chains, wherein each polypeptide chain comprises V_(H) and V_(L) domains joined by a linker that is too short to allow for pairing between two domains on the same chain, thus allowing each domain to pair with a complementary domain on another polypeptide chain (see, e.g., Holliger et al., (1993) Proc. Natl. Acad. Sci. USA 90:6444-48, and Poljak et al., (1994) Structure 2:1121-23). If the two polypeptide chains of a diabody are identical, then a diabody resulting from their pairing will have two identical antigen binding sites. Polypeptide chains having different sequences can be used to make a diabody with two different antigen binding sites. Similarly, tribodies and tetrabodies are antibodies comprising three and four polypeptide chains, respectively, and forming three and four antigen binding sites, respectively, which can be the same or different.

Complementarity determining regions (CDRs) and framework regions (FR) of a given antibody can be identified using the system described by Kabat et al., (1991) “Sequences of Proteins of Immunological Interest”, 5^(th) Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242. Although presented using the Kabat nomenclature system, as desired, the CDRs disclosed herein can also be redefined according an alternative nomenclature scheme, such as that of Chothia (see Chothia & Lesk, (1987) J. Mol. Biol. 196:901-917; Chothia et al., (1989) Nature 342:878-883 or Honegger & Pluckthun, (2001) J. Mol. Biol. 309:657-670). One or more CDRs can be incorporated into a molecule either covalently or noncovalently to make it an antigen binding protein. An antigen binding protein can incorporate the CDR(s) as part of a larger polypeptide chain, can covalently link the CDR(s) to another polypeptide chain, or can incorporate the CDR(s) noncovalently. The CDRs permit the antigen binding protein to specifically bind to a particular antigen of interest.

An antigen binding protein can but need not have one or more binding sites. If there is more than one binding site, the binding sites can be identical to one another or can be different. For example, a naturally occurring human immunoglobulin typically has two identical binding sites, while a “bispecific” or “bifunctional” antibody has two different binding sites. Antigen binding proteins of this bispecific form (e.g., those comprising various heavy and light chain CDRs provided herein) comprise aspects of the instant disclosure.

The term “human antibody” includes all antibodies that have one or more variable and constant regions derived from human immunoglobulin sequences. In one embodiment, all of the variable and constant domains are derived from human immunoglobulin sequences (a fully human antibody). These antibodies can be prepared in a variety of ways, examples of which are described below, including through the immunization with an antigen of interest of a mouse that is genetically modified to express antibodies derived from human heavy and/or light chain-encoding genes, such as a mouse derived from a XENOMOUSE®, ULTIMAB™, HUMAB-MOUSE®, VELOCIMOUSE®, VELOCIMMUNE®, KYMOUSE, or ALIVAMAB system, or derived from human heavy chain transgenic mouse, transgenic rat human antibody repertoire, transgenic rabbit human antibody repertoire or cow human antibody repertoire or HUTARG™ technology. Phage-based approaches can also be employed.

A humanized antibody has a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and/or additions, such that the humanized antibody is less likely to induce an immune response, and/or induces a less severe immune response, as compared to the non-human species antibody, when it is administered to a human subject. In one embodiment, certain amino acids in the framework and constant domains of the heavy and/or light chains of the non-human species antibody are mutated to produce the humanized antibody. In another embodiment, the constant domain(s) from a human antibody are fused to the variable domain(s) of a non-human species. In another embodiment, one or more amino acid residues in one or more CDR sequences of a non-human antibody are changed to reduce the likely immunogenicity of the non-human antibody when it is administered to a human subject, wherein the changed amino acid residues either are not critical for immunospecific binding of the antibody to its antigen, or the changes to the amino acid sequence that are made are conservative changes, such that the binding of the humanized antibody to the antigen is not significantly worse than the binding of the non-human antibody to the antigen. Examples of how to make humanized antibodies can be found in U.S. Pat. Nos. 6,054,297, 5,886,152 and 5,877,293.

The term “chimeric antibody” refers to an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies. In one embodiment, one or more of the CDRs are derived from a human antibody that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In another embodiment, all of the CDRs are derived from a human antibody that binds to a complex β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In another embodiment, the CDRs from more than one human antibody that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c are mixed and matched in a chimeric antibody. For instance, a chimeric antibody can comprise a CDR1 from the light chain of a first human antibody that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, a CDR2 and a CDR3 from the light chain of a second human antibody that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, and the CDRs from the heavy chain from a third antibody that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Further, the framework regions can be derived from one of the same antibodies that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, from one or more different antibodies, such as a human antibody, or from a humanized antibody. In one example of a chimeric antibody, a portion of the heavy and/or light chain is identical with, homologous to, or derived from an antibody from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is/are identical with, homologous to, or derived from an antibody or antibodies from another species or belonging to another antibody class or subclass. Also included are fragments of such antibodies that exhibit the desired biological activity (e.g., the ability to specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c).

The term “light chain” includes a full-length light chain and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length light chain includes a variable region domain, V_(L), and a constant region domain, C_(L). The variable region domain of the light chain is at the amino-terminus of the polypeptide. Light chains include kappa (“κ”) chains and lambda (“λ”) chains.

The term “heavy chain” includes a full-length heavy chain and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length heavy chain includes a variable region domain, V_(H), and three constant region domains, C_(H)1, C_(H)2, and C_(H)3. The V_(H) domain is at the amino-terminus of the polypeptide, and the C_(H) domains are at the carboxyl-terminus, with the C_(H)3 being closest to the carboxy-terminus of the polypeptide. Heavy chains can be of any isotype, including IgG (including IgG1, IgG2, IgG3 and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM and IgE.

The term “immunologically functional fragment” (or simply “fragment”) of an antigen binding protein, e.g., an antibody or immunoglobulin chain (heavy or light chain), as used herein, is an antigen binding protein comprising a portion (regardless of how that portion is obtained or synthesized) of an antibody that lacks at least some of the amino acids present in a full-length chain but which is capable of specifically binding to an antigen. Such fragments are biologically active in that they bind specifically to the target antigen and can compete with other antigen binding proteins, including intact antibodies, for specific binding to a given epitope. In one aspect, such a fragment will retain at least one CDR present in the full-length light or heavy chain, and in some embodiments will comprise a single heavy chain and/or light chain or portion thereof. These biologically active fragments can be produced by recombinant DNA techniques, or can be produced by enzymatic or chemical cleavage of antigen binding proteins, including intact antibodies. Immunologically functional immunoglobulin fragments include, but are not limited to, Fab, Fab′, F(ab′)₂, Fv, domain antibodies and single-chain antibodies, and can be derived from any mammalian source, including but not limited to human, mouse, rat, camelid or rabbit. It is contemplated further that a functional portion of the antigen binding proteins disclosed herein, for example, one or more CDRs, could be covalently bound to a second protein or to a small molecule to create a therapeutic agent directed to a particular target in the body, possessing bifunctional therapeutic properties, or having a prolonged serum half-life.

An “Fc” region contains two heavy chain fragments comprising the C_(H)2 and C_(H)3 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the C_(H)3 domains.

An “Fab′ fragment” contains one light chain and a portion of one heavy chain that contains the V_(H) domain and the C_(H)1 domain and also the region between the C_(H)1 and C_(H)2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab′ fragments to form an F(ab′)₂ molecule.

An “F(ab′)₂ fragment” contains two light chains and two heavy chains containing a portion of the constant region between the C_(H)1 and C_(H)2 domains, such that an interchain disulfide bond is formed between the two heavy chains. A F(ab′)₂ fragment thus is composed of two Fab′ fragments that are held together by a disulfide bond between the two heavy chains.

The “Fv region” comprises the variable regions from both the heavy and light chains, but lacks the constant regions.

A “domain antibody” is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more V_(H) regions are covalently joined with a peptide linker to create a bivalent domain antibody. The two V_(H) regions of a bivalent domain antibody can target the same or different antigens.

A “hemibody” is an immunologically-functional immunoglobulin construct comprising a complete heavy chain, a complete light chain and a second heavy chain Fc region paired with the Fc region of the complete heavy chain. A linker can, but need not, be employed to join the heavy chain Fc region and the second heavy chain Fc region. In particular embodiments a hemibody is a monovalent form of an antigen binding protein disclosed herein. In other embodiments, pairs of charged residues can be employed to associate one Fc region with the second Fc region.

A “bivalent antigen binding protein” or “bivalent antibody” comprises two antigen binding sites. In some instances, the two binding sites have the same antigen specificities. Bivalent antigen binding proteins and bivalent antibodies can be bispecific, as described herein, and form aspects of the instant disclosure.

A “multispecific antigen binding protein” or “multispecific antibody” is one that targets more than one antigen or epitope, and forms another aspect of the instant disclosure.

A “bispecific,” “dual-specific” or “bifunctional” antigen binding protein or antibody is a hybrid antigen binding protein or antibody, respectively, having two different antigen binding sites. Bispecific antigen binding proteins and antibodies are a species of multispecific antigen binding protein or multispecific antibody and can be produced by a variety of methods including, but not limited to, fusion of hybridomas or linking of Fab′ fragments. See, e.g., Songsivilai and Lachmann, (1990) Clin. Exp. Immunol. 79:315-321; Kostelny et al., (1992) J. Immunol. 148:1547-1553. The two binding sites of a bispecific antigen binding protein or antibody will bind to two different epitopes, which can reside on the same (e.g., β-Klotho, FGFR1c, FGFR2c, or FGFR3c) or different protein targets (e.g., 13-Klotho and one of (i) FGFR1c, (ii) FGFR2c, and (iii) FGFR3c).

The terms “FGF21-like signaling” and “induces FGF21-like signaling,” when applied to an antigen binding protein of the present disclosure, means that the antigen binding protein mimics, or modulates, an in vivo biological effect induced by the binding to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c and induces a biological response that otherwise would result from FGF21 binding to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c in vivo. In assessing the binding and specificity of an antigen binding protein, e.g., an antibody or immunologically functional fragment thereof, an antibody or fragment is deemed to induce a biological response when the response is equal to or greater than 5%, and preferably equal to or greater than 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, of the activity of a wild type FGF21 standard comprising the mature form of SEQ ID NO: 2 (i.e., the mature form of the human FGF21 sequence) and has the following properties: exhibiting an efficacy level of equal to or more than 5% of an FGF21 standard, with an EC₅₀ of equal to or less than 100 nM, e.g., 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM or 10 nM in (1) the recombinant FGF21 receptor-mediated luciferase reporter cell assay of Example 4; (2) ERK-phosphorylation in the recombinant FGF21 receptor mediated cell assay of Example 4; and (3) ERK-phosphorylation in human adipocytes as described in Example 4. The “potency” of an antigen binding protein is defined as exhibiting an EC50 of equal to or less than 100 nM, e.g., 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM and preferably less than 10 nM of the antigen binding protein in the following assays: (1) the recombinant FGF21 receptor mediated luciferase-reporter cell assay of Example 4; (2) the ERK-phosphorylation in the recombinant FGF21 receptor mediated cell assay of Example 4; and (3) ERK-phosphorylation in human adipocytes as described in Example 4.

It is noted that not all of the antigen binding proteins of the present disclosure induce FGF21-mediated signaling (e.g., that induce agonistic activity), nor is this property desirable in all circumstances. Nevertheless, antigen binding proteins that do not induce FGF21-mediated signaling form aspects of the present disclosure and may be useful as diagnostic reagents or other applications.

As used herein, the term “FGF21R” means a multimeric receptor complex that FGF21 is known or suspected to form in vivo. In various embodiments, FGF21R comprises (i) an FGFR, e.g., FGFR1c, FGFR2c, FGFR3c or FGFR4, and (ii) β-Klotho.

The term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2′,3′-dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate and phosphoroamidate.

The term “oligonucleotide” means a polynucleotide comprising 200 or fewer nucleotides. In some embodiments, oligonucleotides are 10 to 60 bases in length. In other embodiments, oligonucleotides are 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 nucleotides in length. Oligonucleotides can be single stranded or double stranded, e.g., for use in the construction of a mutant gene. Oligonucleotides can be sense or antisense oligonucleotides. An oligonucleotide can include a label, including a radiolabel, a fluorescent label, a hapten or an antigenic label, for detection assays. Oligonucleotides can be used, for example, as PCR primers, cloning primers or hybridization probes.

An “isolated nucleic acid molecule” means a DNA or RNA of genomic, mRNA, cDNA, or synthetic origin or some combination thereof which is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, or is linked to a polynucleotide to which it is not linked in nature. For purposes of this disclosure, it is understood that “a nucleic acid molecule comprising” a particular nucleotide sequence does not encompass intact chromosomes. Isolated nucleic acid molecules “comprising” specified nucleic acid sequences can include, in addition to the specified sequences, coding sequences for up to ten or even up to twenty other proteins or portions thereof, or can include operably linked regulatory sequences that control expression of the coding region of the recited nucleic acid sequences, and/or can include vector sequences.

Unless specified otherwise, the left-hand end of any single-stranded polynucleotide sequence discussed herein is the 5′ end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5′ direction. The direction of 5′ to 3′ addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA transcript that are 5′ to the 5′ end of the RNA transcript are referred to as “upstream sequences;” sequence regions on the DNA strand having the same sequence as the RNA transcript that are 3′ to the 3′ end of the RNA transcript are referred to as “downstream sequences.”

The term “control sequence” refers to a polynucleotide sequence that can affect the expression and processing of coding sequences to which it is ligated. The nature of such control sequences can depend upon the host organism. In particular embodiments, control sequences for prokaryotes can include a promoter, a ribosomal binding site, and a transcription termination sequence. For example, control sequences for eukaryotes can include promoters comprising one or a plurality of recognition sites for transcription factors, transcription enhancer sequences, and transcription termination sequence. “Control sequences” can include leader sequences and/or fusion partner sequences.

The term “vector” means any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage or virus) used to transfer protein coding information into a host cell.

The term “expression vector” or “expression construct” refers to a vector that is suitable for transformation of a host cell and contains nucleic acid sequences that direct and/or control (in conjunction with the host cell) expression of one or more heterologous coding regions operatively linked thereto. An expression construct can include, but is not limited to, sequences that affect or control transcription, translation, and, if introns are present, affect RNA splicing of a coding region operably linked thereto.

As used herein, “operably linked” means that the components to which the term is applied are in a relationship that allows them to carry out their inherent functions under suitable conditions. For example, a control sequence in a vector that is “operably linked” to a protein coding sequence is ligated thereto so that expression of the protein coding sequence is achieved under conditions compatible with the transcriptional activity of the control sequences.

The term “host cell” means a cell that has been transformed, or is capable of being transformed, with a nucleic acid sequence and thereby expresses a gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent cell, so long as the gene of interest is present.

The term “transduction” means the transfer of genes from one bacterium to another, usually by bacteriophage. “Transduction” also refers to the acquisition and transfer of eukaryotic cellular sequences by replication-defective retroviruses.

The term “transfection” means the uptake of foreign or exogenous DNA by a cell, and a cell has been “transfected” when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham et al., (1973) Virology 52:456; Sambrook et al., (2001), supra; Davis et al., (1986) Basic Methods in Molecular Biology, Elsevier; Chu et al., (1981) Gene 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

The term “transformation” refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain new DNA or RNA. For example, a cell is transformed where it is genetically modified from its native state by introducing new genetic material via transfection, transduction, or other techniques. Following transfection or transduction, the transforming DNA can recombine with that of the cell by physically integrating into a chromosome of the cell, or can be maintained transiently as an episomal element without being replicated, or can replicate independently as a plasmid. A cell is considered to have been “stably transformed” when the transforming DNA is replicated with the division of the cell.

The terms “polypeptide” or “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms also apply to amino acid polymers in which one or more amino acid residues is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The terms can also encompass amino acid polymers that have been modified, e.g., by the addition of carbohydrate residues to form glycoproteins, or phosphorylated. Polypeptides and proteins can be produced by a naturally-occurring and non-recombinant cell, or polypeptides and proteins can be produced by a genetically-engineered or recombinant cell. Polypeptides and proteins can comprise molecules having the amino acid sequence of a native protein, or molecules having deletions from, additions to, and/or substitutions of one or more amino acids of the native sequence. The terms “polypeptide” and “protein” encompass antigen binding proteins that specifically or selectively bind to a complex comprising β-Klotho and an FGFR (e.g., FGFR1c, FGFR2c or FGFR3c), or sequences that have deletions from, additions to, and/or substitutions of one or more amino acids of an antigen binding protein that specifically or selectively binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. The term “polypeptide fragment” refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and/or an internal deletion as compared with the full-length protein. Such fragments can also contain modified amino acids as compared with the full-length protein. In certain embodiments, fragments are about five to 500 amino acids long. For example, fragments can be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids long. Useful polypeptide fragments include immunologically functional fragments of antibodies, including binding domains. In the case of an antigen binding protein that binds to a complex β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, useful fragments include but are not limited to a CDR region, a variable domain of a heavy or light chain, a portion of an antibody chain or just its variable region including two CDRs, and the like.

The term “isolated protein” referred means that a subject protein (1) is free of at least some other proteins with which it would normally be found, (2) is essentially free of other proteins from the same source, e.g., from the same species, (3) is expressed by a cell from a different species, (4) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (5) is operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (6) does not occur in nature. Typically, an “isolated protein” constitutes at least about 5%, at least about 10%, at least about 25%, or at least about 50% of a given sample. Genomic DNA, cDNA, mRNA or other RNA, of synthetic origin, or any combination thereof can encode such an isolated protein. Preferably, the isolated protein is substantially free from proteins or polypeptides or other contaminants that are found in its natural environment that would interfere with its therapeutic, diagnostic, prophylactic, research or other use.

A “variant” of a polypeptide (e.g., an antigen binding protein, or an antibody) comprises an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from and/or substituted into the amino acid sequence relative to another polypeptide sequence. Variants include fusion proteins.

A “derivative” of a polypeptide is a polypeptide (e.g., an antigen binding protein, or an antibody) that has been chemically modified in some manner distinct from insertion, deletion, or substitution variants, e.g., by conjugation to another chemical moiety.

The term “naturally occurring” as used throughout the specification in connection with biological materials such as polypeptides, nucleic acids, host cells, and the like, refers to materials which are found in nature.

“Antigen binding region” means a protein, or a portion of a protein, that specifically binds a specified antigen, e.g., a complex comprising β-Klotho and anβ-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. For example, that portion of an antigen binding protein that contains the amino acid residues that interact with an antigen and confer on the antigen binding protein its specificity and affinity for the antigen is referred to as “antigen binding region.” An antigen binding region typically includes one or more “complementary binding regions” (“CDRs”). Certain antigen binding regions also include one or more “framework” regions. A “CDR” is an amino acid sequence that contributes to antigen binding specificity and affinity. “Framework” regions can aid in maintaining the proper conformation of the CDRs to promote binding between the antigen binding region and an antigen.

In certain aspects, recombinant antigen binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, are provided. In this context, a “recombinant protein” is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as described herein. Methods and techniques for the production of recombinant proteins are well known in the art.

The term “compete” when used in the context of antigen binding proteins (e.g., neutralizing antigen binding proteins, neutralizing antibodies, agonistic antigen binding proteins, agonistic antibodies and binding proteins that bind to a complex comprising 13-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c) that compete for the same epitope or binding site on a target means competition between antigen binding proteins as determined by an assay in which the antigen binding protein (e.g., antibody or immunologically functional fragment thereof) under study prevents or inhibits the specific binding of a reference molecule (e.g., a reference ligand, or reference antigen binding protein, such as a reference antibody) to a common antigen (e.g., FGFR1c, FGFR2c, FGFR3c, 13-Klotho or a fragment thereof, or a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c). Numerous types of competitive binding assays can be used to determine if a test molecule competes with a reference molecule for binding. Examples of assays that can be employed include solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see, e.g., Stahli et al., (1983) Methods in Enzymology 9:242-253); solid phase direct biotin-avidin EIA (see, e.g., Kirkland et al., (1986) J. Immunol. 137:3614-3619) solid phase direct labeled assay, solid phase direct labeled sandwich assay (see, e.g., Harlow and Lane, (1988) supra); solid phase direct label RIA using 1-125 label (see, e.g., Morel et al., (1988) Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (see, e.g., Cheung, et al., (1990) Virology 176:546-552); and direct labeled RIA (Moldenhauer et al., (1990) Scand. J. Immunol. 32:77-82). Typically, such an assay involves the use of a purified antigen bound to a solid surface or cells bearing either of an unlabelled test antigen binding protein or a labeled reference antigen binding protein. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antigen binding protein. Usually the test antigen binding protein is present in excess. Antigen binding proteins identified by competition assay (competing antigen binding proteins) include antigen binding proteins binding to the same epitope as the reference antigen binding proteins and antigen binding proteins binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antigen binding protein for steric hindrance to occur. Additional details regarding methods for determining competitive binding are provided in the examples herein. Usually, when a competing antigen binding protein is present in excess, it will inhibit specific binding of a reference antigen binding protein to a common antigen by at least 40%, 45%, 50%, 55%, 60%, 65%, 70% or 75%. In some instance, binding is inhibited by at least 80%, 85%, 90%, 95%, or 97% or more.

The term “antigen” refers to a molecule or a portion of a molecule capable of being bound by a selective binding agent, such as an antigen binding protein (including, e.g., an antibody or immunological functional fragment thereof), and may also be capable of being used in an animal to produce antibodies capable of binding to that antigen. An antigen can possess one or more epitopes that are capable of interacting with different antigen binding proteins, e.g., antibodies.

The term “epitope” means the amino acids of a target molecule that are contacted by an antigen binding protein (for example, an antibody) when the antigen binding protein is bound to the target molecule. The term includes any subset of the complete list of amino acids of the target molecule that are contacted when an antigen binding protein, such as an antibody, is bound to the target molecule. An epitope can be contiguous or non-contiguous (e.g., (i) in a single-chain polypeptide, amino acid residues that are not contiguous to one another in the polypeptide sequence but that within in context of the target molecule are bound by the antigen binding protein, or (ii) in a multimeric receptor comprising two or more individual components, e.g., a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, amino acid residues that are present on one or more of the individual components, but which are still bound by the antigen binding protein). In certain embodiments, epitopes can be mimetic in that they comprise a three dimensional structure that is similar to an antigenic epitope used to generate the antigen binding protein, yet comprise none or only some of the amino acid residues found in that epitope used to generate the antigen binding protein. Most often, epitopes reside on proteins, but in some instances can reside on other kinds of molecules, such as nucleic acids. Epitope determinants can include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and can have specific three dimensional structural characteristics, and/or specific charge characteristics. Generally, antigen binding proteins specific for a particular target molecule will preferentially recognize an epitope on the target molecule in a complex mixture of proteins and/or macromolecules.

The term “identity” refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent identity” means the percent of identical residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) must be addressed by a particular mathematical model or computer program (i.e., an “algorithm”). Methods that can be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, A. M., ed.), (1988) New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje, G., (1987) Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., (1988) J. Applied Math. 48:1073.

In calculating percent identity, the sequences being compared are aligned in a way that gives the largest match between the sequences. The computer program used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., (1984) Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3× the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. In certain embodiments, a standard comparison matrix (see, Dayhoff et al., (1978) Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., (1992) Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm.

Recommended parameters for determining percent identity for polypeptides or nucleotide sequences using the GAP program are the following:

Algorithm: Needleman et al., 1970, J. Mol. Biol. 48:443-453;

Comparison matrix: BLOSUM 62 from Henikoff et al., 1992, supra;

Gap Penalty: 12 (but with no penalty for end gaps)

Gap Length Penalty: 4

Threshold of Similarity: 0

Certain alignment schemes for aligning two amino acid sequences can result in matching of only a short region of the two sequences, and this small aligned region can have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (e.g., the GAP program) can be adjusted if so desired to result in an alignment that spans at least 50 contiguous amino acids of the target polypeptide.

As used herein, “substantially pure” means that the described species of molecule is the predominant species present, that is, on a molar basis it is more abundant than any other individual species in the same mixture. In certain embodiments, a substantially pure molecule is a composition wherein the object species comprises at least 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition will comprise at least 80%, 85%, 90%, 95%, or 99% of all macromolecular species present in the composition. In other embodiments, the object species is purified to essential homogeneity wherein contaminating species cannot be detected in the composition by conventional detection methods and thus the composition consists of a single detectable macromolecular species.

The terms “treat” and “treating” refer to any indicia of success in the treatment or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. For example, certain methods presented herein can be employed to treat Type 2 diabetes, obesity and/or dyslipidemia, either prophylactically or as an acute treatment, to decrease plasma glucose levels, to decrease circulating triglyceride levels, to decrease circulating cholesterol levels and/or ameliorate a symptom associated with type 2 diabetes, obesity and dyslipidemia.

An “effective amount” is generally an amount sufficient to reduce the severity and/or frequency of symptoms, eliminate the symptoms and/or underlying cause, prevent the occurrence of symptoms and/or their underlying cause, and/or improve or remediate the damage that results from or is associated with diabetes, obesity and dyslipidemia. In some embodiments, the effective amount is a therapeutically effective amount or a prophylactically effective amount. A “therapeutically effective amount” is an amount sufficient to remedy a disease state (e.g., diabetes, obesity or dyslipidemia) or symptoms, particularly a state or symptoms associated with the disease state, or otherwise prevent, hinder, retard or reverse the progression of the disease state or any other undesirable symptom associated with the disease in any way whatsoever. A “prophylactically effective amount” is an amount of a pharmaceutical composition that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of diabetes, obesity or dyslipidemia, or reducing the likelihood of the onset (or reoccurrence) of diabetes, obesity or dyslipidemia or associated symptoms. The full therapeutic or prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically or prophylactically effective amount can be administered in one or more administrations.

“Amino acid” takes its normal meaning in the art. The twenty naturally-occurring amino acids and their abbreviations follow conventional usage. See, Immunology-A Synthesis, 2^(nd) Edition, (E. S. Golub and D. R. Green, eds.), Sinauer Associates: Sunderland, Mass. (1991), incorporated herein by reference for any purpose. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural or non-naturally occurring or encoded amino acids such as α-,α-disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids can also be suitable components for polypeptides and are included in the phrase “amino acid.” Examples of non-natural and non-naturally encoded amino acids (which can be substituted for any naturally-occurring amino acid found in any sequence disclosed herein, as desired) include: 4-hydroxyproline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl-terminal direction, in accordance with standard usage and convention. A non-limiting lists of examples of non-naturally occurring/encoded amino acids that can be inserted into an antigen binding protein sequence or substituted for a wild-type residue in an antigen binding sequence include β-amino acids, homoamino acids, cyclic amino acids and amino acids with derivatized side chains. Examples include (in the L-form or D-form; abbreviated as in parentheses): citrulline (Cit), homocitrulline (hCit), Nα-methylcitrulline (NMeCit), Nα-methylhomocitrulline (Nα-MeHoCit), ornithine (Orn), Nα-Methylornithine (Nα-MeOrn or NMeOrn), sarcosine (Sar), homolysine (hLys or hK), homoarginine (hArg or hR), homoglutamine (hQ), Nα-methylarginine (NMeR), Nα-methylleucine (Nα-MeL or NMeL), N-methylhomolysine (NMeHoK), Nα-methylglutamine (NMeQ), norleucine (Nle), norvaline (Nva), 1,2,3,4-tetrahydroisoquinoline (Tic), Octahydroindole-2-carboxylic acid (Oic), 3-(1-naphthyl)alanine (1-Nal), 3-(2-naphthyl)alanine (2-Nal), 1,2,3,4-tetrahydroisoquinoline (Tic), 2-indanylglycine (IgI), para-iodophenylalanine (pI-Phe), para-aminophenylalanine (4AmP or 4-Amino-Phe), 4-guanidino phenylalanine (Guf), glycyllysine (abbreviated “K(Nε-glycyl)” or “K(glycyl)” or “K(gly)”), nitrophenylalanine (nitrophe), aminophenylalanine (aminophe or Amino-Phe), benzylphenylalanine (benzylphe), γ-carboxyglutamic acid (γ-carboxyglu), hydroxyproline (hydroxypro), p-carboxyl-phenylalanine (Cpa), α-aminoadipic acid (Aad), Nα-methyl valine (NMeVal), N-α-methyl leucine (NMeLeu), Nα-methylnorleucine (NMeNle), cyclopentylglycine (Cpg), cyclohexylglycine (Chg), acetylarginine (acetylarg), α, β-diaminopropionoic acid (Dpr), α,γ-diaminobutyric acid (Dab), diaminopropionic acid (Dap), cyclohexylalanine (Cha), 4-methyl-phenylalanine (MePhe), β,β-diphenyl-alanine (BiPhA), aminobutyric acid (Abu), 4-phenyl-phenylalanine (or biphenylalanine; 4Bip), α-amino-isobutyric acid (Aib), beta-alanine, beta-aminopropionic acid, piperidinic acid, aminocaprioic acid, aminoheptanoic acid, aminopimelic acid, desmosine, diaminopimelic acid, N-ethylglycine, N-ethylaspargine, hydroxylysine, allo-hydroxylysine, isodesmosine, allo-isoleucine, N-methylglycine, N-methylisoleucine, N-methylvaline, 4-hydroxyproline (Hyp), γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω-methylarginine, 4-Amino-O-Phthalic Acid (4APA), and other similar amino acids, and derivatized forms of any of those specifically listed.

II. GENERAL OVERVIEW

Antigen-binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c are provided herein. A unique property of the antigen binding proteins disclosed herein is the agonistic nature of these proteins, specifically the ability to mimic the in vivo effect of FGF21 and to induce FGF21-like signaling. More remarkably and specifically, some of the antigen binding proteins disclosed herein induce FGF21-like signaling in several in vitro cell-based assay, including the ELK-luciferase reporter assay of Example 4 under the following conditions: (1) the binding to and activity of the FGF21 receptor is β-Klotho dependent; (2) the activity is selective to the FGFR/β-Klotho complex; (3) the binding to the FGFR1c/βKlotho complex triggers FGF21-like signaling pathways; and (4) the potency (EC50) is comparable to a wild-type FGF21 standard comprising the mature form of SEQ ID NO: 2, as measured in the following cell-based assays: (1) the recombinant FGF21 receptor mediated luciferase-reporter cell assay of Example 4; (2) the ERK-phosphorylation in the recombinant FGF21 receptor mediated cell assay of Example 4; and (3) ERK-phosphorylation in human adipocytes as described in more details in Example 6. The disclosed antigen binding proteins, therefore, are expected to exhibit activities in vivo that are consistent with the natural biological function of FGF21. This property makes the disclosed antigen binding proteins viable therapeutics for the treatment of metabolic diseases such as type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease, metabolic syndrome and broadly any disease or condition in which it is desirable to mimic or augment the in vivo effects of FGF21.

In some embodiments of the present disclosure the antigen binding proteins provided can comprise polypeptides into which one or more complementary determining regions (CDRs) can be embedded and/or joined. In such antigen binding proteins, the CDRs can be embedded into a “framework” region, which orients the CDR(s) such that the proper antigen binding properties of the CDR(s) is achieved. In general, such antigen binding proteins that are provided can facilitate or enhance the interaction between an FGFR (e.g., FGFR1c, FGFR2c or FGFR3c) and β-Klotho, and can substantially induce FGF21-like signaling. Accordingly, the antigen binding proteins provided herein mimic the in vivo role of FGF21 and are thus “agonistic” and offer potential therapeutic benefit for the range of conditions which benefit from FGF21 therapy, including type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease, metabolic syndrome and broadly any disease or condition in which it is desirable to mimic or augment the in vivo effects of FGF21.

Certain antigen binding proteins described herein are antibodies or are derived from antibodies. In certain embodiments, the polypeptide structure of the antigen binding proteins is based on antibodies, including, but not limited to, monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), hemibodies and fragments thereof. The various structures are further described herein below.

The antigen binding proteins provided herein have been demonstrated to bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, and particularly to a complex comprising human β-Klotho and a human FGFR (e.g., a human FGFR1c, a human FGFR2c or a human FGFR3c). As described and shown in the Examples presented herein, based Western blot results, known commercially-available anti-β-Klotho or anti-FGFR1c antibodies bind to denatured β-Klotho or FGFR1c whereas the antigen binding protein (which are agonistic antibodies) do not. Conversely, the provided antigen binding proteins recognize the native structure of the FGFR1c and β-Klotho on the cell surface whereas the commercial antibodies do not. The antigen binding proteins that are provided therefore mimic the natural in vivo biological activity of FGF21. As a consequence, the antigen binding proteins provided herein are capable of activating FGF21-like signaling activity. In particular, the disclosed antigen binding proteins can have one or more of the following activities in vivo: induction of FGF21-like signal transduction pathways, lowering blood glucose levels, lowering circulating lipid levels, improving metabolic parameters and other physiological effects induced in vivo by the formation of the ternary complex of an FGFR (e.g., FGFR1c, FGFR2c or FGFR3c), β-Klotho and FGF21, for example conditions such as type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease, and metabolic syndrome.

The antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c that are disclosed herein have a variety of utilities. Some of the antigen binding proteins, for instance, are useful in specific binding assays, in the affinity purification of a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, including the human forms of these disclosed proteins, and in screening assays to identify other agonists of FGF21-like signaling activity.

The antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c that are disclosed herein can be used in a variety of treatment applications, as explained herein. For example, certain antigen binding proteins are useful for treating conditions associated with FGF21-like signaling processes in a patient, such as reducing, alleviating, or treating type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease, and metabolic syndrome. Other uses for the antigen binding proteins include, for example, diagnosis of diseases or conditions associated with β-Klotho, FGFR1c, FGFR2c, FGFR3c, FGFR4 or FGF21, and screening assays to determine the presence or absence of these molecules. Some of the antigen binding proteins described herein can be useful in treating conditions, symptoms and/or the pathology associated with decreased FGF21-like signaling activity. Exemplary conditions include, but are not limited to, diabetes, obesity, NASH and dyslipidemia.

FGF21

The antigen binding proteins disclosed herein induce FGF21-mediated signaling, as defined herein. In vivo, the mature form of FGF21 is the active form of the molecule. The nucleotide sequence encoding full length FGF21 is provided; the nucleotides encoding the signal sequence are underlined.

(SEQ ID NO: 1) ATG GAC TCG GAC GAG ACC GGG TTC GAG CAC TCA GGA CTG TGG GTT TCT GTG CTG GCT GGT CTT CTG CTG GGA GCC TGC CAG GCA CAC CCC ATC CCT GAC TCC AGT CCT CTC CTG CAA TTC GGG GGC CAA GTC CGG CAG CGG TAC CTC TAC ACA GAT GAT GCC CAG CAG ACA GAA GCC CAC CTG GAG ATC AGG GAG GAT GGG ACG GTG GGG GGC GCT GCT GAC CAG AGC CCC GAA AGT CTC CTG CAG CTG AAA GCC TTG AAG CCG GGA GTT ATT CAA ATC TTG GGA GTC AAG ACA TCC AGG TTC CTG TGC CAG CGG CCA GAT GGG GCC CTG TAT GGA TCG CTC CAC TTT GAC CCT GAG GCC TGC AGC TTC CGG GAG CTG CTT CTT GAG GAC GGA TAC AAT GTT TAC CAG TCC GAA GCC CAC GGC CTC CCG CTG CAC CTG CCA GGG AAC AAG TCC CCA CAC CGG GAC CCT GCA CCC CGA GGA CCA GCT CGC TTC CTG CCA CTA CCA GGC CTG CCC CCC GCA CCC CCG GAG CCA CCC GGA ATC CTG GCC CCC CAG CCC CCC GAT GTG GGC TCC TCG GAC CCT CTG AGC ATG GTG GGA CCT TCC CAG GGC CGA AGC CCC AGC TAC GCT TCC TGA

The amino acid sequence of full length FGF21 is provided; the amino acids that make up the signal sequence are underlined:

(SEQ ID NO: 2) M D S D E T G F E H S G L W V S V L A G L L L G A C Q A H P I P D S S P L L Q F G G Q V R Q R Y L Y  T D D A Q Q T E A H L E I R E D G T V G G A A D Q S P E S L L Q L K A L K P G V I Q I L G V K T S R F L C Q R P D G A L Y G S L H F D P E A C S F R E L L L E D G Y N V Y Q S E A H G L P L H L P G N K S P H R D P A P R G P A R F L P L P G L P P A P P E P P G I L A P Q P P D V G S S D P L S M V G P S Q G R S P S Y A S

FGFR1c

The antigen binding proteins disclosed herein bind to FGFR1c, in particular human FGFR1c, when associated with β-Klotho. The nucleotide sequence encoding human FGFR1c (GenBank Accession Number NM_(—)023110) is provided:

(SEQ ID NO: 3) ATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAG CCACACTCTGCACCGCTAGGCCGTCCCCGACCTTGCCTGAACAAGC CCAGCCCTGGGGAGCCCCTGTGGAAGTGGAGTCCTTCCTGGTCCAC CCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGATGTGC AGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCA ACCGCACCCGCATCACAGGGGAGGAGGTGGAGGTGCAGGACTCCG TGCCCGCAGACTCCGGCCTCTATGCTTGCGTAACCAGCAGCCCCTC GGGCAGTGACACCACCTACTTCTCCGTCAATGTTTCAGATGCTCTCC CCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGA GAAAGAAACAGATAACACCAAACCAAACCGTATGCCCGTAGCTCC ATATTGGACATCACCAGAAAAGATGGAAAAGAAATTGCATGCAGT GCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCCAGTGGGACA CCAAACCCAACACTGCGCTGGTTGAAAAATGGCAAAGAATTCAAA CCTGACCACAGAATTGGAGGCTACAAGGTCCGTTATGCCACCTGGA GCATCATAATGGACTCTGTGGTGCCCTCTGACAAGGGCAACTACAC CTGCATTGTGGAGAATGAGTACGGCAGCATCAACCACACATACCA GCTGGATGTCGTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCA GGGTTGCCCGCCAACAAAACAGTGGCCCTGGGTAGCAACGTGGAG TTCATGTGTAAGGTGTACAGTGACCCGCAGCCGCACATCCAGTGGC TAAAGCACATCGAGGTGAATGGGAGCAAGATTGGCCCAGACAACC TGCCTTATGTCCAGATCTTGAAGACTGCTGGAGTTAATACCACCGA CAAAGAGATGGAGGTGCTTCACTTAAGAAATGTCTCCTTTGAGGAC GCAGGGGAGTATACGTGCTTGGCGGGTAACTCTATCGGACTCTCCC ATCACTCTGCATGGTTGACCGTTCTGGAAGCCCTGGAAGAGAGGCC GGCAGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTATTGC ACAGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTCT ACAAGATGAAGAGTGGTACCAAGAAGAGTGACTTCCACAGCCAGA TGGCTGTGCACAAGCTGGCCAAGAGCATCCCTCTGCGCAGACAGGT AACAGTGTCTGCTGACTCCAGTGCATCCATGAACTCTGGGGTTCTT CTGGTTCGGCCATCACGGCTCTCCTCCAGTGGGACTCCCATGCTAG CAGGGGTCTCTGAGTATGAGCTTCCCGAAGACCCTCGCTGGGAGCT GCCTCGGGACAGACTGGTCTTAGGCAAACCCCTGGGAGAGGGCTG CTTTGGGCAGGTGGTGTTGGCAGAGGCTATCGGGCTGGACAAGGA CAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTTGAAGTC GGACGCAACAGAGAAAGACTTGTCAGACCTGATCTCAGAAATGGA GATGATGAAGATGATCGGGAAGCATAAGAATATCATCAACCTGCT GGGGGCCTGCACGCAGGATGGTCCCTTGTATGTCATCGTGGAGTAT GCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGGCCCGGAGGCCC CCAGGGCTGGAATACTGCTACAACCCCAGCCACAACCCAGAGGAG CAGCTCTCCTCCAAGGACCTGGTGTCCTGCGCCTACCAGGTGGCCC GAGGCATGGAGTATCTGGCCTCCAAGAAGTGCATACACCGAGACC TGGCAGCCAGGAATGTCCTGGTGACAGAGGACAATGTGATGAAGA TAGCAGACTTTGGCCTCGCACGGGACATTCACCACATCGACTACTA TAAAAAGACAACCAACGGCCGACTGCCTGTGAAGTGGATGGCACC CGAGGCATTATTTGACCGGATCTACACCCACCAGAGTGATGTGTGG TCTTTCGGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCC ATACCCCGGTGTGCCTGTGGAGGAACTTTTCAAGCTGCTGAAGGAG GGTCACCGCATGGACAAGCCCAGTAACTGCACCAACGAGCTGTAC ATGATGATGCGGGACTGCTGGCATGCAGTGCCCTCACAGAGACCCA CCTTCAAGCAGCTGGTGGAAGACCTGGACCGCATCGTGGCCTTGAC CTCCAACCAGGAGTACCTGGACCTGTCCATGCCCCTGGACCAGTAC TCCCCCAGCTTTCCCGACACCCGGAGCTCTACGTGCTCCTCAGGGG AGGATTCCGTCTTCTCTCATGAGCCGCTGCCCGAGGAGCCCTGCCT GCCCCGACACCCAGCCCAGCTTGCCAATGGCGGACTCAAACGCCGC TGA.

The amino acid sequence of human FGFR1c (GenBank Accession Number NP_(—)075598) is provided:

(SEQ ID NO: 4) MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHP GDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPA DSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETD NTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLR WLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEY GSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQ PHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVS FEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLEIIIYC TGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKSIPLRRQVT VSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRD RLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATE KDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLR EYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASK KCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPV KWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKL LKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIV ALTSNQEYLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLP RHPAQLANGGLKRR.

The antigen binding proteins described herein bind the extracellular portion of FGFR1c. An example of an extracellular region of FGFR1c is:

(SEQ ID NO: 5) MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHP GDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPA DSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETD NTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLR WLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEY GSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQ PHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVS FEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLY.

As described herein, FGFR1c proteins can also include fragments. As used herein, the terms are used interchangeably to mean a receptor, in particular and unless otherwise specified, a human receptor, that upon association with β-Klotho and FGF21 induces FGF21-like signaling activity.

The term FGFR1c also includes post-translational modifications of the FGFR1c amino acid sequence, for example, possible N-linked glycosylation sites. Thus, the antigen binding proteins can bind to or be generated from proteins glycosylated at one or more of the positions.

β-Klotho

The antigen binding proteins disclosed herein bind to β-Klotho, in particular human β-Klotho. The nucleotide sequence encoding human β-Klotho (GenBank Accession Number NM_(—)175737) is provided:

(SEQ ID NO: 6) ATGAAGCCAGGCTGTGCGGCAGGATCTCCAGGGAATGAATGGATT TTCTTCAGCACTGATGAAATAACCACACGCTATAGGAATACAATGT CCAACGGGGGATTGCAAAGATCTGTCATCCTGTCAGCACTTATTCT GCTACGAGCTGTTACTGGATTCTCTGGAGATGGAAGAGCTATATGG TCTAAAAATCCTAATTTTACTCCGGTAAATGAAAGTCAGCTGTTTCT CTATGACACTTTCCCTAAAAACTTTTTCTGGGGTATTGGGACTGGA GCATTGCAAGTGGAAGGGAGTTGGAAGAAGGATGGAAAAGGACCT TCTATATGGGATCATTTCATCCACACACACCTTAAAAATGTCAGCA GCACGAATGGTTCCAGTGACAGTTATATTTTTCTGGAAAAAGACTT ATCAGCCCTGGATTTTATAGGAGTTTCTTTTTATCAATTTTCAATTT CCTGGCCAAGGCTTTTCCCCGATGGAATAGTAACAGTTGCCAACGC AAAAGGTCTGCAGTACTACAGTACTCTTCTGGACGCTCTAGTGCTT AGAAACATTGAACCTATAGTTACTTTATACCACTGGGATTTGCCTTT GGCACTACAAGAAAAATATGGGGGGTGGAAAAATGATACCATAAT AGATATCTTCAATGACTATGCCACATACTGTTTCCAGATGTTTGGG GACCGTGTCAAATATTGGATTACAATTCACAACCCATATCTAGTGG CTTGGCATGGGTATGGGACAGGTATGCATGCCCCTGGAGAGAAGG GAAATTTAGCAGCTGTCTACACTGTGGGACACAACTTGATCAAGGC TCACTCGAAAGTTTGGCATAACTACAACACACATTTCCGCCCACAT CAGAAGGGTTGGTTATCGATCACGTTGGGATCTCATTGGATCGAGC CAAACCGGTCGGAAAACACGATGGATATATTCAAATGTCAACAAT CCATGGTTTCTGTGCTTGGATGGTTTGCCAACCCTATCCATGGGGAT GGCGACTATCCAGAGGGGATGAGAAAGAAGTTGTTCTCCGTTCTAC CCATTTTCTCTGAAGCAGAGAAGCATGAGATGAGAGGCACAGCTG ATTTCTTTGCCTTTTCTTTTGGACCCAACAACTTCAAGCCCCTAAAC ACCATGGCTAAAATGGGACAAAATGTTTCACTTAATTTAAGAGAAG CGCTGAACTGGATTAAACTGGAATACAACAACCCTCGAATCTTGAT TGCTGAGAATGGCTGGTTCACAGACAGTCGTGTGAAAACAGAAGA CACCACGGCCATCTACATGATGAAGAATTTCCTCAGCCAGGTGCTT CAAGCAATAAGGTTAGATGAAATACGAGTGTTTGGTTATACTGCCT GGTCTCTCCTGGATGGCTTTGAATGGCAGGATGCTTACACCATCCG CCGAGGATTATTTTATGTGGATTTTAACAGTAAACAGAAAGAGCGG AAACCTAAGTCTTCAGCACACTACTACAAACAGATCATACGAGAA AATGGTTTTTCTTTAAAAGAGTCCACGCCAGATGTGCAGGGCCAGT TTCCCTGTGACTTCTCCTGGGGTGTCACTGAATCTGTTCTTAAGCCC GAGTCTGTGGCTTCGTCCCCACAGTTCAGCGATCCTCATCTGTACGT GTGGAACGCCACTGGCAACAGACTGTTGCACCGAGTGGAAGGGGT GAGGCTGAAAACACGACCCGCTCAATGCACAGATTTTGTAAACATC AAAAAACAACTTGAGATGTTGGCAAGAATGAAAGTCACCCACTAC CGGTTTGCTCTGGATTGGGCCTCGGTCCTTCCCACTGGCAACCTGTC CGCGGTGAACCGACAGGCCCTGAGGTACTACAGGTGCGTGGTCAG TGAGGGGCTGAAGCTTGGCATCTCCGCGATGGTCACCCTGTATTAT CCGACCCACGCCCACCTAGGCCTCCCCGAGCCTCTGTTGCATGCCG ACGGGTGGCTGAACCCATCGACGGCCGAGGCCTTCCAGGCCTACGC TGGGCTGTGCTTCCAGGAGCTGGGGGACCTGGTGAAGCTCTGGATC ACCATCAACGAGCCTAACCGGCTAAGTGACATCTACAACCGCTCTG GCAACGACACCTACGGGGCGGCGCACAACCTGCTGGTGGCCCACG CCCTGGCCTGGCGCCTCTACGACCGGCAGTTCAGGCCCTCACAGCG CGGGGCCGTGTCGCTGTCGCTGCACGCGGACTGGGCGGAACCCGCC AACCCCTATGCTGACTCGCACTGGAGGGCGGCCGAGCGCTTCCTGC AGTTCGAGATCGCCTGGTTCGCCGAGCCGCTCTTCAAGACCGGGGA CTACCCCGCGGCCATGAGGGAATACATTGCCTCCAAGCACCGACGG GGGCTTTCCAGCTCGGCCCTGCCGCGCCTCACCGAGGCCGAAAGGA GGCTGCTCAAGGGCACGGTCGACTTCTGCGCGCTCAACCACTTCAC CACTAGGTTCGTGATGCACGAGCAGCTGGCCGGCAGCCGCTACGAC TCGGACAGGGACATCCAGTTTCTGCAGGACATCACCCGCCTGAGCT CCCCCACGCGCCTGGCTGTGATTCCCTGGGGGGTGCGCAAGCTGCT GCGGTGGGTCCGGAGGAACTACGGCGACATGGACATTTACATCAC CGCCAGTGGCATCGACGACCAGGCTCTGGAGGATGACCGGCTCCG GAAGTACTACCTAGGGAAGTACCTTCAGGAGGTGCTGAAAGCATA CCTGATTGATAAAGTCAGAATCAAAGGCTATTATGCATTCAAACTG GCTGAAGAGAAATCTAAACCCAGATTTGGATTCTTCACATCTGATT TTAAAGCTAAATCCTCAATACAATTTTACAACAAAGTGATCAGCAG CAGGGGCTTCCCTTTTGAGAACAGTAGTTCTAGATGCAGTCAGACC CAAGAAAATACAGAGTGCACTGTCTGCTTATTCCTTGTGCAGAAGA AACCACTGATATTCCTGGGTTGTTGCTTCTTCTCCACCCTGGTTCTA CTCTTATCAATTGCCATTTTTCAAAGGCAGAAGAGAAGAAAGTTTT GGAAAGCAAAAAACTTACAACACATACCATTAAAGAAAGGCAAGA GAGTTGTTAGCTAA.

The amino acid sequence of full length human β-Klotho (GenBank Accession Number NP_(—)783864) is provided:

(SEQ ID NO: 7) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRA VTGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVE GSWKKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGV SFYQFSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYH WDLPLALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNP YLVAWHGYGTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTH FRPHQKGWLSITLGSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIH GDGDYPEGMRKKLFSVLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLN TMAKMGQNVSLNLREALNWIKLEYNNPRILIAENGWFTDSRVKTEDT TAIYMMKNFLSQVLQAIRLDEIRVFGYTAWSLLDGFEWQDAYTIRRGL FYVDFNSKQKERKPKSSAHYYKQIIRENGFSLKESTPDVQGQFPCDFS WGVTESVLKPESVASSPQFSDPHLYVWNATGNRLLHRVEGVRLKTRP AQCTDFVNIKKQLEMLARMKVTHYRFALDWASVLPTGNLSAVNRQA LRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLPEPLLHADGWLNPST AEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYNRSGNDTYGAAHN LLVAHALAWRLYDRQFRPSQRGAVSLSLHADWAEPANPYADSHWRA AERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSSSALPRLTEA ERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFLQDITRLS SPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDDRLRK YYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFKAK SSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFLGC CFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS.

The antigen binding proteins described herein bind the extracellular portion of β-Klotho. An example of an extracellular region of β-Klotho is:

(SEQ ID NO: 8) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRA VTGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVE GSWKKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGV SFYQFSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYH WDLPLALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNP YLVAWHGYGTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTH FRPHQKGWLSITLGSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIH GDGDYPEGMRKKLFSVLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLN TMAKMGQNVSLNLREALNWIKLEYNNPRILIAENGWFTDSRVKTEDT TAIYMMKNFLSQVLQAIRLDEIRVFGYTAWSLLDGFEWQDAYTIRRGL FYVDFNSKQKERKPKSSAHYYKQIIRENGFSLKESTPDVQGQFPCDFS WGVTESVLKPESVASSPQFSDPHLYVWNATGNRLLHRVEGVRLKTRP AQCTDFVNIKKQLEMLARMKVTHYRFALDWASVLPTGNLSAVNRQA LRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLPEPLLHADGWLNPST AEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYNRSGNDTYGAAHN LLVAHALAWRLYDRQFRPSQRGAVSLSLHADWAEPANPYADSHWRA AERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSSSALPRLTEA ERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFLQDITRLS SPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDDRLRK YYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFKAK SSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKP.

The murine form of β-Klotho, and fragments and subsequences thereof, can be of use in studying and/or constructing the molecules provided herein. The nucleotide sequence encoding murine β-Klotho (GenBank Accession Number NM_(—)031180) is provided:

(SEQ ID NO: 9) ATGAAGACAGGCTGTGCAGCAGGGTCTCCGGGGAATGAATGGATT TTCTTCAGCTCTGATGAAAGAAACACACGCTCTAGGAAAACAATGT CCAACAGGGCACTGCAAAGATCTGCCGTGCTGTCTGCGTTTGTTCT GCTGCGAGCTGTTACCGGCTTCTCCGGAGACGGGAAAGCAATATGG GATAAAAAACAGTACGTGAGTCCGGTAAACCCAAGTCAGCTGTTCC TCTATGACACTTTCCCTAAAAACTTTTCCTGGGGCGTTGGGACCGG AGCATTTCAAGTGGAAGGGAGTTGGAAGACAGATGGAAGAGGACC CTCGATCTGGGATCGGTACGTCTACTCACACCTGAGAGGTGTCAAC GGCACAGACAGATCCACTGACAGTTACATCTTTCTGGAAAAAGACT TGTTGGCTCTGGATTTTTTAGGAGTTTCTTTTTATCAGTTCTCAATCT CCTGGCCACGGTTGTTTCCCAATGGAACAGTAGCAGCAGTGAATGC GCAAGGTCTCCGGTACTACCGTGCACTTCTGGACTCGCTGGTACTT AGGAATATCGAGCCCATTGTTACCTTGTACCATTGGGATTTGCCTCT GACGCTCCAGGAAGAATATGGGGGCTGGAAAAATGCAACTATGAT AGATCTCTTCAACGACTATGCCACATACTGCTTCCAGACCTTTGGA GACCGTGTCAAATATTGGATTACAATTCACAACCCTTACCTTGTTGC TTGGCATGGGTTTGGCACAGGTATGCATGCACCAGGAGAGAAGGG AAATTTAACAGCTGTCTACACTGTGGGACACAACCTGATCAAGGCA CATTCGAAAGTGTGGCATAACTACGACAAAAACTTCCGCCCTCATC AGAAGGGTTGGCTCTCCATCACCTTGGGGTCCCATTGGATAGAGCC AAACAGAACAGACAACATGGAGGACGTGATCAACTGCCAGCACTC CATGTCCTCTGTGCTTGGATGGTTCGCCAACCCCATCCACGGGGAC GGCGACTACCCTGAGTTCATGAAGACGGGCGCCATGATCCCCGAGT TCTCTGAGGCAGAGAAGGAGGAGGTGAGGGGCACGGCTGATTTCT TTGCCTTTTCCTTCGGGCCCAACAACTTCAGGCCCTCAAACACCGTG GTGAAAATGGGACAAAATGTATCACTCAACTTAAGGCAGGTGCTG AACTGGATTAAACTGGAATACGATGACCCTCAAATCTTGATTTCGG AGAACGGCTGGTTCACAGATAGCTATATAAAGACAGAGGACACCA CGGCCATCTACATGATGAAGAATTTCCTAAACCAGGTTCTTCAAGC AATAAAATTTGATGAAATCCGCGTGTTTGGTTATACGGCCTGGACT CTCCTGGATGGCTTTGAGTGGCAGGATGCCTATACGACCCGACGAG GGCTGTTTTATGTGGACTTTAACAGTGAGCAGAAAGAGAGGAAAC CCAAGTCCTCGGCTCATTACTACAAGCAGATCATACAAGACAACGG CTTCCCTTTGAAAGAGTCCACGCCAGACATGAAGGGTCGGTTCCCC TGTGATTTCTCTTGGGGAGTCACTGAGTCTGTTCTTAAGCCCGAGTT TACGGTCTCCTCCCCGCAGTTTACCGATCCTCACCTGTATGTGTGGA ATGTCACTGGCAACAGATTGCTCTACCGAGTGGAAGGGGTAAGGCT GAAAACAAGACCATCCCAGTGCACAGATTATGTGAGCATCAAAAA ACGAGTTGAAATGTTGGCAAAAATGAAAGTCACCCACTACCAGTTT GCTCTGGACTGGACCTCTATCCTTCCCACTGGCAATCTGTCCAAAGT TAACAGACAAGTGTTAAGGTACTATAGGTGTGTGGTGAGCGAAGG ACTGAAGCTGGGCGTCTTCCCCATGGTGACGTTGTACCACCCAACC CACTCCCATCTCGGCCTCCCCCTGCCACTTCTGAGCAGTGGGGGGT GGCTAAACATGAACACAGCCAAGGCCTTCCAGGACTACGCTGAGC TGTGCTTCCGGGAGTTGGGGGACTTGGTGAAGCTCTGGATCACCAT CAATGAGCCTAACAGGCTGAGTGACATGTACAACCGCACGAGTAA TGACACCTACCGTGCAGCCCACAACCTGATGATCGCCCATGCCCAG GTCTGGCACCTCTATGATAGGCAGTATAGGCCGGTCCAGCATGGGG CTGTGTCGCTGTCCTTACATTGCGACTGGGCAGAACCTGCCAACCC CTTTGTGGATTCACACTGGAAGGCAGCCGAGCGCTTCCTCCAGTTT GAGATCGCCTGGTTTGCAGATCCGCTCTTCAAGACTGGCGACTATC CATCGGTTATGAAGGAATACATCGCCTCCAAGAACCAGCGAGGGC TGTCTAGCTCAGTCCTGCCGCGCTTCACCGCGAAGGAGAGCAGGCT GGTGAAGGGTACCGTCGACTTCTACGCACTGAACCACTTCACTACG AGGTTCGTGATACACAAGCAGCTGAACACCAACCGCTCAGTTGCAG ACAGGGACGTCCAGTTCCTGCAGGACATCACCCGCCTAAGCTCGCC CAGCCGCCTGGCTGTAACACCCTGGGGAGTGCGCAAGCTCCTTGCG TGGATCCGGAGGAACTACAGAGACAGGGATATCTACATCACAGCC AATGGCATCGATGACCTGGCTCTAGAGGATGATCAGATCCGAAAGT ACTACTTGGAGAAGTATGTCCAGGAGGCTCTGAAAGCATATCTCAT TGACAAGGTCAAAATCAAAGGCTACTATGCATTCAAACTGACTGAA GAGAAATCTAAGCCTAGATTTGGATTTTTCACCTCTGACTTCAGAG CTAAGTCCTCTGTCCAGTTTTACAGCAAGCTGATCAGCAGCAGTGG CCTCCCCGCTGAGAACAGAAGTCCTGCGTGTGGTCAGCCTGCGGAA GACACAGACTGCACCATTTGCTCATTTCTCGTGGAGAAGAAACCAC TCATCTTCTTCGGTTGCTGCTTCATCTCCACTCTGGCTGTACTGCTAT CCATCACCGTTTTTCATCATCAAAAGAGAAGAAAATTCCAGAAAGC AAGGAACTTACAAAATATACCATTGAAGAAAGGCCACAGCAGAGT TTTCAGCTAA.

The amino acid sequence of full length murine β-Klotho (GenBank Accession Number NP_(—)112457) is provided:

(SEQ ID NO: 10) MKTGCAAGSPGNEWIFFSSDERNTRSRKTMSNRALQRSAVLSAFVLLR AVTGFSGDGKAIWDKKQYVSPVNPSQLFLYDTFPKNFSWGVGTGAFQ VEGSWKTDGRGPSIWDRYVYSHLRGVNGTDRSTDSYIFLEKDLLALD FLGVSFYQFSISWPRLFPNGTVAAVNAQGLRYYRALLDSLVLRNIEPIV TLYHWDLPLTLQEEYGGWKNATMIDLFNDYATYCFQTFGDRVKYWI TIHNPYLVAWHGFGTGMHAPGEKGNLTAVYTVGHNLIKAHSKVWHN YDKNFRPHQKGWLSITLGSHWIEPNRTDNMEDVINCQHSMSSVLGWF ANPIHGDGDYPEFMKTGAMIPEFSEAEKEEVRGTADFFAFSFGPNNFRP SNTVVKMGQNVSLNLRQVLNWIKLEYDDPQILISENGWFTDSYIKTED TTAIYMMKNFLNQVLQAIKFDEIRVFGYTAWTLLDGFEWQDAYTTRR GLFYVDFNSEQKERKPKSSAHYYKQIIQDNGFPLKESTPDMKGRFPCD FSWGVTESVLKPEFTVSSPQFTDPHLYVWNVTGNRLLYRVEGVRLKT RPSQCTDYVSIKKRVEMLAKMKVTHYQFALDWTSILPTGNLSKVNRQ VLRYYRCVVSEGLKLGVFPMVTLYHPTHSHLGLPLPLLSSGGWLNMN TAKAFQDYAELCFRELGDLVKLWITINEPNRLSDMYNRTSNDTYRAA HNLMIAHAQVWHLYDRQYRPVQHGAVSLSLHCDWAEPANPFVDSH WKAAERFLQFEIAWFADPLFKTGDYPSVMKEYIASKNQRGLSSSVLPR FTAKESRLVKGTVDFYALNHFTTRFVIHKQLNTNRSVADRDVQFLQDI TRLSSPSRLAVTPWGVRKLLAWIRRNYRDRDIYITANGIDDLALEDDQI RKYYLEKYVQEALKAYLIDKVKIKGYYAFKLTEEKSKPRFGFFTSDFR AKSSVQFYSKLISSSGLPAENRSPACGQPAEDTDCTICSFLVEKKPLIFF GCCFISTLAVLLSITVFHHQKRRKFQKARNLQNIPLKKGHSRVFS.

As described herein, β-Klotho proteins can also include fragments. As used herein, the terms are used interchangeably to mean a co-receptor, in particular and unless otherwise specified, a human co-receptor, that upon association with FGFR1c and FGF21 induces FGF21-like signaling activity.

The term β-Klotho also includes post-translational modifications of the β-Klotho amino acid sequence, for example, possible N-linked glycosylation sites. Thus, the antigen binding proteins can bind to or be generated from proteins glycosylated at one or more of the positions.

Antigen Binding Proteins that Specifically Bind to a Complex Comprising β-Klotho and an FGFR (e.g., FGFR1c, FGFR2c or FGFR3c)

A variety of selective binding agents useful for modulating FGF21-like signaling are provided. These agents include, for instance, antigen binding proteins that contain an antigen binding domain (e.g., single chain antibodies, domain antibodies, hemibodies, immunoadhesions, and polypeptides with an antigen binding region) and specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, in particular a complex comprising human β-Klotho and a human FGFR (e.g., human FGFR1c, human FGFR2c or human FGFR3c). Some of the agents, for example, are useful in mimicking the signaling effect generated in vivo by the association of an FGFR (e.g., FGFR1c, FGFR2c or FGFR3c) with β-Klotho and with FGF21, and can thus be used to enhance or modulate one or more activities associated with FGF21-like signaling.

In general, the antigen binding proteins that are provided typically comprise one or more CDRs as described herein (e.g., 1, 2, 3, 4, 5 or 6 CDRs). In some embodiments the antigen binding proteins are naturally expressed by clones, while in other embodiments, the antigen binding protein can comprise (a) a polypeptide framework structure and (b) one or more CDRs that are inserted into and/or joined to the polypeptide framework structure. In some of these embodiments a CDR forms a component of a heavy or light chains expressed by the clones described herein; in other embodiments a CDR can be inserted into a framework in which the CDR is not naturally expressed. A polypeptide framework structure can take a variety of different forms. For example, a polypeptide framework structure can be, or comprise, the framework of a naturally occurring antibody, or fragment or variant thereof, or it can be completely synthetic in nature. Examples of various antigen binding protein structures are further described below.

In some embodiments in which the antigen binding protein comprises (a) a polypeptide framework structure and (b) one or more CDRs that are inserted into and/or joined to the polypeptide framework structure, the polypeptide framework structure of an antigen binding protein is an antibody or is derived from an antibody, including, but not limited to, monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, antibody fusions (sometimes referred to as “antibody conjugates”), and portions or fragments of each, respectively. In some instances, the antigen binding protein is an immunological fragment of an antibody (e.g., a Fab, a Fab′, a F(ab′)₂, or a scFv).

Certain of the antigen binding proteins as provided herein specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, including the human forms of these proteins. In one embodiment, an antigen binding protein specifically binds to both human FGFR1c comprising the amino acid sequence of SEQ ID NO: 4, and human β-Klotho comprising the amino acid sequence of SEQ ID NO: 7, and in another embodiment an antigen binding protein specifically binds to both human FGFR1c comprising the amino acid sequence of SEQ ID NO: 4 and human β-Klotho having the amino acid sequence of SEQ ID NO: 7 and induces FGF21-like signaling. Thus, an antigen binding protein can, but need not, induce FGF21-like signaling.

Antigen Binding Protein Structure

Some of the antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, including the human forms of these proteins, provided herein have a structure typically associated with naturally occurring antibodies. The structural units of these antibodies typically comprise one or more tetramers, each composed of two identical couplets of polypeptide chains, though some species of mammals also produce antibodies having only a single heavy chain. In a typical antibody, each pair or couplet includes one full-length “light” chain (in certain embodiments, about 25 kDa) and one full-length “heavy” chain (in certain embodiments, about 50-70 kDa).

Each individual immunoglobulin chain is composed of several “immunoglobulin domains,” each consisting of roughly 90 to 110 amino acids and expressing a characteristic folding pattern. These domains are the basic units of which antibody polypeptides are composed. The amino-terminal portion of each chain typically includes a variable domain that is responsible for antigen recognition. The carboxy-terminal portion is more conserved evolutionarily than the other end of the chain and is referred to as the “constant region” or “C region”. Human light chains generally are classified as kappa (“κ”) and lambda (“λ”) light chains, and each of these contains one variable domain and one constant domain. Heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon chains, and these define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subtypes, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM subtypes include IgM, and IgM2. IgA subtypes include IgA1 and IgA2. In humans, the IgA and IgD isotypes contain four heavy chains and four light chains; the IgG and IgE isotypes contain two heavy chains and two light chains; and the IgM isotype contains five heavy chains and five light chains. The heavy chain C region typically comprises one or more domains that can be responsible for effector function. The number of heavy chain constant region domains will depend on the isotype. IgG heavy chains, for example, each contain three C region domains known as C_(H)1, C_(H)2 and C_(H)3. The antibodies that are provided can have any of these isotypes and subtypes. In certain embodiments, an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c is an antibody of the IgG1, IgG2, or IgG4 subtype.

In full-length light and heavy chains, the variable and constant regions are joined by a “J” region of about twelve or more amino acids, with the heavy chain also including a “D” region of about ten more amino acids. See, e.g., Fundamental Immunology, 2nd ed., Ch. 7 (Paul, W., ed.) 1989, New York: Raven Press (hereby incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair typically form the antigen binding site.

One example of an IgG2 heavy constant domain of an exemplary monoclonal antibody that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c has the amino acid sequence:

(SEQ ID NO: 11) ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKT VERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDW LNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSK LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.

One example of a kappa light constant domain of an exemplary monoclonal antibody that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c has the amino acid sequence:

(SEQ ID NO: 12) TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNRGEC.

One example of a lambda light constant domain of an exemplary monoclonal antibody that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c has the amino acid sequence:

(SEQ ID NO: 13) QPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPV KAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTV EKTVAPTECS.

Variable regions of immunoglobulin chains generally exhibit the same overall structure, comprising relatively conserved framework regions (FR) joined by three hypervariable regions, more often called “complementarity determining regions” or CDRs. The CDRs from the two chains of each heavy chain/light chain pair mentioned above typically are aligned by the framework regions to form a structure that binds specifically with a specific epitope on the target protein (e.g., a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. From N-terminal to C-terminal, naturally-occurring light and heavy chain variable regions both typically conform with the following order of these elements: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. A numbering system has been devised for assigning numbers to amino acids that occupy positions in each of these domains. This numbering system is defined in Kabat et al., (1991) “Sequences of Proteins of Immunological Interest”, 5^(th) Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242. Although presented using the Kabat nomenclature system, as desired, the CDRs disclosed herein can also be redefined according an alternative nomenclature scheme, such as that of Chothia (see Chothia & Lesk, (1987) J. Mol. Biol. 196:901-917; Chothia et al., (1989) Nature 342:878-883 or Honegger & Pluckthun, (2001) J. Mol. Biol. 309:657-670).

The various heavy chain and light chain variable regions of antigen binding proteins provided herein are depicted in Table 2. Each of these variable regions can be attached to the disclosed heavy and light chain constant regions to form a complete antibody heavy and light chain, respectively. Further, each of the so-generated heavy and light chain sequences can be combined to form a complete antibody structure. It should be understood that the heavy chain and light chain variable regions provided herein can also be attached to other constant domains having different sequences than the exemplary sequences listed above.

Specific examples of some of the full length light and heavy chains of the antibodies that are provided and their corresponding amino acid sequences are summarized in Tables 1A and 1B. Table 1A shows exemplary light chain sequences, and Table 1B shows exemplary heavy chain sequences.

TABLE 1A Exemplary Antibody Light Chain Sequences Contained SEQ ID in Clone Designation NO: Amino Acid Sequence 63E6 L6 14 DIQMTQSPSSLSASVGDRVTITCRTSQSISSYL NWYQQKPGKAPNLLIYAASSLQSGVPSRFSG SGSGTDFTLTISGLQPEDFSTYYCQQSYSTSL TFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 66F7 L7 15 DIQMTQSPSSLSASVGDRVTITCRTSQSISNY LNWYQQKPGKAPNLLIYAASSLQSGVPSRFS GSGSGTDFTLTISGLQPEDFSTYYCQQSYSTS LTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 66D4 L18 16 DIQMTQSPSSLSASVGDRITITCRASQIISRYL NWYQQNPGKAPKLLISAASSLQSGVPSRFSG SGSGPDFTLTISSLQPEDFTTYYCQQSYSSPLT FGGGTKVEVKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 66B4 L11 17 DIQMTQSPSSVSSSVGDRVTITCRASQGISRW LAWYQQKPGKAPKLLIYAASSLKSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQANSFP PTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 65B1 L19 18 DIQMTQSPSSLSASVGDRVTITCRASQNINNY LNWYRQKPGKAPELLIYTTSSLQSGVPSRFS GSGSGTDFTLTISSLETEDFETYYCQQSYSTP LTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 65B4 L21 19 SYVLTQPPSVSVAPGQTARITCGGNNIGSKSV QWYQQKPGQAPVLVVYDDSDRPSGIPERFS GSNSGNTASLTISRVEAGDEADYYCQVWDS SSDHVVFGGGTKLTVLGQPKANPTVTLFPPS SEELQANKATLVCLISDFYPGAVTVAWKAD GSPVKAGVETTKPSKQSNNKYAASSYLSLTP EQWKSHRSYSCQVTHEGSTVEKTVAPTECS 67A4 L20 20 SYVLTQPPSVSVAPGQTARITCGGNNIGSKSV HWYQQKPGQAPVLVVYDDSDRPSGIPERFS GSNSGNTATLTISRVEAGDEADYYCQVWDS SSDHVVFGGGTKLTVLGQPKANPTVTLFPPS SEELQANKATLVCLISDFYPGAVTVAWKAD GSPVKAGVETTKPSKQSNNKYAASSYLSLTP EQWKSHRSYSCQVTHEGSTVEKTVAPTECS 63A10v1 L22 21 SYELTQPHSVSVATAQMARITCGGNNIGSKA VHWYQQKPGQDPVLVIYCDSNRPSGIPER FSGSNPGNTATLTISRIEAGDEADYYCQVWD SSSDGVFGGGTKLTVLGQPKANPTVTLFPPS SEELQANKATLVCLISDFYPGAVTVAWKAD GSPVKAGVETTKPSKQSNNKYAASSYLSLTP EQWKSHRSYSCQVTHEGSTVEKTVAPTECS 63A10v2 L101 1835 SYELTQPHSVSVATAQMARITCGGNNIGSKA VHWYQQKPGQDPVLVIYCDSNRPSGIPER FSGSNPGNTATLTISRIEAGDEADYYCQAWD STTVVFGGGTKLTVLGQPKANPTVTLFPPSS EELQANKATLVCLISDFYPGAVTVAWKADG SPVKAGVETTKPSKQSNNKYAASSYLSLTPE QWKSHRSYSCQVTHEGSTVEKTVAPTECS 63A10v3 L102 1836 SYELTQPPSVSVSPGQTANITCSGDKLGNRY TCWYQQKSGQSPVLVIYQDSERPSGIPER FSGSNSGNTATLTISGTQAMDEADYYCQAW DSTTVVFGGGTKLTVLGQPKANPTVTLFPPS SEELQANKATLVCLISDFYPGAVTVAWKAD GSPVKAGVETTKPSKQSNNKYAASSYLSLTP EQWKSHRSYSCQVTHEGSTVEKTVAPTECS 65H11v1 L23 22 SYELTQPHSVSVATAQMARITCGGNNIGSKT VHWFQQKPGQDPVLVIYSDSNRPSGIPERFS GSNPGNTATLTISRIEAGDEADYYCQVWDSS CDGVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 65H11v2 L103 1837 SYELTQPPSVSVSPGQTANITCSGDKLGDRY VCWYQQKPGQSPVLVIYQDSKRPSGIPEQFS GSNSGNTATLTISGTQAIDEADYYCQAWDSI TVVFGGGTKLTVLGQPKANPTVTLFPPSSEE LQANKATLVCLISDFYPGAVTVAWKADGSP VKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 67G10v1 L9 23 SYELTQPHSVSVATAQMARITCGGNNIGSKA VHWYQQKPGQDPVLVIYSDSNRPSGIPERFS GSNPGNTATLTISRIEAGDEADYYCQVWDSS SDGVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 67G10v2 L10 24 SYELTQPPSVSVSPGQTASITCSGDKLGDKY ACWYQQKPGQSPVLVIYQDNERPSGIPERFS GSNSGNTATLTISGTQAMDEADYYCQAWDS TTVVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 64C8 L24 25 DVVMTQSPLSLPVTLGQPASISRRSSPSLVYS DGNTYLNCFQQRPGHSPRRLIYKGSNWDSG VPDRFSGSGSGTDFTLKISRVEAEDVGIYYCI QDTHWPTCSFGQGTKLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKV DNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC 64A8 L1 26 DIQMTQSPSSLSASVGDRVTITCRASQDIRND 67B4 LGWYQQKPGKAPKRLIYAASNLQRGVPSRF SGSGSGTEFTLTISTLQPEDFATYSCLQHNSY PLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 63G8v1 L104 1838 DIQMTQSPSSLSASVGDRVTITCRASQDIRND LGWYQQKPGKAPKRLIYAASNLQRGVPSRF SGSGSGTEFTLTISTLQPDDFATYSCLQHNSY PLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 63G8v2 L105 1839 DIQMTQSPSSLSASVGDRVTITCRASQGIRSG LGWYQQKPGKAPKRLIYAASNLQRGVPSRF SGSGSGTEFTLTVSSLQPEDFATYSCLQHNSY PLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 63G8v3 L106 1840 DIQMTQSPSSLSASVGDRVTITCRASQGIRSG LGWYQQKPGKAPKRLIYAASNLQRGVPSRF SGSGSGTEFTLTVSSLQPEDFATYSCLQHNTY PLTFGGGTKGEIRRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 66G2 L12 27 DIQMTQSPSSLSASVGDRVTITCRASQGIRND LGWYQQKPGKAPKRLIYAASNLQSGVPSRFS GSGSGTKFTLTINSLQPEDFATYYCLQLNGY PLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 68D3v1 L2 28 DIQMTQSPSSLSASVGDRVTITCRASQDIRND 68D3v2 LGWYQQKPGKAPKRLIYAASNLQRGVPSRF SGSGSGTEFTLTISTLQPDDFATYSCLQHNSY PLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 65D1 L27 29 SYDLTQPPSVSVSPGQTASITCSGDKLGDKY VCWYQQKPGQSPVLVIYQDSKRPSGIPERFS GSNSGNTATLTISGIQAMDEADYYCQAWDS RVFGGGTKLTVLGQPKANPTVTLFPPSSEEL QANKATLVCLISDFYPGAVTVAWKADGSPV KAGVETTKPSKQSNNKYAASSYLSLTPEQW KSHRSYSCQVTHEGSTVEKTVAPTECS 64H5 L8 30 SYEMTQPLSVSVALGQTARITCGGNNIGSKN 65G4 VHWYQQKPGQAPVLVIYRDSKRPSGIPERFS GSNSGNTATLTISRAQAGDEADYYCQVWDS SSVVFGGGTKLTVLGQPKANPTVTLFPPSSEE LQANKATLVCLISDFYPGAVTVAWKADGSP VKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 65D4 L26 31 SYELTQPLSVSVALGQTARIPCGGNDIGSKN VHWYQQKPGQAPVLVIYRDRNRPSGIPERFS GSNSGNTATLTISRAQAGDEADYYCQVWDS NPVVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 65E3 L25 32 SYELTQPLSVSVALGQTARITCGGNNIGSKN VHWYQQKPGQAPVLVIYRDRNRPSGIPERFS GSNSGNTATLTISRAQAGDEADYYCQVWDS STVVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 67G8 L28 33 SYELTQPLSVSVALGQTARITCGGNNIGSYN VFWYQQKPGQAPVLVIYRDSKRPSGIPERFS GSNSGNTATLTISRAQAGDEADYHCQVWDS STVVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 65B7v1 L29 34 EIVLTQSPGTLSLSPGERATLSCRASQSVSSIY LAWYQQKPGQAPRLLIYGASSRATGIPDRFS GSGSGTDFTLTISRLEPEDFAVYYCQQYGSSC SFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 65B7v2 L107 1841 DVVMTQSPLSLPVTLGQPASISYRSSQSLVYS DGDTYLNWFQQRPGQSPRRLIYKVSNWDSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQGTHWRGWTFGQGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQ WKVDNALQSGNSQESVTEQDSKDSTYSLSS TLTLSKADYEKHKVYACEVTHQGLSSPVTK SFNRGEC 63B6 L4 35 EIVLTQSPGTLSLSPGERATLSCRASQSVSNS 64D4 YLAWYQQKPGQAPRLLIYGAFSRATGIPDRF SGSGSGTDFTLTISRLEPEDFAVYYCQQFGRS FTFGGGTKVEIRRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 63F5 L14 36 EVVLTQSPGTLSLSPGERATLSCRASQTVRN NYLAWYQQQPGQAPRLLIFGASSRATGIPDR FSGSGSGTDFTLTISRLEPEDFAVYYCQQFGS SLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 65E8 L3 37 EIVLTQSPGTLSLSPGERATLSCRASQSVRNS 63H11 YLAWYQQQPGQAPRLLIYGAFSRASGIPDRF 64E6 SGSGSGTDFTLTISRLEPEDFAVYYCQQFGSS 67G7 LTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS 65F11 GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 65C1 L16 38 EIVLTQSPGTLSLSPGERATLSCRASQTIRNSY LAWYQQQPGQAPRLLIYGAFSRATGIPDRFS GGGSGTDFTLTISRLEPEDFAVYYCQQFGSSL TFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 66F6 L15 39 EIVLTQSPGTLSLSPGERATLSCRASQSVRNS YLAWYQQQPGQAPRLLIYGAFSRATGIPDRF SGSGSGTDFTLTISRLEPEDFAVYYCQQFGSS LTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 64A6 L30 40 EILMTQSPATLSVSPGERATLSCRASQSVNSN LAWYQQKPGQAPRLLIYGTSTRATGVPARF GGSGSGTEFTLTISSLQSEDFAFYYCQQYNT WPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQ LKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 65F9 L31 41 EILMTQSPATLSVSPGERATLSCRASQSVSSN LAWYQQKPGQSPRLLIYGASTRATGIPARFG GSGSGTDFTLTISSLQSEDFAFYYCQQYNTW PWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 64A7 L17 42 EIVLTQSPGTLSLSPGERATLSCRASQSVSRN YLAWYQQKPGQAPRLLIYGASSRATGVPDR FSGSGSGTDFTLTISRLEPEDFAVYYCQQYGS SSLCSFGQGTNLDIRRTVAAPSVFIFPPSDEQL KSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 65C3 L5 43 EMVMTQSPATLSVSPGERATLSCRASQSVSS 68D5 QLAWYQEKPGRAPRLLIYGASNRAIDIPARL SGSGSGTEFTLTISSLQSEDFAVYYCQQYNN WPWTFGQGTKVEFKRTVAAPSVFIFPPSDEQ LKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 67F5 L32 44 EIVMTQSPATLSVSPGERVTLSCRASQSVSSN LAWYQQKPGQAPRLLIHGSSNRAIGIPARFS GSGSGTEFTLTISSLQSADFAVYNCQQYEIWP WTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 64B10v1 L33 45 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNN 64B10v2 YVAWYQQLPGTAPKLLIYDNDKRPSGIPDRF SGSKSGTSATLGITGLQTGDEADYYCGTWDS SLSAVVFGGGTKLTVLGQPKANPTVTLFPPS SEELQANKATLVCLISDFYPGAVTVAWKAD GSPVKAGVETTKPSKQSNNKYAASSYLSLTP EQWKSHRSYSCQVTHEGSTVEKTVAPTECS 68C8 L34 46 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNN YVSWYQQLPGTAPKLLIYDNNKRPSGIPDRF SGSKSGTSATLGITGLQTGDEADYYCGTWDS SLSAVVFGGGTKLTVLGQPKANPTVTLFPPS SEELQANKATLVCLISDFYPGAVTVAWKAD GSPVKAGVETTKPSKQSNNKYAASSYLSLTP EQWKSHRSYSCQVTHEGSTVEKTVAPTECS 67A5 L35 47 DIVMTQTPLSLPVTPGEPASISCRSSQSLLNSD DGNTYLDWYLQKPGQSPQLLIYTLSYRASG VPDRFSGTGSGTEFTLKISRVEAEDVGVYYC MQRLEFPITFGQGTRLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRG EC 67C10 L36 48 DFVMTQTPLSLPVTPGEPASISCRSSQSLLNS DDGNTYLDWYLQKPGQSPQLLIYTLSYRAS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYY CMQRIEFPITFGQGTRLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKV DNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC 64H6 L37 49 SYELTQPLSVSVALGQTARITCGGNNIGSKN VHWYQQKPGQAPVVVIYRDSKRPSGIPERFS GSNSGNTATLTISRAQAGDEADYYCQVWDS SPVVFGGGTKLTVLGQPKANPTVTLFPPSSEE LQANKATLVCLISDFYPGAVTVAWKADGSP VKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 63F9 L38 50 DIQMTQSPSSLSVSVGDRVTITCRASQDIRND LAWYQQTPGKAPKRLIYASSSLQSGVPSRFS GTGSGTEFTLTISSLQPEDFATYFCLQRNSYP LTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 67F6v1 L39 51 DIVMTQTPLSLPVIPGEPASIFCRSSQSLLNSD AGTTYLDWYLQKPGQSPQLLIYTLSFRASGV PDRFSGSGSGTDFTLKITRVEAEDVGVYYCM QRIEFPITFGQGTRLEIKRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSK ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 67F6v2 L108 1842 DIVMTQTPLSLPVIPGEPASIFCRSSQSLLNSD AGTTYLDWYLQKPGRSPQLLIYTLSFRASGV PDRFSGSGSGTDFTLKITRVEAEDVGVYYCM QRIEFPITFGQGTRLEIKRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSK ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 48C9 L78 52 DIQMTQSPSSLSASIGDRVTITCRASQNIRTYL 49A12 NWYQQKPGKAPKLLIYVASSLESGVPSRFSG 51E2 TGSGTDFALTISSLQPEDFATYYCQQSDSIPR TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 48F3 L77 53 DIQMTQSPSSLSASVGDRVTITCRASQRISSY LNWYQQKPGKAPKFLIYAVSSLQSGVPSRFS GSGSGTDFTLTISSLEPEDFATYYCQQSYSAT FTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 48F8 L49 54 EIVLTQSPDFQSVTPKEKVTITCRASQDIGNS 53B9 LHWYQQKPDQSPKLLIKFASQSFSGVPSRFS 56B4 GSGSGTDFALTINSLEAEDAATYYCHQSSDL 57E7 PLTFGGGTKVDIKRTVAAPSVFIFPPSDEQLK 57F11 SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 48H11 L40 55 DIQMTQSPSSLSTSVGDRVTITCRASQNIRSY LNWYQLKPGKAPKVLIYGASNLQSGVPSRFS GSGSGTDFTLTISNLQSEDFAIYYCQQSYNTP CSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 49A10 L65 56 DIVMTQTPLSLPVTPGEPASISCRSSQSLLDSD 48D4 DGNTYLDWYLQKPGQSPQLLIYTLSYRASG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQRIEFPITFGQGTRLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRG EC 49C8 L45 57 DIQMTQSPSSLSASVGDRVTFTCQASQDINIY 52H1 LNWYQQKPGKAPKLLIYDVSNLETGVPSRFS GSGSGTDFTFTISSLQPEDIATYFCQQYDNLP FTFGPGTKVDLKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 49G2 L66 58 DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSD 50C12 DGDTYLDWYLQKPGQSPQLLIYTLSYRASG 55G11 VPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQHIEFPSTFGQGTRLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRG EC 49G3 L47 59 DIQMTQSPSSLSASIGDRVTITCQASQGISNYL NWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTFTISSLQPEDIATYYCHQYDDLPL TFGGGTKVEIRRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 49H12 L43 60 DIQMTQSPSSLSASVGDRVTITCQASQDITKY LNWYQQKPGKAPKLLIYDTFILETGVPSRFS GSGSGTDFTFTISSLQPEDIATYYCQQYDNLP LTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 51A8 L61 61 NFILTQPHSVSESPGKTVTISCTRSSGSIASDY VQWYQQRPGSSPTTVIYEDKERSSGVPDRFS GSIDSSSNSASLTISGLKTEDEADYYCQSYDR NNHVVFGGGTKLTVLGQPKANPTVTLFPPSS EELQANKATLVCLISDFYPGAVTVAWKADG SPVKAGVETTKPSKQSNNKYAASSYLSLTPE QWKSHRSYSCQVTHEGSTVEKTVAPTECS 51C10.1 L55 62 SYELTQPPSVSVSPGQTARITCSGDALPKKYA YWYQQKSGQAPVLVIYEDSKRPSGIPERFSG SISGTMATLTISGAQVEDEADYYCYSTDSSV NHVVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 51C10.2 L70 63 SYDLTQPPSVSVSPGQTASITCSGDELGDKY ACWYQQKPGQSPVLVIYQDTKRPSGIPERFS GSNSGNTATLTISGTQAMDEADYYCQAWDS GTVVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 51E5 L79 64 DIQMTQSPSSLSASVGDRVTITCRASQDIRND LGWYQQKPGKAPNRLIYAASSLQFGVPSRFS GSGSGTEFTLTISSLQPEDFATYYCLQHSSYP LTFGGGTRVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 51G2 L51 65 DIQMTQSPSSVSASVGDRVTITCRASQGISSW LAWYQQKPGKAPKLLIYDASSLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQTNSFP PWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 52A8 L41 66 DIQMTQSPSFLSASVGDRVTITCRASQTISSY LNWHQQKPGKAPKLLIYAASSLQSGVPSRFS GSGSGTDFSLTISSLQPEDFATYYCQQSYSTP LTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 52B8 L82 67 EVVLTQSPATLSVSPGGRATLSCRASQSVSDI LAWYQQKPGQAPRLLIYGASTRATGIPARFS GGGSGTEFTLTISSLQSEDFAVYFCQQYNNW PLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 52C1 L67 68 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGINY VSWYQQLPGTAPKLLIYDNNKRPSGIPDRFS GSKSGTSATLGITGLQTGDEADYCCGTWDSS LSAVVFGGGTKLTVLGQPKANPTVTLFPPSS EELQANKATLVCLISDFYPGAVTVAWKADG SPVKAGVETTKPSKQSNNKYAASSYLSLTPE QWKSHRSYSCQVTHEGSTVEKTVAPTECS 52F8 L42 69 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSN GYNYLDWYLQKPGQSPQLLIYLGSNRASGV PDRFSGRGSGTDFSLKISRVEAEDVGIYYCM QALQTPFTFGPGTNVDIKQTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRG EC 52H2 L84 70 ENVLTQSPGTLSLSPGERATLSCRASQSVRSS YLAWYQQRPGQAPRLLIFGASRRATGIPDRF SGSGSGTDFTLTISRLEPEDFAVYYCQQYGSS PRSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 53F6 L63 71 DIVMTQSPLSLPVTPGEPASISCRSSQSLQHSN GYNYLDWYLQKPGQSPQLLIYLDSNRASGV PDRFSGSGSGTDFTLKISRVEAEDIGVYYCM QGLQTPPTFGGGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRG EC 53H5.2 L62 72 DIQMTQSPSSLSASVGDRVTITCRASQGIRND LGWYQQKPGKAPKRLIYAASSLQSGVPSRFS GSGSGTEFTLTISSLQPEDFATYYCLQHKSYP FTFGPGTKMDIKGTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 53H5.3 L80 73 EIVMTQSPVTLSVSPGERAIISCRASQSVSSNV AWYQQKPGQTPRLLIYGASTRATGLPTRFSG SGSGTVFTLTISSLQPEDFAVYYCQQFSNSITF GQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTA SVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC 54A1 L44 74 DIQMAQSPSSLSASVGDRVTITCQASQDISIY 55G9 LNWYQLKPGKAPKLLIYDVSNLETGVPSRFS GGGSGTDFTFTISSLQPEDIATYYCQQYDNLP LTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 54H10.1 L53 75 EIVVTQSPGTLSLSVGERAILSCRASQSFSSSY 55D1 LAWYQQKPGQAPRLLIYGASSRATGIPDRFS 48H3 GSGSGTDFTLTISRLEPEDFAVYYCQQYGSSR 53C11 TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 55D3 L71 76 DIQMTQSPSSLSVSVGDRVTITCRASQDISNY LAWFQQKPGKAPKSLIYAASSLQSGVPSKFS GSGSGTDFTLTISSLQPEDFATYYCQQYNIYP RTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 55E4 L75 77 DIQMTQSPSSLSTSIGDRITITCRASQSISNYLN 49B11 WFQQIPGKAPRLLIYTASSLQSGVPSRFSGSG 50H10 SGTDFTLTISSLQPEDFATYYCQQSSSIPWTF 53C1 GQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA SVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC 55E9 L68 78 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSN GFNYLDWYLQKPGQSPQVLIYLGSNRASGV PDRFSGSGSGTDFTLKISRVEAEDVGIYYCM QALQTLITFGQGTRLEIKRTVAAPSVFIFPPSD EQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSK ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 55G5 L83 79 SYELTQPPSVSVSPGQTASITCSGDNLGDKY AFWYQQKPGQSPVLVIYQDNKRPSGIPERFS GSNSGNTATLTISGTQAVDEADYYCQAWDS ATVIFGGGTKLTVLGQPKANPTVTLFPPSSEE LQANKATLVCLISDFYPGAVTVAWKADGSP VKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 56A7 L52 80 DIQMTQSPSSVSASVGDRVTITCRASQDISSW 56E4 LAWYQQKPGKAPKFLIYDASTLQSGVPSRFS GSGSGADFTLTINNLQPEDFATYYCQQTNSF PPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQL KSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 56C11 L64 81 SYVLTQPPSVSVAPGQAARITCGGNDIGSKS VHWYQQKPGQAPVLVVYDDSDRPSGIPERF SGSKSGNTATLIISRVEAGEEADYYCQVWDS SSDVVFGGGTKLTVLGQPKANPTVTLFPPSS EELQANKATLVCLISDFYPGAVTVAWKADG SPVKAGVETTKPSKQSNNKYAASSYLSLTPE QWKSHRSYSCQVTHEGSTVEKTVAPTECS 56E7 L86 82 DLQMTQSPSSLSASVGDRVTITCQASQDIKK FLNWYQQKPGKAPNLLIYDASNLETGVPSRF SGSGSGTDFTFTISSLQPEDIATYYCQQYAILP FTFGPGTTVDIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 56G1 L76 83 DIQMTQSPSSLSASVGDRVTITCRASQSISNY LNWFLQIPGKAPKLLIYAASSLQSGVPSRFSG SGSGTDFTLTINSLQPEDFGTYYCQQSSTIPW TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 56G3.3 L81 84 EIVLTQSPGTLSLSPGERATLSCRASQSVSRD 55B10 YLAWYRQKPGQAPRLLVYGASARATGIPDR FSGSGSGTDFTLTISRLEPEDFAVYYCQQYGR SLFTFGPGTKVDIKRTVAAPSVFIFPPSDEQL KSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 57B12 L72 85 DIQMTQSPSSLSVSVGDRVTITCRASHDISNY LAWFQQKPGKAPKSLIYAASSLQSGVPSKFS GSGSGTDFTLTISSLQPEDFATYYCQQYNTYP RTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 57D9 L87 86 EIVLTQSPGTLSLSPGERATLSCRASPSVSSSY LAWYQQKPAQAPRLLIYGASSRATGIPDRFS GSGSGTDFTLTISRLEPEDFAVYYCHQYGTSP CSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 59A10 L48 87 DIQMTQSPSSVSASVGDRVTITCRASQGISSW 49H4 LAWYQQKPGKAPKLLIYGASSLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQTNSFP PWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 59C9 L50 88 DIQMTQSPSSVSASVGDRVTITCRASQDIDS 58A5 WLVWYQQKPGKAPNLLIYAASNLQRGVPSR 57A4 FSGSGSGTDFTLTIASLQPEDFATYYCQQTNS 57F9 FPPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQ LKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 59G10.2 L60 89 SYELSQPPSVSVSPGQTVSITCSGDNLGDKYA CWYQQRPGQSPVLVIYQDTKRPSGIPERFSG SNSGNTATLTISGTQAMDEADYYCQAWDSS TTWVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 59G10.3 L54 90 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGDN YVSWYQQFPGTAPKLLIYDNNKRPSGIPDRF SGSKSGTSATLGITGLQTGDEADYYCGTWDS SLSVMVFGGGTKLTVLGQPKANPTVTLFPPS SEELQANKATLVCLISDFYPGAVTVAWKAD GSPVKAGVETTKPSKQSNNKYAASSYLSLTP EQWKSHRSYSCQVTHEGSTVEKTVAPTECS 60D7 L69 91 DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSD DGDTYLDWYLQKPGQSPQLLIYTLSYRASG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQRIEFPLTFGGGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRG EC 60F9 L58 92 EIMLTQSPGTLSLSPGERATLSCRASQRVPSS 48B4 YIVWYQQKPGQAPRLLIYGSSNRATGIPDRF 52D6 SGSGSGTDFTLTIGRLEPEDFAVYYCQQYGS SPPWTFGQGTKVAIKRTVAAPSVFIFPPSDEQ LKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 60G5.2 L46 93 SYELTQPPSVSVSPGQTASITCSGNKLGDKY VCWYQQKPGQSPVLVIYQDSKRPSGIPERFS GSNSGNTATLTISGTQALDEADYYCQAWDS STWVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 61G5 L59 94 EIMLTQSPGTLSLSPGERATLSCRASQRVPSS YLVWYQQKPGQAPRLLIYGASNRATGIPDRF SGSGSGTDFTLTIGRLEPEDFAVYYCQQYGS SPPWTFGQGTKVAIKRTVAAPSVFIFPPSDEQ LKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 52C5 L73 95 DIQMTQSPSSLSASIGDRVTITCRASQSISNYL NWFQQIPGKAPRLLIYAASSLQSGVPSRFSGS GSGTDFTLTISSLQPEDFAIYYCQQSSSIPWTF GQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA SVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC 61H5 L88 96 EIVLTQSPGTLSLSPGERATLSCRASQSVSRD 52B9 YLAWYRQKPGQAPRLLIYGASSRATGIPDRF SGSGSGTDFTLTISRLEPEDFAVYYCQQYGRS LFTFGPGTTVDIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 59D10v1 L56 97 SYELTQPPSVSVSPGQTARITCSGDAVPKKY ANWYQQKSGQAPVLVIYEDSKRPSGIPERFS GSSSGTMATLTISGAQVEDEADYYCYSTDSS GNHVVFGGGTKLTVLGQPKANPTVTLFPPSS EELQANKATLVCLISDFYPGAVTVAWKADG SPVKAGVETTKPSKQSNNKYAASSYLSLTPE QWKSHRSYSCQVTHEGSTVEKTVAPTECS 59D10v2 L57 98 SYELTQPPSVSVSPGQTASITCSGDKLGDKY VCWYQQMPGQSPVLVIHQNNKRPSGIPERFS GSNSGNTATLTISGTQAMDEADYYCQAWDS STAVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 56G3.2 L85 99 ETVMTQSPATLSVSPGERATLSCRARQSVGS NLIWYQQKPGQAPRLLIFGASSRDTGIPARFS GSGSGTEFTLTISSLQSEDFAVYYCQQYNNW PLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 68G5 L13 100 SYELTQPLSVSVALGQTARLTCGGNNIGSIN VHWYQQKPGQAPVLVIYRDRNRPSGIPERFS GSNSGNTATLTISRAQAGDEADYYCQLWDS STVVFGGGTKLTVLGQPKANPTVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADGS PVKAGVETTKPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS 60G5.1 L74 1843 DIQMTQSPSSLSASIGDRVTITCRASQSISNYL NWFQQIPGKAPRLLIYAASSLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQSSSIPWT FGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC 48G4 L89 101 EIVLTQSPGTLSLSPGERATLSCRASQSVASS 53C3.1 YLVWYQQKPGQAPRLLIYGAFSRATGIPDRF SGSGSGTDFTLTIRRLEPEDFAVYYCQQYGT SPFTFGPGTKVDLKRTVAAPSVFIFPPSDEQL KSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC 50G1 L90 102 DIVMTQTPLSLPVSPGEPASISCRSSQSLLDSD DGDTYLDWYLQKPGQSPQLLIYTLSYRASG VPDRFSVSGSGTDFTLKISRVEAEDVGVYYC MQRIEFPLTFGGGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRG EC 58C2 L91 103 EIVMTQTPLSLPVTPGEPASISCRSSQSLFDND DGDTYLDWYLQKPGQSPQLLIYTLSYRASG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQRLEFPITFGQGTRLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRG EC 50D4 L92 104 DIQMTQSPSSLSASVGDRVTITCRASQDISNY LAWYQQKPGKVPTLLIYAASTLLSGVPSRFS GSGSGTDFTLTISSLQPEDVAAYYCQKYYSA PFTFGPGTKVDINRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 50G5v1 L93 105 DIQMTQSPSSLSASVGDRVTITCRASQGIRND LGWYQQKPGKAPNRLIYAASSLQSGVPSRFS GSGSGTEFTLTISSLQPEDFATYYCLQHNSYP RTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 50G5v2 L94 106 DVVMTQCPLSLPVTLGQPASISCRSSQRLVY SDGNTYLNWVQQRPGQSPRRLIYKVSNWDS GVPDRFSGSGSGTDFTLKISRVEAEDVGVNY CMEGTHWPRDFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQW KVDNALQSGNSQESVTEQDSKDSTYSLSSTL TLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC 51C1 L95 107 DIQMTQSPSSLSASIGDRVTITCRASQSISNYL NWFQQIPGKAPRLLIYAASSLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQSSSIPWT FGQGTTVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC 53C3.2 L96 108 DIVMTQSPATLSVSPGERATLSCRASQSISSN LAWYQQTPGQAPRLLIYGTSIRASTIPARFSG SGSGTEFTLTISSLQSEDFAIYYCHQYTNWPR TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 54H10.3 L97 109 DIQMTQSPSSLSASVGDRVTITCRASQTISIYL NWYQQKPGKAPKFLIYSASSLQSGVPSRFSG SGSGTDFTLTISSLQPEDFSTYFCQQSYSSPLT FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC 55A7 L98 110 DIQMTQSPSSLSASVGDRVTITCRASQSISSYL NWYQQKPGKAPKLLIYAASSLQSGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQTYSAPF TFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC 55E6 L99 111 EIVLTQSPGTLSLSPGERATLSCRASQSVSRS HLAWYQQNSGQAPRLLIYGASSRATGIPDRF SGSGSGTDFTLTISRLEPEDFAVYYCQQYGSS PWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC 61E1 L100 112 DIQMTQSPSSLSASIRDRVTITCRASQSIGTFL NWYQQKPGTAPKLLIYAASSLQSGVPSRFSG SGSGTDFTLTISSLHPEDFASYYCQQSFSTPLT FGGGTKVEITRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC

TABLE 1B Exemplary Antibody Heavy Chain Sequences SEQ Contained ID in Clone Designation NO: Amino Acid Sequence 63E6 H6 113 QVQLMQSGAEVKKPGASVKVSCKASGYTFTG 66F7 YYMHWVRQAPGQGLEWMGWMNPNSGATKY AQKFQGRVTMTRDTSISTAYMELSRLRSDDTA VYYCARELGDYPFFDYWGQGTLGIVSSASTKG PSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCV ECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK 66D4 H17 114 QVQLVQSGAEVKKPGASVKVSCRASGYTFTG YYIHWMRQAPGHGLEWMGWINPPSGATNYA QKFRGRVAVTRDTSISTVYMELSRLRSDDTAV YYCARETGTWNFFDYWGQGTLVTVSSASTKG PSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCV ECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK 66B4 H10 115 QVQLVQSGAEVKKPGASVKVSCKASGYTFTG YYLHWVRQAPGQGLEWMGWINPNSGGTDYA QKFQGRVTMTRDTSISTAYMELSRLRSDDTAV YYCVGDAATGRYYFDNWGQGTLVTVSSASTK GPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSNFGTQTYTCNVDHKPSNTKVDKTVERKC CVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYK CKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK 65B1 H18 116 QVQLVQSGAEVKRPGASVKVSCKASGYTFTG YFMHWVRQAPGQGLEWMGWINPNSGATNYA QKFHGRVTMTRDTSITTVYMELSRLRSDDTAV YYCTRELGIFNWFDPWGQGTLVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 65B4 H20 117 EVQLVESGGGLVQPGGSLRLSCAASGFAFSSY DMHWVRQATGKGLEWVSTIDTAGDAYYPGSV KGRFTISRENAKTSLYLQMNSLRAGDTAVYYC TRDRSSGRFGDFYGMDVWGQGTAVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 67A4 H19 118 EVQLEESGGGLVQPGGSLRLSCAASGFTFRTYD MHWVRQVTGKGLEWVSAIGIAGDTYYSDSVK GRFTISRENAKNSLYLQMNSLRVGDTAVYYCA RDRSSGRFGDYYGMDVWGQGTTVTVSSASTK GPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSNFGTQTYTCNVDHKPSNTKVDKTVERKC CVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYK CKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK 63A10v1 H21 119 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNA 63A10v2 WMSWVRQAPGKGLEWVGRIKSKTDGGTTDY 63A10v3 AAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTA VYYCTTDSSGSYYVEDYFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTV ERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTFRVVSVLTVVHQDWLN GKEYKCKVSNKGLPAPIEKTISKTKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPMLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 65H11v1 H22 120 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNA 65H11v2 WMSWVRQAPGKGLEWVGRIIGKTDGGTTDYA APVKGRFTISRDDSKNTLYLQMNSLKTEDTAV YYCTSDSSGSYYVEDYFDYWGQGTLVAVSSAS TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 67G10v1 H9 121 EVQLVESGGGLVKPGGSLRLACAASGITFNNA 67G10v2 WMSWVRQAPGKGLEWVGRIKSKTDGGTTDY AAPVKGRFTISRDDSKSILYLQMNSLKSEDTAV YYCTTDSSGSYYVEDYFDYWGQGTLVTVSSAS TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 64C8 H23 122 QVQLVESGGGVVQPGRSLRLSCVASGFTFSSY GMHWVRQDPGKGLEWVAVISYDGSNKHYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARELLWFGEYGVDHGMDVWGQGTTVTVS SASTKGPSVFPLAPCSRSTSESTAALGCLVKDY FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKT VERKCCVECPPCPAPPVAGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTFRVVSVLTVVHQDWL NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPMLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 63G8v1 H1 123 QAQLVESGGGVVQPGRSLRLSCAASGFTFSSY 63G8v2 GIHWVRQAPGKGLEWVAVISYDGSNKYYADS 63G8v3 VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY 68D3v1 CATTVTKEDYYYYGMDVWGQGTTVTVSSAST 64A8 KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP 67B4 VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 68D3v2 H95 1844 QAQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGKGLEWVAFISYAGSNKYY ADSVKGRFTISRDNSKNTLYLQMSSLRAEDTA VYYCATTVTEEDYYYYGMDVWGQGTTVT VSSASTKGPSVFPLAPCSRSTSESTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKV DKTVERKCCVECPPCPAPPVAGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPMLDSDGSFFLYSK LTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK 66G2 H11 124 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGKGLEWVAGISYDGSNKNYAD SVKGRITISRDNPKNTLYLQMNSLRAEDTAVY YCATTVTKEDYYYYGMDVWGQGTTVTVSSAS TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 65D1 H26 125 QVQLVESGGGVVQPGRSLRLSCAASGFTFSYY YIHWVRQAPGKGLEWVALIWYDGSNKDYADS VKGRFTISRDNSKNTLYLHVNSLRAEDTAVYY CAREGTTRRGFDYWGQGTLVTVSSASTKGPSV FPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS NFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 64H5 H7 126 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGKGLEWVAVIWDDGSNKYYAD SVKGRFTISRDNSKNTLSLQMNSLRAEDTAVY YCAREYVAEAGFDYWGQGTLVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 65D4 H25 127 QEQLVESGGGVVQPGRSLRLSCAVSGFTFSFYG MHWVRQAPGKGLEWVAVIWYDGSNKYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CTRALNWNFFDYWGQGTLVTVSSASTKGPSVF PLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSN FGTQTYTCNVDHKPSNTKVDKTVERKCCVECP PCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVQFNWYVDGVEVHNAKTKPRE EQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK 65E3 H24 128 QVQLVESGGGVVQPGRSLRLSCAASGFTLSNY NMHWVRQAPGKGLEWVAVLWYDGNTKYYA DSVKGRVTISRDNSKNTLYLQMNSLRAEDTAV YYCARDVYGDYFAYWGQGTLVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 65G4 H8 129 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGKGLEWVAVIWDDGSNKYY ADSVKGRFTISRDNSKNTLSLQMNSLRAEDTA VYYCAREYVAEAGFDYWGQGTLVTVSSASTK GPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSNFGTQTYTCNVDHKPSNTKVDKTVERKC CVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYK CKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK 68G5 H12 130 QVQLVESGGGVVQPGRSLRLSCTASGFTFSSYG MHWVRQAPGKGLEWVAVIWYDGSNKYHADS VKGRFTISRDDSKNALYLQMNSLRAEDTAVYY CVRDPGYSYGHFDYWGQGTLVTVSSASTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 67G8 H27 131 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGKGLEWVAVIWYDGSNKDYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARSAVALYNWFDPWGQGTLVTVSSASTKG PSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCV ECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK 65B7v1 H28 132 QVQLQESGPGLVNPSQTLSLTCTVSGGSISSDA 65B7v2 YYWSWIRQHPGKGLEWIGYIFYSGSTYYNPSL KSRVTISVDTSKNRFSLKLSSVTAADTAVYYCA RESRILYFNGYFQHWGQGTLVTVSSASTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 63B6 H4 133 QVQLQESGPGLVKPSQTLSLTCAVSGGSISSGD 64D4 YYWSWIRQHPGKGLEWIGYIYYSGTTYYNPSL KSRVTISVDTSKNQFSLKLTSVTAADTAVYYC ARMTTPYWYFGLWGRGTLVTVSSASTKGPSVF PLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSN FGTQTYTCNVDHKPSNTKVDKTVERKCCVECP PCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVQFNWYVDGVEVHNAKTKPRE EQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK 63F5 H13 134 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGD YYWTWIRQHPGKDLEWITYIYYSGSAYYNPSL KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCA RMTTPYWYFDLWGRGTLVTVSSASTKGPSVFP LAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF GTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 63H11 H3 135 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGD YYWTWIRQHPGKGLEWIAYIYYSGSTYYNPSL KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCA RMTTPYWYFDLWGRGTLVTVSSASTKGPSVFP LAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF GTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 64E6 H2 136 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGD 65E8 YYWTWIRQHPGKGLEWIAYIYYTGSTYYNPSL 65F11 KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCA 67G7 RMTTPYWYFDLWGRGTLVTVSSASTKGPSVFP LAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF GTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 65C1 H15 137 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGD YYWTWIRQHPGKGLEWIAYIFYSGSTYYNPSL KSRVTISLDTSKNQFSLKLNSVTAADTAVYYC ARMTSPYWYFDLWGRGTLVTVSSASTKGPSVF PLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSN FGTQTYTCNVDHKPSNTKVDKTVERKCCVECP PCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVQFNWYVDGVEVHNAKTKPRE EQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK 66F6 H14 138 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGD YYWTWIRHHPGKGLEWIAYIYYSGSTYYNPSL KSRVTISVDTSKNQFSLKLNSVTAADTAVYYC ARMTTPYWYFDLWGRGTLVTVSSASTKGPSVF PLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSN FGTQTYTCNVDHKPSNTKVDKTVERKCCVECP PCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVQFNWYVDGVEVHNAKTKPRE EQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK 64A6 H29 139 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGG YYWSWIRQRPGKGLEWVGYIYYSGGTHYNPS LKSRVTISIDTSENQFSLKLSSVTAADTAVYYC ARVLHYSDSRGYSYYSDFWGQGTLVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 65F9 H30 140 QVQLQESGPGLVKPSQTLSLTCTLSGGSFSSGD YYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSL KSRVTISIDTSKNQFSLKLTSVTAADTAVYYCA RVLHYYDSSGYSYYFDYWGQGTLVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 64A7 H16 141 QLQLQESGPGLVKPSETLSLTCTVSGGSISSDTS YWGWIRQPPGKGLEWIGNIYYSGTTYFNPSLK SRVSVSVDTSKNQFSLKLSSVTAADTAVFYCA RLRGVYWYFDLWGRGTLVTVSSASTKGPSVFP LAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF GTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 65C3 H5 142 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYY 68D5 WSWIRQPPGKGLEWIGYIYYTGSTNYNPSLKSR VTISVDTSKNQFSLKLSSVTAADTAVYYCARE YYYGSGSYYPWGQGTLVTVSSASTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFG TQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 67F5 H31 143 QVQLKESGPGLVKPSETLSLTCTVSGGSISSYY WSWIRQPPGKGLEWIGYIYYSGNTNYNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYCARE YYYGSGSYYPWGQGTLVTVSSASTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFG TQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 64B10v1 H32 144 QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDY YWSWIRQPPGKGLEWIGFIYYSGGTNYNPSLKS RVTISIDTSKNQFSLKLNSVTAADTAVYYCARY SSTWDYYYGVDVWGQGTTVTVSSASTKGPSV FPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS NFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 64B10v2 H96 1845 QVQLLESGPGLVKPSETLSLTCTVSGGSVSSGD YYWSWIRQPPGKGLEWIGFIYYSGGTNYNPPL KSRVTISIDTSKNQFSLKLSSVTAADTAVYYCA RYSSTWDYYYGVDVWGQGTTVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 68C8 H33 145 QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGD NYWSWIRQPPGKGLEWIGFMFYSGSTNYNPSL KSRVTISLHTSKNQFSLRLSSVTAADTAVYYCG RYRSDWDYYYGMDVWGQGTTVTVSSASTKG PSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCV ECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK 67A5 H34 146 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSY WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSF QGQVTISADKSINTAYLQWSSLKASDTAIYFCA RRASRGYRFGLAFAIWGQGTMVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 67C10 H35 147 EVQLVQSGAEVKKPGESLKISCQGSGYSFSSY WIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSF QGQVTISADKSINTAYLQWSSLKASDTAIYYCA RRASRGYRYGLAFAIWGQGTMVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 64H6 H36 148 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSY WIGWVRQMPGKGLEWMGIIYPGDSETRYSPSF QGQVTISADKSISTAYLQWNSLKTSDTAMYFC ATVAVSAFNWFDPWGQGTLVTVSSASTKGPSV FPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS NFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 63F9 H37 149 QVQLKESGPGLVKPSQTLSLTCTVSGGSISSGG YYWNWIRQHPGKGLEWIGYIYDSGSTYYNPSL KSRVTMSVDTSKNQFSLKLSSVTAADTAVYYC ARDVLMVYTKGGYYYYGVDVWGQGTTVTVS SASTKGPSVFPLAPCSRSTSESTAALGCLVKDY FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKT VERKCCVECPPCPAPPVAGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTFRVVSVLTVVHQDWL NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPMLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 67F6v1 H38 150 EVQLVQSGAEVKKPGESLKISCKGSGYSFTGY 67F6v2 WIGWVRQLPGKGLEWMGIIYPGDSDTRYSPSF QGQVTISVDKSINTAYLQWSSLKASDTAMYYC ARRASRGYSYGHAFDFWGQGTMVTVSSASTK GPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSNFGTQTYTCNVDHKPSNTKVDKTVERKC CVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYK CKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK 48C9 H73 151 QVQLQQWGAGLLKPSETLSLTCSVYGGSFSGY 49A12 YWTWIRQPPGKGLEWIGEINHSENTNYNPSLKS 51E2 RVTISIDTSKNQFSLKLSSVTAADTAVYYCARE SGNFPFDYWGQGTLVTVSSASTKGPSVFPLAPC SRSTSESTAALGCLVKDYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQT YTCNVDHKPSNTKVDKTVERKCCVECPPCPAP PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVQFNWYVDGVEVHNAKTKPREEQFN STFRVVSVLTVVHQDWLNGKEYKCKVSNKGL PAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK 48F3 H72 152 QVQLQQWGAGPLKPSETLSLTCAVYGGSISGY YWSWIRQPPGKGLEWIGEITHTGSSNYNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR GGILWFGEQAFDIWGQGTMVTVSSASTKGPSV FPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS NFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 48F8 H48 153 EVQLVESGGGLVKPGGSLRLSCTASGFTFRSYS 53B9 MNWVRQAPGKGLEWVSSISSSSSYEYYVDSVK 56B4 GRFTISRDIAKSSLWLQMNSLRAEDTAVYYCA 57E7 RSLSIAVAASDYWGKGTLVTVSSASTKGPSVFP 57F11 LAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF GTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 48H11 H39 154 QVQLVQSGAEVKKPGASVKVSCKASGYTFTG YYKHWVRQAPGQGLEWMGWINPNSGATKYA QKFQGRVTMTRDTSISTVYMELSRLRSVDTAL YYCAREVPDGIVVAGSNAFDFWGQGTMVTVS SASTKGPSVFPLAPCSRSTSESTAALGCLVKDY FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKT VERKCCVECPPCPAPPVAGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTFRVVSVLTVVHQDWL NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPMLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 49A10 H62 155 QVHLVESGGGVVQPGRSLRLSCAASGFTFSNY 48D4 GMHWVRQAPGKGLEWVAIIWYDGSNKNYAD SVKGRFTISRDNSKNTLYLEMNSLRAEDTAVY YCARDQDYDFWSGYPYFYYYGMDVWGQGTT VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKV DKTVERKCCVECPPCPAPPVAGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPMLDSDGSFFLYSK LTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK 49C8 H44 156 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSY 52H1 DIDWVRQATGQGLEWMGWMNPNGGNTGYA QKFQGRVTMTRNTSINTAYMELSSLRSEDTAIY YCARGKEFSRAEFDYWGQGTLVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 49G2 H63 157 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNY 50C12 GMRWVRQAPGKGLEWVALIWYDGSNKFYAD 55G11 SVKGRFTISRDNSKNTLNLQMNSLRAEDTAVY YCARDRYYDFWSGYPYFFYYGLDVWGQGTTV TVSSASTKGPSVFPLAPCSRSTSESTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKV DKTVERKCCVECPPCPAPPVAGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPMLDSDGSFFLYSK LTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK 49G3 H46 158 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPR MGVSWIRQPPGKALEWLTHIFSNDEKSYSTSLK SRLTISKDTSKSQVVLSMTNMDPVDTATYYCV RVDTLNYHYYGMDVWGQGTTVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 49H12 H42 159 QVQLVQSGAEVKKPGASVKVSCMASGYIFTSY DINWVRQATGQGPEWMGWMNPYSGSTGYAQ NFQGRVTMTRNTSINTAYMELSSLRSEDTAVY YCAKYNWNYGAFDFWGQGTMVTVSSASTKG PSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCV ECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK 51A8 H58 160 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGKGLEWVAVISYDGSNKYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARADGDYPYYYYYYGMDVWGQGTTVTVS SASTKGPSVFPLAPCSRSTSESTAALGCLVKDY FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKT VERKCCVECPPCPAPPVAGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTFRVVSVLTVVHQDWL NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPMLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 51C10.2 H67 161 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGG YYWSWIRQHPGKGLEWIGYIYYNGSPYDNPSL KRRVTISIDASKNQFSLKLSSMTAADTAVYYCA RGALYGMDVWGQGTTVTVSSASTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFG TQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 51E5 H74 162 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGY YWSWIRQPPGKGLEWIGELDHSGSINYNPSLKS RVTISVDTSKNQFSLKLTSVTAADTAVYYCAR VLGSTLDYWGQGTLVTVSSASTKGPSVFPLAP CSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQ TYTCNVDHKPSNTKVDKTVERKCCVECPPCPA PPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKG LPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK 51G2 H50 163 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS MNWVRQAPGKGLEWVSSISSSSTYIYYADSVK GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA RDTYISGWNYGMDVWGQGTTVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 52A8 H40 164 QVQLVQSGAEVKKPGASVKVSCKASGYTFTG YYLHWVRQAPGQGLEWMGWINPNSAATNYA PKFQGRVTVTRDTSISTAYMELSRLRSDDTAVY YCAREGGTYNWFDPWGQGTLVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 52B8 H77 165 QVQLQESGPGLMKPSETLSLTCTVSGGSISYYY WSWIRQSPGKGLEWIGYIYYSGSTNYNPSLKSR VTMSVDTSKNQFSLKLSSVTAADTAVYYCASG TRAFDIWGQGTMVTVSSASTKGPSVFPLAPCSR STSESTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYT CNVDHKPSNTKVDKTVERKCCVECPPCPAPPV AGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTF RVVSVLTVVHQDWLNGKEYKCKVSNKGLPAP IEKTISKTKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPP MLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 52C1 H64 166 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGKGLEWVAVIWYDGSNNYYAD SVKGRFTISRDNSKSTLFLQMNSLRAEDTAIYY CARDRAGASPGMDVWGQGTTVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 52F8 H41 167 QVQLVQSGAEVKKPGASVKVSCKASGFTFIGY YTHWVRQAPGQGLEWMGWINPSSGDTKYAQ KFQGRVTLARDTSISTAYMELSRLRSDDTAVY YCANSGWYPSYYYGMDVWGQGTTVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 52H2 H79 168 QVQLQESGPGLVKPSETLSLTCTVSGGSISTYY WSWIRQPPGTGLEWIGYIFYNGNANYSPSLKSR VTFSVDTSKNQFSLKLSSVTAADTAVYFCARET DYGDYARPFEYWGQGTLVTVSSASTKGPSVFP LAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF GTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 53F6 H60 169 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTY GMHWVRQAPGKGLEWVAVIWYDGSNKYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARGHYDSSGPRDYWGQGTLVTVSSASTKG PSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCV ECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK 53H5.2 H59 170 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGQGLEWVALISYDGSNKYYAD SVKGRFTISRDKSKNTLYLQMNSLRAEDTAVY YCAREANWGYNYYGMDVWGQGTTVTVSSAS TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 53H5.3 H75 171 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDY YWNWIRQPPGKGPEWIGEINHSGTTNYNPSLK SRVTISVDTSKNQFSLKLSSVTAADTAVYYCVG ILRYFDWLEYYFDYWGQGTLVTVSSASTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 54A1 H43 172 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSY 55G9 DINWVRQATGQGLEWMGWMNPHSGNTGYAQ KFQGRVTMTRNTSINTAYMELSSLRSEDTAVY YCAKYNWNYGAFDFWGQGTMVTVSSASTKG PSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCV ECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK 54H10.1 H52 173 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 55D1 MSWVRQAPGKGLEWVSAISGSGRTTYSADSV 48H3 KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC 53C11 AKEQQWLVYFDYWGQGTLVTVSSASTKGPSV FPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS NFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 55D3 H68 174 QVQLQESGPGLVKPSQTLSLTCTVSGGSITSGV YYWNWIRQHPGKGLEWIGYLYYSGSTYYNPS LKSRLTISADMSKNQFSLKLSSVTVADTAVYY CARDGITMVRGVTHYYGMDVWGQGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTV ERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTFRVVSVLTVVHQDWLN GKEYKCKVSNKGLPAPIEKTISKTKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPMLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 55E4 H70 175 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGY 52C5 YWSWIRQPPGKGLEWIGEINHSENTNYNPSLKS 60G5.1 RVTISLDTSNDQFSLRLTSVTAADTAVYYCARV 49B11 TGTDAFDFWGQGTMVTVSSASTKGPSVFPLAP 50H10 CSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL 53C1 TSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQ TYTCNVDHKPSNTKVDKTVERKCCVECPPCPA PPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKG LPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK 55E9 H65 176 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFG MHWVRQAPGKGLEWVALIWYDGDNKYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARNSGWDYFYYYGMDVWGQGTTVTVSSAS TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 55G5 H78 177 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYY WSWIRQPAGKGLEWIGRIYISGSTNYNPSLENR VTMSGDTSKNQFSLKLNSVTAADTAVYYCAG SGSYSFDYWGQGTLVTVSSASTKGPSVFPLAPC SRSTSESTAALGCLVKDYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQT YTCNVDHKPSNTKVDKTVERKCCVECPPCPAP PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVQFNWYVDGVEVHNAKTKPREEQFN STFRVVSVLTVVHQDWLNGKEYKCKVSNKGL PAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK 50G1 H84 178 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GLHWVRQAPGKGLEWVAVIWNDGSNKLYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARDQYYDFWSGYPYYHYYGMDVWGQGTT VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKV DKTVERKCCVECPPCPAPPVAGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPMLDSDGSFFLYSK LTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK 56A7 H51 179 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS 56E4 MNWVRQAPGKGLEWVSSISSSSTYIYYADSVK GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA RDIYSSGWSYGMDVWGQGTTVTVSSASTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 56C11 H61 180 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY GMHWVRQAPGKGLEWVAVIWYDGSYQFYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARDHVWRTYRYIFDYWGQGTLVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 56E7 H81 181 EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYW IGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ GQVTISADTSISTAYLQWSRLKASDTAVYYCA RAQLGIFDYWGQGTLVTVSSASTKGPSVFPLAP CSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQ TYTCNVDHKPSNTKVDKTVERKCCVECPPCPA PPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKG LPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK 56G1 H71 182 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGY YWSWIRQPPGKGLEWIGEINHSENTNYNPSLKS RVTISLDTSNKQFSLRLTSVTAADTAVYYCARV TGTDAFDFWGQGTMVTVSSASTKGPSVFPLAP CSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQ TYTCNVDHKPSNTKVDKTVERKCCVECPPCPA PPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKG LPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK 56G3.3 H76 183 QLQLQESGPGLVKPSETLSLTCTVSGDSISSSSY 55B10 YWGWIRQPPGKGLEWIGMIYYSGTTYYNPSLK SRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR VAAVYWYFDLWGRGTLVTVSSASTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFG TQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 57B12 H69 184 QVQLQESGPGLVKPSQTLSLTCTVSGGSITSGV YYWSWIRQLPGKGLEWIGYIYYSGSTYYNPSL KSRLTISADTSKNQFSLKLSSVTVADTAVYYCA RDGITMVRGVTHYYGMDVWGQGTTVTVSSAS TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 57D9 H82 185 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNS ATWNWIRQSPSRGLEWLGRTYYRSKWYNDYA VSVKSRITINPDTSKNQFSLQLNSVTPEDTAVY YCVGIVVVPAVLFDYWGQGTLVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 58C2 H85 186 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNY GMHWVRQAPGKGLEWVAVIWNDGNNKYYA DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDQNYDFWNGYPYYFYYGMDVWGQG TTVTVSSASTKGPSVFPLAPCSRSTSESTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNT KVDKTVERKCCVECPPCPAPPVAGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTFRVVSVLTVVH QDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQ PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPMLDSDGSFFLY SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK 59A10 H47 187 QVQVVESGGGLVKPGGSLRLSCAASGFTFSDS 49H4 YMSWIRQAPGKGLEWISSISSSGSIVYFADSVK GRFTISRDIAKNSLYLHMNSLRAEDTAVYYCA RETFSSGWFDAFDIWGQGTMVTVSSASTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 59C9 H49 188 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS 58A5 MSWVRQAPGKGLEWVSSISSSSTYIYYADSLK 57A4 GRFTISRDNAKNSLFLQVNSLRAEDSAVYYCA 57F9 RDRWSSGWNEGFDYWGQGTLVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 59G10.2 H57 189 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNY GMHWVRQAPGKGLEWVAITSYGGSNKNYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCAREAGYSFDYWGQGTLVTVSSASTKGPSVF PLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSN FGTQTYTCNVDHKPSNTKVDKTVERKCCVECP PCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVQFNWYVDGVEVHNAKTKPRE EQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK 59G10.3 H53 190 EVQLLGSGGGLVQPGGSLRLSCAASGFTFNHY AMSWVRQAPGKGLEWVSAISGSGAGTFYADS MKGRFTISRDNSENTLHLQMNSLRAEDTAIYY CAKDLRIAVAGSFDYWGQGTLVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 60D7 H66 191 QVQLVESGGGVVQPGRSLRLSCAASGFNFSSY GMHWVRQAPGKGLEWVAVIWYDGSNKYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVF YCARDQYFDFWSGYPFFYYYGMDVWGQGTT VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKV DKTVERKCCVECPPCPAPPVAGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPMLDSDGSFFLYSK LTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK 60F9 H55 192 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 48B4 MSWVRQAPGKGLEWVSVISDSGGSTYYADSV 52D6 KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKDHSSGWYYYGMDVWGQGTTVTVSSASTK GPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSNFGTQTYTCNVDHKPSNTKVDKTVERKC CVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYK CKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK 60G5.2 H45 193 QVQLVQSGAEVKTPGASVRVSCKASGYTFTNY GISWVRQAPGQGLEWMGWISAYNGYSNYAQK FQDRVTMTTDTSTSTAYMELRSLRSDDTAVYY CAREEKQLVKDYYYYGMDVWGQGSTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTV ERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTFRVVSVLTVVHQDWLN GKEYKCKVSNKGLPAPIEKTISKTKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPMLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 61G5 H56 194 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA MSWVRQSPGKGLEWVSVISGSGGDTYYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKDHTSGWYYYGMDVWGQGTTVTVSSASTK GPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSNFGTQTYTCNVDHKPSNTKVDKTVERKC CVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYK CKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK 59D10v1 H54 195 EVQLLESGGGLVQPGGSLRLSCAASGFTFRNY 59D10v2 AMSWVRQAPGKGLEWVSGISGSSAGTYYADS 51C10.1 VKGRFTISRDNSKNTLFLQMDSLRAEDTAVYY CAQDWSIAVAGTFDYWGQGTLVTVSSASTKG PSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCV ECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK 56G3.2 H80 196 QVQLQESGPGLVKPSETLSLTCTVSDGSISSYY WNWIRQPAGKGLEWIGRIYTSGSTNYNPSLKS RVTMSVDTSKNQFSLNLTSVTAADTAVYYCAR GPLWFDYWGQGTLVTVSSASTKGPSVFPLAPC SRSTSESTAALGCLVKDYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQT YTCNVDHKPSNTKVDKTVERKCCVECPPCPAP PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVQFNWYVDGVEVHNAKTKPREEQFN STFRVVSVLTVVHQDWLNGKEYKCKVSNKGL PAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK 48G4 H83 197 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTEL 53C3.1 SIHWVRQAPGKGLEWMGGFDPEDGETIYAQKF QGRVTMTEDTSTDTAYMELSSLRSEDTAVYYC ATHSGSGRFYYYYYGMDVWGQGTTVTVSSAS TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 61H5 H86 198 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSY 52B9 YWGWIRQPPGKGLEWIGSIYYSGTTYYNPSLK SRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR VAAVYWYFDLWGRGTLVTVSSASTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFG TQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN KGLPAPIEKTISKTKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 50D4 H87 199 QVQLVQSGAEVKKTGASVKVSCKASGYTFTSH DINWVRQATGHGLEWMGWMNPYSGSTGLAQ RFQDRVTMTRNTSISTAYMELSSLRSEDTAVY YCARDLSSGYYYYGLDVWGQGTTVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 50G5v1 H88 200 QVQLVQSGAEVKKPGASVKVSCKASGYPFIGY 50G5v2 YMHWVRQAPGQGLEWMGWINPDSGGTNYAQ KFQGRVTMTRDTSITTAYMELSRLRSDDTAVF YCARGGYSYGYEDYYGMDVWGQGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTV ERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTFRVVSVLTVVHQDWLN GKEYKCKVSNKGLPAPIEKTISKTKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPMLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 51C1 H89 201 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGY YWSWIRQPPGKGLEWIGEINHSENTNYNPSLKS RVTISLDTSHDQFSLRLTSVTAADTAVYYCARV TGTDAFDFWGQGTMVTVSSASTKGPSVFPLAP CSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQ TYTCNVDHKPSNTKVDKTVERKCCVECPPCPA PPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKG LPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK 53C3.2 H90 202 QVQLQESGPGLVKPSQTLSLTCTVSNGSINSGN YYWSWIRQHPGKGLEWIGYIYHSGSAYYNPSL KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCA RTTGASDIWGQGIMVTVSSASTKGPSVFPLAPC SRSTSESTAALGCLVKDYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQT YTCNVDHKPSNTKVDKTVERKCCVECPPCPAP PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVQFNWYVDGVEVHNAKTKPREEQFN STFRVVSVLTVVHQDWLNGKEYKCKVSNKGL PAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK 54H10.3 H91 203 QVQVVQSGTEVKKPGASVKVSCKASGYTFTG YYIHWVRQAPGQGLEWMGWINPNSGGTNYA QKFRGRVTMTRDTSISTAYMELSRLRSDDTAV YYCAREEDYSDHHYFDYWGQGTLVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 55A7 H92 204 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYY WSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSR VTISVDTSKNQFSLRLSSVTAADTAVYYCARGI TGTIDFWGQGTLVTVSSASTKGPSVFPLAPCSR STSESTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYT CNVDHKPSNTKVDKTVERKCCVECPPCPAPPV AGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTF RVVSVLTVVHQDWLNGKEYKCKVSNKGLPAP IEKTISKTKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPP MLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 55E6 H93 205 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYS MNWVRQAPGKGLEWISYISSGSSTIYHADSVK GRFTISRDNAKNSLYLQMNSLRDEDTAVYYCA REGYYDSSGYYYNGMDVWGQGTTVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKE YKCKVSNKGLPAPIEKTISKTKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 61E1 H94 206 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNS AAWNWIRQSPSRGLEWLGRTYYRSKWYNDY AVSVKSRITITPDTSKNQFSLQLKSVTPEDTAIY YCAREGSWSSFFDYWGQGTLVTVSSASTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SNFGTQTYTCNVDHKPSNTKVDKTVERKCCVE CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCK VSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

Each of the exemplary heavy chains (H1, H2, H3 etc.) listed in Table 1B, infra, can be combined with any of the exemplary light chains shown in Table 1A, infra, to form an antibody. Examples of such combinations include H1 combined with any of L1 through L100; H2 combined with any of L1 through L100; H3 combined with any of L1 through L100, and so on. In some instances, the antibodies include at least one heavy chain and one light chain from those listed in Tables 1A and 1B, infra; particular examples pairings of light chains and heavy chains include L1 with H1, L2 with H1, L3 with H2 or H3, L4 with H4, L5 with H5, L6 with H6, L7 with H6, L8 with H7 or H8, L9 with H9, L10 with H9, L11 with H10, L12 with H11, L13 with H12, L13 with H14, L14 with H13, L15 with H14, L16 with H15, L17 with H16, L18 with H17, L19 with H18, L20 with H19, L21 with H20, L22 with H21, L23 with H22, L24 with H23, L25 with H24, L26 with H25, L27 with H26, L28 with H27, L29 with H28, L30 with H29, L31 with H30, L32 with H31, L33 with H32, L34 with H33, L35 with H34, L36 with H35, L37 with H36, L38 with H37, L39 with H38, L40 with H39, L41 with H40, L42 with H41, L43 with H42, L44 with H43, L45 with H44, L46 with H45, L47 with H46, L48 with H47, L49 with H48, L50 with H49, L51 with H50, L52 with H51, L53 with H52, L54 with H53, L55 with H54, and L56 with H54, L57 with H54, L58 with H55, L59 with H56, L60 with H57, L61 with H58, L62 with H59, L63 with H60, L64 with H1, L65 with H62, L66 with H63, L67 with H64, L68 with H65, L69 with H66, L70 with H67, L71 with H68, L72 with H69, L73 with H70, L74 with H70, and L75 with H70, L76 with H71, L77 with H72, L78 with H73, L79 with H74, L80 with H75, L81 with H76, L82 with H77, L83 with H78, L84 with H79, L85 with H80, L86 with H81, L87 with H82, L88 with H86, L89 with H83, L90 with H84, L91 with H85, L92 with H87, L93 with H88, L94 with H88, L95 with H89, L96 with H90, L97 with H91, L98 with H92, L99 with H93, and L100 with H94. In addition to antigen binding proteins comprising a heavy and a light chain from the same clone, a heavy chain from a first clone can be paired with a light chain from a second clone (e.g., a heavy chain from a first clone paired with a light chain from a second clone or a heavy chain from a first clone paired with a light chain from a second clone). Generally, such pairings can include VL with 90% or greater homology can be paired with the heavy chain of the naturally occurring clone.

In some instances, the antibodies comprise two different heavy chains and two different light chains listed in Tables 1A and 1B, infra. In other instances, the antibodies contain two identical light chains and two identical heavy chains. As an example, an antibody or immunologically functional fragment can include two L1 light chains with two H1 heavy chains, two L2 light chains with two H1 heavy chains, two L3 light chains with two H2 heavy chains or two H3 heavy chains, two L4 light chains with two H4 heavy chains, two L5 light chains with two H5 heavy chains, two L6 light chains with two H6 heavy chains, two L7 light chains with two H6 heavy chains, two L8 light chains with two H7 heavy chains or two H8 heavy chains, two L9 light chains with two H9 heavy chains, two L10 light chains with two H9 heavy chains, two L11 light chains with two H10 heavy chains, two L12 light chains with two H11 heavy chains, two L13 light chains with two H12 heavy chains, two L13 light chains with two H14 heavy chains, two L14 light chains with two H13 heavy chains, two L15 light chains with two H14 heavy chains, two L16 light chains with two H15 heavy chains, two L17 light chains with two H16 heavy chains, two L18 light chains with two H17 heavy chains, two L19 light chains with two H18 heavy chains, two L20 light chains with two H19 heavy chains, two L21 light chains with two H20 heavy chains, two L22 light chains with two H21 heavy chains, two L23 light chains with two H22 heavy chains, two L24 light chains with two H23 heavy chains, two L25 light chains with two H24 heavy chains, two L26 light chains with two H25 heavy chains, two L27 light chains with two H26 heavy chains, two L28 light chains with two H27 heavy chains, two L29 light chains with two H28 heavy chains, two L30 light chains with two H29 heavy chains, two L31 light chains with two H30 heavy chains, two L32 light chains with two H31 heavy chains, two L33 light chains with two H32 heavy chains, two L34 light chains with two H33 heavy chains, two L35 chains with two H34 heavy chains, two L36 chains with two H35 heavy chains, two L37 light chains with two H36 heavy chains, two L38 light chains with two H37 heavy chains, two L39 light chains with two H38 heavy chains, two L40 light chains with two H39 heavy chains, two L41 light chains with two H40 heavy chains, two L42 light chains with two H41 heavy chains, two L43 light chains with two H42 heavy chains, two L44 light chains with two H43 heavy chains, two L45 light chains with two H44 heavy chains, two L46 light chains with two H45 heavy chains, two L47 light chains with two H46 heavy chains, two L48 light chains with two H47 heavy chains, two L49 light chains with two H48 heavy chains, two L50 light chains with two H49 heavy chains, two L51 light chains with two H50 heavy chains, two L52 light chains with two H51 heavy chains, two L53 light chains with two H52 heavy chains, two L54 light chains with two H53 heavy chains, two L55 light chains with two H54 heavy chains, and two L56 light chains with two H54 heavy chains, two L57 light chains with two H54 heavy chains, two L58 light chains with two H55 heavy chains, two L59 light chains with two H56 heavy chains, two L60 light chains with two H57 heavy chains, two L61 light chains with two H58 heavy chains, two L62 light chains with two H59 heavy chains, two L63 light chains with two H60 heavy chains, two L64 light chains with two H1 heavy chains, two L65 light chains with two H62 heavy chains, two L66 light chains with two H63 heavy chains, two L67 light chains with two H64 heavy chains, two L68 light chains with two H65 heavy chains, two L69 light chains with two H66 heavy chains, two L70 light chains with two H67 heavy chains, two L71 light chains with two H68 heavy chains, two L72 light chains with two H69 heavy chains, two L73 light chains with two H70 heavy chains, two L74 light chains with two H70 heavy chains, and two L75 light chains with two H70 heavy chains, two L76 light chains with two H71 heavy chains, two L77 light chains with two H72 heavy chains, two L78 light chains with two H73 heavy chains, two L79 light chains with two H74 heavy chains, two L80 light chains with two H75 heavy chains, two L81 light chains with two H76 heavy chains, two L82 light chains with two H77 heavy chains, two L83 light chains with two H78 heavy chains, two L84 light chains with two H79 heavy chains, two L85 light chains with two H80 heavy chains, two L86 light chains with two H81 heavy chains, two L87 light chains with two H82 heavy chains, two L88 light chains with two H86 heavy chains, two L89 light chains with two H83 heavy chains, two L90 light chains with two H84 heavy chains, two L91 light chains with two H85 heavy chains, two L92 light chains with two H87 heavy chains, two L93 light chains with two H88 heavy chains, two L94 light chains with two H88 heavy chains, two L95 light chains with two H89 heavy chains, two L96 light chains with two H90 heavy chains, two L97 light chains with two H91 heavy chains, two L98 light chains with two H92 heavy chains, two L99 light chains with two H93 heavy chains, and two L100 light chains with two H94 heavy chains, as well as other similar combinations of pairs comprising the light chains and pairs of heavy chains as listed in Tables 1A and 1B, infra.

In another aspect of the instant disclosure, “hemibodies” are provided. A hemibody is a monovalent antigen binding protein comprising (i) an intact light chain, and (ii) a heavy chain fused to an Fc region (e.g., an IgG2 Fc region of SEQ ID NO: 11), optionally via a linker, The linker can be a (G₄S)_(x) linker (SEQ ID NO: 207) where “x” is a non-zero integer (e.g., (G₄S)₂, (G₄S)₃, (G₄S)₄, (G₄S)₅, (G₄S)₆, (G₄S)₇, (G₄S)₈, (G₄S)₉, (G₄S)₁₀; SEQ ID NOS: 208-216, respectively). Hemibodies can be constructed using the provided heavy and light chain components.

Other antigen binding proteins that are provided are variants of antibodies formed by combination of the heavy and light chains shown in Tables 1A and 1B, infra and comprise light and/or heavy chains that each have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequences of these chains. In some instances, such antibodies include at least one heavy chain and one light chain, whereas in other instances the variant forms contain two identical light chains and two identical heavy chains.

Variable Domains of Antigen Binding Proteins

Also provided are antigen binding proteins that contain an antibody heavy chain variable region selected from the group consisting of V_(H)1, V_(H)2, V_(H)3, V_(H)4, V_(H)5, V_(H)6, V_(H)7, V_(H)8, V_(H)9, V_(H)10, V_(H)11, V_(H)12, V_(H)13, V_(H)14, V_(H)15, V_(H)16, V_(H)17, V_(H)18, V_(H)19, V_(H)20, V_(H)21 V_(H)22, V_(H)23, V_(H)24, V_(H)25, V_(H)26, V_(H)27, V_(H)28, V_(H)29, V_(H)30, V_(H)31, V_(H)32, V_(H)33, V_(H)34, V_(H)35, V_(H)36, V_(H)37, V_(H)38, V_(H)39, V_(H)40, V_(H)41, V_(H)42, V_(H)43, V_(H)44, V_(H)45, V_(H)46, V_(H)47, V_(H)48, V_(H)49, V_(H)50, V_(H)51, V_(H)52, V_(H)53, V_(H)54, V_(H)55, V_(H)56, V_(H)57, V_(H)58, V_(H)59, V_(H)60, V_(H)61, V_(H)62, V_(H)63, V_(H)64, V_(H)65, V_(H)66, V_(H)67, V_(H)68, V_(H)69, V_(H)70, V_(H)71, V_(H)72, V_(H)73, V_(H)74, V_(H)75, V_(H)76, V_(H)77, V_(H)78, V_(H)79, V_(H)80, 81, V_(H)82, V_(H)83, V_(H)84, V_(H)85, V_(H) 86, V_(H) 87, V_(H)88, V_(H)89, V_(H)90, V_(H)91, V_(H)92, V_(H)93, and V_(H)94 as shown in Table 2B and/or an antibody light chain variable region selected from the group consisting of V_(L)1, V_(L)2, V_(L)3, V_(L)4, V_(L)S, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100 as shown in Table 2A, and immunologically functional fragments, derivatives, muteins and variants of these light chain and heavy chain variable regions.

TABLE 2A Exemplary Antibody Variable Light (V_(L)) Chains Contained SEQ ID in Clone Designation NO. Amino Acid Sequence 63E6 V_(L)6 217 DIQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWY QQKPGKAPNLLIYAASSLQSGVPSRFSGSGSGTDFT LTISGLQPEDFSTYYCQQSYSTSLTFGGGTKVEIKR 66F7 V_(L)7 218 DIQMTQSPSSLSASVGDRVTITCRTSQSISNYLNWY QQKPGKAPNLLIYAASSLQSGVPSRFSGSGSGTDFT LTISGLQPEDFSTYYCQQSYSTSLTFGGGTKVEIKR 66D4 V_(L)18 219 DIQMTQSPSSLSASVGDRITITCRASQIISRYLNWY QQNPGKAPKLLISAASSLQSGVPSRFSGSGSGPDFT LTISSLQPEDFTTYYCQQSYSSPLTFGGGTKVEVKR 66B4 V_(L)11 220 DIQMTQSPSSVSSSVGDRVTITCRASQGISRWLAW YQQKPGKAPKLLIYAASSLKSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQANSFPPTFGQGTKVEI KR 65B1 V_(L)19 221 DIQMTQSPSSLSASVGDRVTITCRASQNINNYLNW YRQKPGKAPELLIYTTSSLQSGVPSRFSGSGSGTDF TLTISSLETEDFETYYCQQSYSTPLTFGGGTKVEIKR 65B4 V_(L)21 222 SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVQWY QQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTA SLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTK LTVLG 67A4 V_(L)20 223 SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWY QQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTA TLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTK LTVLG 63A10v1 V_(L)22 224 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHW YQQKPGQDPVLVIYCDSNRPSGIPER FSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSD GVFGGGTKLTVLG 63A10v2 V_(L)101 1846 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHW YQQKPGQDPVLVIYCDSNRPSGIPER FSGSNPGNTATLTISRIEAGDEADYYCQAWDSTTV VFGGGTKLTVLG 63A10v3 V_(L)102 1847 SYELTQPPSVSVSPGQTANITCSGDKLGNRYTCWY QQKSGQSPVLVIYQDSERPSGIPER FSGSNSGNTATLTISGTQAMDEADYYCQAWDSTT VVFGGGTKLTVLG 65H11v1 V_(L)23 225 SYELTQPHSVSVATAQMARITCGGNNIGSKTVHW FQQKPGQDPVLVIYSDSNRPSGIPERFSGSNPGNTA TLTISRIEAGDEADYYCQVWDSSCDGVFGGGTKLT VLG 65H11v2 V_(L)103 1848 SYELTQPPSVSVSPGQTANITCSGDKLGDRYVCWY QQKPGQSPVLVIYQDSKRPSGIPEQFSGSNSGNTAT LTISGTQAIDEADYYCQAWDSITVVFGGGTKLTVLG 67G10v1 V_(L)9 226 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHW YQQKPGQDPVLVIYSDSNRPSGIPERFSGSNPGNTA TLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLT VLG 67G10v2 V_(L)10 227 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWY QQKPGQSPVLVIYQDNERPSGIPERFSGSNSGNTAT LTISGTQAMDEADYYCQAWDSTTVVFGGGTKLTV LG 64C8 V_(L)24 228 DVVMTQSPLSLPVTLGQPASISRRSSPSLVYSDGNT YLNCFQQRPGHSPRRLIYKGSNWDSGVPDRFSGSG SGTDFTLKISRVEAEDVGIYYCIQDTHWPTCSFGQ GTKLEIKR 64A8 V_(L)1 229 DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGW 67B4 YQQKPGKAPKRLIYAASNLQRGVPSRFSGSGSGTE FTLTISTLQPEDFATYSCLQHNSYPLTFGGGTKVEI KR 63G8v1 V_(L)104 1849 DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGW YQQKPGKAPKRLIYAASNLQRGVPSRFSGSGSGTE FTLTISTLQPDDFATYSCLQHNSYPLTFGGGTKVEI KR 63G8v2 V_(L)105 1850 DIQMTQSPSSLSASVGDRVTITCRASQGIRSGLGW YQQKPGKAPKRLIYAASNLQRGVPSRFSGSGSGTE FTLTVSSLQPEDFATYSCLQHNSYPLTFGGGTKVEI KR 63G8v3 V_(L)106 1851 DIQMTQSPSSLSASVGDRVTITCRASQGIRSGLGW YQQKPGKAPKRLIYAASNLQRGVPSRFSGSGSGTE FTLTVSSLQPEDFATYSCLQHNTYPLTFGGGTKGEI RR 66G2 V_(L)12 230 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGW YQQKPGKAPKRLIYAASNLQSGVPSRFSGSGSGTK FTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEI KR 68D3v1 V_(L)2 231 DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGW 68D3v2 YQQKPGKAPKRLIYAASNLQRGVPSRFSGSGSGTE FTLTISTLQPDDFATYSCLQHNSYPLTFGGGTKVEI KR 65D1 V_(L)27 232 SYDLTQPPSVSVSPGQTASITCSGDKLGDKYVCWY QQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTAT LTISGIQAMDEADYYCQAWDSRVFGGGTKLTVLG 64H5 V_(L)8 233 SYEMTQPLSVSVALGQTARITCGGNNIGSKNVHW 65G4 YQQKPGQAPVLVIYRDSKRPSGIPERFSGSNSGNT ATLTISRAQAGDEADYYCQVWDSSSVVFGGGTKL TVLG 65D4 V_(L)26 234 SYELTQPLSVSVALGQTARIPCGGNDIGSKNVHWY QQKPGQAPVLVIYRDRNRPSGIPERFSGSNSGNTA TLTISRAQAGDEADYYCQVWDSNPVVFGGGTKLT VLG 65E3 V_(L)25 235 SYELTQPLSVSVALGQTARITCGGNNIGSKNVHWY QQKPGQAPVLVIYRDRNRPSGIPERFSGSNSGNTA TLTISRAQAGDEADYYCQVWDSSTVVFGGGTKLT VLG 68G5 V_(L)13 236 SYELTQPLSVSVALGQTARLTCGGNNIGSINVHWY QQKPGQAPVLVIYRDRNRPSGIPERFSGSNSGNTA TLTISRAQAGDEADYYCQLWDSSTVVFGGGTKLT VLG 67G8 V_(L)28 237 SYELTQPLSVSVALGQTARITCGGNNIGSYNVFWY QQKPGQAPVLVIYRDSKRPSGIPERFSGSNSGNTAT LTISRAQAGDEADYHCQVWDSSTVVFGGGTKLTV LG 65B7v1 V_(L)29 238 EIVLTQSPGTLSLSPGERATLSCRASQSVSSIYLAW YQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDF TLTISRLEPEDFAVYYCQQYGSSCSFGQGTKLEIKR 65B7v2 V_(L)107 1852 DVVMTQSPLSLPVTLGQPASISYRSSQSLVYSDGD TYLNWFQQRPGQSPRRLIYKVSNWDSGVPDRFSG SGSGTDFTLKISRVEAEDVGVYYCMQGTHWRGW TFGQGTKVEIKR 63B6 V_(L)4 239 EIVLTQSPGTLSLSPGERATLSCRASQSVSNSYLAW 64D4 YQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDF TLTISRLEPEDFAVYYCQQFGRSFTFGGGTKVEIRR 63F5 V_(L)14 240 EVVLTQSPGTLSLSPGERATLSCRASQTVRNNYLA WYQQQPGQAPRLLIFGASSRATGIPDRFSGSGSGT DFTLTISRLEPEDFAVYYCQQFGSSLTFGGGTKVEI KR 65E8 V_(L)3 241 EIVLTQSPGTLSLSPGERATLSCRASQSVRNSYLAW 63H11 YQQQPGQAPRLLIYGAFSRASGIPDRFSGSGSGTDF 64E6 TLTISRLEPEDFAVYYCQQFGSSLTFGGGTKVEIKR 65F11 67G7 65C1 V_(L)16 242 EIVLTQSPGTLSLSPGERATLSCRASQTIRNSYLAW YQQQPGQAPRLLIYGAFSRATGIPDRFSGGGSGTD FTLTISRLEPEDFAVYYCQQFGSSLTFGGGTKVEIKR 66F6 V_(L)15 243 EIVLTQSPGTLSLSPGERATLSCRASQSVRNSYLAW YQQQPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDF TLTISRLEPEDFAVYYCQQFGSSLTFGGGTKVEIKR 64A6 V_(L)30 244 EILMTQSPATLSVSPGERATLSCRASQSVNSNLAW YQQKPGQAPRLLIYGTSTRATGVPARFGGSGSGTE FTLTISSLQSEDFAFYYCQQYNTWPWTFGQGTKVE IKR 65F9 V_(L)31 245 EILMTQSPATLSVSPGERATLSCRASQSVSSNLAW YQQKPGQSPRLLIYGASTRATGIPARFGGSGSGTDF TLTISSLQSEDFAFYYCQQYNTWPWTFGQGTKVEI KR 64A7 V_(L)17 246 EIVLTQSPGTLSLSPGERATLSCRASQSVSRNYLAW YQQKPGQAPRLLIYGASSRATGVPDRFSGSGSGTD FTLTISRLEPEDFAVYYCQQYGSSSLCSFGQGTNLD IRR 65C3 V_(L)5 247 EMVMTQSPATLSVSPGERATLSCRASQSVSSQLA 68D5 WYQEKPGRAPRLLIYGASNRAIDIPARLSGSGSGTE FTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKV EFKR 67F5 V_(L)32 248 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAW YQQKPGQAPRLLIHGSSNRAIGIPARFSGSGSGTEF TLTISSLQSADFAVYNCQQYEIWPWTFGQGTKVEI KR 64B10v1 V_(L)33 249 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVA 64B10v2 WYQQLPGTAPKLLIYDNDKRPSGIPDRFSGSKSGT SATLGITGLQTGDEADYYCGTWDSSLSAVVFGGG TKLTVLG 68C8 V_(L)34 250 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVS WYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGT SATLGITGLQTGDEADYYCGTWDSSLSAVVFGGG TKLTVLG 67A5 V_(L)35 251 DIVMTQTPLSLPVTPGEPASISCRSSQSLLNSDDGN TYLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGT GSGTEFTLKISRVEAEDVGVYYCMQRLEFPITFGQ GTRLEIKR 67C10 V_(L)36 252 DFVMTQTPLSLPVTPGEPASISCRSSQSLLNSDDGN TYLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGS GSGTDFTLKISRVEAEDVGVYYCMQRIEFPITFGQ GTRLEIKR 64H6 V_(L)37 253 SYELTQPLSVSVALGQTARITCGGNNIGSKNVHWY QQKPGQAPVVVIYRDSKRPSGIPERFSGSNSGNTA TLTISRAQAGDEADYYCQVWDSSPVVFGGGTKLT VLG 63F9 V_(L)38 254 DIQMTQSPSSLSVSVGDRVTITCRASQDIRNDLAW YQQTPGKAPKRLIYASSSLQSGVPSRFSGTGSGTEF TLTISSLQPEDFATYFCLQRNSYPLTFGGGTKVEIKR 67F6v1 V_(L)39 255 DIVMTQTPLSLPVIPGEPASIFCRSSQSLLNSDAGTT YLDWYLQKPGQSPQLLIYTLSFRASGVPDRFSGSG SGTDFTLKITRVEAEDVGVYYCMQRIEFPITFGQGT RLEIKR 67F6v2 V_(L)108 1853 DIVMTQTPLSLPVIPGEPASIFCRSSQSLLNSDAGTT YLDWYLQKPGRSPQLLIYTLSFRASGVPDRFSGSG SGTDFTLKITRVEAEDVGVYYCMQRIEFPITFGQGT RLEIKR 48C9 V_(L)78 256 DIQMTQSPSSLSASIGDRVTITCRASQNIRTYLNWY 49A12 QQKPGKAPKLLIYVASSLESGVPSRFSGTGSGTDF 51E2 ALTISSLQPEDFATYYCQQSDSIPRTFGQGTKVEIKR 48F3 V_(L)77 257 DIQMTQSPSSLSASVGDRVTITCRASQRISSYLNWY QQKPGKAPKFLIYAVSSLQSGVPSRFSGSGSGTDFT LTISSLEPEDFATYYCQQSYSATFTFGPGTKVDIKR 48F8 V_(L)49 258 EIVLTQSPDFQSVTPKEKVTITCRASQDIGNSLHWY 53B9 QQKPDQSPKLLIKFASQSFSGVPSRFSGSGSGTDFA 56B4 LTINSLEAEDAATYYCHQSSDLPLTFGGGTKVDIKR 57E7 57F11 48H11 V_(L)40 259 DIQMTQSPSSLSTSVGDRVTITCRASQNIRSYLNWY QLKPGKAPKVLIYGASNLQSGVPSRFSGSGSGTDF TLTISNLQSEDFAIYYCQQSYNTPCSFGQGTKLEIKR 49A10 V_(L)65 260 DIVMTQTPLSLPVTPGEPASISCRSSQSLLDSDDGN 48D4 TYLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGS GSGTDFTLKISRVEAEDVGVYYCMQRIEFPITFGQ GTRLEIKR 49C8 V_(L)45 261 DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNW 52H1 YQQKPGKAPKLLIYDVSNLETGVPSRFSGSGSGTD FTFTISSLQPEDIATYFCQQYDNLPFTFGPGTKVDL KR 49G2 V_(L)66 262 DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSDDGDT 50C12 YLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGSG 55G11 SGTDFTLKISRVEAEDVGVYYCMQHIEFPSTFGQG TRLEIKR 49G3 V_(L)47 263 DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWY QQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDF TFTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR 49H12 V_(L)43 264 DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNW YQQKPGKAPKLLIYDTFILETGVPSRFSGSGSGTDF TFTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIKR 51A8 V_(L)61 265 NFILTQPHSVSESPGKTVTISCTRSSGSIASDYVQW YQQRPGSSPTTVIYEDKERSSGVPDRFSGSIDSSSNS ASLTISGLKTEDEADYYCQSYDRNNHVVFGGGTK LTVLG 51C10.1 V_(L)55 266 SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWY QQKSGQAPVLVIYEDSKRPSGIPERFSGSISGTMAT LTISGAQVEDEADYYCYSTDSSVNHVVFGGGTKL TVLG 51C10.2 V_(L)70 267 SYDLTQPPSVSVSPGQTASITCSGDELGDKYACWY QQKPGQSPVLVIYQDTKRPSGIPERFSGSNSGNTAT LTISGTQAMDEADYYCQAWDSGTVVFGGGTKLT VLG 51E5 V_(L)79 268 DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGW YQQKPGKAPNRLIYAASSLQFGVPSRFSGSGSGTE FTLTISSLQPEDFATYYCLQHSSYPLTFGGGTRVEI KR 51G2 V_(L)51 269 DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAW YQQKPGKAPKLLIYDASSLQSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQTNSFPPWTFGQGTKVE IKR 52A8 V_(L)41 270 DIQMTQSPSFLSASVGDRVTITCRASQTISSYLNWH QQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFS LTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKR 52B8 V_(L)82 271 EVVLTQSPATLSVSPGGRATLSCRASQSVSDILAW YQQKPGQAPRLLIYGASTRATGIPARFSGGGSGTE FTLTISSLQSEDFAVYFCQQYNNWPLTFGGGTKVE IKR 52C1 V_(L)67 272 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGINYVSW YQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSA TLGITGLQTGDEADYCCGTWDSSLSAVVFGGGTK LTVLG 52F8 V_(L)42 273 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYN YLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGR GSGTDFSLKISRVEAEDVGIYYCMQALQTPFTFGP GTNVDIKQ 52H2 V_(L)84 274 ENVLTQSPGTLSLSPGERATLSCRASQSVRSSYLA WYQQRPGQAPRLLIFGASRRATGIPDRFSGSGSGT DFTLTISRLEPEDFAVYYCQQYGSSPRSFGQGTKLE IKR 53F6 V_(L)63 275 DIVMTQSPLSLPVTPGEPASISCRSSQSLQHSNGYN YLDWYLQKPGQSPQLLIYLDSNRASGVPDRFSGSG SGTDFTLKISRVEAEDIGVYYCMQGLQTPPTFGGG TKVEIKR 53H5.2 V_(L)62 276 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGW YQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTE FTLTISSLQPEDFATYYCLQHKSYPFTFGPGTKMDI KG 53H5.3 V_(L)80 277 EIVMTQSPVTLSVSPGERAIISCRASQSVSSNVAWY QQKPGQTPRLLIYGASTRATGLPTRFSGSGSGTVFT LTISSLQPEDFAVYYCQQFSNSITFGQGTRLEIKR 54A1 V_(L)44 278 DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWY 55G9 QLKPGKAPKLLIYDVSNLETGVPSRFSGGGSGTDF TFTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR 54H10.1 V_(L)53 279 EIVVTQSPGTLSLSVGERAILSCRASQSFSSSYLAW 55D1 YQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDF 48H3 TLTISRLEPEDFAVYYCQQYGSSRTFGQGTKVEIKR 53C11 55D3 V_(L)71 280 DIQMTQSPSSLSVSVGDRVTITCRASQDISNYLAWF QQKPGKAPKSLIYAASSLQSGVPSKFSGSGSGTDFT LTISSLQPEDFATYYCQQYNIYPRTFGQGTKVEIKR 55E4 V_(L)75 281 DIQMTQSPSSLSTSIGDRITITCRASQSISNYLNWFQ 49B11 QIPGKAPRLLIYTASSLQSGVPSRFSGSGSGTDFTLT 50H10 ISSLQPEDFATYYCQQSSSIPWTFGQGTKVEIKR 53C1 55E9 V_(L)68 282 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGFN YLDWYLQKPGQSPQVLIYLGSNRASGVPDRFSGS GSGTDFTLKISRVEAEDVGIYYCMQALQTLITFGQ GTRLEIKR 55G5 V_(L)83 283 SYELTQPPSVSVSPGQTASITCSGDNLGDKYAFWY QQKPGQSPVLIYQDNKRPSGIPERFSGSNSGNTAT LTISGTQAVDEADYYCQAWDSATVIFGGGTKLTV LG 56A7 V_(L)52 284 DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAW 56E4 YQQKPGKAPKFLIYDASTLQSGVPSRFSGSGSGAD FTLTINNLQPEDFATYYCQQTNSFPPWTFGQGTKV EIKR 56C11 V_(L)64 285 SYVLTQPPSVSVAPGQAARITCGGNDIGSKSVHWY QQKPGQAPVLVVYDDSDRPSGIPERFSGSKSGNTA TLIISRVEAGEEADYYCQVWDSSSDVVFGGGTKLT VLG 56E7 V_(L)86 286 DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNW YQQKPGKAPNLLIYDASNLETGVPSRFSGSGSGTD FTFTISSLQPEDIATYYCQQYAILPFTFGPGTTVDIKR 56G1 V_(L)76 287 DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWF LQIPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFT LTINSLQPEDFGTYYCQQSSTIPWTFGQGTKVEIKR 56G3.3 V_(L)81 288 EIVLTQSPGTLSLSPGERATLSCRASQSVSRDYLAW 55B10 YRQKPGQAPRLLVYGASARATGIPDRFSGSGSGTD FTLTISRLEPEDFAVYYCQQYGRSLFTFGPGTKVDI KR 57B12 V_(L)72 289 DIQMTQSPSSLSVSVGDRVTITCRASHDISNYLAWF QQKPGKAPKSLIYAASSLQSGVPSKFSGSGSGTDFT LTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIKR 57D9 V_(L)87 290 EIVLTQSPGTLSLSPGERATLSCRASPSVSSSYLAW YQQKPAQAPRLLIYGASSRATGIPDRFSGSGSGTDF TLTISRLEPEDFAVYYCHQYGTSPCSFGQGTKLEIKR 59A10 V_(L)48 291 DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAW 49H4 YQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQTNSFPPWTFGQGTKVE IKR 59C9 V_(L)50 292 DIQMTQSPSSVSASVGDRVTITCRASQDIDSWLVW 58A5 YQQKPGKAPNLLIYAASNLQRGVPSRFSGSGSGTD 57A4 FTLTIASLQPEDFATYYCQQTNSFPPWTFGQGTKV 57F9 EIKR 59G10.2 V_(L)60 293 SYELSQPPSVSVSPGQTVSITCSGDNLGDKYACWY QQRPGQSPVLVIYQDTKRPSGIPERFSGSNSGNTAT LTISGTQAMDEADYYCQAWDSSTTWVFGGGTKL TVLG 59G10.3 V_(L)54 294 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGDNYVS WYQQFPGTAPKLLIYDNNKRPSGIPDRFSGSKSGT SATLGITGLQTGDEADYYCGTWDSSLSVMVFGGG TKLTVLG 60D7 V_(L)69 295 DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSDDGDT YLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGSG SGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGG TKVEIKR 60F9 V_(L)58 296 EIMLTQSPGTLSLSPGERATLSCRASQRVPSSYIVW 48B4 YQQKPGQAPRLLIYGSSNRATGIPDRFSGSGSGTDF 52D6 TLTIGRLEPEDFAVYYCQQYGSSPPWTFGQGTKVA IKR 60G5.2 V_(L)46 297 SYELTQPPSVSVSPGQTASITCSGNKLGDKYVCWY QQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTAT LTISGTQALDEADYYCQAWDSSTWVFGGGTKLTV LG 61G5 V_(L)59 298 EIMLTQSPGTLSLSPGERATLSCRASQRVPSSYLVW YQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTD FTLTIGRLEPEDFAVYYCQQYGSSPPWTFGQGTKV AIKR 52C5 V_(L)73 299 DIQMTQSPSSLSASIGDRVTITCRASQSISNYLNWF QQIPGKAPRLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFAIYYCQQSSSIPWTFGQGTKVEIKR 61H5 V_(L)88 300 EIVLTQSPGTLSLSPGERATLSCRASQSVSRDYLAW 52B9 YRQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDF TLTISRLEPEDFAVYYCQQYGRSLFTFGPGTTVDIKR 59D10v1 V_(L)56 301 SYELTQPPSVSVSPGQTARITCSGDAVPKKYANWY QQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMAT LTISGAQVEDEADYYCYSTDSSGNHVVFGGGTKL TVLG 59D10v2 V_(L)57 302 SYELTQPPSVSVSPGQTASITCSGDKLGDKYVCWY QQMPGQSPVLVIHQNNKRPSGIPERFSGSNSGNTA TLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLT VLG 56G3.2 V_(L)85 303 ETVMTQSPATLSVSPGERATLSCRARQSVGSNLIW YQQKPGQAPRLLIFGASSRDTGIPARFSGSGSGTEF TLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEI KR 48G4 V_(L)89 304 EIVLTQSPGTLSLSPGERATLSCRASQSVASSYLVW 53C3.1 YQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDF TLTIRRLEPEDFAVYYCQQYGTSPFTFGPGTKVDL KR 50G1 V_(L)90 305 DIVMTQTPLSLPVSPGEPASISCRSSQSLLDSDDGD TYLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSVS GSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGG GTKVEIKR 58C2 V_(L)91 306 EIVMTQTPLSLPVTPGEPASISCRSSQSLFDNDDGD TYLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGS GSGTDFTLKISRVEAEDVGVYYCMQRLEFPITFGQ GTRLEIKR 60G5.1 V_(L)74 1854 DIQMTQSPSSLSASIGDRVTITCRASQSISNYLNWF QQIPGKAPRLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQSSSIPWTFGQGTKVEIKR 50D4 V_(L)92 307 DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAW YQQKPGKVPTLLIYAASTLLSGVPSRFSGSGSGTDF TLTISSLQPEDVAAYYCQKYYSAPFTFGPGTKVDI NR 50G5 v1 V_(L)93 308 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGW YQQKPGKAPNRLIYAASSLQSGVPSRFSGSGSGTE FTLTISSLQPEDFATYYCLQHNSYPRTFGQGTKVEI KR 50G5 v2 V_(L)94 309 DVVMTQCPLSLPVTLGQPASISCRSSQRLVYSDGN TYLNWVQQRPGQSPRRLIYKVSNWDSGVPDRFSG SGSGTDFTLKISRVEAEDVGVNYCMEGTHWPRDF GQGTRLEIKR 51C1 V_(L)95 310 DIQMTQSPSSLSASIGDRVTITCRASQSISNYLNWF QQIPGKAPRLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQSSSIPWTFGQGTTVEIKR 53C3.2 V_(L)96 311 DIVMTQSPATLSVSPGERATLSCRASQSISSNLAWY QQTPGQAPRLLIYGTSIRASTIPARFSGSGSGTEFTL TISSLQSEDFAIYYCHQYTNWPRTFGQGTKVEIKR 54H10.3 V_(L)97 312 DIQMTQSPSSLSASVGDRVTITCRASQTISIYLNWY QQKPGKAPKFLIYSASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFSTYFCQQSYSSPLTFGGGTKVEIKR 55A7 V_(L)98 313 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWY QQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQTYSAPFTFGPGTKVDIKR 55E6 V_(L)99 314 EIVLTQSPGTLSLSPGERATLSCRASQSVSRSHLAW YQQNSGQAPRLLIYGASSRATGIPDRFSGSGSGTDF TLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEI KR 61E1 V_(L)100 315 DIQMTQSPSSLSASIRDRVTITCRASQSIGTFLNWY QQKPGTAPKLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLHPEDFASYYCQQSFSTPLTFGGGTKVEITR

TABLE 2B Exemplary Antibody Variable Heavy (V_(H)) Chains Contained SEQ ID in Clone Designation NO. Amino Acid Sequence 63E6 V_(H) 6 316 QVQLMQSGAEVKKPGASVKVSCKASGYTFTGY 66F7 YMHWVRQAPGQGLEWMGWMNPNSGATKYA QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY YCARELGDYPFFDYWGQGTLGIVSS 66D4 V_(H)17 317 QVQLVQSGAEVKKPGASVKVSCRASGYTFTGY YIHWMRQAPGHGLEWMGWINPPSGATNYAQK FRGRVAVTRDTSISTVYMELSRLRSDDTAVYYC ARETGTWNFFDYWGQGTLVTVSS 66B4 V_(H)10 318 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGY YLHWVRQAPGQGLEWMGWINPNSGGTDYAQK FQGRVTMTRDTSISTAYMELSRLRSDDTAVYYC VGDAATGRYYFDNWGQGTLVTVSS 65B1 V_(H)18 319 QVQLVQSGAEVKRPGASVKVSCKASGYTFTGY FMHWVRQAPGQGLEWMGWINPNSGATNYAQ KFHGRVTMTRDTSITTVYMELSRLRSDDTAVY YCTRELGIFNWFDPWGQGTLVTVSS 65B4 V_(H)20 320 EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYD MHWVRQATGKGLEWVSTIDTAGDAYYPGSVK GRFTISRENAKTSLYLQMNSLRAGDTAVYYCTR DRSSGRFGDFYGMDVWGQGTAVTVSS 67A4 V_(H)19 321 EVQLEESGGGLVQPGGSLRLSCAASGFTFRTYD MHWVRQVTGKGLEWVSAIGIAGDTYYSDSVK GRFTISRENAKNSLYLQMNSLRVGDTAVYYCA RDRSSGRFGDYYGMDVWGQGTTVTVSS 63A10v1 V_(H)21 322 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAW 63A10v2 MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAA 63A10v3 PVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVY YCTTDSSGSYYVEDYFDYWGQGTLVTVSS 65H11v1 V_(H)22 323 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW 65H11v2 MSWVRQAPGKGLEWVGRIIGKTDGGTTDYAAP VKGRFTISRDDSKNTLYLQMNSLKTEDTAVYY CTSDSSGSYYVEDYFDYWGQGTLVAVSS 67G10v1 V_(H)9 324 EVQLVESGGGLVKPGGSLRLACAASGITFNNA 67G10v2 WMSWVRQAPGKGLEWVGRIKSKTDGGTTDYA APVKGRFTISRDDSKSILYLQMNSLKSEDTAVY YCTTDSSGSYYVEDYFDYWGQGTLVTVSS 64C8 V_(H)23 325 QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYG MHWVRQDPGKGLEWVAVISYDGSNKHYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARELLWFGEYGVDHGMDVWGQGTTVTVSS 63G8v1 V_(H)1 326 QAQLVESGGGVVQPGRSLRLSCAASGFTFSSYG 63G8v2 IHWVRQAPGKGLEWVAVISYDGSNKYYADSVK 63G8v3 GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAT 68D3v1 TVTKEDYYYYGMDVWGQGTTVTVSS 64A8 67B4 68D3v2 V_(H)95 1855 QAQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKGLEWVAFISYAGSNKYY ADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAV YYCATTVTEEDYYYYGMDVWGQGTTVT VSS 66G2 V_(H)11 327 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKGLEWVAGISYDGSNKNYADSV KGRITISRDNPKNTLYLQMNSLRAEDTAVYYCA TTVTKEDYYYYGMDVWGQGTTVTVSS 65D1 V_(H)26 328 QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYY IHWVRQAPGKGLEWVALIWYDGSNKDYADSV KGRFTISRDNSKNTLYLHVNSLRAEDTAVYYCA REGTTRRGFDYWGQGTLVTVSS 64H5 V_(H)7 329 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKGLEWVAVIWDDGSNKYYADS VKGRFTISRDNSKNTLSLQMNSLRAEDTAVYYC AREYVAEAGFDYWGQGTLVTVSS 65D4 V_(H)25 330 QEQLVESGGGVVQPGRSLRLSCAVSGFTFSFYG MHWVRQAPGKGLEWVAVIWYDGSNKYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CTRALNWNFFDYWGQGTLVTVSS 65E3 V_(H)24 331 QVQLVESGGGVVQPGRSLRLSCAASGFTLSNYN MHWVRQAPGKGLEWVAVLWYDGNTKYYADS VKGRVTISRDNSKNTLYLQMNSLRAEDTAVYY CARDVYGDYFAYWGQGTLVTVSS 65G4 V_(H)8 332 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKGLEWVAVIWDDGSNKYY ADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAV YYCAREYVAEAGFDYWGQGTLVTVSS 68G5 V_(H)12 333 QVQLVESGGGVVQPGRSLRLSCTASGFTFSSYG MHWVRQAPGKGLEWVAVIWYDGSNKYHADS VKGRFTISRDDSKNALYLQMNSLRAEDTAVYY CVRDPGYSYGHFDYWGQGTLVTVSS 67G8 V_(H)27 334 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKGLEWVAVIWYDGSNKDYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARSAVALYNWFDPWGQGTLVTVSS 65B7v1 V_(H)28 335 QVQLQESGPGLVNPSQTLSLTCTVSGGSISSDAY 65B7v2 YWSWIRQHPGKGLEWIGYIFYSGSTYYNPSLKS RVTISVDTSKNRFSLKLSSVTAADTAVYYCARE SRILYFNGYFQHWGQGTLVTVSS 63B6 V_(H)4 336 QVQLQESGPGLVKPSQTLSLTCAVSGGSISSGDY 64D4 YWSWIRQHPGKGLEWIGYIYYSGTTYYNPSLKS RVTISVDTSKNQFSLKLTSVTAADTAVYYCARM TTPYWYFGLWGRGTLVTVSS 63F5 V_(H)13 337 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGDY YWTWIRQHPGKDLEWITYIYYSGSAYYNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYCARM TTPYWYFDLWGRGTLVTVSS 63H11 V_(H)3 338 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGDY YWTWIRQHPGKGLEWIAYIYYSGSTYYNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYCARM TTPYWYFDLWGRGTLVTVSS 65E8 V_(H)2 339 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGDY 64E6 YWTWIRQHPGKGLEWIAYIYYTGSTYYNPSLKS 65F11 RVTISVDTSKNQFSLKLSSVTAADTAVYYCARM 67G7 TTPYWYFDLWGRGTLVTVSS 65C1 V_(H)15 340 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGDY YWTWIRQHPGKGLEWIAYIFYSGSTYYNPSLKS RVTISLDTSKNQFSLKLNSVTAADTAVYYCARM TSPYWYFDLWGRGTLVTVSS 66F6 V_(H)14 341 QVQLQESGPGLVKPSQTLSLTCPVSGGSISSGDY YWTWIRHHPGKGLEWIAYIYYSGSTYYNPSLKS RVTISVDTSKNQFSLKLNSVTAADTAVYYCAR MTTPYWYFDLWGRGTLVTVSS 64A6 V_(H)29 342 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY YWSWIRQRPGKGLEWVGYIYYSGGTHYNPSLK SRVTISIDTSENQFSLKLSSVTAADTAVYYCARV LHYSDSRGYSYYSDFWGQGTLVTVSS 65F9 V_(H)30 343 QVQLQESGPGLVKPSQTLSLTCTLSGGSFSSGDY YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS RVTISIDTSKNQFSLKLTSVTAADTAVYYCARV LHYYDSSGYSYYFDYWGQGTLVTVSS 64A7 V_(H)16 344 QLQLQESGPGLVKPSETLSLTCTVSGGSISSDTS YWGWIRQPPGKGLEWIGNIYYSGTTYFNPSLKS RVSVSVDTSKNQFSLKLSSVTAADTAVFYCARL RGVYWYFDLWGRGTLVTVSS 65C3 V_(H)5 345 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW 68D5 SWIRQPPGKGLEWIGYIYYTGSTNYNPSLKSRV TISVDTSKNQFSLKLSSVTAADTAVYYCAREYY YGSGSYYPWGQGTLVTVSS 67F5 V_(H)31 346 QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYW SWIRQPPGKGLEWIGYIYYSGNTNYNPSLKSRV TISVDTSKNQFSLKLSSVTAADTAVYYCAREYY YGSGSYYPWGQGTLVTVSS 64B10v1 V_(H)32 347 QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDY YWSWIRQPPGKGLEWIGFIYYSGGTNYNPSLKS RVTISIDTSKNQFSLKLNSVTAADTAVYYCARY SSTWDYYYGVDVWGQGTTVTVSS 64B10v2 V_(H)96 1856 QVQLLESGPGLVKPSETLSLTCTVSGGSVSSGD YYWSWIRQPPGKGLEWIGFIYYSGGTNYNPPLK SRVTISIDTSKNQFSLKLSSVTAADTAVYYCARY SSTWDYYYGVDVWGQGTTVTVSS 68C8 V_(H)33 348 QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGD NYWSWIRQPPGKGLEWIGFMFYSGSTNYNPSL KSRVTISLHTSKNQFSLRLSSVTAADTAVYYCG RYRSDWDYYYGMDVWGQGTTVTVSS 67A5 V_(H)34 349 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYW IGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG QVTISADKSINTAYLQWSSLKASDTAIYFCARR ASRGYRFGLAFAIWGQGTMVTVSS 67C10 V_(H)35 350 EVQLVQSGAEVKKPGESLKISCQGSGYSFSSYW IGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG QVTISADKSINTAYLQWSSLKASDTAIYYCARR ASRGYRYGLAFAIWGQGTMVTVSS 64H6 V_(H)36 351 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYW IGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQG QVTISADKSISTAYLQWNSLKTSDTAMYFCATV AVSAFNWFDPWGQGTLVTVSS 63F9 V_(H)37 352 QVQLKESGPGLVKPSQTLSLTCTVSGGSISSGGY YWNWIRQHPGKGLEWIGYIYDSGSTYYNPSLKS RVTMSVDTSKNQFSLKLSSVTAADTAVYYCAR DVLMVYTKGGYYYYGVDVWGQGTTVTVSS 67F6v1 V_(H)38 353 EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYW 67F6v2 IGWVRQLPGKGLEWMGIIYPGDSDTRYSPSFQG QVTISVDKSINTAYLQWSSLKASDTAMYYCAR RASRGYSYGHAFDFWGQGTMVTVSS 48C9 V_(H)73 354 QVQLQQWGAGLLKPSETLSLTCSVYGGSFSGY 49A12 YWTWIRQPPGKGLEWIGEINHSENTNYNPSLKS 51E2 RVTISIDTSKNQFSLKLSSVTAADTAVYYCARES GNFPFDYWGQGTLVTVSS 48F3 V_(H)72 355 QVQLQQWGAGPLKPSETLSLTCAVYGGSISGYY WSWIRQPPGKGLEWIGEITHTGSSNYNPSLKSR VTISVDTSKNQFSLKLSSVTAADTAVYYCARGG ILWFGEQAFDIWGQGTMVTVSS 48F8 V_(H)48 356 EVQLVESGGGLVKPGGSLRLSCTASGFTFRSYS 53B9 MNWVRQAPGKGLEWVSSISSSSSYEYYVDSVK 56B4 GRFTISRDIAKSSLWLQMNSLRAEDTAVYYCAR 57E7 SLSIAVAASDYWGKGTLVTVSS 57F11 48H11 V_(H)39 357 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGY YKHWVRQAPGQGLEWMGWINPNSGATKYAQ KFQGRVTMTRDTSISTVYMELSRLRSVDTALYY CAREVPDGIVVAGSNAFDFWGQGTMVTVSS 49A10 V_(H)62 358 QVHLVESGGGVVQPGRSLRLSCAASGFTFSNYG 48D4 MHWVRQAPGKGLEWVAIIWYDGSNKNYADSV KGRFTISRDNSKNTLYLEMNSLRAEDTAVYYCA RDQDYDFWSGYPYFYYYGMDVWGQGTTVTVSS 49C8 V_(H)44 359 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSY 52H1 DIDWVRQATGQGLEWMGWMNPNGGNTGYAQ KFQGRVTMTRNTSINTAYMELSSLRSEDTAIYY CARGKEFSRAEFDYWGQGTLVTVSS 49G2 V_(H)63 360 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG 50C12 MRWVRQAPGKGLEWVALIWYDGSNKFYADSV 55G11 KGRFTISRDNSKNTLNLQMNSLRAEDTAVYYC ARDRYYDFWSGYPYFFYYGLDVWGQGTTVTV SS 49G3 V_(H)46 361 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRM GVSWIRQPPGKALEWLTHIFSNDEKSYSTSLKSR LTISKDTSKSQVVLSMTNMDPVDTATYYCVRV DTLNYHYYGMDVWGQGTTVTVSS 49H12 V_(H)42 362 QVQLVQSGAEVKKPGASVKVSCMASGYIFTSY DINWVRQATGQGPEWMGWMNPYSGSTGYAQ NFQGRVTMTRNTSINTAYMELSSLRSEDTAVYY CAKYNWNYGAFDFWGQGTMVTVSS 51A8 V_(H)58 363 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKGLEWVAVISYDGSNKYYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARADGDYPYYYYYYGMDVWGQGTTVTVSS 51C10.1 V_(H)54 364 EVQLLESGGGLVQPGGSLRLSCAASGFTFRNYA 59D10v1 MSWVRQAPGKGLEWVSGISGSSAGTYYADSVK 59D10v2 GRFTISRDNSKNTLFLQMDSLRAEDTAVYYCAQ DWSIAVAGTFDYWGQGTLVTVSS 51C10.2 V_(H)67 365 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY YWSWIRQHPGKGLEWIGYIYYNGSPYDNPSLK RRVTISIDASKNQFSLKLSSMTAADTAVYYCAR GALYGMDVWGQGTTVTVSS 51E5 V_(H)74 366 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGY YWSWIRQPPGKGLEWIGELDHSGSINYNPSLKS RVTISVDTSKNQFSLKLTSVTAADTAVYYCARV LGSTLDYWGQGTLVTVSS 51G2 V_(H)50 367 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS MNWVRQAPGKGLEWVSSISSSSTYIYYADSVK GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA RDTYISGWNYGMDVWGQGTTVTVSS 52A8 V_(H)40 368 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGY YLHWVRQAPGQGLEWMGWINPNSAATNYAPK FQGRVTVTRDTSISTAYMELSRLRSDDTAVYYC AREGGTYNWFDPWGQGTLVTVSS 52B8 V_(H)77 369 QVQLQESGPGLMKPSETLSLTCTVSGGSISYYY WSWIRQSPGKGLEWIGYIYYSGSTNYNPSLKSR VTMSVDTSKNQFSLKLSSVTAADTAVYYCASG TRAFDIWGQGTMVTVSS 52C1 V_(H)64 370 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKGLEWVAVIWYDGSNNYYADS VKGRFTISRDNSKSTLFLQMNSLRAEDTAIYYC ARDRAGASPGMDVWGQGTTVTVSS 52F8 V_(H)41 371 QVQLVQSGAEVKKPGASVKVSCKASGFTFIGY YTHWVRQAPGQGLEWMGWINPSSGDTKYAQK FQGRVTLARDTSISTAYMELSRLRSDDTAVYYC ANSGWYPSYYYGMDVWGQGTTVTVSS 52H2 V_(H)79 372 QVQLQESGPGLVKPSETLSLTCTVSGGSISTYY WSWIRQPPGTGLEWIGYIFYNGNANYSPSLKSR VTFSVDTSKNQFSLKLSSVTAADTAVYFCARET DYGDYARPFEYWGQGTLVTVSS 53F6 V_(H)60 373 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYG MHWVRQAPGKGLEWVAVIWYDGSNKYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARGHYDSSGPRDYWGQGTLVTVSS 53H5.2 V_(H)59 374 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGQGLEWVALISYDGSNKYYADSV KGRFTISRDKSKNTLYLQMNSLRAEDTAVYYC AREANWGYNYYGMDVWGQGTTVTVSS 53H5.3 V_(H)75 375 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDY YWNWIRQPPGKGPEWIGEINHSGTTNYNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYCVGI LRYFDWLEYYFDYWGQGTLVTVSS 54A1 V_(H)43 376 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSY 55G9 DINWVRQATGQGLEWMGWMNPHSGNTGYAQ KFQGRVTMTRNTSINTAYMELSSLRSEDTAVYY CAKYNWNYGAFDFWGQGTMVTVSS 54H10.1 V_(H)52 377 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 55D1 MSWVRQAPGKGLEWVSAISGSGRTTYSADSVK 48H3 GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA 53C11 KEQQWLVYFDYWGQGTLVTVSS 55D3 V_(H)68 378 QVQLQESGPGLVKPSQTLSLTCTVSGGSITSGVY YWNWIRQHPGKGLEWIGYLYYSGSTYYNPSLK SRLTISADMSKNQFSLKLSSVTVADTAVYYCAR DGITMVRGVTHYYGMDVWGQGTTVTVSS 55E4 V_(H)70 379 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGY 49B11 YWSWIRQPPGKGLEWIGEINHSENTNYNPSLKS 50H10 RVTISLDTSNDQFSLRLTSVTAADTAVYYCARV 53C1 TGTDAFDFWGQGTMVTVSS 52C5 60G5.1 55E9 V_(H)65 380 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFG MHWVRQAPGKGLEWVALIWYDGDNKYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARNSGWDYFYYYGMDVWGQGTTVTVSS 55G5 V_(H)78 381 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW SWIRQPAGKGLEWIGRIYISGSTNYNPSLENRVT MSGDTSKNQFSLKLNSVTAADTAVYYCAGSGS YSFDYWGQGTLVTVSS 50G1 V_(H)84 382 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG LHWVRQAPGKGLEWVAVIWNDGSNKLYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARDQYYDFWSGYPYYHYYGMDVWGQGTTVT VSS 56A7 V_(H)51 383 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS 56E4 MNWVRQAPGKGLEWVSSISSSSTYIYYADSVK GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA RDIYSSGWSYGMDVWGQGTTVTVSS 56C11 V_(H)61 384 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKGLEWVAVIWYDGSYQFYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARDHVWRTYRYIFDYWGQGTLVTVSS 56E7 V_(H)81 385 EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWI GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG QVTISADTSISTAYLQWSRLKASDTAVYYCARA QLGIFDYWGQGTLVTVSS 56G1 V_(H)71 386 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGY YWSWIRQPPGKGLEWIGEINHSENTNYNPSLKS RVTISLDTSNKQFSLRLTSVTAADTAVYYCARV TGTDAFDFWGQGTMVTVSS 56G3.3 V_(H)76 387 QLQLQESGPGLVKPSETLSLTCTVSGDSISSSSY 55B10 YWGWIRQPPGKGLEWIGMIYYSGTTYYNPSLK SRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR VAAVYWYFDLWGRGTLVTVSS 57B12 V_(H)69 388 QVQLQESGPGLVKPSQTLSLTCTVSGGSITSGVY YWSWIRQLPGKGLEWIGYIYYSGSTYYNPSLKS RLTISADTSKNQFSLKLSSVTVADTAVYYCARD GITMVRGVTHYYGMDVWGQGTTVTVSS 57D9 V_(H)82 389 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSA TWNWIRQSPSRGLEWLGRTYYRSKWYNDYAV SVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYC VGIVVVPAVLFDYWGQGTLVTVSS 58C2 V_(H)85 390 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG MHWVRQAPGKGLEWVAVIWNDGNNKYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARDQNYDFWNGYPYYFYYGMDVWGQGTTV TVSS 59A10 V_(H)47 391 QVQVVESGGGLVKPGGSLRLSCAASGFTFSDSY 49H4 MSWIRQAPGKGLEWISSISSSGSIVYFADSVKGR FTISRDIAKNSLYLHMNSLRAEDTAVYYCARET FSSGWFDAFDIWGQGTMVTVSS 59C9 V_(H)49 392 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS 58A5 MSWVRQAPGKGLEWVSSISSSSTYIYYADSLKG 57A4 RFTISRDNAKNSLFLQVNSLRAEDSAVYYCARD 57F9 RWSSGWNEGFDYWGQGTLVTVSS 59G10.2 V_(H)57 393 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG MHWVRQAPGKGLEWVAITSYGGSNKNYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AREAGYSFDYWGQGTLVTVSS 59G10.3 V_(H)53 394 EVQLLGSGGGLVQPGGSLRLSCAASGFTFNHYA MSWVRQAPGKGLEWVSAISGSGAGTFYADSM KGRFTISRDNSENTLHLQMNSLRAEDTAIYYCA KDLRIAVAGSFDYWGQGTLVTVSS 60D7 V_(H)66 395 QVQLVESGGGVVQPGRSLRLSCAASGFNFSSYG MHWVRQAPGKGLEWVAVIWYDGSNKYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYC ARDQYFDFWSGYPFFYYYGMDVWGQGTTVTV SS 60F9 V_(H)55 396 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA 48B4 MSWVRQAPGKGLEWVSVISDSGGSTYYADSVK 52D6 GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA KDHSSGWYYYGMDVWGQGTTVTVSS 60G5.2 V_(H)45 397 QVQLVQSGAEVKTPGASVRVSCKASGYTFTNY GISWVRQAPGQGLEWMGWISAYNGYSNYAQK FQDRVTMTTDTSTSTAYMELRSLRSDDTAVYY CAREEKQLVKDYYYYGMDVWGQGSTVTVSS 61G5 V_(H)56 398 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA MSWVRQSPGKGLEWVSVISGSGGDTYYADSVK GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA KDHTSGWYYYGMDVWGQGTTVTVSS 56G3.2 V_(H)80 399 QVQLQESGPGLVKPSETLSLTCTVSDGSISSYYW NWIRQPAGKGLEWIGRIYTSGSTNYNPSLKSRV TMSVDTSKNQFSLNLTSVTAADTAVYYCARGP LWFDYWGQGTLVTVSS 48G4 V_(H)83 400 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTEL 53C3.1 SIHWVRQAPGKGLEWMGGFDPEDGETIYAQKF QGRVTMTEDTSTDTAYMELSSLRSEDTAVYYC ATHSGSGRFYYYYYGMDVWGQGTTVTVSS 61H5 V_(H)86 401 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSY 52B9 YWGWIRQPPGKGLEWIGSIYYSGTTYYNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYCARV AAVYWYFDLWGRGTLVTVSS 50D4 V_(H)87 402 QVQLVQSGAEVKKTGASVKVSCKASGYTFTSH DINWVRQATGHGLEWMGWMNPYSGSTGLAQR FQDRVTMTRNTSISTAYMELSSLRSEDTAVYYC ARDLSSGYYYYGLDVWGQGTTVTVSS 50G5v1 V_(H)88 403 QVQLVQSGAEVKKPGASVKVSCKASGYPFIGY 50G5v2 YMHWVRQAPGQGLEWMGWINPDSGGTNYAQ KFQGRVTMTRDTSITTAYMELSRLRSDDTAVFY CARGGYSYGYEDYYGMDVWGQGTTVTVSS 51C1 V_(H)89 404 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGY YWSWIRQPPGKGLEWIGEINHSENTNYNPSLKS RVTISLDTSHDQFSLRLTSVTAADTAVYYCARV TGTDAFDFWGQGTMVTVSS 53C3.2 V_(H)90 405 QVQLQESGPGLVKPSQTLSLTCTVSNGSINSGN YYWSWIRQHPGKGLEWIGYIYHSGSAYYNPSL KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCA RTTGASDIWGQGIMVTVSS 54H10.3 V_(H)91 406 DIQMTQSPSSLSASVGDRVTITCRASQTISIYLN WYQQKPGKAPKFLIYSASSLQSGVPSRFSGSGS GTDFTLTISSLQPEDFSTYFCQQSYSSPLTFGGGT KVEIKR 55A7 V_(H)92 407 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT ISVDTSKNQFSLRLSSVTAADTAVYYCARGITGT IDFWGQGTLVTVSS 55E6 V_(H)93 408 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYS MNWVRQAPGKGLEWISYISSGSSTIYHADSVKG RFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR EGYYDSSGYYYNGMDVWGQGTTVTVSS 61E1 V_(H)94 409 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSA AWNWIRQSPSRGLEWLGRTYYRSKWYNDYAV SVKSRITITPDTSKNQFSLQLKSVTPEDTAIYYCA REGSWSSFFDYWGQGTLVTVSS

TABLE 2C Coding Sequence for Antibody Variable Light (V_(L)) Chains Contained SEQ ID in Clone Designation NO. Coding Sequence 63E6 V_(L)6 410 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGACAAGTCAGAGTATTAGCAGCTATTTAA ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTA ACCTCCTGATCTATGCTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAGATTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCGGTCTG CAACCTGAAGATTTTTCAACTTACTACTGTCAAC AGAGTTACAGTACCTCGCTCACTTTCGGCGGAG GGACCAAGGTGGAGATCAAACGA 66D4 V_(L)18 411 GACATCCAGATGACCCAGTCGCCATCCTCCCTGT CTGCATCTGTAGGAGACAGGATCACCATCACTT GCCGGGCAAGTCAGATCATTAGCAGGTATTTAA ATTGGTATCAGCAGAACCCAGGGAAAGCCCCTA AGCTCCTGATCTCTGCTGCATCCAGTTTGCAAAG TGGAGTCCCATCAAGGTTCAGTGGCAGTGGATC TGGGCCAGATTTCACTCTCACCATCAGCAGTCTG CAACCTGAAGATTTTACAACTTACTACTGTCAAC AGAGTTACAGTTCCCCGCTCACTTTCGGCGGAG GGACCAAGGTGGAGGTCAAACGA 66B4 V_(L)11 412 GACATCCAGATGACCCAGTCTCCATCTTCCGTGT CTTCATCTGTAGGAGACAGAGTCACCATCACTT GTCGGGCGAGTCAGGGTATTAGCAGGTGGTTAG CCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTATGCTGCATCCAGTTTGAAAAG TGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGCCT GCAGCCTGAAGATTTTGCAACTTACTATTGTCAA CAGGCTAACAGTTTCCCTCCGACGTTCGGCCAA GGGACCAAGGTGGAAATCAAACGA 65B1 V_(L)19 413 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGAACATTAACAACTATTTAA ATTGGTATCGGCAGAAACCAGGGAAAGCCCCTG AACTCCTGATCTATACTACATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGTCTG GAAACTGAAGATTTTGAAACTTACTACTGTCAA CAGAGTTACAGTACCCCTCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 65B4 V_(L)21 414 TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAG TGGCCCCAGGACAGACGGCCAGGATTACCTGTG GGGGAAACAACATTGGAAGTAAAAGTGTGCAGT GGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGC TGGTCGTCTACGATGATAGCGACCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAACTCTGG GAACACGGCCTCCCTGACCATCAGCAGGGTCGA AGCCGGGGATGAGGCCGACTATTACTGTCAGGT GTGGGATAGTAGTAGTGATCATGTGGTATTCGG CGGAGGGACCAAGCTGACCGTCCTAGGT 67A4 V_(L)20 415 TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAG TGGCCCCAGGACAGACGGCCAGGATTACCTGTG GGGGAAACAACATTGGAAGTAAAAGTGTGCACT GGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGC TGGTCGTCTATGATGATAGCGACCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAACTCTGG GAACACGGCCACCCTGACCATCAGCAGGGTCGA AGCCGGGGATGAGGCCGACTATTACTGTCAGGT GTGGGATAGTAGTAGTGATCATGTGGTATTCGG CGGAGGGACCAAGCTGACCGTCCTAGGT 63A10v1 V_(L)22 416 TCCTATGAGCTGACTCAGCCACACTCAGTGTCA GTGGCCACAGCACAGATGGCCAGGATC ACCTGTGGGGGAAACAACATTGGAAGTAAAGCT GTGCACTGGTACCAGCAAAAGCCAGGC CAGGACCCTGTGCTGGTCATCTATTGCGATAGC AACCGGCCCTCAGGGATCCCTGAGCGA TTCTCTGGCTCCAACCCAGGGAACACCGCCACC CTAACCATCAGCAGGATCGAGGCTGGG GATGAGGCTGACTATTACTGTCAGGTGTGGGAC AGTAGTAGTGATGGGGTATTCGGCGGA GGGACCAAGCTGACCGTCCTAGGT 63A10v2 V_(L)101 1857 TCCTATGAGCTGACTCAGCCACACTCAGTGTCA GTGGCCACAGCACAGATGGCCAGGATC ACCTGTGGGGGAAACAACATTGGAAGTAAAGCT GTGCACTGGTACCAGCAAAAGCCAGGC CAGGACCCTGTGCTGGTCATCTATTGCGATAGC AACCGGCCCTCAGGGATCCCTGAGCGA TTCTCTGGCTCCAACCCAGGGAACACCGCCACC CTAACCATCAGCAGGATCGAGGCTGGG GATGAGGCTGACTATTACTGTCAGGCGTGGGAC AGCACCACTGTGGTATTCGGCGGAGGG ACCAAGTTGACCGTCCTAGGT 63A10v3 V_(L)102 1858 ACCTGCTCTGGAGATAAATTGGGGAATAGATAT ACTTGCTGGTATCAGCAGAAGTCAGGC CAGTCCCCTGTGCTGGTCATCTATCAAGATAGCG AGCGGCCCTCAGGGATCCCTGAGCGA TTCTCTGGCTCCAACTCTGGGAACACAGCCACTC TGACCATCAGCGGGACCCAGGCTATG GATGAGGCTGACTATTACTGTCAGGCGTGGGAC AGCACCACTGTGGTATTCGGCGGAGGG ACCAAGTTGACCGTCCTAGGT 65H11v1 V_(L)23 417 TCCTATGAGCTGACTCAGCCACACTCAGTGTCA GTGGCCACAGCACAGATGGCCAGGATCACCTGT GGGGGAAACAACATTGGAAGTAAAACTGTGCAC TGGTTCCAGCAAAAGCCAGGCCAGGACCCTGTG CTGGTCATCTATAGCGATAGCAACCGGCCCTCA GGGATCCCTGAGCGATTCTCTGGCTCCAACCCA GGGAACACCGCCACCCTAACCATCAGCAGGATC GAGGCTGGGGATGAGGCTGACTATTACTGTCAG GTGTGGGACAGTAGTTGTGATGGGGTATTCGGC GGAGGGACCAAGCTGACCGTCCTAGGT 65H11v2 V_(L)103 1859 TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCG TGTCCCCAGGACAGACAGCCAACATC ACCTGCTCTGGAGATAAATTGGGGGATAGATAT GTTTGTTGGTATCAGCAGAAGCCAGGC CAGTCCCCTGTGCTGGTCATCTATCAAGATAGCA AGCGGCCCTCAGGGATCCCTGAACAA TTCTCTGGCTCCAACTCTGGGAACACAGCCACTC TGACCATCAGCGGGACCCAGGCTATA GATGAGGCTGACTATTACTGTCAGGCGTGGGAC AGCATCACTGTGGTATTCGGCGGAGGG ACCAAGCTGACCGTCCTAGGT 67G10v1 V_(L)9 418 TCCTATGAGCTGACTCAGCCACACTCAGTGTCA GTGGCCACAGCACAGATGGCCAGGATCACCTGT GGGGGAAACAACATTGGAAGTAAAGCTGTGCAC TGGTACCAGCAAAAGCCAGGCCAGGACCCTGTG CTGGTCATCTATAGCGATAGCAACCGGCCCTCA GGGATCCCTGAGCGATTCTCTGGCTCCAACCCA GGGAACACCGCCACCCTAACCATCAGCAGGATC GAGGCTGGGGATGAGGCTGACTATTACTGTCAG GTGTGGGACAGTAGTAGTGATGGGGTATTCGGC GGAGGGACCAAGCTGACCGTCCTAGGT 67G10v2 V_(L)10 419 TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCG TGTCCCCAGGACAGACAGCCAGCATCACCTGCT CTGGAGATAAATTGGGGGATAAATATGCTTGCT GGTATCAGCAGAAGCCAGGCCAGTCCCCTGTGC TGGTCATCTATCAAGATAACGAGCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAACTCTGG GAACACAGCCACTCTGACCATCAGCGGGACCCA GGCTATGGATGAGGCTGACTATTACTGTCAGGC GTGGGACAGCACCACTGTGGTATTCGGCGGAGG GACCAAGCTGACCGTCCTAGGT 64C8 V_(L)24 420 GATGTTGTGATGACTCAGTCTCCGCTCTCCCTGC CCGTCACCCTTGGACAGCCGGCCTCCATCTCCCG CAGGTCTAGTCCAAGCCTCGTATACAGTGATGG AAACACCTACTTGAATTGCTTTCAGCAGAGGCC AGGCCACTCTCCAAGGCGCCTAATTTATAAGGG TTCTAACTGGGACTCAGGGGTCCCAGACAGATT CAGCGGCAGTGGGTCAGGCACTGATTTCACTCT GAAAATCAGCAGGGTGGAGGCTGAGGATGTTGG TATTTATTACTGCATACAAGATACACACTGGCCC ACGTGCAGTTTTGGCCAGGGGACCAAGCTGGAG ATCAAACGA 64A8 V_(L)1 421 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT 67B4 CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGGACATTAGAAATGATTTAG GCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCGCCTGATCTATGCTGCATCCAATTTGCAAA GGGGGGTCCCATCAAGGTTCAGCGGCAGTGGAT CTGGGACAGAATTCACTCTCACAATCAGCACCC TGCAGCCTGAAGATTTTGCAACTTATTCCTGTCT CCAGCATAATAGTTACCCTCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 63G8v1 V_(L)104 1860 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACC ATCACTTGCCGGGCAAGTCAGGACATTAGAAAT GATTTAGGCTGGTATCAACAGAAACCA GGGAAAGCCCCTAAGCGCCTGATCTATGCTGCA TCCAATTTGCAAAGGGGGGTCCCATCA AGGTTCAGCGGCAGTGGATCTGGGACAGAATTC ACTCTCACAATCAGCACCCTGCAGCCT GACGATTTTGCAACTTATTCCTGTCTCCAGCATA ATAGTTACCCTCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 63G8v2 V_(L)105 1861 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACC ATCACTTGCCGGGCAAGTCAGGGCATTAGAAGT GGTTTAGGCTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCGCCTGATCTATGCTGCA TCCAATTTGCAAAGGGGGGTCCCATCA AGGTTCAGCGGCAGTGGATCTGGGACAGAATTC ACTCTCACAGTCAGCAGTCTGCAGCCT GAAGATTTTGCAACTTATTCCTGTCTCCAGCATA ATAGTTACCCTCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 63G8v3 V_(L)106 1862 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACC ATCACTTGCCGGGCAAGTCAGGGCATTAGAAGT GGTTTAGGCTGGTATCAACAGAAACCA GGGAAAGCCCCTAAGCGCCTGATCTATGCTGCA TCCAATTTGCAAAGGGGGGTCCCATCA AGGTTCAGCGGCAGTGGATCTGGGACAGAATTC ACTCTCACAGTCAGCAGTCTGCAGCCT GAAGATTTTGCAACTTATTCCTGTCTCCAACATA ATACTTACCCTCTCACTTTCGGCGGA GGGACCAAGGGGGAGATCAGACGA 66G2 V_(L)12 422 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGGGCATTAGAAATGATTTAG GCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCGCCTGATCTATGCTGCATCCAATTTGCAAA GTGGGGTCCCATCAAGGTTCAGCGGCAGTGGAT CTGGGACAAAATTCACTCTCACAATCAACAGCC TGCAGCCTGAAGATTTTGCAACTTATTACTGTCT ACAACTTAATGGTTACCCTCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 68D3v1 V_(L)2 423 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT 68D3v2 CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGGACATTAGAAATGATTTAG GCTGGTATCAACAGAAACCAGGGAAAGCCCCTA AGCGCCTGATCTATGCTGCATCCAATTTGCAAA GGGGGGTCCCATCAAGGTTCAGCGGCAGTGGAT CTGGGACAGAATTCACTCTCACAATCAGCACCC TGCAGCCTGACGATTTTGCAACTTATTCCTGTCT CCAGCATAATAGTTACCCTCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 65D1 V_(L)27 424 TCCTATGACCTGACTCAGCCACCCTCAGTGTCCG TGTCCCCAGGACAGACAGCCAGCATCACCTGCT CTGGAGATAAATTGGGGGATAAATATGTTTGCT GGTATCAGCAGAAGCCAGGCCAGTCCCCTGTGC TGGTCATCTATCAAGATAGTAAGCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAACTCTGG GAACACAGCCACTCTGACCATCAGCGGGATCCA GGCTATGGATGAGGCTGACTATTACTGTCAGGC GTGGGACAGCAGGGTATTCGGCGGAGGGACCA AGCTGACCGTCCTAGGT 65G4 V_(L)8 425 TCCTATGAGATGACTCAGCCACTCTCAGTGTCAG 64H5 TGGCCCTGGGACAGACGGCCAGGATTACCTGTG GGGGAAACAACATTGGAAGTAAAAATGTACACT GGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGT TGGTCATCTATAGGGATAGCAAGCGGCCCTCTG GGATCCCTGAGCGATTCTCTGGCTCCAACTCGG GGAACACGGCCACCCTGACCATCAGCAGAGCCC AAGCCGGGGATGAGGCTGACTATTACTGTCAGG TGTGGGACAGCAGTAGTGTGGTATTCGGCGGAG GGACCAAGCTGACCGTCCTAGGT 65D4 V_(L)26 426 TCCTATGAGCTGACTCAGCCACTCTCAGTGTCTG TGGCCCTGGGCCAGACGGCCAGGATTCCCTGTG GGGGAAATGACATTGGAAGTAAAAATGTGCACT GGTACCAGCAGAAACCAGGCCAGGCCCCTGTGC TGGTCATCTATAGGGATCGCAACCGGCCCTCTG GGATCCCTGAGCGATTCTCTGGCTCCAACTCGG GGAACACGGCCACCCTGACCATCAGCAGAGCCC AAGCCGGGGATGAGGCTGACTATTACTGTCAGG TGTGGGACAGCAACCCTGTGGTATTCGGCGGAG GGACCAAGCTGACCGTCCTAGGT 65E3 V_(L)25 427 TCCTATGAGCTGACTCAGCCACTCTCAGTGTCAG TGGCCCTGGGACAGACGGCCAGGATTACCTGTG GGGGAAACAACATTGGAAGTAAAAATGTGCACT GGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGC TGGTCATCTATAGGGATAGAAACCGGCCCTCTG GGATCCCTGAGCGATTCTCTGGCTCCAACTCGG GGAACACGGCCACCCTGACCATCAGCAGAGCCC AAGCCGGGGATGAGGCTGACTATTACTGTCAGG TGTGGGACAGCAGCACTGTGGTCTTCGGCGGAG GGACCAAGCTGACCGTCCTAGGT 68G5 V_(L)13 428 TCCTATGAGCTGACTCAGCCACTCTCAGTGTCAG TGGCCCTGGGACAGACGGCCAGGCTTACCTGTG GGGGTAACAACATTGGAAGTATAAATGTGCACT GGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGT TGGTCATCTATAGGGATAGGAACCGGCCCTCTG GGATCCCTGAGCGATTCTCTGGCTCCAACTCGG GTAACACGGCCACCCTGACCATCAGCAGAGCCC AAGCCGGGGATGAGGCTGACTATTACTGTCAGT TGTGGGACAGCAGCACTGTGGTTTTCGGCGGAG GGACCAAGCTGACCGTCCTAGGT 67G8 V_(L)28 429 TCCTATGAGCTGACTCAGCCACTCTCAGTGTCAG TGGCCCTGGGACAGACGGCCAGGATTACCTGTG GGGGAAACAACATTGGAAGTTACAATGTGTTCT GGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGC TGGTCATCTATAGGGATAGCAAGCGGCCCTCTG GGATCCCTGAGCGATTCTCTGGCTCCAACTCGG GGAACACGGCCACCCTGACCATCAGCAGAGCCC AAGCCGGGGATGAGGCTGACTATCACTGTCAGG TGTGGGACAGCAGCACTGTGGTATTCGGCGGAG GGACCAAGCTGACCGTCCTAGGT 65B7v1 V_(L)29 430 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACC CTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGC ATCTACTTAGCCTGGTACCAGCAGAAA CCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTG CATCCAGCAGGGCCACTGGCATCCCA GACAGGTTCAGTGGCAGTGGGTCTGGGACAGAC TTCACTCTCACCATCAGCAGACTGGAG CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGT ATGGTAGCTCGTGCAGTTTTGGCCAG GGGACCAAGCTGGAGATCAAACGA 65B7v2 V_(L)107 1863 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGC CCGTCACCCTTGGACAGCCGGCCTCC ATCTCCTACAGGTCTAGTCAAAGCCTCGTATACA GTGATGGAGACACCTACTTGAATTGG TTTCAGCAGAGGCCAGGCCAATCTCCAAGGCGC CTAATTTATAAGGTTTCTAACTGGGAC TCTGGGGTCCCAGACAGATTCAGCGGCAGTGGG TCAGGCACTGATTTCACACTGAAAATC AGCAGGGTGGAGGCTGAGGATGTTGGGGTTTAT TACTGCATGCAAGGTACACACTGGCGG GGTTGGACGTTCGGCCAAGGGACCAAGGTGGAA ATCAAACGA 63B6 V_(L)4 431 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG 64D4 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGTAACAGCTACT TAGCCTGGTACCAGCAGAAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATTCAGTAGGGC CACTGGCATCCCAGACAGGTTCAGTGGCAGTGG GTCTGGGACAGACTTCACTCTCACCATCAGCAG ACTGGAGCCTGAAGATTTTGCAGTATATTACTGT CAGCAGTTTGGTAGGTCATTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAGACGA 63F5 V_(L)14 432 GAAGTTGTGTTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGACTGTTAGGAACAACTACT TAGCCTGGTACCAGCAGCAACCTGGCCAGGCTC CCAGGCTCCTCATCTTTGGTGCGTCCAGCAGGGC CACTGGCATCCCAGACAGGTTCAGTGGCAGTGG GTCTGGGACAGACTTCACTCTCACCATCAGCAG ACTGGAGCCTGAAGATTTTGCAGTGTATTACTGT CAGCAGTTTGGTAGTTCACTCACTTTCGGCGGAG GGACCAAGGTGGAGATCAAACGA 65E8 V_(L)3 433 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG 63H11 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT 64E6 GCAGGGCCAGTCAGAGTGTTAGGAACAGCTACT 65F11 TAGCCTGGTACCAGCAGCAACCTGGCCAGGCTC 67G7 CCAGGCTCCTCATCTATGGTGCATTTAGCAGGGC CTCTGGCATCCCAGACAGGTTCAGTGGCAGTGG GTCTGGGACAGACTTCACTCTCACCATCAGCAG ACTGGAGCCTGAAGATTTTGCAGTGTATTACTGT CAGCAGTTTGGAAGCTCACTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 65C1 V_(L)16 434 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGACTATTAGGAACAGCTACT TAGCCTGGTACCAGCAGCAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATTCAGCAGGG CCACTGGCATCCCAGACAGGTTCAGTGGCGGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAGTTTGGTAGCTCACTCACTTTCGGCGG AGGGACCAAGGTGGAGATCAAACGA 66F6 V_(L)15 435 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGGAACAGCTACT TAGCCTGGTACCAGCAGCAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATTCAGCAGGG CCACTGGCATCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAGTTTGGTAGCTCACTCACTTTCGGCGG AGGGACCAAGGTGGAGATCAAACGA 64A6 V_(L)30 436 GAAATACTGATGACGCAGTCTCCAGCCACCCTG TCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAACAGCAACTTAG CCTGGTACCAGCAGAAACCTGGCCAGGCTCCCA GGCTCCTCATCTATGGTACATCCACCAGGGCCA CTGGTGTCCCAGCCAGGTTCGGTGGCAGTGGGT CTGGGACAGAATTCACTCTCACCATCAGCAGCC TGCAGTCTGAAGATTTTGCATTTTATTACTGTCA GCAATATAATACCTGGCCGTGGACGTTCGGCCA AGGGACCAAGGTGGAAATCAAACGA 65F9 V_(L)31 437 GAAATACTGATGACGCAGTCTCCAGCCACCCTG TCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAG CCTGGTACCAGCAGAAACCTGGCCAGTCTCCCA GGCTCCTCATCTATGGTGCATCCACCAGGGCCA CTGGTATCCCAGCCAGGTTCGGTGGCAGTGGGT CTGGGACAGACTTCACTCTCACCATCAGCAGCC TGCAGTCTGAAGATTTTGCATTTTATTACTGTCA GCAGTATAATACCTGGCCGTGGACGTTCGGCCA AGGGACCAAGGTGGAAATCAAACGA 64A7 V_(L)17 438 GAAATTGTATTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGTCGCAACTACT TAGCCTGGTACCAGCAGAAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATCCAGCAGGG CCACTGGCGTCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAGTATGGTAGTTCATCTCTGTGCAGTTT TGGCCAGGGGACCAACCTGGACATCAGACGA 65C3 V_(L)5 439 GAAATGGTGATGACGCAGTCCCCAGCCACCCTG 68D5 TCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGCAGCCAGTTAG CCTGGTACCAGGAGAAACCTGGCCGGGCTCCCA GGCTCCTCATCTATGGTGCCTCCAACAGGGCCAT TGATATCCCAGCCAGGTTAAGTGGCAGTGGGTC TGGGACAGAGTTCACTCTCACCATCAGCAGCCT GCAGTCTGAAGATTTTGCTGTTTATTACTGTCAG CAGTATAATAACTGGCCGTGGACGTTCGGCCAA GGGACCAAGGTGGAATTCAAACGA 67F5 V_(L)32 440 GAAATAGTGATGACGCAGTCTCCAGCCACCCTG TCTGTGTCTCCAGGGGAAAGAGTCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAG CCTGGTACCAGCAGAAACCTGGCCAGGCTCCCA GGCTCCTCATACATGGTTCATCCAACAGGGCCA TTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGT CTGGGACAGAGTTCACTCTCACCATCAGCAGCC TGCAGTCTGCAGATTTTGCTGTTTATAACTGTCA GCAGTATGAAATTTGGCCGTGGACGTTCGGCCA AGGGACCAAGGTGGAAATCAAACGA 64B10v1 V_(L)33 441 CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTG 64B10v2 CGGCCCCAGGACAGAAGGTCACCATCTCCTGCT CTGGAAGCAGCTCCAATATTGGGAATAATTATG TAGCCTGGTACCAGCAGCTCCCAGGAACAGCCC CCAAACTCCTCATTTATGACAATGATAAGCGAC CCTCAGGGATTCCTGACCGATTCTCTGGCTCCAA GTCTGGCACGTCAGCCACCCTGGGCATCACCGG ACTCCAGACTGGGGACGAGGCCGATTATTACTG CGGAACATGGGATAGCAGCCTGAGTGCTGTGGT ATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGT 68C8 V_(L)34 442 CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTG CGGCCCCAGGACAGAAGGTCACCATCTCCTGCT CTGGAAGCAGTTCCAACATTGGAAATAATTATG TATCCTGGTACCAGCAGCTCCCAGGAACAGCCC CCAAACTCCTCATTTATGACAATAATAAGCGAC CCTCAGGGATTCCTGACCGATTCTCTGGCTCCAA GTCTGGCACGTCAGCCACCCTGGGCATCACCGG ACTCCAGACTGGGGACGAGGCCGATTATTACTG CGGAACATGGGATAGCAGCCTGAGTGCTGTGGT ATTCGGCGGAGGGACCAAACTGACCGTCCTAGGT 67A5 V_(L)35 443 GATATTGTGATGACCCAGACTCCACTCTCCCTGC CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAGAGCCTCTTAAATAGTGATGA TGGAAATACCTATTTGGACTGGTACCTGCAGAA GCCAGGGCAGTCTCCACAACTCCTGATCTATAC GCTTTCCTATCGGGCCTCTGGAGTCCCAGACAG GTTCAGTGGCACTGGGTCAGGCACTGAATTCAC ACTGAAAATCAGCAGGGTGGAGGCTGAGGATGT TGGAGTTTATTACTGCATGCAACGTCTAGAGTTT CCTATTACCTTCGGCCAAGGGACACGACTGGAG ATTAAACGA 67C10 V_(L)36 444 GATTTTGTGATGACCCAGACTCCACTCTCCCTGC CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAGAGCCTCTTAAATAGTGATGA TGGAAACACCTATTTGGACTGGTACCTGCAGAA GCCAGGGCAGTCTCCACAGCTCCTGATCTATAC GCTTTCCTATCGGGCCTCTGGAGTCCCAGACAG GTTCAGTGGCAGTGGGTCAGGCACTGATTTCAC ACTGAAAATCAGCAGGGTGGAGGCTGAGGATGT TGGAGTTTATTACTGCATGCAACGTATAGAGTTT CCTATCACCTTCGGCCAAGGGACACGACTGGAG ATTAAACGA 64H6 V_(L)37 445 TCCTACGAGCTGACTCAGCCACTCTCAGTGTCAG TGGCCCTGGGACAGACGGCCAGGATTACCTGTG GGGGAAACAACATTGGAAGTAAAAATGTGCACT GGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGG TGGTCATCTATAGGGATAGCAAGCGGCCCTCTG GGATCCCTGAGCGATTCTCTGGCTCCAACTCGG GGAACACGGCCACCCTGACCATCAGCAGAGCCC AAGCCGGGGATGAGGCTGACTATTACTGTCAGG TGTGGGACAGCAGTCCTGTGGTATTCGGCGGAG GGACCAAGCTGACCGTCCTAGGT 63F9 V_(L)38 446 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGTATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGGACATTAGAAATGATTTAG CCTGGTATCAGCAGACACCAGGGAAAGCCCCTA AGCGCCTGATCTATGCTTCATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGCGGCACTGGATC TGGGACAGAATTCACTCTCACAATCAGCAGCCT GCAGCCTGAAGATTTTGCAACTTATTTCTGTCTA CAGCGTAATAGTTACCCGCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 67F6v1 V_(L)39 447 GATATTGTAATGACCCAGACCCCACTCTCCCTGC CCGTCATCCCTGGAGAGCCGGCCTCCATCTTCTG CAGGTCTAGTCAGAGCCTCTTAAATAGTGATGC TGGTACCACCTATTTGGACTGGTACCTGCAGAA GCCAGGGCAGTCTCCACAACTCCTGATCTATAC GCTTTCCTTTCGGGCCTCTGGAGTCCCAGACAGG TTCAGTGGCAGTGGGTCAGGCACTGATTTCACA CTGAAAATCACTAGGGTGGAGGCTGAGGATGTT GGAGTTTATTATTGCATGCAACGTATAGAGTTCC CTATCACCTTCGGCCAAGGGACACGACTGGAGA TTAAACGA 67F6v2 V_(L)108 1864 GATATTGTAATGACCCAGACCCCACTCTCCCTGC CCGTCATCCCTGGAGAGCCGGCCTCCATCTTCTG CAGGTCTAGTCAGAGCCTCTTAAATAGTGATGC TGGTACCACCTATTTGGACTGGTACCTGCAGAA GCCAGGGCGGTCTCCACAACTCCTGATCTATAC GCTTTCCTTTCGGGCCTCTGGAGTCCCAGACAGG TTCAGTGGCAGTGGGTCAGGCACTGATTTCACA CTGAAAATCACTAGGGTGGAGGCTGAGGATGTT GGAGTTTATTATTGCATGCAACGTATAGAGTTCC CTATCACCTTCGGCCAAGGGACACGACTGGAGA TTAAACGA 48C9 V_(L)78 448 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT 49A12 CTGCATCTATAGGAGACAGAGTCACCATCACTT 51E2 GCCGGGCAAGTCAGAACATTAGGACCTATTTAA ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATTTATGTTGCATCCAGTTTGGAAAG TGGGGTCCCATCAAGGTTCAGTGGCACTGGATC TGGGACAGATTTCGCTCTCACCATCAGCAGTCTC CAACCTGAAGATTTTGCAACTTACTACTGTCAAC AGAGTGACAGTATCCCTCGGACGTTCGGCCAAG GGACCAAGGTGGAAATCAAACGA 48F3 V_(L)77 449 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGAGGATTAGCAGTTATTTAA ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGTTCTTGATATATGCTGTATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGTCTG GAACCTGAAGATTTTGCAACTTACTACTGTCAAC AGAGTTACAGTGCTACATTCACTTTCGGCCCTGG GACCAAAGTGGATATCAAACGA 48F8 V_(L)49 450 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAGT 53B9 CTGTGACTCCAAAGGAGAAAGTCACCATCACCT 56B4 GCCGGGCCAGTCAGGACATTGGTAATAGCTTAC 57E7 ACTGGTACCAGCAGAAACCAGATCAGTCTCCAA 57F11 AGCTCCTCATCAAGTTTGCTTCCCAGTCCTTCTC AGGGGTCCCCTCGAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCGCCCTCACCATCAATAGCCT GGAAGCTGAAGATGCTGCAACGTATTACTGTCA TCAGAGTAGTGATTTACCGCTCACTTTCGGCGGA GGGACCAAGGTGGACATCAAACGA 48H11 V_(L)40 451 GACATCCAGATGACCCAGTCTCCATCCTCTCTGT CTACATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGAACATTAGGAGCTATTTAA ATTGGTATCAACTGAAACCAGGGAAAGCCCCTA AGGTCCTGATCTATGGTGCATCTAATTTACAGAG TGGGGTCCCATCAAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAATCTG CAATCTGAAGATTTTGCAATTTACTACTGTCAAC AGAGTTACAATACCCCGTGCAGTTTTGGCCAGG GGACCAAGCTGGAGATCAAACGA 49A10 V_(L)65 452 GATATTGTGATGACCCAGACTCCACTCTCCCTGC 48D4 CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAGAGCCTCTTGGATAGTGATGA TGGAAACACCTATTTGGACTGGTACCTGCAGAA GCCAGGGCAGTCTCCACAGCTCCTGATCTATAC GCTTTCCTATCGGGCCTCTGGAGTCCCAGACAG GTTCAGTGGCAGTGGGTCAGGCACTGATTTCAC ACTGAAAATCAGCAGGGTGGAGGCTGAGGATGT TGGAGTTTATTACTGCATGCAACGTATAGAGTTT CCGATCACCTTCGGCCAAGGGACACGACTGGAG ATTAAACGA 49C8 V_(L)45 453 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT 52H1 CTGCATCTGTAGGAGACAGAGTCACCTTCACTT GCCAGGCGAGTCAGGACATTAACATCTATTTAA ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTACGATGTATCCAATTTGGAAAC AGGGGTCCCATCAAGGTTCAGTGGAAGTGGATC TGGGACAGATTTTACTTTCACCATCAGCAGCCTG CAGCCTGAAGATATTGCAACATATTTCTGTCAAC AATATGATAATCTCCCATTCACTTTCGGCCCTGG GACCAAAGTGGATCTCAAACGA 49G2 V_(L)66 454 GATATTGTGTTGACCCAGACTCCACTCTCCCTGC 50C12 CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG 55G11 CAGGTCTAGTCAGAGCCTCTTGGATAGTGATGA TGGAGACACCTATTTGGACTGGTACCTGCAGAA GCCAGGGCAGTCTCCACAGCTCCTGATCTATAC GCTTTCCTATCGGGCCTCTGGAGTCCCAGACAG GTTCAGTGGCAGTGGGTCAGGCACTGATTTCAC ACTGAAAATCAGCAGGGTGGAGGCTGAGGATGT TGGAGTTTATTACTGCATGCAACATATAGAATTT CCTTCGACCTTCGGCCAAGGGACACGACTGGAG ATTAAACGA 49G3 V_(L)47 455 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTATAGGAGACAGAGTCACCATCACTT GCCAGGCGAGTCAGGGCATTAGCAACTATTTAA ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTACGATGCATCCAATTTGGAAA CAGGGGTCCCATCAAGGTTCAGTGGAAGTGGAT CTGGGACAGATTTTACTTTCACCATCAGCAGCCT GCAGCCTGAAGATATTGCTACATATTACTGTCAC CAGTATGATGATCTCCCGCTCACTTTCGGCGGAG GGACCAAGGTGGAGATCAGACGA 49H12 V_(L)43 456 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCAGGCGAGTCAAGACATTACCAAATATTTAA ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTACGATACATTCATTTTGGAAAC AGGGGTCCCATCAAGGTTCAGTGGAAGTGGATC TGGGACAGATTTTACTTTCACCATCAGCAGCCTG CAGCCTGAAGATATTGCAACATATTACTGTCAA CAGTATGACAATTTACCGCTCACCTTCGGCCAA GGGACACGACTGGAGATTAAACGA 51A8 V_(L)61 457 AATTTTATACTGACTCAGCCCCACTCTGTGTCGG AGTCTCCGGGGAAGACGGTAACCATCTCCTGCA CCCGCAGCAGTGGCAGCATTGCCAGCGACTATG TGCAGTGGTACCAGCAGCGCCCGGGCAGTTCCC CCACCACTGTGATCTATGAGGATAAAGAAAGAT CCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCAT CGACAGTTCCTCCAACTCTGCCTCCCTCACCATC TCTGGACTGAAGACTGAGGACGAGGCTGACTAC TACTGTCAGTCTTATGATCGCAACAATCATGTGG TTTTCGGCGGAGGGACCAAGCTGACCGTCCTAG GT 51C10.1 V_(L)55 458 TCCTATGAGTTGACACAGCCGCCCTCGGTGTCTG TGTCCCCAGGCCAAACGGCCAGGATCACCTGCT CTGGAGATGCATTGCCAAAAAAATATGCTTATT GGTACCAGCAGAAGTCAGGCCAGGCCCCTGTGC TGGTCATCTATGAGGACAGCAAACGACCCTCCG GGATCCCTGAGAGATTCTCTGGCTCCATCTCAGG GACAATGGCCACCTTGACTATCAGTGGGGCCCA GGTGGAGGATGAAGCTGACTACTACTGTTACTC AACAGACAGCAGTGTTAATCATGTGGTATTCGG CGGAGGGACCAAGCTGACCGTCCTAGGT 51C10.2 V_(L)70 459 TCCTATGACCTGACTCAGCCACCCTCAGTGTCCG TGTCCCCAGGACAGACAGCCAGCATCACCTGCT CTGGAGACGAATTGGGGGATAAATATGCTTGCT GGTATCAGCAGAAGCCAGGCCAGTCCCCTGTGC TGGTCATCTATCAAGATACCAAGCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAACTCTGG GAACACAGCCACTCTGACCATCAGCGGGACCCA GGCTATGGATGAGGCTGACTATTACTGTCAGGC GTGGGACAGCGGCACTGTGGTATTCGGCGGAGG GACCAAACTGACCGTCCTAGGT 51E5 V_(L)79 460 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGGACATTAGAAATGATTTAG GCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA ACCGCCTGATCTATGCTGCATCCAGTTTGCAATT TGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC TGGGACAGAATTCACTCTCACAATCAGCAGCCT GCAGCCTGAAGATTTTGCAACTTATTACTGTCTA CAACATAGTAGTTACCCGCTCACTTTCGGCGGA GGGACCAGGGTGGAGATCAAACGA 51G2 V_(L)51 461 GACATCCAGATGACCCAGTCTCCATCTTCCGTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAG CCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTATGATGCATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGCCT GCAGCCTGAAGATTTTGCAACTTACTATTGTCAA CAGACTAACAGTTTCCCTCCGTGGACGTTCGGCC AAGGGACCAAGGTGGAAATCAAACGA 52A8 V_(L)41 462 GACATCCAGATGACCCAGTCTCCATCCTTCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGACTATTAGCAGTTATTTAA ATTGGCATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTATGCTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCAGTCTCACCATCAGCAGTCT GCAACCTGAAGATTTTGCAACTTACTACTGTCAG CAGAGTTACAGTACCCCGCTCACTTTCGGCGGC GGGACCAAGGTGGAGATCAAACGA 52B8 V_(L)82 463 GAAGTTGTGCTGACGCAGTCTCCAGCCACCCTG TCTGTGTCTCCAGGGGGAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGCGACATCTTAG CCTGGTACCAACAGAAACCTGGCCAGGCTCCCA GGCTCCTCATCTATGGTGCATCCACCAGGGCCA CTGGTATCCCAGCCAGGTTCAGTGGCGGTGGGT CTGGGACAGAGTTCACTCTCACCATCAGTAGCC TGCAGTCTGAAGATTTTGCAGTTTATTTCTGTCA GCAGTATAATAACTGGCCGCTCACTTTCGGCGG AGGGACCAAGGTGGAGATCAAACGA 52C1 V_(L)67 464 CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTG CGGCCCCAGGACAGAAGGTCACCATCTCCTGCT CTGGAAGCAGCTCCAACATTGGGATTAATTATG TATCCTGGTACCAGCAGCTCCCAGGAACAGCCC CCAAACTCCTCATTTATGACAATAATAAGCGAC CCTCAGGGATTCCTGACCGATTCTCTGGCTCCAA GTCTGGCACGTCAGCCACCCTGGGCATCACCGG ACTCCAGACTGGGGACGAGGCCGATTATTGCTG CGGAACATGGGATAGCAGCCTGAGTGCTGTGGT ATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGT 52F8 V_(L)42 465 GATATTGTGATGACTCAGTCTCCACTCTCCCTGC CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAGAGCCTCCTGCATAGTAATGG ATACAACTATTTGGATTGGTACCTGCAGAAGCC AGGGCAGTCTCCACAGCTCCTGATCTATTTGGGT TCTAATCGGGCCTCCGGGGTCCCTGACAGGTTC AGTGGCAGGGGGTCAGGCACAGATTTTTCACTG AAAATCAGCAGAGTGGAGGCTGAGGATGTTGGG ATTTATTACTGCATGCAAGCTCTACAAACTCCAT TCACTTTCGGCCCTGGGACCAATGTGGATATCA AACAA 52H2 V_(L)84 466 GAAAATGTGTTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCTT GTAGGGCCAGTCAGAGTGTTAGAAGCAGCTACT TAGCCTGGTACCAGCAGAGACCTGGCCAGGCTC CCAGGCTCCTCATCTTTGGTGCATCCAGGAGGG CCACTGGCATCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAGTATGGTAGTTCACCTCGCAGTTTTGG CCAGGGGACCAAGCTGGAGATCAAACGA 53F6 V_(L)63 467 GATATTGTGATGACTCAGTCTCCACTCTCCCTGC CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAGAGCCTCCAGCATAGTAATGG ATACAACTATTTGGATTGGTACCTGCAGAAGCC AGGACAGTCTCCACAGTTATTGATCTATTTGGAT TCTAATCGGGCCTCCGGGGTCCCTGACAGGTTC AGTGGCAGTGGATCAGGCACAGATTTTACACTG AAAATCAGCAGAGTGGAGGCTGAGGATATTGGG GTTTATTACTGCATGCAAGGTCTACAAACTCCTC CCACTTTCGGCGGAGGGACCAAGGTGGAGATCA AACGA 53H5.2 V_(L)62 468 GACATCCAGATGACCCAGTCTCCATCTTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGGGCATTAGAAATGATTTAG GCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCGCCTGATCTATGCTGCATCCAGTTTGCAAA GTGGGGTCCCATCAAGGTTCAGCGGCAGCGGAT CTGGGACAGAATTCACTCTCACAATCAGCAGCC TGCAGCCTGAAGATTTTGCAACTTATTACTGTCT ACAGCATAAGAGTTACCCATTCACTTTCGGCCCT GGGACCAAAATGGATATCAAAGGA 53H5.3 V_(L)80 469 GAAATAGTGATGACGCAGTCTCCAGTCACCTTG TCTGTGTCTCCAGGGGAAAGAGCCATCATCTCCT GCAGGGCCAGTCAGAGTGTTAGCAGCAACGTCG CCTGGTACCAGCAGAAACCTGGCCAGACTCCCA GGCTCCTCATCTATGGTGCATCCACCAGGGCCA CTGGTCTCCCAACCAGGTTTAGTGGCAGTGGGT CTGGGACAGTGTTCACTCTCACCATCAGCAGCCT GCAGCCTGAAGATTTTGCAGTTTATTACTGTCAG CAGTTTAGTAACTCAATCACCTTCGGCCAAGGG ACACGACTGGAGATTAAACGA 54A1 V_(L)44 470 GACATCCAGATGGCCCAGTCTCCATCCTCCCTGT 55G9 CTGCATCTGTTGGAGACAGAGTCACCATCACTT GCCAGGCGAGTCAGGACATTAGCATCTATTTAA ATTGGTATCAGCTGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTACGATGTATCCAATTTGGAAAC AGGGGTCCCATCAAGGTTCAGTGGAGGTGGATC TGGGACAGATTTTACTTTCACCATCAGCAGCCTG CAGCCTGAAGATATTGCAACATATTACTGTCAA CAGTATGATAATCTCCCTCTCACTTTCGGCCCTG GGACCAAAGTGGATATCAAACGA 54H10.1 V_(L)53 471 GAAATTGTGGTGACGCAGTCTCCAGGCACCCTG 55D1 TCTTTGTCTGTAGGGGAAAGAGCCATCCTCTCCT 48H3 GCAGGGCCAGTCAGAGTTTTAGCAGCAGTTACT 53C11 TAGCCTGGTACCAGCAGAAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATCCAGCAGGG CCACTGGCATCCCAGACAGGTTCAGCGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGTA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAGTATGGTAGCTCACGGACGTTCGGCC AAGGGACCAAGGTGGAAATCAAACGA 55D3 V_(L)71 472 GACATCCAGATGACCCAGTCTCCATCCTCACTGT CTGTATCTGTAGGAGACAGAGTCACCATCACTT GTCGGGCGAGTCAGGACATTAGCAATTATTTAG CCTGGTTTCAGCAGAAACCAGGGAAAGCCCCTA AGTCCCTGATCTATGCTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAAGTTCAGCGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGCCT GCAGCCTGAAGATTTTGCAACTTATTACTGCCAA CAGTATAATATTTACCCTCGGACGTTCGGCCAA GGGACCAAGGTGGAAATCAAGCGA 55E4 V_(L)75 473 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT 49B11 CTACATCTATAGGAGACAGAATCACCATCACTT 50H10 GCCGGGCAAGTCAGAGCATTAGTAACTATTTAA 53C1 ATTGGTTTCAGCAGATCCCAGGGAAAGCCCCTA GGCTCCTGATCTATACAGCTTCCAGTTTGCAAAG TGGGGTCCCATCGAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGTCTG CAACCTGAAGATTTTGCAACTTACTACTGTCAAC AGAGTTCCAGTATCCCTTGGACGTTCGGCCAAG GGACCAAGGTGGAAATCAAACGA 55E9 V_(L)68 474 GATATTGTGATGACTCAGTCTCCACTCTCCCTGC CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAGAGCCTCCTGCATAGTAACGG ATTCAACTATTTGGATTGGTACCTGCAGAAGCC AGGGCAGTCTCCACAGGTCCTGATCTATTTGGGT TCTAATCGGGCCTCCGGGGTCCCTGACAGGTTC AGTGGCAGTGGATCAGGCACAGATTTTACACTG AAAATCAGCAGAGTGGAGGCTGAGGATGTTGGG ATTTATTACTGCATGCAAGCTCTACAAACTCTCA TCACCTTCGGCCAAGGGACACGACTGGAGATTA AACGA 55G5 V_(L)83 475 TCCTATGAACTGACTCAGCCACCCTCAGTGTCCG TGTCCCCAGGACAGACAGCCAGCATCACCTGCT CTGGAGATAATTTGGGGGATAAATATGCTTTCT GGTATCAACAGAAGCCAGGCCAGTCCCCTGTAT TGGTCATCTATCAAGATAACAAGCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAACTCTGG GAACACAGCCACTCTGACCATCAGCGGGACCCA GGCTGTGGATGAGGCTGACTATTACTGTCAGGC GTGGGACAGCGCCACTGTGATTTTCGGCGGAGG GACCAAGTTGACCGTCCTAGGT 56A7 V_(L)52 476 GACATCCAAATGACCCAGTCTCCATCTTCCGTGT 56E4 CTGCATCTGTAGGAGACAGAGTCACCATCACTT GTCGGGCGAGTCAGGATATTAGCAGTTGGTTAG CCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AATTCCTGATCTATGATGCATCCACTTTGCAAAG TGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC TGGGGCAGATTTCACTCTCACCATCAACAACCT GCAGCCTGAAGATTTTGCAACTTACTATTGTCAA CAGACTAACAGTTTTCCTCCGTGGACGTTCGGCC AAGGGACCAAGGTGGAAATCAAACGA 56C11 V_(L)64 477 TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAG TGGCCCCAGGACAGGCGGCCAGGATTACCTGTG GGGGAAACGACATTGGAAGTAAAAGTGTGCACT GGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGC TGGTCGTCTATGATGATAGCGACCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAAGTCTGG GAACACGGCCACCCTGATTATCAGCAGGGTCGA AGCCGGGGAAGAGGCCGACTATTATTGTCAGGT GTGGGATAGTAGTAGTGATGTGGTATTCGGCGG AGGGACCAAGTTGACCGTCCTAGGT 56E7 V_(L)86 478 GACCTCCAGATGACCCAGTCTCCTTCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCAGGCGAGTCAGGACATTAAAAAATTTTTAA ATTGGTATCAGCAGAAACCAGGTAAAGCCCCTA ACCTCCTGATCTACGATGCATCCAATTTGGAAAC AGGGGTCCCATCAAGGTTCAGTGGAAGTGGATC TGGGACAGATTTTACTTTCACCATCAGCAGCCTG CAGCCTGAAGATATTGCAACATATTACTGTCAA CAATATGCTATTCTCCCATTCACTTTCGGCCCTG GGACCACAGTGGATATCAAACGA 56G1 V_(L)76 479 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGAGCATTAGCAACTATTTAA ATTGGTTTCTGCAGATACCAGGGAAAGCCCCTA AACTCCTGATCTATGCAGCTTCCAGTTTACAAAG TGGGGTCCCATCGAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAACAGTCTG CAACCTGAAGATTTTGGAACTTACTACTGCCAA CAGAGTTCCACTATCCCTTGGACGTTCGGCCAA GGGACCAAGGTGGAAATCAAACGA 56G3.3 V_(L)81 480 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG 55B10 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGCAGAGACTACT TAGCCTGGTATCGGCAGAAACCTGGCCAGGCTC CCAGGCTCCTCGTCTATGGTGCATCCGCCAGGG CCACTGGCATCCCAGACAGATTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAATATGGTAGATCACTATTCACTTTCGG CCCTGGGACCAAAGTGGATATCAAACGA 57B12 V_(L)72 481 GACATCCAGATGACCCAGTCTCCATCCTCACTGT CTGTATCTGTAGGAGACAGAGTCACCATCACTT GTCGGGCGAGTCATGACATTAGCAATTATTTAG CCTGGTTTCAGCAGAAACCAGGGAAAGCCCCTA AGTCCCTGATCTATGCTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAAGTTCAGCGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGCCT GCAGCCTGAAGATTTTGCAACTTATTACTGCCAA CAATATAATACTTACCCTCGGACGTTCGGCCAA GGGACCAAGGTGGAAATCAAGCGA 57D9 V_(L)87 482 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCCGAGTGTTAGCAGCAGCTACT TAGCCTGGTACCAGCAGAAACCTGCCCAGGCTC CCAGGCTCCTCATCTATGGTGCATCCAGTAGGG CCACTGGCATCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCATCAGTATGGTACCTCACCGTGCAGTTTTGG CCAGGGGACCAAGCTGGAGATCAAACGA 59A10 V_(L)48 483 GACATCCAGATGACCCAGTCTCCATCTTCCGTGT 49H4 CTGCATCTGTAGGAGACAGAGTCACCATCACTT GTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAG CCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AACTCCTGATCTATGGTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGCCT GCAGCCTGAAGATTTTGCAACTTATTATTGTCAA CAGACTAACAGTTTCCCTCCGTGGACGTTCGGCC AAGGGACCAAGGTGGAAATCAAACGA 59C9 V_(L)50 484 GACATCCAGATGACCCAGTCTCCATCTTCCGTGT 58A5 CTGCATCTGTAGGAGACAGAGTCACCATCACTT 57A4 GTCGGGCGAGTCAGGATATTGACAGCTGGTTAG 57F9 TCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA ACCTCCTGATCTATGCTGCATCCAATTTGCAAAG AGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCGCCAGCCTG CAGCCTGAAGATTTTGCAACTTACTATTGTCAGC AGACTAACAGTTTCCCTCCGTGGACGTTCGGCC AAGGGACCAAGGTGGAAATCAAACGA 59G10.2 V_(L)60 485 TCCTATGAGCTGTCTCAGCCACCCTCAGTGTCCG TGTCCCCAGGACAGACAGTCAGCATCACCTGCT CTGGAGATAATTTGGGGGATAAATATGCTTGCT GGTATCAGCAGAGGCCAGGCCAGTCCCCTGTCC TGGTCATCTATCAAGATACCAAGCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAATTCTGG GAACACAGCCACTCTGACCATCAGCGGGACCCA GGCTATGGATGAGGCTGACTATTACTGTCAGGC GTGGGACAGCAGCACTACATGGGTGTTCGGCGG AGGGACCAAGCTGACCGTCCTAGGT 59G10.3 V_(L)54 486 CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTG CGGCCCCAGGACAGAAGGTCACCATCTCCTGCT CTGGAAGCAGCTCCAACATTGGGGATAATTATG TATCCTGGTACCAGCAGTTCCCAGGAACAGCCC CCAAACTCCTCATTTATGACAATAATAAGCGAC CCTCAGGGATTCCTGACCGATTCTCTGGCTCCAA GTCTGGCACGTCAGCCACCCTGGGCATCACCGG ACTCCAGACTGGGGACGAGGCCGATTATTACTG CGGAACATGGGACAGCAGCCTGAGTGTTATGGT TTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGT 60D7 V_(L)69 487 GATATTGTGCTGACCCAGACTCCACTCTCCCTGC CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAGAGCCTCTTGGATAGTGATGA TGGAGACACCTATTTGGACTGGTACCTGCAGAA GCCAGGGCAGTCTCCACAGCTCCTGATCTATAC GCTTTCCTATCGGGCCTCTGGAGTCCCAGACAG GTTCAGTGGCAGTGGGTCAGGCACTGATTTCAC ACTGAAAATCAGCAGGGTGGAGGCTGAGGATGT TGGAGTTTATTACTGCATGCAACGTATAGAGTTT CCGCTCACTTTCGGCGGAGGGACCAAGGTGGAG ATCAAACGA 60F9 V_(L)58 488 GAAATTATGTTGACGCAGTCTCCAGGCACCCTG 48B4 TCTTTGTCTCCAGGGGAAAGGGCCACCCTCTCCT 52D6 GCAGGGCCAGTCAGAGGGTTCCCAGCAGCTACA TAGTCTGGTACCAGCAGAAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTTCATCCAACAGGGC CACTGGCATCCCAGACAGGTTCAGTGGCAGTGG GTCTGGGACAGACTTCACTCTCACCATCGGCAG ACTGGAGCCTGAAGATTTTGCAGTGTACTACTGT CAGCAGTATGGTAGCTCACCTCCGTGGACGTTC GGCCAAGGGACCAAGGTGGCAATCAAACGA 60G5.2 V_(L)46 489 TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCG TGTCCCCAGGACAGACAGCCAGCATCACCTGCT CTGGAAATAAATTGGGGGATAAATATGTTTGCT GGTATCAGCAGAAGCCAGGCCAGTCCCCTGTCT TGGTCATCTATCAAGATAGCAAGCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAACTCTGG GAACACAGCCACTCTGACCATCAGCGGGACCCA GGCTTTGGATGAGGCTGACTATTACTGTCAGGC GTGGGACAGCAGCACTTGGGTGTTCGGCGGAGG GACCAAGCTGACCGTCCTAGGT 61G5 V_(L)59 490 GAAATTATGTTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGAGTTCCCAGCAGCTACT TAGTCTGGTACCAGCAGAAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATCCAACAGGG CCACAGGCATCCCAGACAGGTTCAGCGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCGGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAGTATGGTAGTTCACCTCCGTGGACGTT CGGCCAAGGGACCAAGGTGGCAATCAAACGA 52C5 V_(L)73 491 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTATAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGAGCATTAGCAACTATTTAA ATTGGTTTCAGCAGATCCCAGGGAAAGCCCCTA GGCTCCTGATCTATGCAGCTTCCAGTTTGCAAAG TGGGGTCCCATCGAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGTCTG CAACCTGAAGATTTTGCAATTTACTACTGTCAAC AGAGTTCCAGTATCCCTTGGACGTTCGGCCAAG GGACCAAGGTGGAAATCAAACGA 61H5 V_(L)88 492 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG 52B9 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGCAGAGACTACT TAGCCTGGTACCGGCAGAAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATCCAGCAGGG CCACTGGCATCCCAGACAGATTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAATATGGTAGATCACTATTCACTTTCGG CCCTGGGACCACAGTGGATATCAAACGA 59D10v1 V_(L)56 493 TCCTATGAGCTGACACAGCCACCCTCGGTGTCTG TGTCCCCAGGCCAAACGGCCAGGATCACCTGCT CTGGAGATGCAGTGCCAAAAAAATATGCTAATT GGTACCAGCAGAAGTCAGGCCAGGCCCCTGTGC TGGTCATCTATGAGGACAGCAAACGACCCTCCG GGATCCCTGAGAGATTCTCTGGCTCCAGCTCAG GGACAATGGCCACCTTGACTATCAGTGGGGCCC AGGTGGAGGATGAAGCTGACTACTACTGTTACT CAACAGACAGCAGTGGTAATCATGTGGTATTCG GCGGAGGGACCAAGCTGACCGTCCTAGGT 59D10v2 V_(L)57 494 TCCTATGAGTTGACTCAGCCACCCTCAGTGTCCG TGTCCCCAGGACAGACAGCCAGCATCACCTGCT CTGGAGATAAATTGGGGGATAAATACGTTTGCT GGTATCAGCAGATGCCAGGCCAGTCCCCTGTGT TGGTCATCCATCAAAATAACAAGCGGCCCTCAG GGATCCCTGAGCGATTCTCTGGCTCCAACTCTGG GAACACAGCCACTCTGACCATCAGCGGGACCCA GGCTATGGATGAGGCTGACTATTATTGTCAGGC GTGGGATAGTAGTACTGCGGTATTCGGCGGAGG GACCAAGCTGACCGTCCTAGGT 56G3.2 V_(L)85 495 GAAACAGTGATGACGCAGTCTCCAGCCACCCTG TCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGGCAGAGTGTTGGCAGTAACTTAA TCTGGTACCAGCAGAAACCTGGCCAGGCTCCCA GGCTCCTCATCTTTGGTGCATCCAGCAGGGACA CTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGT CTGGGACAGAGTTCACTCTCACCATCAGCAGCC TGCAGTCTGAAGATTTTGCAGTTTATTACTGTCA GCAGTATAATAATTGGCCTCTCACTTTCGGCGGA GGGACCAAGGTGGAGATCAAACGA 66F7 V_(L)7 496 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGACAAGTCAGAGCATTAGCAACTATTTAA ATTGGTATCAGCAGAAACCAGGAAAAGCCCCTA ACCTCCTGATCTATGCTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAGATTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCGGTCTG CAACCTGAGGATTTTTCAACTTACTACTGTCAAC AGAGTTACAGTACCTCGCTCACTTTCGGCGGAG GGACCAAGGTGGAGATCAAACGA 48G4 V_(L)89 497 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG 53C3.1 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTGCCAGCAGTTACT TAGTCTGGTACCAACAGAAACCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATTCAGCAGGG CCACTGGCATCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGGA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAGTATGGTACCTCACCATTTACTTTCGG CCCTGGGACCAAAGTGGATCTCAAACGA 50G1 V_(L)90 498 GACATTGTGATGACCCAGACTCCACTCTCCCTGC CCGTCAGCCCTGGAGAGCCGGCCTCCATCTCCT GCAGGTCTAGTCAGAGCCTCTTGGATAGTGATG ATGGAGACACCTATTTGGACTGGTACCTGCAGA AGCCAGGGCAGTCTCCACAGCTCCTGATCTATA CGCTTTCCTATCGGGCCTCTGGAGTCCCAGACAG GTTCAGTGTCAGTGGGTCAGGCACTGATTTCAC ACTGAAAATCAGCAGGGTGGAGGCTGAGGATGT TGGAGTTTATTACTGCATGCAACGTATAGAGTTT CCGCTCACTTTCGGCGGAGGGACCAAGGTGGAG ATCAAACGA 58C2 V_(L)91 499 GAAATTGTGATGACCCAGACTCCACTCTCCCTGC CCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAGAGCCTCTTCGATAATGATGA TGGAGACACCTATTTGGACTGGTACCTGCAGAA GCCAGGGCAGTCTCCACAACTCCTGATCTATAC GCTTTCCTATCGGGCCTCTGGAGTCCCAGACAG GTTCAGTGGCAGTGGGTCAGGCACTGATTTCAC ACTGAAAATCAGCAGGGTGGAGGCTGAGGATGT TGGAGTTTATTACTGCATGCAACGTTTAGAGTTT CCGATCACCTTCGGGCAAGGGACACGACTGGAG ATTAAACGA 60G5.1 V_(L)74 1865 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTATAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGAGCATTAGCAACTATTTAA ATTGGTTTCAGCAGATCCCAGGGAAAGCCCCTA GGCTCCTGATCTATGCAGCTTCCAGTTTGCAAAG TGGGGTCCCATCGAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGTCTG CAACCTGAAGATTTTGCAACTTACTACTGTCAAC AGAGTTCCAGTATCCCTTGGACGTTCGGCCAAG GGACCAAGGTGGAAATCAAACGA 50D4 V_(L)92 500 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCGAGTCAGGACATTAGCAATTATTTAG CCTGGTATCAGCAGAAACCAGGGAAAGTTCCTA CGCTCCTGATCTATGCTGCATCCACTTTGCTATC AGGGGTCCCATCTCGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGCCT GCAGCCTGAAGATGTTGCAGCTTATTACTGTCA AAAGTATTACAGTGCCCCTTTCACTTTCGGCCCT GGGACCAAAGTGGATATCAACCGA 50G5v1 V_(L)93 501 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACTATCACTT GCCGGGCAAGTCAGGGCATTAGAAATGATTTAG GCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA ACCGCCTGATCTATGCTGCGTCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC TGGGACAGAATTCACTCTCACAATCAGCAGCCT GCAGCCTGAAGATTTTGCAACTTATTACTGTCTA CAGCATAATAGTTACCCTCGGACGTTCGGCCAA GGGACCAAGGTGGAAATCAAACGA 50G5v2 V_(L)94 502 GATGTTGTGATGACTCAGTGTCCACTCTCCCTGC CCGTCACCCTTGGACAGCCGGCCTCCATCTCCTG CAGGTCTAGTCAAAGACTCGTATACAGTGATGG AAACACCTACTTGAATTGGGTTCAGCAGAGGCC AGGCCAATCTCCAAGGCGCCTAATTTATAAGGT TTCTAACTGGGACTCTGGGGTCCCAGACAGATT CAGCGGCAGTGGGTCAGGCACTGATTTCACACT GAAAATCAGCAGGGTGGAGGCTGAGGATGTTGG GGTTAATTACTGCATGGAAGGTACACACTGGCC TCGGGACTTCGGCCAAGGGACACGACTGGAGAT TAAACGA 51C1 V_(L)95 503 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTATAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGAGCATTAGCAACTATTTAA ATTGGTTTCAGCAGATCCCAGGGAAAGCCCCTA GACTCCTGATCTATGCAGCTTCCAGTTTGCAAAG TGGGGTCCCATCGAGGTTTAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGTCTG CAACCTGAAGATTTTGCAACTTACTACTGTCAAC AGAGTTCCAGTATCCCTTGGACGTTCGGCCAAG GGACCACGGTGGAAATCAAACGA 53C3.2 V_(L)96 504 GACATAGTGATGACGCAGTCTCCAGCCACCCTG TCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTATTAGCAGCAATTTAG CCTGGTACCAGCAGACACCTGGCCAGGCTCCCA GGCTCCTCATCTATGGTACATCCATCAGGGCCA GTACTATCCCAGCCAGGTTCAGTGGCAGTGGGT CTGGGACAGAGTTCACTCTCACCATCAGCAGCC TGCAGTCTGAAGATTTTGCAATTTATTACTGTCA CCAGTATACTAACTGGCCTCGGACGTTCGGCCA AGGGACCAAGGTGGAAATCAAACGA 54H10.3 V_(L)97 505 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGACCATTAGCATCTATTTAA ATTGGTATCAGCAAAAACCAGGGAAAGCCCCTA AGTTCCTGATCTATTCTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGTCTG CAACCTGAAGATTTTTCAACTTACTTCTGTCAAC AGAGTTACAGTTCCCCGCTCACTTTCGGCGGAG GGACCAAGGTGGAGATCAAACGA 55A7 V_(L)98 506 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCGGGCAAGTCAGAGCATTAGCAGCTATTTAA ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTATGCTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGTGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGTCTG CAACCTGAAGATTTTGCAACTTACTACTGTCAAC AGACTTACAGTGCCCCATTCACTTTCGGCCCTGG GACCAAAGTGGATATCAAACGA 55E6 V_(L)99 507 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTG TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGTCGCAGCCACT TAGCCTGGTACCAGCAGAACTCTGGCCAGGCTC CCAGGCTCCTCATCTATGGTGCATCCAGCAGGG CCACTGGCATCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCA GACTGGAGCCTGAAGATTTTGCAGTGTATTACT GTCAGCAGTATGGTAGTTCACCGTGGACGTTCG GCCAAGGGACCAAGGTGGAAATCAAACGA 61E1 V_(L)100 508 GACATCCAGATGACCCAGTCTCCATCCTCCCTGT CTGCATCTATTAGAGACCGAGTCACCATCACTTG CCGGGCAAGTCAGAGCATTGGCACCTTTTTAAA TTGGTATCAGCAGAAACCAGGGACAGCCCCTAA GCTCCTGATCTATGCTGCGTCCAGTTTGCAAAGT GGGGTCCCATCAAGGTTCAGTGGCAGTGGATCT GGGACAGATTTCACTCTCACCATCAGCAGTCTA CATCCTGAAGATTTTGCGTCTTACTATTGTCAAC AGAGTTTCAGTACCCCGCTCACTTTCGGCGGAG GGACCAAGGTGGAGATCACACGA

TABLE 2D Coding Sequence for Antibody Variable Heavy (V_(H)) Chains Contained SEQ ID in Clone Designation NO. Coding Sequence 63E6 V_(H)6 509 CAGGTGCAGCTTATGCAGTCTGGGGCTGAGGTG 66F7 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATACACCTTCACCGGCTACTATA TGCACTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGATGGATGAACCCTAATAGTG GTGCCACAAAGTATGCACAGAAGTTTCAGGGCA GGGTCACCATGACCAGGGACACGTCCATCAGCA CAGCCTACATGGAGCTGAGCAGGCTGAGATCTG ACGACACGGCCGTGTATTACTGTGCGAGAGAAC TCGGTGACTACCCCTTTTTTGACTACTGGGGCCA GGGAACCCTGGGCATCGTCTCCTCA 66D4 V_(H)17 510 CAGGTGCAACTGGTGCAGTCTGGGGCTGAGGTG AAGAAGCCTGGGGCCTCAGTGAAGGTC TCCTGCAGGGCTTCTGGGTACACCTTCACCGGCT ACTATATACACTGGATGCGACAGGCC CCTGGCCATGGGCTGGAGTGGATGGGATGGATC AACCCTCCCAGTGGTGCCACAAACTAT GCACAGAAGTTTCGGGGCAGGGTCGCCGTGACC AGGGACACGTCCATCAGCACAGTCTAC ATGGAACTGAGCAGGCTGAGATCTGACGACACG GCCGTATATTACTGTGCGAGAGAGACT GGAACTTGGAACTTCTTTGACTACTGGGGCCAG GGAACCCTGGTCACCGTCTCCTCA 66B4 V_(H)10 511 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTG AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCATCTGGATACACCTTCACCGGCTACTATT TGCACTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGATGGATCAACCCTAACAGTG GTGGCACAGACTATGCACAGAAGTTTCAGGGCC GGGTCACCATGACCAGGGACACGTCCATCAGTA CAGCCTACATGGAGCTGAGCAGGCTGAGATCTG ACGACACGGCCGTGTATTACTGTGTGGGAGACG CAGCAACTGGTCGCTACTACTTTGACAACTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCA 65B1 V_(H)18 512 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTG AAGAGGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATACACCTTCACCGGCTACTTTA TGCACTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGATGGATCAACCCTAACAGTG GTGCCACAAACTATGCACAGAAGTTTCACGGCA GGGTCACCATGACCAGGGACACGTCCATCACCA CAGTCTACATGGAGCTGAGCAGGCTGAGATCTG ACGACACGGCCGTGTATTACTGTACGAGAGAAC TGGGGATCTTCAACTGGTTCGACCCCTGGGGCC AGGGAACCCTGGTCACCGTCTCCTCA 65B4 V_(H)20 513 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTG GTACAGCCTGGGGGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCGCCTTCAGTAGTTACGACA TGCACTGGGTCCGCCAAGCTACAGGAAAAGGTC TGGAGTGGGTCTCAACTATTGATACTGCTGGTG ACGCTTACTATCCAGGCTCCGTGAAGGGCCGAT TCACCATCTCCAGAGAAAATGCCAAGACCTCCT TGTATCTTCAAATGAACAGCCTGAGAGCCGGGG ACACGGCTGTGTATTACTGTACAAGAGATCGGA GCAGTGGCCGGTTCGGGGACTTCTACGGTATGG ACGTCTGGGGCCAAGGGACCGCGGTCACCGTCT CCTCA 67A4 V_(H)19 514 GAGGTGCAGCTGGAGGAGTCTGGGGGAGGCTTG GTACAGCCTGGGGGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTCAGGACCTACGAC ATGCACTGGGTCCGCCAAGTTACAGGAAAAGGT CTGGAGTGGGTCTCAGCTATTGGTATTGCTGGTG ACACATACTATTCAGACTCCGTGAAGGGCCGAT TCACCATCTCCAGAGAAAATGCCAAGAACTCCC TGTATCTTCAAATGAACAGTCTAAGAGTCGGGG ACACGGCTGTGTATTACTGTGCAAGAGATCGGA GCAGTGGCCGGTTCGGGGACTACTACGGTATGG ACGTCTGGGGCCAAGGGACCACGGTCACCGTCT CCTCA 63A10v1 V_(H)21 515 GAGGTGCAGCTGGTGGAGTCTGGGGGAGACTTG 63A10v2 GTAAAGCCTGGGGGGTCCCTTAGACTCTCCTGT 63A10v3 GCAGTCTCTGGAATCACTTTCAGTAACGCCTGG ATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGG CTGGAGTGGGTTGGCCGTATTAAAAGCAAAACT GATGGTGGGACAACAGACTACGCTGCACCCGTG AAAGGCAGATTCACCGTCTCAAGAGATGGTTCA AAAAATACGCTGTATCTGCAAATGAACAGCCTG AAAACCGAGGACACAGCCGTGTATTACTGTACC ACAGATAGTAGTGGGAGCTACTACGTGGAGGAC TACTTTGACTACTGGGGCCAGGGAACCCTGGTC ACCGTCTCCTCA 65H11v1 V_(H)22 516 GAGGTGCAACTGGTGGAGTCTGGGGGAGGCTTG 65H11v2 GTAAAGCCTGGGGGGTCCCTTAGACTCTCCTGT GCAGCCTCTGGATTCACTTTCAGTAACGCCTGGA TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTTGGCCGTATTATAGGCAAAACTG ATGGTGGGACAACAGACTACGCTGCACCCGTGA AAGGCAGATTCACCATTTCAAGAGATGATTCAA AAAACACGCTGTATCTGCAAATGAACAGCCTGA AAACCGAGGACACAGCCGTGTATTACTGTACCT CAGATAGTAGTGGGAGCTACTACGTGGAGGACT ACTTTGACTACTGGGGCCAGGGAACCCTGGTCG CCGTCTCCTCA 67G10v1 V_(H)9 517 GAGGTGCAACTGGTGGAGTCTGGGGGAGGCTTG 67G10v2 GTAAAGCCGGGGGGGTCCCTTAGACTCGCCTGT GCAGCCTCTGGAATCACTTTCAATAACGCCTGG ATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGG CTGGAATGGGTTGGCCGTATTAAAAGCAAAACT GATGGTGGGACAACAGACTACGCTGCACCCGTG AAAGGCAGATTCACCATCTCAAGAGATGATTCA AAAAGTATACTGTATCTGCAAATGAACAGCCTG AAATCCGAGGACACAGCCGTGTATTATTGTACC ACAGATAGTAGTGGGAGCTACTACGTGGAGGAC TACTTTGACTACTGGGGCCAGGGAACCCTG GTCACCGTCTCCTCA 64C8 V_(H)23 518 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GTAGCCTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGATCCAGGCAAGGGGC TGGAGTGGGTGGCAGTTATATCATATGATGGAA GTAACAAACACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTGCAAATGAACAGCCTGAGAGCTG AGGACACGGCTGTGTATTACTGTGCGAGGGAAT TACTATGGTTCGGGGAGTATGGGGTAGACCACG GTATGGACGTCTGGGGCCAAGGGACCACGGTCA CCGTCTCCTCA 63G8v1 V_(H)1 519 CAGGCGCAGCTGGTGGAGTCTGGGGGAGGCGTG 63G8v2 GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT 63G8v3 GCAGCCTCTGGATTCACCTTCAGTAGCTATGGCA 68D3v1 TACACTGGGTCCGCCAGGCTCCAGGCAAGGGGC 64A8 TGGAGTGGGTGGCAGTTATATCATATGATGGAA 67B4 GTAATAAATACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTGCAAATGAACAGCCTGAGAGCTG AGGACACGGCTGTGTATTACTGTGCGACTACGG TGACTAAGGAGGACTACTACTACTACGGTATGG ACGTCTGGGGCCAAGGGACCACGGTCACCGTCT CCTCA 68D3v2 V_(H)95 1866 CAGGCGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTC TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCT ATGGCATGCACTGGGTCCGCCAGGCT CCAGGCAAGGGGCTGGAGTGGGTGGCATTTATA TCATATGCTGGAAGTAATAAATACTAT GCAGACTCCGTGAAGGGCCGATTCACCATCTCC AGAGACAATTCCAAGAACACGCTGTAT CTGCAAATGAGCAGCCTGAGAGCTGAGGACACG GCTGTGTATTACTGTGCGACTACGGTG ACTGAGGAGGACTACTACTACTACGGTATGGAC GTCTGGGGCCAAGGGACCACGGTCACC GTCTCCTCA 66G2 V_(H)11 520 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCCTCAGGATTCACCTTCAGTAGCTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGGTATATCATATGATGGA AGTAATAAAAACTATGCAGACTCCGTGAAGGGC CGAATCACCATCTCCAGAGACAATCCCAAGAAC ACGCTGTATCTGCAAATGAACAGCCTGAGAGCT GAGGACACGGCTGTGTATTACTGTGCGACTACG GTGACTAAGGAGGACTACTACTACTACGGTATG GACGTCTGGGGCCAAGGGACCACGGTCACCGTC TCCTCA 65D1 V_(H)26 521 CAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTTACTATTACA TTCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCACTTATATGGTATGATGGAA GTAATAAAGACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTGCATGTGAACAGCCTGAGAGCCG AGGACACGGCTGTGTATTACTGTGCGAGAGAAG GGACAACTCGACGGGGATTTGACTACTGGGGCC AGGGAACCCTGGTCACCGTCTCCTCA 64H5 V_(H)7 522 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGAGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAGCTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGTTATATGGGATGATGGA AGTAATAAATACTATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTCTCTGCAAATGAACAGCCTGAGGGCC GAGGACACGGCTGTTTATTACTGTGCGAGAGAA TACGTAGCAGAAGCTGGTTTTGACTACTGGGGC CAGGGAACCCTGGTCACCGTCTCCTCA 65D4 V_(H)25 523 CAGGAGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGTGTCTGGATTCACCTTCAGTTTCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCAGTTATATGGTATGATGGAA GTAATAAATACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATTTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCTGTGTATTACTGTACGAGAGCCC TCAACTGGAACTTTTTTGACTACTGGGGCCAGG GAACCCTGGTCACCGTCTCCTCA 65E3 V_(H)24 524 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCCTCAGTAACTATAAC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGTTTTATGGTATGATGGA AATACTAAATACTATGCAGACTCCGTGAAGGGC CGAGTCACCATCTCTAGAGACAATTCCAAGAAC ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTATTACTGTGCGAGAGAT GTCTACGGTGACTATTTTGCGTACTGGGGCCAG GGAACCCTGGTCACCGTCTCCTCA 65G4 V_(H)8 525 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAGCTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGTTATATGGGATGATGGA AGTAATAAATACTATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTCTCTGCAAATGAACAGCCTGAGGGCC GAGGACACGGCTGTTTATTACTGTGCGAGAGAA TACGTAGCAGAAGCTGGTTTTGACTACTGGGGC CAGGGAACCCTGGTCACCGTCTCCTCA 68G5 V_(H)12 526 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT ACAGCGTCTGGATTCACCTTCAGTAGCTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGTTATATGGTATGATGGA AGTAATAAATACCATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACGATTCCAAGAAC GCGCTTTATCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTATTACTGTGTGAGAGAT CCTGGATACAGCTATGGTCACTTTGACTACTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCA 67G8 V_(H)27 527 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAGCTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGTTATATGGTATGATGGA AGTAATAAAGACTATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTATCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTATTACTGTGCGAGATCA GCAGTGGCTTTGTACAACTGGTTCGACCCCTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCA 65B7v1 V_(H)28 528 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG 65B7v2 GTGAACCCTTCACAGACCCTGTCCCTCACCTGCA CTGTCTCTGGTGGCTCCATCAGCAGTGATGCTTA CTACTGGAGCTGGATCCGCCAGCACCCAGGGAA GGGCCTGGAGTGGATTGGGTACATCTTTTACAG TGGGAGCACCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATTTCAGTAGACACGTCTAAGAA CCGGTTCTCCCTGAAGCTGAGCTCTGTGACTGCC GCGGACACGGCCGTGTATTACTGTGCGAGAGAG TCTAGGATATTGTACTTCAACGGGTACTTCCAGC ACTGGGGCCAGGGCACCCTGGTCACCGTCTCCT CA 63B6 V_(H)4 529 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG 64D4 GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCG CTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTA CTACTGGAGCTGGATCCGCCAGCACCCAGGGAA GGGCCTGGAGTGGATTGGGTACATCTATTACAG TGGGACCACCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATATCAGTAGACACGTCCAAGAA CCAGTTCTCCCTGAAGCTGACCTCTGTGACTGCC GCGGACACGGCCGTATATTACTGTGCGAGAATG ACTACTCCTTACTGGTACTTCGGTCTCTGGGGCC GTGGCACCCTGGTCACTGTCTCCTCA 63F5 V_(H)13 530 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCC CTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTA TTACTGGACCTGGATCCGCCAGCACCCAGGGAA GGACCTGGAGTGGATTACATACATCTATTACAG TGGGAGCGCCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATATCAGTAGACACGTCTAAGAA CCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCC GCGGACACGGCCGTATATTATTGTGCGAGGATG ACTACCCCTTATTGGTACTTCGATCTCTGGGGCC GTGGCACCCTGGTCACTGTCTCCTCA 63H11 V_(H)3 531 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCC CTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTA CTACTGGACCTGGATCCGCCAGCACCCAGGGAA GGGCCTGGAGTGGATTGCATACATCTATTACAG TGGGAGCACCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATATCAGTAGACACGTCTAAGAA CCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCC GCGGACACGGCCGTATATTACTGTGCGAGGATG ACTACCCCTTACTGGTACTTCGATCTCTGGGGCC GTGGCACCCTGGTCACTGTCTCCTCA 65E8 V_(H)2 532 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG 64E6 GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCC 65F11 CTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTA 67G7 CTACTGGACCTGGATCCGCCAGCACCCAGGGAA GGGCCTGGAGTGGATTGCATACATCTATTACAC TGGGAGCACCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATATCAGTAGACACGTCTAAGAA CCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCC GCGGACACGGCCGTATATTACTGTGCGAGGATG ACTACCCCTTACTGGTACTTCGATCTCTGGGGCC GTGGCACCCTGGTCACTGTCTCCTCA 65C1 V_(H)15 533 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCC CTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTA CTACTGGACCTGGATCCGCCAACACCCAGGGAA GGGCCTGGAGTGGATTGCATACATTTTTTACAGT GGGAGCACCTACTACAACCCGTCCCTCAAGAGT CGAGTTACCATATCACTTGACACGTCTAAGAAC CAGTTCTCCCTGAAGCTGAACTCTGTGACTGCCG CGGACACGGCCGTATATTACTGTGCGAGGATGA CTTCCCCTTACTGGTACTTCGATCTCTGGGGCCG TGGCACCCTGGTCACTGTCTCCTCA 66F6 V_(H)14 534 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCC CTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTA CTACTGGACCTGGATCCGCCATCACCCAGGGAA GGGCCTGGAGTGGATTGCATACATTTATTACAG TGGGAGCACCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATATCAGTTGACACGTCTAAGAA CCAGTTTTCCCTGAAGCTGAACTCTGTGACTGCC GCGGACACGGCCGTTTATTACTGTGCGAGGATG ACTACCCCTTACTGGTACTTCGATCTCTGGGGCC GTGGCACCCTGGTCACTGTCTCCTCA 64A6 V_(H)29 535 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCA CTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTA TTACTGGAGCTGGATCCGCCAGCGCCCAGGGAA GGGCCTGGAGTGGGTTGGGTACATCTATTACAG TGGGGGCACCCACTACAACCCGTCCCTCAAAAG TCGAGTTACCATATCAATAGACACGTCTGAGAA CCAGTTCTCCCTGAAGCTGAGTTCTGTGACTGCC GCGGACACGGCCGTGTATTACTGTGCGAGAGTC CTCCATTACTCTGATAGTCGTGGTTACTCGTACT ACTCTGACTTCTGGGGCCAGGGAACCCTGGTCA CCGTCTCCTCA 65F9 V_(H)30 536 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCA CTCTCTCTGGTGGCTCCTTCAGCAGTGGTGATTA CTACTGGAGCTGGATCCGCCAGCACCCAGGGAA GGGCCTGGAGTGGATTGGGTACATCTATTACAG TGGGAGCACCTACTACAACCCATCCCTCAAGAG TCGAGTTACCATATCAATAGACACGTCTAAGAA CCAGTTCTCCCTGAAACTGACCTCTGTGACTGCC GCGGACACGGCCGTGTATTACTGTGCGAGAGTC CTCCATTACTATGATAGTAGTGGTTACTCGTACT ACTTTGACTACTGGGGCCAGGGAACCCTGGTCA CCGTCTCCTCA 64A7 V_(H)16 537 CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCATCAGCAGTGATACTT CCTACTGGGGCTGGATCCGCCAGCCCCCAGGAA AGGGGCTGGAGTGGATTGGGAATATCTATTATA GTGGGACCACCTACTTCAACCCGTCCCTCAAGA GTCGAGTCAGCGTATCCGTAGACACATCCAAGA ACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC CGCAGACACGGCTGTGTTTTATTGTGCGAGACTC CGAGGGGTCTACTGGTACTTCGATCTCTGGGGC CGTGGCACCCTGGTCACTGTCTCCTCA 65C3 V_(H)5 538 CAGGTGCAGCTACAGGAGTCGGGTCCAGGACTG 68D5 GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCATCAGTAGTTACTACT GGAGCTGGATCCGGCAGCCCCCAGGGAAGGGA CTGGAGTGGATTGGGTATATCTATTACACTGGG AGCACCAACTACAACCCCTCCCTCAAGAGTCGA GTCACCATATCAGTAGACACGTCCAAGAACCAG TTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGG ACACGGCCGTGTATTACTGTGCGAGAGAATATT ACTATGGTTCGGGGAGTTATTATCCTTGGGGCCA GGGAACCCTGGTCACCGTCTCCTCA 67F5 V_(H)31 539 CAGGTGCAGCTGAAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTC ACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTT ACTACTGGAGCTGGATCCGGCAGCCC CCAGGGAAGGGACTGGAGTGGATTGGGTATATC TATTACAGTGGGAACACCAACTACAAC CCCTCCCTCAAGAGTCGAGTCACCATATCAGTA GACACGTCCAAGAACCAGTTCTCCCTG AAGCTGAGCTCTGTGACCGCTGCGGACACGGCC GTGTATTACTGTGCGAGAGAATATTAC TATGGTTCGGGGAGTTATTATCCTTGGGGCCAG GGAACCCTGGTCACCGTCTCCTCA 64B10v1 V_(H)32 540 CAGATTCAGCTGCTGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCGTCAGTAGTGGTGATT ACTACTGGAGCTGGATCCGGCAGCCCCCAGGGA AGGGACTGGAGTGGATTGGGTTTATCTATTACA GTGGGGGCACCAACTACAACCCCTCCCTCAAGA GTCGAGTCACCATATCAATAGACACGTCCAAGA ACCAGTTCTCCCTGAAGCTGAACTCTGTGACCGC TGCGGACACGGCCGTGTATTACTGTGCGAGATA TAGCAGCACCTGGGACTACTATTACGGTGTGGA CGTCTGGGGCCAAGGGACCACGGTCACCGTCTC CTCA 64B10v2 V_(H)96 1867 CAGGTGCAGCTGCTGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCGTCAGCAGTGGTGATT ACTACTGGAGCTGGATCCGGCAGCCCCCAGGGA AGGGACTGGAGTGGATTGGGTTTATTTATTACA GTGGGGGCACCAACTACAACCCCCCCCTCAAGA GTCGAGTCACCATATCAATAGACACGTCCAAGA ACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGC TGCGGACACGGCCGTGTATTACTGTGCGAGATA TAGCAGCACCTGGGACTACTATTACGGTGTGGA CGTCTGGGGCCAAGGGACCACGGTCACC GTCTCCTCA 68C8 V_(H)33 541 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGACTCTGTCAGCAGTGGTGATA ACTACTGGAGCTGGATCCGGCAGCCCCCAGGGA AGGGACTGGAGTGGATTGGGTTCATGTTTTACA GTGGGAGTACCAACTACAACCCCTCCCTCAAGA GTCGAGTCACCATATCACTACACACGTCCAAGA ACCAGTTCTCCCTGAGGCTGAGCTCTGTGACCGC TGCGGACACGGCCGTGTATTACTGTGGGAGATA TAGGAGTGACTGGGACTACTACTACGGTATGGA CGTCTGGGGCCAAGGGACCACGGTCACCGTCTC CTCA 67A5 V_(H)34 542 GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG AAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGT AAGGGTTCTGGATACAGCTTTACCAGTTACTGG ATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGC CTGGAGTGGATGGGGATCATCTATCCTGGTGAC TCTGATACCAGATACAGCCCGTCCTTCCAAGGC CAGGTCACCATCTCAGCCGACAAGTCCATCAAC ACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCC TCGGACACCGCCATATACTTCTGTGCGAGACGG GCCTCACGTGGATACAGATTTGGTCTTGCTTTTG CGATCTGGGGCCAAGGGACAATGGTCACCGTCT CCTCA 67C10 V_(H)35 543 GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG AAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGT CAGGGTTCTGGATACAGCTTTAGCAGTTACTGG ATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGC CTGGAGTGGATGGGGATCATCTATCCTGGTGAC TCTGATACCAGATACAGCCCGTCCTTCCAAGGC CAGGTCACCATCTCAGCCGACAAGTCCATCAAT ACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCC TCGGACACCGCCATATATTACTGTGCGAGACGG GCCTCACGTGGATACAGATATGGTCTTGCTTTTG CTATCTGGGGCCAAGGGACAATGGTCACCGTCT CTTCA 64H6 V_(H)36 544 GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG AAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGT AAGGGTTCTGGATACAGTTTTACCAGTTATTGGA TCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCC TGGAGTGGATGGGGATCATCTATCCTGGTGACT CTGAAACCAGATACAGCCCGTCCTTTCAAGGCC AGGTCACCATCTCAGCCGACAAGTCCATCAGCA CCGCCTACCTGCAGTGGAACAGCCTGAAGACCT CGGACACCGCCATGTATTTCTGTGCGACCGTAG CAGTGTCTGCCTTCAACTGGTTCGACCCCTGGGG CCAGGGAACCCTGGTCACCGTCTCCTCC 63F9 V_(H)37 545 CAGGTGCAGCTGAAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCA CTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTA CTACTGGAACTGGATCCGCCAGCACCCAGGGAA GGGCCTGGAGTGGATTGGGTACATCTATGACAG TGGGAGCACCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATGTCAGTAGACACGTCTAAGAA CCAGTTCTCCCTGAAGTTGAGCTCTGTGACTGCC GCGGACACGGCCGTGTATTACTGTGCGAGAGAT GTTCTAATGGTGTATACTAAAGGGGGCTACTAC TATTACGGTGTGGACGTCTGGGGCCAAGGGACC ACGGTCACCGTCTCCTCA 67F6v1 V_(H)38 546 GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 67F6v2 AAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGT AAGGGTTCTGGATACAGCTTTACCGGCTACTGG ATCGGCTGGGTGCGCCAGCTGCCCGGGAAAGGC CTGGAGTGGATGGGGATCATCTATCCTGGTGAC TCTGATACCAGATACAGCCCGTCCTTCCAAGGC CAGGTCACCATCTCAGTCGACAAGTCCATCAAC ACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCC TCGGACACCGCCATGTATTACTGTGCGAGACGG GCCTCACGTGGATACAGCTATGGTCATGCTTTTG ATTTCTGGGGCCAAGGGACAATGGTCACCGTGT CTTCA 48C9 V_(H)73 547 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTG 49A12 TTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCT 51E2 CTGTCTATGGTGGGTCCTTCAGTGGTTACTACTG GACCTGGATCCGCCAGCCCCCAGGGAAGGGGCT GGAGTGGATTGGGGAAATCAATCATAGTGAAAA CACCAACTACAACCCGTCCCTCAAGAGTCGAGT CACCATATCAATAGACACGTCCAAGAACCAGTT CTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGA CACGGCTGTGTATTACTGTGCGAGAGAGAGTGG GAACTTCCCCTTTGACTACTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCA 48F3 V_(H)72 548 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACCG TTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCG CTGTCTATGGTGGGTCCATCAGTGGTTACTACTG GAGCTGGATCCGCCAGCCCCCAGGGAAGGGGCT GGAGTGGATTGGGGAAATCACTCATACTGGAAG CTCCAACTACAACCCGTCCCTCAAGAGTCGAGT CACCATATCAGTAGACACGTCCAAGAACCAGTT CTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGA CACGGCTGTGTATTACTGTGCGAGAGGCGGGAT TTTATGGTTCGGGGAGCAGGCTTTTGATATCTGG GGCCAAGGGACAATGGTCACCGTCTCTTCA 48F8 V_(H)48 549 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTG 53B9 GTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGT 56B4 ACAGCCTCTGGATTCACCTTCAGAAGCTATAGC 57E7 ATGAACTGGGTCCGCCAGGCTCCGGGGAAGGGG 57F11 CTGGAGTGGGTCTCATCCATTAGTAGTAGTAGT AGTTACGAATACTACGTAGACTCAGTGAAGGGC CGATTCACCATCTCCAGAGACATCGCCAAGAGC TCACTGTGGCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTATTACTGTGCGAGATCC CTAAGTATAGCAGTGGCTGCCTCTGACTACTGG GGCAAGGGAACCCTGGTCACCGTCTCCTCA 48H11 V_(H)39 550 CAGGTGCAACTGGTGCAGTCTGGGGCTGAGGTG AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATACACCTTCACCGGCTACTATA AGCACTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGATGGATCAACCCTAACAGTG GTGCCACAAAGTATGCACAGAAGTTTCAGGGCA GGGTCACCATGACCAGGGACACGTCCATCAGCA CAGTGTACATGGAGCTGAGCAGGCTGAGATCTG TCGACACGGCCCTGTATTACTGTGCGAGAGAGG TACCCGACGGTATAGTAGTGGCTGGTTCAAATG CTTTTGATTTCTGGGGCCAAGGGACAATGGTCA CCGTCTCTTCA 49A10 V_(H)62 551 CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTG 48D4 GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAACTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAATTATATGGTATGATGGA AGTAATAAAAACTATGCAGACTCCGTGAAGGGC CGCTTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTATCTGGAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTATTACTGTGCGAGAGAT CAGGATTACGATTTTTGGAGTGGTTATCCTTACT TCTACTACTACGGTATGGACGTCTGGGGCCAAG GGACCACGGTCACCGTCTCCTCA 49C8 V_(H)44 552 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTG 52H1 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATACACCTTCACCAGTTATGATA TCGACTGGGTGCGACAGGCCACTGGACAAGGGC TTGAGTGGATGGGATGGATGAACCCTAACGGTG GTAACACAGGCTATGCACAGAAGTTCCAGGGCA GAGTCACCATGACCAGGAACACCTCCATAAACA CGGCCTATATGGAACTGAGCAGCCTGAGATCTG AGGACACGGCCATATATTACTGTGCGAGAGGGA AGGAATTTAGCAGGGCGGAGTTTGACTACTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCA 49G2 V_(H)63 553 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG 50C12 GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT 55G11 GCAGCGTCTGGATTCACCTTCAGTAACTATGGC ATGCGCTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCACTTATATGGTATGATGGA AGTAATAAGTTCTATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTGAATCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTATTACTGTGCGAGAGAT CGGTATTACGATTTTTGGAGTGGTTATCCATACT TCTTCTACTACGGTCTGGACGTCTGGGGCCAAG GGACCACGGTCACCGTCTCCTCA 49G3 V_(H)46 554 CAGGTCACCTTGAAGGAGTCTGGTCCTGTGCTG GTGAAACCCACAGAGACCCTCACGCTGACCTGC ACCGTCTCTGGGTTCTCACTCAGTAATCCTAGAA TGGGTGTGAGCTGGATCCGTCAGCCCCCAGGGA AGGCCCTGGAGTGGCTTACACACATTTTTTCGAA TGACGAAAAATCCTACAGCACATCTCTGAAGAG CAGGCTCACCATCTCCAAGGACACCTCCAAAAG CCAGGTGGTCCTTTCCATGACCAACATGGACCCT GTGGACACAGCCACATATTACTGTGTACGGGTA GATACCTTGAACTACCACTACTACGGTATGGAC GTCTGGGGCCAAGGGACCACGGTCACCGTCTCC TCA 49H12 V_(H)42 555 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTG AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC ATGGCATCTGGATACATTTTCACCAGTTACGATA TCAACTGGGTGCGACAGGCCACTGGACAAGGGC CTGAGTGGATGGGATGGATGAACCCCTACAGTG GGAGCACAGGCTATGCACAGAATTTCCAGGGCA GAGTCACCATGACCAGGAATACCTCCATAAACA CAGCCTACATGGAGCTGAGCAGCCTGAGATCTG AGGACACGGCCGTGTATTACTGTGCGAAGTATA ATTGGAACTATGGGGCTTTTGATTTCTGGGGCCA AGGGACAATGGTCACCGTCTCTTCA 51A8 V_(H)58 556 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCAGTTATATCATATGATGGAA GTAATAAATACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGTTGTATCTGCAAATGAACAGCCTGAGAGCTG AGGACACGGCTGTGTATTACTGTGCGAGAGCGG ACGGTGACTACCCATATTACTACTACTACTACGG TATGGACGTCTGGGGCCAAGGGACCACGGTCAC CGTCTCCTCA 51C10.1 V_(H)54 557 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTG 59D10v1 GTACAGCCGGGGGGGTCCCTGAGACTCTCCTGT 59D10v2 GCAGCCTCTGGATTCACCTTTCGCAACTATGCCA TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTCTCAGGTATTAGTGGTAGTAGTG CTGGCACATACTACGCAGACTCCGTGAAGGGCC GGTTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTTTCTGCAAATGGACAGCCTGAGAGCCG AGGACACGGCCGTATATTACTGTGCGCAAGATT GGAGTATAGCAGTGGCTGGTACTTTTGACTACT GGGGCCAGGGAACCCTGGTCACCGTCTCCTCA 51C10.2 V_(H)67 558 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCA CTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTA CTACTGGAGCTGGATCCGCCAGCACCCAGGGAA GGGCCTGGAGTGGATTGGGTACATCTATTACAA TGGGAGTCCCTACGACAACCCGTCCCTCAAGAG GCGAGTTACCATCTCAATAGATGCGTCTAAGAA CCAGTTCTCCCTGAAGCTGAGCTCTATGACTGCC GCGGACACGGCCGTGTATTACTGTGCGAGAGGG GCCCTCTACGGTATGGACGTCTGGGGCCAAGGG ACCACGGTCACCGTCTCCTCA 51E5 V_(H)74 559 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTG TTGAAGCCTTCGGAGACCCTTTCCCTCACCTGCG CTGTCTATGGTGGGTCCTTCAGTGGTTACTACTG GAGCTGGATCCGCCAGCCCCCAGGGAAGGGGCT GGAGTGGATTGGGGAACTCGATCATAGTGGAAG TATCAACTACAACCCGTCCCTCAAGAGTCGAGT CACCATATCAGTAGACACGTCCAAGAACCAGTT CTCCCTGAAGCTGACCTCTGTGACCGCCGCGGA CACGGCTGTGTATTACTGTGCGAGAGTCCTGGG ATCTACTCTTGACTATTGGGGCCAGGGAACCCT GGTCACCGTCTCCTCA 51G2 V_(H)50 560 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTG GTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTCAGTAGTTATAGCA TGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTCTCATCCATTAGTAGTAGTAGTA CTTACATATACTACGCAGACTCAGTGAAGGGCC GATTCACCATCTCCAGAGACAACGCCAAGAACT CACTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCTGTGTATTACTGTGCGAGAGATA CTTATATCAGTGGCTGGAACTACGGTATGGACG TCTGGGGCCAAGGGACCACGGTCACCGTCTCCT CA 52A8 V_(H)40 561 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTG AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATACACCTTCACCGGCTACTATT TGCACTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGATGGATCAACCCTAACAGTG CTGCCACAAACTATGCACCGAAGTTTCAGGGCA GGGTCACCGTGACCAGGGACACGTCCATCAGCA CAGCCTACATGGAACTGAGCAGGCTGAGATCTG ACGACACGGCCGTGTATTACTGTGCGAGAGAGG GTGGAACTTACAACTGGTTCGACCCCTGGGGCC AGGGAACCCTGGTCACCGTCTCCTCA 52B8 V_(H)77 562 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG ATGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCATCAGTTATTATTACT GGAGTTGGATCCGGCAGTCCCCAGGGAAGGGAC TGGAGTGGATTGGGTATATCTATTATAGTGGGA GCACCAACTACAACCCCTCCCTCAAGAGTCGAG TCACCATGTCAGTAGACACGTCCAAGAACCAGT TCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGG ACACGGCCGTGTATTACTGTGCGTCTGGAACTA GGGCTTTTGATATCTGGGGCCAAGGGACAATGG TCACCGTCTCTTCA 52C1 V_(H)64 563 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAGCTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGC CTGGAGTGGGTGGCAGTTATATGGTATGATGGA AGTAATAACTATTATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACAATTCCAAGAGC ACGCTGTTTCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCTATATATTACTGTGCGAGAGAT CGGGCGGGAGCCTCTCCCGGAATGGACGTCTGG GGCCAAGGGACCACGGTCACCGTCTCCTCA 52F8 V_(H)41 564 CAGGTGCAACTGGTGCAGTCTGGGGCGGAGGTG AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATTCACCTTCATCGGCTACTATA CACACTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGATGGATCAACCCTAGCAGTG GTGACACAAAGTATGCACAGAAGTTTCAGGGCA GGGTCACCTTGGCCAGGGACACGTCCATCAGCA CAGCCTACATGGAGCTGAGCAGGCTGAGATCTG ACGACACGGCCGTGTATTACTGTGCGAACAGTG GCTGGTACCCGTCCTACTACTACGGTATGGACGT CTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA 52H2 V_(H)79 565 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCATCAGTACTTACTACT GGAGCTGGATCCGGCAGCCCCCAGGGACGGGAC TGGAATGGATTGGGTATATCTTTTACAATGGGA ACGCCAACTACAGCCCCTCCCTGAAGAGTCGAG TCACCTTTTCAGTGGACACGTCCAAGAACCAGTT CTCCCTGAAACTGAGTTCTGTGACCGCTGCGGA CACGGCCGTGTATTTTTGTGCGAGAGAAACGGA CTACGGTGACTACGCACGTCCTTTTGAATACTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCA 53F6 V_(H)60 566 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTACCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCAGTTATATGGTATGATGGAA GTAATAAATACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCTGTGTATTACTGTGCGAGAGGCC ACTATGATAGTAGTGGTCCCAGGGACTACTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCA 53H5.2 V_(H)59 567 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCCAGGGGC TGGAGTGGGTGGCACTTATATCATATGATGGAA GTAATAAATACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAAATCCAAGAACA CGCTGTATCTGCAAATGAACAGCCTGAGAGCTG AGGACACGGCTGTATATTACTGTGCGAGAGAGG CTAACTGGGGCTACAACTACTACGGTATGGACG TCTGGGGCCAAGGGACCACGGTCACCGTCTCCT CA 53H5.3 V_(H)75 568 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTG TTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCG CTGTCTATGGTGGGTCCTTCAGTGATTACTACTG GAACTGGATCCGCCAGCCCCCAGGGAAGGGGCC AGAGTGGATTGGGGAAATCAATCATAGTGGAAC CACCAACTACAATCCGTCCCTCAAGAGTCGAGT CACCATATCAGTAGACACGTCCAAGAACCAGTT CTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGA CACGGCTGTATATTACTGTGTGGGGATATTACG ATATTTTGACTGGTTAGAATACTACTTTGACTAC TGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA 54A1 V_(H)43 569 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTG 55G9 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATACACCTTCACCAGTTATGATA TCAACTGGGTGCGACAGGCCACTGGACAAGGGC TTGAGTGGATGGGATGGATGAACCCTCACAGTG GTAACACAGGCTATGCACAGAAGTTCCAGGGCA GAGTCACCATGACCAGGAACACCTCCATAAATA CAGCCTACATGGAGCTGAGCAGCCTGAGATCTG AGGACACGGCCGTGTATTACTGTGCGAAATATA ACTGGAACTACGGCGCTTTTGATTTCTGGGGCCA AGGGACAATGGTCACCGTCTCTTCA 54H10.1 V_(H)52 570 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTG 55D1 GTACAGCCTGGGGGGTCCCTGAGACTCTCCTGT 48H3 GCAGCCTCTGGATTCACCTTTAGCAGCTATGCCA 53C11 TGAGCTGGGTCCGCCAGGCTCCGGGGAAGGGGC TGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTC GTACCACATACTCCGCAGACTCCGTGAAGGGCC GGTTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCCGTATATTACTGTGCGAAAGAAC AGCAGTGGCTGGTTTATTTTGACTACTGGGGCCA GGGAACCCTGGTCACCGTCTCCTCA 55D3 V_(H)68 571 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCA CTGTCTCTGGTGGCTCCATCACCAGTGGTGTTTA CTACTGGAACTGGATCCGCCAGCACCCAGGGAA GGGCCTGGAGTGGATTGGGTACCTCTATTACAG TGGGAGCACCTACTACAACCCGTCCCTCAAGAG TCGCCTTACCATTTCAGCAGACATGTCTAAGAAC CAGTTCTCCCTAAAGCTGAGCTCTGTGACTGTCG CGGACACGGCCGTGTATTACTGTGCGAGAGATG GTATTACTATGGTTCGGGGAGTTACTCACTACTA CGGTATGGACGTCTGGGGCCAAGGGACCACGGT CACCGTCTCCTCA 55E4 V_(H)70 572 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTG 49B11 TTGAAGCCTTCGGAGACCCTGTCCCTCACTTGCG 50H10 CTGTCTATGGTGGGTCCTTCAGTGGTTACTACTG 53C1 GAGCTGGATCCGCCAGCCCCCAGGGAAGGGTCT 52C5 GGAGTGGATTGGGGAAATCAATCATAGTGAAAA 60G5.1 CACCAACTACAACCCGTCCCTCAAGAGTCGAGT CACCATATCACTAGACACGTCCAATGACCAGTT CTCCCTAAGACTAACCTCAGTGACCGCCGCGGA CACGGCTGTCTATTACTGTGCGAGAGTAACTGG AACGGATGCTTTTGATTTCTGGGGCCAAGGGAC AATGGTCACCGTCTCTTCA 55E9 V_(H)65 573 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAGCTTTGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCACTTATATGGTATGATGGAG ATAATAAATACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCTGTGTATTACTGTGCGAGAAACA GTGGCTGGGATTACTTCTACTACTACGGTATGGA CGTCTGGGGCCAAGGGACCACGGTCACCGTCTC CTCA 55G5 V_(H)78 574 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCATCAGTAGTTACTACT GGAGCTGGATCCGGCAGCCCGCCGGGAAGGGA CTGGAGTGGATTGGGCGTATCTATATCAGTGGG AGCACCAACTACAACCCCTCCCTCGAGAATCGA GTCACCATGTCAGGAGACACGTCCAAGAACCAG TTCTCCCTGAAGCTGAATTCTGTGACCGCCGCGG ACACGGCCGTATATTACTGTGCGGGAAGTGGGA GCTACTCCTTTGACTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCTCA 50G1 V_(H)84 575 CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAGCTATGGCC TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCAGTTATATGGAATGATGGAA GTAATAAGCTTTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCTGTGTATTACTGTGCGAGAGATC AGTATTACGATTTTTGGAGCGGTTACCCATACTA TCACTACTACGGTATGGACGTCTGGGGCCAAGG GACCACGGTCACCGTCTCCTCA 56A7 V_(H)51 576 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTG 56E4 GTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTCAGTAGTTATAGCA TGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTCTCATCCATTAGTAGTAGTAGTA CTTACATATACTACGCAGACTCAGTGAAGGGCC GATTCACCATCTCCAGAGACAACGCCAAGAACT CACTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCTGTGTATTACTGTGCGAGAGATA TCTATAGCAGTGGCTGGAGCTACGGTATGGACG TCTGGGGCCAAGGGACCACGGTCACCGTCTCCT CA 56C11 V_(H)61 577 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAGCTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGA CTGGAGTGGGTGGCAGTTATATGGTATGATGGA AGTTATCAATTCTATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGTTGTATCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTATTACTGTGCGAGAGAT CACGTTTGGAGGACTTATCGTTATATCTTTGACT ACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT CA 56E7 V_(H)81 578 GAGGTGCAGCTGGTGCAGTCTGGACCAGAGGTG AAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGT AAGGGTTCGGGATACAGTTTAACCAGCTACTGG ATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGC CTGGAGTGGATGGGGATCATCTATCCTGGTGAC TCTGATACCAGATACAGCCCGTCCTTCCAAGGC CAGGTCACCATCTCAGCCGACACGTCCATCAGC ACCGCCTACCTGCAGTGGAGCAGGTTGAAGGCC TCGGACACCGCCGTATATTACTGTGCGAGGGCA CAACTGGGGATCTTTGACTACTGGGGCCAGGGA ACCCTGGTCACCGTCTCCTCA 56G1 V_(H)71 579 CAGGTGCAACTACAGCAGTGGGGCGCAGGACTG TTGAAGCCTTCGGAGACCCTGTCCCTCACTTGCG CTGTCTATGGTGGGTCCTTCAGTGGTTACTACTG GAGCTGGATCCGCCAGCCCCCAGGGAAGGGTCT GGAGTGGATTGGGGAAATCAATCATAGTGAAAA CACCAACTACAACCCGTCCCTCAAGAGTCGAGT CACCATATCACTAGACACGTCCAATAAGCAGTT CTCCCTAAGACTAACCTCTGTGACCGCCGCGGA CACGGCTGTCTATTACTGTGCGAGAGTAACTGG AACGGATGCTTTTGATTTCTGGGGCCAAGGGAC AATGGTCACCGTCTCTTCA 56G3.3 V_(H)76 580 CAGTTGCAGTTGCAGGAATCGGGCCCAGGACTG 55B10 GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGACTCCATCAGTAGTAGTAGTT ACTACTGGGGCTGGATCCGCCAGCCCCCAGGGA AGGGGCTGGAGTGGATTGGGATGATCTATTATA GTGGGACCACCTACTACAACCCGTCCCTCAAGA GTCGAGTCACCATATCCGTAGACACGTCCAAGA ATCAGTTTTCCCTGAAGCTGAGTTCTGTGACCGC CGCAGACACGGCTGTGTATTATTGTGCGAGAGT GGCAGCAGTTTACTGGTATTTCGATCTCTGGGGC CGTGGCACCCTGGTCACTGTCTCCTCA 57B12 V_(H)69 581 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCA CTGTCTCTGGTGGCTCCATCACCAGTGGTGTTTA CTACTGGAGCTGGATCCGCCAGCTCCCAGGGAA GGGCCTGGAGTGGATTGGGTACATCTATTACAG TGGGAGCACCTACTACAACCCGTCCCTCAAGAG TCGCCTTACCATATCAGCAGACACGTCTAAGAA CCAGTTCTCCCTAAAGCTGAGCTCTGTGACTGTC GCGGACACGGCCGTGTATTACTGTGCGAGAGAT GGTATTACTATGGTTCGGGGAGTTACTCACTACT ACGGTATGGACGTCTGGGGCCAAGGGACCACGG TCACCGTCTCCTCA 57D9 V_(H)82 582 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTG GTGAAGCCCTCGCAGACCCTCTCACTCACCTGTG CCATCTCCGGGGACAGTGTCTCTAGCAACAGTG CTACTTGGAACTGGATCAGGCAGTCCCCATCGA GAGGCCTTGAGTGGCTGGGAAGGACATACTACA GGTCCAAGTGGTATAATGATTATGCAGTATCTGT GAAAAGTCGAATAACCATCAACCCAGACACATC CAAGAACCAGTTCTCCCTGCAGCTGAACTCTGT GACTCCCGAGGACACGGCTGTGTATTACTGTGT GGGTATTGTAGTAGTACCAGCTGTTCTCTTTGAC TACTGGGGCCAGGGAACCCTGGTCACCGTCTCC TCA 58C2 V_(H)85 583 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCACCTTCAGTAACTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGTTATATGGAATGATGGA AATAACAAATACTATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTATATCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTATTACTGTGCGAGAGAT CAGAATTACGATTTTTGGAATGGTTATCCCTACT ACTTCTACTACGGTATGGACGTCTGGGGCCAAG GGACCACGGTCACCGTCTCCTCA 59A10 V_(H)47 584 CAGGTGCAGGTGGTGGAGTCTGGGGGAGGCTTG 49H4 GTCAAGCCTGGAGGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTCAGTGACTCCTACA TGAGCTGGATCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGATTTCTTCCATTAGTAGTAGTGGTAG TATCGTATACTTCGCAGACTCTGTGAAGGGCCG ATTCACCATCTCCAGGGACATCGCCAAGAACTC ACTGTATCTGCACATGAACAGCCTGAGAGCCGA GGACACGGCCGTGTATTACTGTGCGAGAGAGAC GTTTAGCAGTGGCTGGTTCGATGCTTTTGATATC TGGGGCCAAGGGACAATGGTCACCGTCTCTTCA 59C9 V_(H)49 585 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTG 58A5 GTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGT 57A4 GCAGCCTCTGGATTCACCTTCAGTAGCTATAGCA 57F9 TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTCTCATCCATTAGTAGTAGTAGTA CTTACATATACTACGCAGACTCACTGAAGGGCC GATTCACCATCTCCAGAGACAACGCCAAGAACT CACTGTTTCTGCAAGTGAACAGCCTGAGAGCCG AAGACTCGGCTGTGTATTACTGTGCGAGAGATC GATGGAGCAGTGGCTGGAACGAAGGTTTTGACT ATTGGGGCCAGGGAACCCTGGTCACCGTCTCCT CA 59G10.2 V_(H)57 586 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTCAGTAACTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCAATTACATCATATGGAGGAA GTAATAAAAATTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTGCAAATGAACAGCCTGAGAGCTG AGGACACGGCTGTGTATTATTGTGCGAGAGAGG CCGGGTATAGCTTTGACTACTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCA 59G10.3 V_(H)53 587 GAGGTGCAACTGTTGGGATCTGGGGGAGGCTTG GTACAGCCTGGGGGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTTAACCACTATGCCA TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTG CTGGCACATTCTACGCGGACTCCATGAAGGGCC GGTTCACCATCTCCAGAGACAATTCCGAGAACA CGCTGCATCTGCAGATGAACAGCCTGAGAGCCG AGGACACGGCCATATATTACTGTGCGAAAGATC TTAGAATAGCAGTGGCTGGTTCATTTGACTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCA 60D7 V_(H)66 588 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT GCAGCGTCTGGATTCAACTTCAGTAGCTATGGC ATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGTTATATGGTATGATGGA AGTAATAAATACTATGCAGACTCCGTGAAGGGC CGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTATCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCTGTGTTTTACTGTGCGAGAGAT CAGTATTTCGATTTTTGGAGTGGTTATCCTTTCTT CTACTACTACGGTATGGACGTCTGGGGCCAAGG GACCACGGTCACCGTCTCCTCA 60F9 V_(H)55 589 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTG 48B4 GTACAGCCTGGGGGGTCCCTGAGACTCTCCTGT 52D6 GCAGCCTCTGGATTCACCTTTAGCAGCTATGCCA TGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTCTCAGTTATTAGTGACAGTGGTG GTAGCACATACTACGCAGACTCCGTGAAGGGCC GGTTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTACAAATGAACAGCCTGAGAGCCG AGGATACGGCCGTATATTACTGTGCGAAAGATC ATAGCAGTGGCTGGTACTACTACGGTATGGACG TCTGGGGCCAAGGGACCACGGTCACCGTCTCCT CA 60G5.2 V_(H)45 590 CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTG AAGACGCCCGGGGCCTCAGTGAGGGTCTCCTGC AAGGCTTCTGGTTACACCTTTACCAACTATGGTA TCAGCTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGATGGATCAGCGCTTACAATG GTTACTCAAACTATGCACAGAAGTTCCAGGACA GAGTCACCATGACCACAGACACATCCACGAGCA CAGCCTACATGGAGCTGAGGAGCCTGAGATCTG ACGACACGGCCGTGTATTACTGTGCGAGAGAGG AGAAGCAGCTCGTCAAAGACTATTACTACTACG GTATGGACGTCTGGGGCCAGGGGTCCACGGTCA CCGTCTCCTCA 61G5 V_(H)56 591 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTG GTACAGCCTGGGGGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTTAGCAGCTATGCCA TGAGCTGGGTCCGCCAGTCTCCAGGGAAGGGGC TGGAGTGGGTCTCAGTTATTAGTGGTAGTGGTG GTGACACATACTACGCAGACTCCGTGAAGGGCC GGTTCACCATCTCCAGAGACAATTCCAAGAACA CGCTGTATCTACAAATGAACAGCCTGAGAGCCG AGGATACGGCCGTATATTACTGTGCGAAAGATC ATACCAGTGGCTGGTACTACTACGGTATGGACG TCTGGGGCCAAGGGACCACGGTCACCGTCTCCT CA 56G3.2 V_(H)80 592 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGATGGCTCCATCAGTAGTTACTACT GGAACTGGATCCGGCAGCCCGCCGGGAAGGGA CTGGAGTGGATTGGGCGTATCTATACCAGTGGG AGCACCAACTACAATCCCTCCCTCAAGAGTCGA GTCACCATGTCAGTAGACACGTCCAAGAACCAG TTCTCCCTGAACCTGACCTCTGTGACCGCCGCGG ACACGGCCGTGTATTACTGTGCGAGAGGCCCTC TTTGGTTTGACTACTGGGGCCAGGGAACCCTGG TCACCGTCTCCTCA 48G4 V_(H)83 593 CAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTG 53C3.1 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGTTTCCGGATACACCCTCACTGAATTATCCA TACACTGGGTGCGACAGGCTCCTGGAAAAGGGC TTGAGTGGATGGGAGGTTTTGATCCTGAAGATG GTGAAACAATCTACGCACAGAAGTTCCAGGGCA GAGTCACCATGACCGAGGACACATCTACAGACA CAGCCTACATGGAGCTGAGCAGCCTGAGATCTG AGGACACGGCCGTGTATTACTGTGCAACACATT CTGGTTCGGGGAGGTTTTACTACTACTACTACGG TATGGACGTCTGGGGCCAAGGGACCACGGTCAC CGTCTCCTCA 61H5 V_(H)86 594 CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTG 52B9 GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCATCAGCAGTAGTAGTT ACTACTGGGGCTGGATCCGCCAGCCCCCAGGGA AGGGGCTGGAGTGGATTGGGAGTATCTATTATA GTGGGACCACCTACTACAACCCGTCCCTCAAGA GTCGAGTCACCATATCCGTAGACACGTCCAAGA ACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGC CGCAGACACGGCTGTGTATTACTGTGCGAGAGT GGCAGCAGTTTACTGGTACTTCGATCTCTGGGGC CGTGGCACCCTGGTCACTGTCTCCTCA 50D4 V_(H)87 595 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTG AAGAAGACTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATACACCTTCACCAGTCATGAT ATCAACTGGGTGCGACAGGCCACTGGACACGGG CTTGAGTGGATGGGATGGATGAACCCTTACAGT GGTAGCACAGGCCTCGCACAGAGGTTCCAGGAC AGAGTCACCATGACCAGGAACACCTCCATAAGC ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT GAGGACACGGCCGTGTATTACTGTGCGAGAGAC CTTAGCAGTGGCTACTACTACTACGGTTTGGACG TGTGGGGCCAAGGGACCACGGTCACCGTCTCCT CA 50G5v1 V_(H)88 596 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTG 50G5v2 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCCTCTGGATACCCCTTCATCGGCTACTATA TGCACTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGATGGATCAACCCTGACAGTG GTGGCACAAACTATGCACAGAAGTTTCAGGGCA GGGTCACCATGACCAGGGACACGTCCATCACCA CAGCCTACATGGAGCTGAGCAGGCTGAGATCTG ACGACACGGCCGTTTTTTACTGTGCGAGAGGCG GATACAGCTATGGTTACGAGGACTACTACGGTA TGGACGTCTGGGGCCAAGGGACCACGGTCACCG TCTCCTCA 51C1 V_(H)89 597 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTG TTGAAGCCTTCGGAGACCCTGTCCCTCACTTGCG CTGTCTATGGTGGGTCCTTCAGTGGTTACTACTG GAGCTGGATCCGCCAGCCCCCAGGGAAGGGTCT GGAGTGGATTGGGGAAATCAATCATAGTGAAAA CACCAACTACAACCCGTCCCTCAAGAGTCGAGT CACCATATCACTAGACACGTCCCATGACCAGTT CTCCCTAAGACTAACCTCTGTGACCGCCGCGGA CACGGCTGTCTATTACTGTGCGAGAGTAACTGG AACGGATGCTTTTGATTTCTGGGGCCAAGGGAC AATGGTCACCGTCTCTTCA 53C3.2 V_(H)90 598 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCACAGACCCTGTCCCTCACCTGCA CTGTCTCTAATGGCTCCATCAATAGTGGTAATTA CTACTGGAGCTGGATCCGCCAGCACCCAGGAAA GGGCCTGGAGTGGATTGGGTACATCTATCACAG TGGGAGCGCCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATATCAGTGGACACGTCTAAGAA CCAGTTCTCCCTAAAGCTGAGTTCTGTGACTGCC GCGGACACGGCCGTGTATTACTGTGCGAGAACT ACGGGTGCTTCTGATATCTGGGGCCAAGGGATA ATGGTCACCGTCTCTTCA 54H10.3 V_(H)91 599 CAGGTGCAGGTAGTGCAGTCTGGGACTGAGGTG AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC AAGGCTTCTGGATACACCTTCACAGGCTACTAT ATACATTGGGTGCGACAGGCCCCTGGACAAGGG CTTGAGTGGATGGGATGGATCAACCCTAACAGT GGTGGCACAAACTATGCACAGAAGTTTCGGGGC AGGGTCACCATGACCAGGGACACGTCCATCAGC ACAGCCTACATGGAGCTGAGCAGGCTGAGATCT GACGACACGGCCGTGTATTACTGTGCGAGAGAG GAAGACTACAGTGACCACCACTACTTTGACTAC TGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA 55A7 V_(H)92 600 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTG GTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC ACTGTCTCTGGTGGCTCCATCAGTAGTTACTACT GGAGCTGGATCCGGCAGCCCCCAGGGAAGGGA CTGGAGTGGATTGGGTATATCTATTACAGTGGG AGCACCAACTACAACCCCTCCCTCAAGAGTCGA GTCACCATATCAGTAGACACGTCCAAGAACCAG TTCTCCCTGAGGCTGAGCTCTGTGACCGCTGCGG ACACGGCCGTGTATTACTGTGCGAGAGGGATAA CTGGAACTATTGACTTCTGGGGCCAGGGAACCC TGGTCACCGTCTCCTCA 55E6 V_(H)93 601 GAAGTGCAGTTGGTGGAGTCTGGGGGAGGCTTG GTACAGCCTGGGGGGTCCCTGAGACTCTCCTGT GCAGCCTCTGGATTCACCTTCAGTAGCTATAGCA TGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGATTTCATACATTAGTAGTGGTAGTA GTACCATATACCACGCAGACTCTGTGAAGGGCC GATTCACCATTTCCAGAGACAATGCCAAGAACT CACTGTATCTGCAAATGAACAGCCTGAGAGACG AGGACACGGCTGTGTATTACTGTGCGAGAGAAG GGTACTATGATAGTAGTGGTTATTACTACAACG GTATGGACGTCTGGGGCCAAGGGACCACGGTCA CCGTCTCCTCA 61E1 V_(H)94 602 CAGGTACAGCTACAGCAGTCAGGTCCAGGACTG GTGAAGCCCTCGCAGACCCTCTCACTCACCTGTG CCATCTCCGGGGACAGTGTCTCTAGCAACAGTG CTGCTTGGAACTGGATCAGGCAGTCCCCATCGA GAGGCCTTGAGTGGCTGGGAAGGACATACTACA GGTCCAAGTGGTATAATGATTATGCAGTATCTGT GAAAAGTCGAATAACCATCACCCCAGACACATC CAAGAACCAGTTCTCCCTGCAGCTGAAGTCTGT GACTCCCGAGGACACGGCTATTTATTACTGTGC AAGAGAGGGCAGCTGGTCCTCCTTCTTTGACTA CTGGGGCCAGGGAACCCTGGTCACCGTTTCCTCA

Each of the heavy chain variable regions listed in Table 2B can be combined with any of the light chain variable regions shown in Table 2A to form an antigen binding protein. Examples of such combinations include V_(H)1 combined with any of V_(L)1, V_(L)2, V_(L)3, V_(L)4, V_(L)5, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100; V_(H)2 combined with any of V_(L)1, V_(L)2, V_(L)3, V_(L)4, V_(L)5, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100; V_(H)3 combined with any of V_(L)1, V_(L)2, V_(L)3, V_(L)4, V_(L)5, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100; and so on.

In some instances, the antigen binding protein includes at least one heavy chain variable region and/or one light chain variable region from those listed in Tables 2A and 2B. In some instances, the antigen binding protein includes at least two different heavy chain variable regions and/or light chain variable regions from those listed in Table 2B. An example of such an antigen binding protein comprises (a) one V_(H)1, and (b) one of V_(H)2, V_(H)3, V_(H)4, V_(H)5, V_(H)6, V_(H)7, V_(H)8, V_(H)9, V_(H)10, V_(H)11, V_(H)12, V_(H)13, V_(H)14, V_(H)15, V_(H)16, V_(H)17, V_(H)18, V_(H)19, V_(H)20, V_(H)21 V_(H)22, V_(H)23, V_(H)24, V_(H)25, V_(H)26, V_(H)27, V_(H)28, V_(H)29, V_(H)30, V_(H)31, V_(H)32, V_(H)33, V_(H)34, V_(H)35, V_(H)36, V_(H)37, V_(H)38, V_(H)39, V_(H)40, V_(H)41, V_(H)42, V_(H)43, V_(H)44, V_(H)45, V_(H)46, V_(H)47, V_(H)48, V_(H)49, V_(H)50, V_(H)51, V_(H)52, V_(H)53, V_(H)54, V_(H)55, V_(H)56, V_(H)57, V_(H)58, V_(H)59, V_(H)60, V_(H)61, V_(H)62, V_(H)63, V_(H)64, V_(H)65, V_(H)66, V_(H)67, V_(H)68, V_(H)69, V_(H)70, V_(H)71, V_(H)72, V_(H)73, V_(H)74, V_(H)75, V_(H)76, V_(H)77, V_(H)78, V_(H)79, V_(H)80, 81, V_(H)82, V_(H)83, V_(H)84, V_(H)85, V_(H) 86, V_(H) 87, V_(H)88, V_(H)89, V_(H)90, V_(H)91, V_(H)92, V_(H)93, and V_(H)94. Another example comprises (a) one V_(H)2, and (b) one of V_(H)1, V_(H)3, V_(H)4, V_(H)5, V_(H)6, V_(H)7, V_(H)8, V_(H)9, V_(H)10, V_(H)11, V_(H)12, V_(H)13, V_(H)14, V_(H)15, V_(H)16, V_(H)17, V_(H)18, V_(H)19, V_(H)20, V_(H)21 V_(H)22, V_(H)23, V_(H)24, V_(H)25, V_(H)26, V_(H)27, V_(H)28, V_(H)29, V_(H)30, V_(H)31, V_(H)32, V_(H)33, V_(H)34, V_(H)35, V_(H)36, V_(H)37, V_(H)38, V_(H)39, V_(H)40, V_(H)41, V_(H)42, V_(H)43, V_(H)44, V_(H)45, V_(H)46, V_(H)47, V_(H)48, V_(H)49, V_(H)50, V_(H)51, V_(H)52, V_(H)53, V_(H)54, V_(H)55, V_(H)56, V_(H)57, V_(H)58, V_(H)59, V_(H)60, V_(H)61, V_(H)62, V_(H)63, V_(H)64, V_(H)65, V_(H)66, V_(H)67, V_(H)68, V_(H)69, V_(H)70, V_(H)71, V_(H)72, V_(H)73, V_(H)74, V_(H)75, V_(H)76, V_(H)77, V_(H)78, V_(H)79, V_(H)80, 81, V_(H)82, V_(H)83, V_(H)84, V_(H)85, V_(H) 86, V_(H) 87, V_(H)88, V_(H)89, V_(H)90, V_(H)91, V_(H)92, V_(H)93, and V_(H)94. Yet another example comprises (a) one V_(H)3, and (b) one of V_(H)1, V_(H)2, V_(H)4, V_(H)5, V_(H)6, V_(H)7, V_(H)8, V_(H)9, V_(H)10, V_(H)11, V_(H)12, V_(H)13, V_(H)14, V_(H)15, V_(H)16, V_(H)17, V_(H)18, V_(H)19, V_(H)20, V_(H)21 V_(H)22, V_(H)23, V_(H)24, V_(H)25, V_(H)26, V_(H)27, V_(H)28, V_(H)29, V_(H)30, V_(H)31, V_(H)32, V_(H)33, V_(H)34, V_(H)35, V_(H)36, V_(H)37, V_(H)38, V_(H)39, V_(H)40, V_(H)41, V_(H)42, V_(H)43, V_(H)44, V_(H)45, V_(H)46, V_(H)47, V_(H)48, V_(H)49, V_(H)50, V_(H)51, V_(H)52, V_(H)53, V_(H)54, V_(H)55, V_(H)56, V_(H)57, V_(H)58, V_(H)59, V_(H)60, V_(H)61, V_(H)62, V_(H)63, V_(H)64, V_(H)65, V_(H)66, V_(H)67, V_(H)68, V_(H)69, V_(H)70, V_(H)71, V_(H)72, V_(H)73, V_(H)74, V_(H)75, V_(H)76, V_(H)77, V_(H)78, V_(H)79, V_(H)80, 81, V_(H)82, V_(H)83, V_(H)84, V_(H)85, V_(H) 86, V_(H) 87, V_(H)88, V_(H)89, V_(H)90, V_(H)91, V_(H)92, V_(H)93, and V_(H)94, etc. Still another example of such an antigen binding protein comprises (a) one V_(L)1, and (b) one of V_(L)2, V_(L)3, V_(L)4, V_(L)S, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100. Again another example of such an antigen binding protein comprises (a) one V_(L)2, and (b) one of V_(L)1, V_(L)3, V_(L)4, V_(L)5, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100. Again another example of such an antigen binding protein comprises (a) one V_(L)3, and (b) one of V_(L)1, V_(L)2, V_(L)4, V_(L)5, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100, etc.

The various combinations of heavy chain variable regions can be combined with any of the various combinations of light chain variable regions.

In other embodiments, an antigen binding protein comprises two identical light chain variable regions and/or two identical heavy chain variable regions. As an example, the antigen binding protein can be an antibody or immunologically functional fragment thereof that includes two light chain variable regions and two heavy chain variable regions in combinations of pairs of light chain variable regions and pairs of heavy chain variable regions as listed in Tables 2A and 2B.

Some antigen binding proteins that are provided comprise a heavy chain variable domain comprising a sequence of amino acids that differs from the sequence of a heavy chain variable domain selected from V_(H)1, V_(H)2, V_(H)3, V_(H)4, V_(H)5, V_(H)6, V_(H)7, V_(H)8, V_(H)9, V_(H)10, V_(H)11, V_(H)12, V_(H)13, V_(H)14, V_(H)15, V_(H)16, V_(H)17, V_(H)18, V_(H)19, V_(H)20, V_(H)21 V_(H)22, V_(H)23, V_(H)24, V_(H)25, V_(H)26, V_(H)27, V_(H)28, V_(H)29, V_(H)30, V_(H)31, V_(H)32, V_(H)33, V_(H)34, V_(H)35, V_(H)36, V_(H)37, V_(H)38, V_(H)39, V_(H)40, V_(H)41, V_(H)42, V_(H)43, V_(H)44, V_(H)45, V_(H)46, V_(H)47, V_(H)48, V_(H)49, V_(H)50, V_(H)51, V_(H)52, V_(H)53, V_(H)54, V_(H)55, V_(H)56, V_(H)57, V_(H)58, V_(H)59, V_(H)60, V_(H)61, V_(H)62, V_(H)63, V_(H)64, V_(H)65, V_(H)66, V_(H)67, V_(H)68, V_(H)69, V_(H)70, V_(H)71, V_(H)72, V_(H)73, V_(H)74, V_(H)75, V_(H)76, V_(H)77, V_(H)78, V_(H)79, V_(H)80, 81, V_(H)82, V_(H)83, V_(H)84, V_(H)85, V_(H) 86, V_(H) 87, V_(H)88, V_(H)89, V_(H)90, V_(H)91, V_(H)92, V_(H)93, and V_(H)94 at only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues, wherein each such sequence difference is independently either a deletion, insertion or substitution of one amino acid, with the deletions, insertions and/or substitutions resulting in no more than 15 amino acid changes relative to the foregoing variable domain sequences. The heavy chain variable region in some antigen binding proteins comprises a sequence of amino acids that has at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% sequence identity to the amino acid sequences of the heavy chain variable region of V_(H)1, V_(H)2, V_(H)3, V_(H)4, V_(H)5, V_(H)6, V_(H)7, V_(H)8, V_(H)9, V_(H)10, V_(H)11, V_(H)12, V_(H)13, V_(H)14, V_(H)15, V_(H)16, V_(H)17, V_(H)18, V_(H)19, V_(H)20, V_(H)21 V_(H)22, V_(H)23, V_(H)24, V_(H)25, V_(H)26, V_(H)27, V_(H)28, V_(H)29, V_(H)30, V_(H)31, V_(H)32, V_(H)33, V_(H)34, V_(H)35, V_(H)36, V_(H)37, V_(H)38, V_(H)39, V_(H)40, V_(H)41, V_(H)42, V_(H)43, V_(H)44, V_(H)45, V_(H)46, V_(H)47, V_(H)48, V_(H)49, V_(H)50, V_(H)51, V_(H)52, V_(H)53, V_(H)54, V_(H)55, V_(H)56, V_(H)57, V_(H)58, V_(H)59, V_(H)60, V_(H)61, V_(H)62, V_(H)63, V_(H)64, V_(H)65, V_(H)66, V_(H)67, V_(H)68, V_(H)69, V_(H)70, V_(H)71, V_(H)72, V_(H)73, V_(H)74, V_(H)75, V_(H)76, V_(H)77, V_(H)78, V_(H)79, V_(H)80, 81, V_(H)82, V_(H)83, V_(H)84, V_(H)85, V_(H) 86, V_(H) 87, V_(H)88, V_(H)89, V_(H)90, V_(H)91, V_(H)92, V_(H)93, and V_(H)94.

Certain antigen binding proteins comprise a light chain variable domain comprising a sequence of amino acids that differs from the sequence of a light chain variable domain selected from V_(L)1, V_(L)2, V_(L)3, V_(L)4, V_(L)S, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100 at only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues, wherein each such sequence difference is independently either a deletion, insertion or substitution of one amino acid, with the deletions, insertions and/or substitutions resulting in no more than 15 amino acid changes relative to the foregoing variable domain sequences. The light chain variable region in some antigen binding proteins comprises a sequence of amino acids that has at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% sequence identity to the amino acid sequences of the light chain variable region of V_(L)1, V_(L)2, V_(L)3, V_(L)4, V_(L)S, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100.

In additional instances, antigen binding proteins comprise the following pairings of light chain and heavy chain variable domains: V_(L)1 with V_(H)1, V_(L)2 with V_(H)1, V_(L)3 with V_(H)2 or V_(H)3, V_(L)4 with V_(H)4, V_(L)5 with V_(H)5, V_(L)6 with V_(H)6, V_(L)7 with V_(H)6, V_(L)8 with V_(H)7 or V_(H)8, V_(L)9 with V_(H)9, V_(L)10 with V_(H)9, V_(L)11 with V_(H) 10, V_(L)12 with V_(H)11, V_(L)13 with V_(H)12, V_(L)13 with V_(H)14, V_(L)14 with V_(H)13, V_(L)15 with V_(H)14, V_(L)16 with V_(H)15, V_(L)17 with V_(H)16, V_(L)18 with V_(H)17, V_(L)19 with V_(H)18, V_(L)20 with V_(H)19, V_(L)21 with V_(H)20, V_(L)22 with V_(H)21, V_(L)23 with V_(H)22, V_(L)24 with V_(H)23, V_(L)25 with V_(H)24, V_(L)26 with V_(H)25, V_(L)27 with V_(H)26, V_(L)28 with V_(H)27, V_(L)29 with V_(H)28, V_(L)30 with V_(H)29, V_(L)31 with V_(H)30, V_(L)32 with V_(H)31, V_(L)33 with V_(H)32, V_(L)34 with V_(H)33, V_(L)35 with V_(H)34, V_(L)36 with V_(H)35, V_(L)37 with V_(H)36, V_(L)38 with V_(H)37, V_(L)39 with V_(H)38, V_(L)40 with V_(H)39, V_(L)41 with V_(H)40, V_(L)42 with V_(H)41, V_(L)43 with V_(H)42, V_(L)44 with V_(H)43, V_(L)45 with V_(H)44, V_(L)46 with V_(H)45, V_(L)47 with V_(H)46, V_(L)48 with V_(H)47, V_(L)49 with V_(H)48, V_(L)50 with V_(H)49, V_(L)51 with V_(H)50, 52 with V_(H)51, V_(L)53 with V_(H)52, V_(L)54 with V_(H)53, V_(L)55 with 54, and V_(L)56 with V_(H)54, V_(L)57 with V_(H)54, V_(L)58 with V_(H)55, V_(L)59 with V_(H)56, V_(L)60 with V_(H)57, V_(L)61 with V_(H)58, V_(L)62 with V_(H)59, V_(L)63 with V_(H)60, V_(L)64 with V_(H)1, V_(L)65 with V_(H)62, V_(L)66 with V_(H)63, V_(L)67 with V_(H)64, V_(L)68 with V_(H)65, V_(L)69 with V_(H)66, V_(L)70 with V_(H)67, V_(L)71 with V_(H)68, V_(L)72 with V_(H)69, V_(L)73 with V_(H)70, V_(L)74 with V_(H)70, and V_(L)75 with V_(H)70, V_(L)76 with V_(H)71, V_(L)77 with V_(H)72, V_(L)78 with V_(H)73, V_(L)79 with V_(H)74, V_(L)80 with V_(H)75, V_(L)81 with V_(H)76, V_(L)82 with V_(H)77, V_(L)83 with V_(H)78, V_(L)84 with V_(H)79, V_(L)85 with V_(H)80, V_(L)86 with V_(H)81, V_(L)87 with V_(H)82, V_(L)88 with V_(H)86, V_(L)89 with V_(H)83, V_(L)90 with V_(H)84, V_(L)91 with V_(H)85, V_(L) 92 with V_(H) 87, V_(L) 93 with V_(H) 88, V_(L) 94 with V_(H) 88, V_(L) 95 with V_(H) 89, V_(L) 96 with V_(H) 90, V_(L) 97 with V_(H) 91, V_(L) 98 with V_(H) 92, V_(L) 99 with V_(H) 93, and V_(L) 100 with V_(H) 94.

In some instances, the antigen binding proteins in the above pairings can comprise amino acid sequences that have 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the specified variable domains.

Still other antigen binding proteins, e.g., antibodies or immunologically functional fragments, include variant forms of a variant heavy chain and a variant light chain as just described.

Antigen Binding Protein CDRs

In various embodiments, the antigen binding proteins disclosed herein can comprise polypeptides into which one or more CDRs are grafted, inserted and/or joined. An antigen binding protein can have 1, 2, 3, 4, 5 or 6 CDRs. An antigen binding protein thus can have, for example, one heavy chain CDR1 (“CDRH1”), and/or one heavy chain CDR2 (“CDRH2”), and/or one heavy chain CDR3 (“CDRH3”), and/or one light chain CDR1 (“CDRL1”), and/or one light chain CDR2 (“CDRL2”), and/or one light chain CDR3 (“CDRL3”). Some antigen binding proteins include both a CDRH3 and a CDRL3. Specific heavy and light chain CDRs are identified in Tables 3A and 3B, respectively, infra.

Complementarity determining regions (CDRs) and framework regions (FR) of a given antibody can be identified using the system described by Kabat et al., (1991) “Sequences of Proteins of Immunological Interest”, 5^(th) Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242. Although presented in the Kabat nomenclature scheme, as desired, the CDRs disclosed herein can also be redefined according an alternative nomenclature scheme, such as that of Chothia (see Chothia & Lesk, (1987) J. Mol. Biol. 196:901-917; Chothia et al., (1989) Nature 342:878-883 or Honegger & Pluckthun, (2001) J. Mol. Biol. 309:657-670). Certain antibodies that are disclosed herein comprise one or more amino acid sequences that are identical or have substantial sequence identity to the amino acid sequences of one or more of the CDRs presented in Table 3A (CDRHs) and Table 3B (CDRLs), infra.

TABLE 3A Exemplary CDRH Sequences SEQ ID Contained in Clone NO: Reference Designation Sequence 48C9 603 V_(H)73 CDRH1-1 GYYWT 49A12 V_(H)73 51E2 V_(H)73 48F3 604 V_(H)72 CDRH1-2 GYYWS 51E5 V_(H)74 52C5 V_(H)70 55E4 V_(H)70 60G5.1 V_(H)70 49B11 V_(H)70 50H10 V_(H)70 53C1 V_(H)70 56G1 V_(H)71 51C1 V_(H)89 48F8 605 V_(H)48 CDRH1-3 SYSMN 51G2 V_(H)50 56A7 V_(H)51 53B9 V_(H)48 56B4 V_(H)48 57E7 V_(H)48 57F11 V_(H)48 56E4 V_(H)51 55E6 V_(H)93 48H11 606 V_(H)39 CDRH1-4 GYYKH 48G4 607 V_(H)83 CDRH1-5 ELSIH 53C3.1 V_(H)83 49A10 608 V_(H)62 CDRH1-6 NYGMH 58C2 V_(H)85 59G10.2 V_(H)57 48D4 V_(H)62 49C8 609 V_(H)44 CDRH1-7 SYDID 52H1 V_(H)44 49G2 610 V_(H)63 CDRH1-8 NYGMR 50C12 V_(H)63 55G11 V_(H)63 49G3 611 V_(H)46 CDRH1-9 NPRMGVS 49H12 612 V_(H)42 CDRH1-10 SYDIN 54A1 V_(H)43 55G9 V_(H)43 50G1 613 V_(H)84 CDRH1-11 SYGLH 51A8 614 V_(H)58 CDRH1-12 SYGMH 52C1 V_(H)64 53H5.2 V_(H)59 56C11 V_(H)61 60D7 V_(H)66 64H5 V_(H)7 65G4 V_(H)8 66G2 V_(H)11 68G5 V_(H)12 64C8 V_(H)23 67G8 V_(H)27 68D3v2 51C10.1 615 V_(H)54 CDRH1-13 NYAMS 59D10v1 V_(H)54 59D10v2 V_(H)54 51C10.2 616 V_(H)67 CDRH1-14 SGGYYWS 64A6 V_(H)29 52A8 617 V_(H)40 CDRH1-15 GYYLH 66B4 V_(H)10 52B8 618 V_(H)77 CDRH1-16 YYYWS 52F8 619 V_(H)41 CDRH1-17 GYYTH 52H2 620 V_(H)79 CDRH1-18 TYYWS 53F6 621 V_(H)60 CDRH1-19 TYGMH 53H5.3 622 V_(H)75 CDRH1-20 DYYWN 54H10.1 623 V_(H)52 CDRH1-21 SYAMS 60F9 V_(H)55 61G5 V_(H)56 55D1 V_(H)52 48H3 V_(H)52 53C11 V_(H)52 48B4 V_(H)55 52D6 V_(H)55 55D3 624 V_(H)68 CDRH1-22 SGVYYWN 55E9 625 V_(H)65 CDRH1-23 SFGMH 55G5 626 V_(H)78 CDRH1-24 SYYWS 65C3 V_(H)5 68D5 V_(H)5 67F5 V_(H)31 55A7 V_(H)92 56E7 627 V_(H)81 CDRH1-25 SYWIG 67A5 V_(H)34 67C10 V_(H)35 64H6 V_(H)36 56G3.2 628 V_(H)80 CDRH1-26 SYYWN 56G3.3 629 V_(H)76 CDRH1-27 SSSYYWG 55B10 V_(H)76 61H5 V_(H)86 52B9 V_(H)86 57B12 630 V_(H)69 CDRH1-28 SGVYYWS 57D9 631 V_(H)82 CDRH1-29 SNSATWN 59A10 632 V_(H)47 CDRH1-30 DSYMS 49H4 V_(H)47 59C9 633 V_(H)49 CDRH1-31 SYSMS 58A5 V_(H)49 57A4 V_(H)49 57F9 V_(H)49 59G10.3 634 V_(H)53 CDRH1-32 HYAMS 60G5.2 635 V_(H)45 CDRH1-33 NYGIS 63G8 636 V_(H)1 CDRH1-34 SYGIH 64A8 V_(H)1 67B4 V_(H)1 68D3 V_(H)1 64E6 637 V_(H)2 CDRH1-35 SGDYYWT 65E8 V_(H)2 65F11 V_(H)2 67G7 V_(H)2 63H11 V_(H)3 63F5 V_(H)13 65C1 V_(H)15 66F6 V_(H)14 63B6 638 V_(H)4 CDRH1-36 SGDYYWS 64D4 V_(H)4 65F9 V_(H)30 64B10 V_(H)32 64B10v2 63E6 639 V_(H)6 CDRH1-37 GYYMH 66F7 V_(H)6 50G5 v1 V_(H)88 50G5 v2 V_(H)88 67G10v1 640 V_(H)9 CDRH1-38 NAWMS 67G10v2 V_(H)9V_(H)21 63A10 V_(H)22 65H11 53C3.2 641 V_(H)90 CDRH1-39 SGNYYWS 64A7 642 V_(H)16 CDRH1-40 SDTSYWG 50D4 643 V_(H)87 CDRH1-41 SHDIN 61E1 644 V_(H)94 CDRH1-42 SNSAAWN 66D4 645 V_(H)17 CDRH1-43 GYYIH 54H10.3 V_(H)91 65B1 646 V_(H)18 CDRH1-44 GYFMH 67A4 647 V_(H)19 CDRH1-45 TYDMH 65B4 648 V_(H)20 CDRH1-46 SYDMH 65E3 649 V_(H)24 CDRH1-47 NYNMH 65D4 650 V_(H)25 CDRH1-48 FYGMH 65D1 651 V_(H)26 CDRH1-49 YYYIH 65B7 652 V_(H)28 CDRH1-50 SDAYYWS 68C8 653 V_(H)33 CDRH1-51 SGDNYWS 63F9 654 V_(H)37 CDRH1-52 SGGYYWN 67F6v1 655 V_(H)38 CDRH1-53 GYWIG 67F6v2 V_(H)38 48C9 656 V_(H)73 CDRH2-1 EINHSENTNYNPSLKS 52C5 V_(H)70 55E4 V_(H)70 56G1 V_(H)71 49A12 V_(H)73 51E2 V_(H)73 60G5.1 V_(H)70 49B11 V_(H)70 50H10 V_(H)70 53C1 V_(H)70 51C1 V_(H)89 48F3 657 V_(H)72 CDRH2-2 EITHTGSSNYNPSLKS 48F8 658 V_(H)48 CDRH2-3 SISSSSSYEYYVDSVKG 53B9 V_(H)48 56B4 V_(H)48 57E7 V_(H)48 57F11 V_(H)48 48H11 659 V_(H)39 CDRH2-4 WINPNSGATKYAQKFQG 48G4 660 V_(H)83 CDRH2-5 GFDPEDGETIYAQKFQG 53C3.1 V_(H)83 49A10 661 V_(H)62 CDRH2-6 IIWYDGSNKNYADSVKG 48D4 V_(H)62 49C8 662 V_(H)44 CDRH2-7 WMNPNGGNTGYAQKFQG 52H1 V_(H)44 49G2 663 V_(H)63 CDRH2-8 LIWYDGSNKFYADSVKG 50C12 V_(H)63 55G11 V_(H)63 49G3 664 V_(H)46 CDRH2-9 HIFSNDEKSYSTSLKS 49H12 665 V_(H)42 CDRH2-10 WMNPYSGSTGYAQNFQG 50G1 666 V_(H)84 CDRH2-11 VIWNDGSNKLYADSVKG 51A8 667 V_(H)58 CDRH2-12 VISYDGSNKYYADSVKG 63G8 V_(H)1 64A8 V_(H)1 67B4 V_(H)1 68D3 V_(H)1 51C10.1 668 V_(H)54 CDRH2-13 GISGSSAGTYYADSVKG 59D10v1 V_(H)54 59D10v2 V_(H)54 51C10.2 669 V_(H)67 CDRH2-14 YIYYNGSPYDNPSLKR 51E5 670 V_(H)74 CDRH2-15 ELDHSGSINYNPSLKS 51G2 671 V_(H)50 CDRH2-16 SISSSSTYIYYADSVKG 56A7 V_(H)51 56E4 V_(H)51 52A8 672 V_(H)40 CDRH2-17 WINPNSAATNYAPKFQG 52B8 673 V_(H)77 CDRH2-18 YIYYSGSTNYNPSLKS 55A7 V_(H)92 52C1 674 V_(H)64 CDRH2-19 VIWYDGSNNYYADSVKG 52F8 675 V_(H)41 CDRH2-20 WINPSSGDTKYAQKFQG 52H2 676 V_(H)79 CDRH2-21 YIFYNGNANYSPSLKS 53F6 677 V_(H)60 CDRH2-22 VIWYDGSNKYYADSVKG 60D7 V_(H)66 65D4 V_(H)25 53H5.2 678 V_(H)59 CDRH2-23 LISYDGSNKYYADSVKG 53H5.3 679 V_(H)75 CDRH2-24 EINHSGTTNYNPSLKS 54A1 680 V_(H)43 CDRH2-25 WMNPHSGNTGYAQKFQG 55G9 V_(H)43 54H10.1 681 V_(H)52 CDRH2-26 AISGSGRTTYSADSVKG 55D1 V_(H)52 48H3 V_(H)52 53C11 V_(H)52 55D3 682 V_(H)68 CDRH2-27 YLYYSGSTYYNPSLKS 55E9 683 V_(H)65 CDRH2-28 LIWYDGDNKYYADSVKG 55G5 684 V_(H)78 CDRH2-29 RIYISGSTNYNPSLEN 56C11 685 V_(H)61 CDRH2-30 VIWYDGSYQFYADSVKG 56E7 686 V_(H)81 CDRH2-31 IIYPGDSDTRYSPSFQG 67A5 V_(H)34 67C10 V_(H)35 67F6v1 V_(H)38 67F6v2 V_(H)38 56G3.2 687 V_(H)80 CDRH2-32 RIYTSGSTNYNPSLKS 56G3.3 688 V_(H)76 CDRH2-33 MIYYSGTTYYNPSLKS 55B10 V_(H)76 56G3.3 V_(H)76 57B12 689 V_(H)69 CDRH2-34 YIYYSGSTYYNPSLKS 63H11 V_(H)3 66F6 V_(H)14 65F9 V_(H)30 57D9 690 V_(H)82 CDRH2-35 RTYYRSKWYNDYAVSVKS 61E1 V_(H)94 58C2 691 V_(H)85 CDRH2-36 VIWNDGNNKYYADSVKG 59A10 692 V_(H)47 CDRH2-37 SISSSGSIVYFADSVKG 49H4 V_(H)47 59C9 693 V_(H)49 CDRH2-38 SISSSSTYIYYADSLKG 58A5 V_(H)49 57A4 V_(H)49 57F9 V_(H)49 59G10.2 694 V_(H)57 CDRH2-39 ITSYGGSNKNYADSVKG 59G10.3 695 V_(H)53 CDRH2-40 AISGSGAGTFYADSMKG 60F9 696 V_(H)55 CDRH2-41 VISDSGGSTYYADSVKG 48B4 V_(H)55 52D6 V_(H)55 60G5.2 697 V_(H)45 CDRH2-42 WISAYNGYSNYAQKFQD 61G5 698 V_(H)56 CDRH2-43 VISGSGGDTYYADSVKG 64E6 699 V_(H)2 CDRH2-44 YIYYTGSTYYNPSLKS 65E8 V_(H)2 65F11 V_(H)2 67G7 V_(H)2 63B6 700 V_(H)4 CDRH2-45 YIYYSGTTYYNPSLKS 64D4 V_(H)4 65C3 701 V_(H)5 CDRH2-46 YIYYTGSTNYNPSLKS 68D5 V_(H)5 63E6 702 V_(H)6 CDRH2-47 WMNPNSGATKYAQKFQG 66F7 V_(H)6 64H5 703 V_(H)7 CDRH2-48 VIWDDGSNKYYADSVKG 65G4 V_(H)8 67G10v1 704 V_(H)9 CDRH2-49 RIKSKTDGGTTEYAAPVKG 67G10v2 V_(H)9 63F5 705 V_(H)13 CDRH2-50 YIYYSGSAYYNPSLKS 64A7 706 V_(H)16 CDRH2-51 NIYYSGTTYFNPSLKS 65C1 707 V_(H)15 CDRH2-52 YIFYSGSTYYNPSLKS 65B7 V_(H)28 66B4 708 V_(H)10 CDRH2-53 WINPNSGGTDYAQKFQG 66G2 709 V_(H)11 CDRH2-54 GISYDGSNKNYADSVKG 68G5 710 V_(H)12 CDRH2-55 VIWYDGSNKYHADSVKG 66D4 711 V_(H)17 CDRH2-56 WINPPSGATNYAQKFRG 65B1 712 V_(H)18 CDRH2-57 WINPNSGATNYAQKFHG 67A4 713 V_(H)19 CDRH2-58 AIGIAGDTYYSDSVKG 65B4 714 V_(H)20 CDRH2-59 TIDTAGDAYYPGSVKG 63A10 715 V_(H)21 CDRH2-60 RIKSKTDGGTTDYAAPVKG 67G10v1 67G10v2 65H11 716 V_(H)22 CDRH2-61 RIIGKTDGGTTDYAAPVKG 64C8 717 V_(H)23 CDRH2-62 VISYDGSNKHYADSVKG 65E3 718 V_(H)24 CDRH2-63 VLWYDGNTKYYADSVKG 65D1 719 V_(H)26 CDRH2-64 LIWYDGSNKDYADSVKG 67G8 720 V_(H)27 CDRH2-65 VIWYDGSNKDYADSVKG 64A6 721 V_(H)29 CDRH2-66 YIYYSGGTHYNPSLKS 67F5 722 V_(H)31 CDRH2-67 YIYYSGNTNYNPSLKS 64B10 723 V_(H)32 CDRH2-68 FIYYSGGTNYNPSLKS 68C8 724 V_(H)33 CDRH2-69 FMFYSGSTNYNPSLKS 64H6 725 V_(H)36 CDRH2-70 IIYPGDSETRYSPSFQG 63F9 726 V_(H)37 CDRH2-71 YIYDSGSTYYNPSLKS 61H5 727 V_(H)86 CDRH2-72 SIYYSGTTYYNPSLKS 52B9 V_(H)86 50G5v1 728 V_(H)88 CDRH2-73 WINPDSGGTNYAQKFQG 50G5v2 V_(H)88 54H10.3 729 V_(H)91 CDRH2-74 WINPNSGGTNYAQKFRG 50D4 730 V_(H)87 CDRH2-75 WMNPYSGSTGLAQRFQD 55E6 731 V_(H)93 CDRH2-76 YISSGSSTIYHADSVKG 53C3.2 732 V_(H)90 CDRH2-77 YIYHSGSAYYNPSLKS 64B10v2 1868 V_(H)96 CDRH2-78 FIYYSGGTNYNPPLKS 68D3v2 1869 V_(H)95 CDRH2-79 FISYAGSNKYYADSVKG 48C9 733 V_(H)73 CDRH3-1 ESGNFPFDY 49A12 V_(H)73 51E2 V_(H)73 48F3 734 V_(H)72 CDRH3-2 GGILWFGEQAFDI 48F8 735 V_(H)48 CDRH3-3 SLSIAVAASDY 53B9 V_(H)48 56B4 V_(H)48 57E7 V_(H)48 57F11 V_(H)48 48H11 736 V_(H)39 CDRH3-4 EVPDGIVVAGSNAFDF 48G4 737 V_(H)83 CDRH3-5 HSGSGRFYYYYYGMDV 53C3.1 V_(H)83 49A10 738 V_(H)62 CDRH3-6 DQDYDFWSGYPYFYYYGMDV 48D4 V_(H)62 49C8 739 V_(H)44 CDRH3-7 GKEFSRAEFDY 52H1 V_(H)44 49G2 740 V_(H)63 CDRH3-8 DRYYDFWSGYPYFFYYGLDV 50C12 V_(H)63 55G11 V_(H)63 49G3 741 V_(H)46 CDRH3-9 VDTLNYHYYGMDV 49H12 742 V_(H)42 CDRH3-10 YNWNYGAFDF 54A1 V_(H)43 55G9 V_(H)43 50G1 743 V_(H)84 CDRH3-11 DQYYDFWSGYPYYHYYGMDV 51A8 744 V_(H)58 CDRH3-12 ADGDYPYYYYYYGMDV 51C10.1 745 V_(H)54 CDRH3-13 DWSIAVAGTFDY 59D10v1 V_(H)54 59D10v2 V_(H)54 51C10.2 746 V_(H)67 CDRH3-14 GALYGMDV 51E5 747 V_(H)74 CDRH3-15 VLGSTLDY 51G2 748 V_(H)50 CDRH3-16 DTYISGWNYGMDV 52A8 749 V_(H)40 CDRH3-17 EGGTYNWFDP 52B8 750 V_(H)77 CDRH3-18 GTRAFDI 52C1 751 V_(H)64 CDRH3-19 DRAGASPGMDV 52C5 752 V_(H)70 CDRH3-20 VTGTDAFDF 60G5.1 V_(H)70 49B11 V_(H)70 50H10 V_(H)70 53C1 V_(H)70 51C1 V_(H)89 55E4 V_(H)70 56G1 V_(H)71 52F8 753 V_(H)41 CDRH3-21 SGWYPSYYYGMDV 52H2 754 V_(H)79 CDRH3-22 ETDYGDYARPFEY 53F6 755 V_(H)60 CDRH3-23 GHYDSSGPRDY 53H5.2 756 V_(H)59 CDRH3-24 EANWGYNYYGMDV 53H5.3 757 V_(H)75 CDRH3-25 ILRYFDWLEYYFDY 61E1 758 V_(H)94 CDRH3-26 EGSWSSFFDY 54H10 759 V_(H)52 CDRH3-27 EQQWLVYFDY 55D1 V_(H)52 48H3 V_(H)52 53C11 V_(H)52 55D3 760 V_(H)68 CDRH3-28 DGITMVRGVTHYYGMDV 57B12 V_(H)69 55E6 761 V_(H)93 CDRH3-29 EGYYDSSGYYYNGMDV 55E9 762 V_(H)65 CDRH3-30 NSGWDYFYYYGMDV 55G5 763 V_(H)78 CDRH3-31 SGSYSFDY 56A7 764 V_(H)51 CDRH3-32 DIYSSGWSYGMDV 56E4 V_(H)51 56C11 765 V_(H)61 CDRH3-33 DHVWRTYRYIFDY 56E7 766 V_(H)81 CDRH3-34 AQLGIFDY 50G5v1 767 V_(H)88 CDRH3-35 GGYSYGYEDYYGMDV 50G5v2 V_(H)88 56G3.2 768 V_(H)80 CDRH3-36 GPLWFDY 56G3.3 769 V_(H)76 CDRH3-37 VAAVYWYFDL 55B10 V_(H)76 61H5 V_(H)86 52B9 V_(H)86 55A7 770 V_(H)92 CDRH3-38 GITGTIDF 57D9 771 V_(H)82 CDRH3-39 IVVVPAVLFDY 58C2 772 V_(H)85 CDRH3-40 DQNYDFWNGYPYYFYYGMDV 59A10 773 V_(H)47 CDRH3-41 ETFSSGWFDAFDI 49H4 V_(H)47 59C9 774 V_(H)49 CDRH3-42 DRWSSGWNEGFDY 58A5 V_(H)49 57A4 V_(H)49 57F9 V_(H)49 53C3.2 775 V_(H)90 CDRH3-43 TTGASDI 59G10.2 776 V_(H)57 CDRH3-44 EAGYSFDY 59G10.3 777 V_(H)53 CDRH3-45 DLRIAVAGSFDY 60D7 778 V_(H)66 CDRH3-46 DQYFDFWSGYPFFYYYGMDV 60F9 779 V_(H)55 CDRH3-47 DHSSGWYYYGMDV 48B4 V_(H)55 52D6 V_(H)55 60G5.2 780 V_(H)45 CDRH3-48 EEKQLVKDYYYYGMDV 61G5 781 V_(H)56 CDRH3-49 DHTSGWYYYGMDV 63G8 782 V_(H)1 CDRH3-50 TVTKEDYYYYGMDV 64A8 V_(H)1 67B4 V_(H)1 68D3 V_(H)1 66G2 V_(H)11 64E6 783 V_(H)2 CDRH3-51 MTTPYWYFDL 65E8 V_(H)2 65F11 V_(H)2 67G7 V_(H)2 63H11 V_(H)3 63F5 V_(H)13 66F6 V_(H)14 63B6 784 V_(H)4 CDRH3-52 MTTPYWYFGL 64D4 V_(H)4 65C3 785 V_(H)5 CDRH3-53 EYYYGSGSYYP 68D5 V_(H)5 67F5 V_(H)31 63E6 786 V_(H)6 CDRH3-54 ELGDYPFFDY 66F7 V_(H)6 64H5 787 V_(H)7 CDRH3-55 EYVAEAGFDY 65G4 V_(H)8 67G10v1 788 V_(H)9 CDRH3-56 DSSGSYYVEDYFDY 67G10 v2 V_(H)9 63A10 V_(H)21 65H11 V_(H)22 64A7 789 V_(H)16 CDRH3-57 LRGVYWYFDL 65C1 790 V_(H)15 CDRH3-58 MTSPYWYFDL 66B4 791 V_(H)10 CDRH3-59 DAATGRYYFDN 68G5 792 V_(H)12 CDRH3-60 DPGYSYGHFDY 66D4 793 V_(H)17 CDRH3-61 ETGTWSFFDY 65B1 794 V_(H)18 CDRH3-62 ELGIFNWFDP 67A4 795 V_(H)19 CDRH3-63 DRSSGRFGDYYGMDV 65B4 796 V_(H)20 CDRH3-64 DRSSGRFGDFYGMDV 64C8 797 V_(H)23 CDRH3-65 ELLWFGEYGVDHGMDV 65E3 798 V_(H)24 CDRH3-66 DVYGDYFAY 65D4 799 V_(H)25 CDRH3-67 ALNWNFFDY 65D1 800 V_(H)26 CDRH3-68 EGTTRRGFDY 67G8 801 V_(H)27 CDRH3-69 SAVALYNWFDP 65B7 802 V_(H)28 CDRH3-70 ESRILYFNGYFQH 64A6 803 V_(H)29 CDRH3-71 VLHYSDSRGYSYYSDF 65F9 804 V_(H)30 CDRH3-72 VLHYYDSSGYSYYFDY 64B10v1 805 V_(H)32 CDRH3-73 YSSTWDYYYGVDV 64B10v2 V_(H)32 68C8 806 V_(H)33 CDRH3-74 YRSDWDYYYGMDV 67A5 807 V_(H)34 CDRH3-75 RASRGYRFGLAFAI 67C10 808 V_(H)35 CDRH3-76 RASRGYRYGLAFAI 64H6 809 V_(H)36 CDRH3-77 VAVSAFNWFDP 63F9 810 V_(H)37 CDRH3-78 DVLMVYTKGGYYYYGVDV 67F6v1 811 V_(H)38 CDRH3-79 RASRGYSYGHAFDF 67F6v2 V_(H)38 50D4 812 V_(H)87 CDRH3-80 DLSSGYYYYGLDV 54H10.3 813 V_(H)91 CDRH3-81 EEDYSDHHYFDY 66D4 1870 V_(H)17 CDRH3-82 ETGTWNFFDY 68D3v2 1871 V_(H)95 CDRH3-83 TVTEEDYYYYGMDV

TABLE 3B Exemplary CDRL Sequences SEQ Contained ID in Designa- Amino Acid Clone NO: Reference tion Sequence 48C9 814 V_(L)78 CDRL1-1 RASQNIRTYLN 49A12 V_(L)78 51E2 V_(L)78 48F3 815 V_(L)77 CDRL1-2 RASQRISSYLN 48F8 816 V_(L)49 CDRL1-3 RASQDIGNSLH 53B9 V_(L)49 56B4 V_(L)49 57E7 V_(L)49 57F11 V_(L)49 48H11 817 V_(L)40 CDRL1-4 RASQNIRSYLN 49A10 818 V_(L)65 CDRL1-5 RSSQSLLDSDDGNTYLD 48D4 V_(L)65 49C8 819 V_(L)45 CDRL1-6 QASQDINIYLN 52H1 V_(L)45 49G2 820 V_(L)66 CDRL1-7 RSSQSLLDSDDGDTYLD 50C12 V_(L)66 55G11 V_(L)66 60D7 V_(L)69 50G1 V_(L)90 49G3 821 V_(L)47 CDRL1-8 QASQGISNYLN 49H12 822 V_(L)43 CDRL1-9 QASQDITKYLN 51A8 823 V_(L)61 CDRL1-10 TRSSGSIASDYVQ 51C10.1 824 V_(L)55 CDRL1-11 SGDALPKKYAY 51C10.2 825 V_(L)70 CDRL1-12 SGDELGDKYAC 51E5 826 V_(L)79 CDRL1-13 RASQDIRNDLG 63G8v1 V_(L)104 64A8 V_(L)1 67B4 V_(L)1 68D3 V_(L)2 51G2 827 V_(L)51 CDRL1-14 RASQGISSWLA 59A10 V_(L)48 49H4 V_(L)48 52A8 828 V_(L)41 CDRL1-15 RASQTISSYLN 52B8 829 V_(L)82 CDRL1-16 RASQSVSDILA 52C1 830 V_(L)67 CDRL1-17 SGSSSNIGINYVS 52C5 831 V_(L)73 CDRL1-18 RASQSISNYLN 55E4 V_(L)75 49B11 V_(L)75 50H10 V_(L)75 53C1 V_(L)75 56G1 V_(L)76 51C1 V_(L)95 60G5.1 V_(L)74 52F8 832 V_(L)42 CDRL1-19 RSSQSLLHSNGYNYLD 52H2 833 V_(L)84 CDRL1-20 RASQSVRSSYLA 53F6 834 V_(L)63 CDRL1-21 RSSQSLQHSNGYNYLD 53H5.2 835 V_(L)62 CDRL1-22 RASQGIRNDLG 50G5 v1 V_(L)93 66G2 V_(L)12 53H5.3 836 V_(L)80 CDRL1-23 RASQSVSSNVA 54A1 837 V_(L)44 CDRL1-24 QASQDISIYLN 55G9 V_(L)44 54H10.1 838 V_(L)53 CDRL1-25 RASQSFSSSYLA 55D1 V_(L)53 48H3 V_(L)53 53C11 V_(L)53 55D3 839 V_(L)71 CDRL1-26 RASQDISNYLA 50D4 V_(L)92 55E9 840 V_(L)68 CDRL1-27 RSSQSLLHSNGFNYLD 55G5 841 V_(L)83 CDRL1-28 SGDNLGDKYAF 56A7 842 V_(L)52 CDRL1-29 RASQDISSWLA 56E4 V_(L)52 56C11 843 V_(L)64 CDRL1-30 GGNDIGSKSVH 56E7 844 V_(L)86 CDRL1-31 QASQDIKKFLN 56G3.2 845 V_(L)85 CDRL1-32 RARQSVGSNLI 56G3.3 846 V_(L)81 CDRL1-33 RASQSVSRDYLA 55B10 V_(L)81 61H5 V_(L)88 52B9 V_(L)88 57B12 847 V_(L)72 CDRL1-34 RASHDISNYLA 57D9 848 V_(L)87 CDRL1-35 RASPSVSSSYLA 53C3.2 849 V_(L)96 CDRL1-36 RASQSISSNLA 59C9 850 V_(L)50 CDRL1-37 RASQDIDSWLV 58A5 V_(L)50 57A4 V_(L)50 57F9 V_(L)50 59D10 v1 851 V_(L)56 CDRL1-38 SGDAVPKKYAN 59D10 v2 852 V_(L)57 CDRL1-39 SGDKLGDKYVC 65D1 V_(L)27 59G10.2 853 V_(L)60 CDRL1-40 SGDNLGDKYAC 59G10.3 854 V_(L)54 CDRL1-41 SGSSSNIGDNYVS 54H10.3 855 V_(L)97 CDRL1-84 RASQTISIYLN 60F9 856 V_(L)58 CDRL1-43 RASQRVPSSYIV 48B4 V_(L)58 52D6 V_(L)58 60G5.2 857 V_(L)46 CDRL1-44 SGNKLGDKYVC 61G5 858 V_(L)59 CDRL1-45 RASQRVPSSYLV 64E6 859 V_(L)3 CDRL1-46 RASQSVRNSYLA 65E8 V_(L)3 65F11 V_(L)3 67G7 V_(L)3 63H11 V_(L)3 66F6 V_(L)15 63B6 860 V_(L)4 CDRL1-47 RASQSVSNSYLA 64D4 V_(L)4 65C3 861 V_(L)5 CDRL1-48 RASQSVSSQLA 68D5 V_(L)5 63E6 862 V_(L)6 CDRL1-49 RTSQSISSYLN 66F7 863 V_(L)7 CDRL1-50 RTSQSISNYLN 64H5 864 V_(L)8 CDRL1-51 GGNNIGSKNVH 65G4 V_(L)8 65E3 V_(L)25 64H6 V_(L)37 67G10 v1 865 V_(L)9 CDRL1-52 GGNNIGSKAVH 63A10 v1 V_(L)22 63A10v2 V_(L)101 67G10 v2 866 V_(L)10 CDRL1-53 SGDKLGDKYAC 63F5 867 V_(L)14 CDRL1-54 RASQTVRNNYLA 64A7 868 V_(L)17 CDRL1-55 RASQSVSRNYLA 65C1 869 V_(L)16 CDRL1-56 RASQTIRNSYLA 66B4 870 V_(L)11 CDRL1-57 RASQGISRWLA 55A7 871 V_(L)98 CDRL1-58 RASQSISSYLN 68G5 872 V_(L)13 CDRL1-59 GGNNIGSINVH 66D4 873 V_(L)18 CDRL1-60 RASQIISRYLN 65B1 874 V_(L)19 CDRL1-61 RASQNINNYLN 67A4 875 V_(L)20 CDRL1-62 GGNNIGSKSVH 65B4 876 V_(L)21 CDRL1-63 GGNNIGSKSVQ 55E6 877 V_(L)99 CDRL1-64 RASQSVSRSHLA 65H11 878 V_(L)23 CDRL1-65 GGNNIGSKTVH 64C8 879 V_(L)24 CDRL1-66 RSSPSLVYSDGNTYLN 65D4 880 V_(L)26 CDRL1-67 GGNDIGSKNVH 61E1 881 V_(L)100 CDRL1-68 RASQSIGTFLN 67G8 882 V_(L)28 CDRL1-69 GGNNIGSYNVF 65B7 883 V_(L)29 CDRL1-70 RASQSVSSMYLA 64A6 884 V_(L)30 CDRL1-71 RASQSVNSNLA 65F9 885 V_(L)31 CDRL1-72 RASQSVSSNLA 67F5 V_(L)32 64B10 886 V_(L)33 CDRL1-73 SGSSSNIGNNYVA 68C8 887 V_(L)34 CDRL1-74 SGSSSNIGNNYVS 67A5 888 V_(L)35 CDRL1-75 RSSQSLLNSDDGNTYLD 67C10 V_(L)36 63F9 889 V_(L)38 CDRL1-76 RASQDIRNDLA 67F6v1 890 V_(L)39 CDRL1-77 RSSQSLLNSDAGTTYLD 50G5v2 891 V_(L)94 CDRL1-78 RSSQRLVYSDGNTYLN 48G4 892 V_(L)89 CDRL1-79 RASQSVASSYLV 53C3.1 V_(L)89 58C2 893 V_(L)91 CDRL1-81 RSSQSLFDNDDGDTYLD 68G8v2 1872 V_(L)105 CDRL1-82 RASQGIRSGLG 68G8v3 V_(L)106 65B7v1 1873 V_(L)29 CDRL1-83 RASQSVSSIYLA 67F6v2 1874 V_(L)108 CDRL1-84 RSSQSLLNSDAGTTYLD 65B7v2 1875 V_(L)107 CDRL1-85 RSSQSLVYSDGDTYLN 65H11v2 1876 V_(L)103 CDRL1-86 SGDKLGDRYVC 63A10v3 1877 V_(L)102 CDRL1-87 SGDKLGNRYTC 48C9 894 V_(L)78 CDRL2-1 VASSLES 49A12 V_(L)78 51E2 V_(L)78 48F3 895 V_(L)77 CDRL2-2 AVSSLQS 48F8 896 V_(L)49 CDRL2-3 FASQSFS 53B9 V_(L)49 56B4 V_(L)49 57E7 V_(L)49 57F11 V_(L)49 48H11 897 V_(L)40 CDRL2-4 GASNLQS 49A10 898 V_(L)65 CDRL2-5 TLSYRAS 48D4 V_(L)65 49G2 V_(L)66 50C12 V_(L)66 55G11 V_(L)66 60D7 V_(L)69 67A5 V_(L)35 67C10 V_(L)36 50G1 V_(L)90 58C2 V_(L)91 49C8 899 V_(L)45 CDRL2-6 DVSNLET 52H1 V_(L)45 54A1 V_(L)44 55G9 V_(L)44 49G3 900 V_(L)47 CDRL2-7 DASNLET 56E7 V_(L)86 49H12 901 V_(L)43 CDRL2-8 DTFILET 51A8 902 V_(L)61 CDRL2-9 EDKERSS 51C10.1 903 V_(L)55 CDRL2-10 EDSKRPS 59D10v1 V_(L)56 51C10.2 904 V_(L)70 CDRL2-11 QDTKRPS 59G10.2 V_(L)60 51E5 905 V_(L)79 CDRL2-12 AASSLQF 51G2 906 V_(L)51 CDRL2-13 DASSLQS 52A8 907 V_(L)41 CDRL2-14 AASSLQS 52C5 V_(L)73 53H5.2 V_(L)62 55D3 V_(L)71 56G1 V_(L)76 57B12 V_(L)72 63E6 V_(L)6 66F7 V_(L)7 66D4 V_(L)18 50G5 v1 V_(L)93 51C1 V_(L)95 55A7 V_(L)98 61E1 V_(L)100 60G5.1 V_(L)74 52B8 908 V_(L)82 CDRL2-15 GASTRAT 53H5.3 V_(L)80 65F9 V_(L)31 52C1 909 V_(L)67 CDRL2-16 DNNKRPS 59G10.3 V_(L)54 68C8 V_(L)34 52F8 910 V_(L)42 CDRL2-17 LGSNRAS 55E9 V_(L)68 52H2 911 V_(L)84 CDRL2-18 GASRRAT 53F6 912 V_(L)63 CDRL2-19 LDSNRAS 54H10.1 913 V_(L)53 CDRL2-20 GASSRAT 55D1 V_(L)53 48H3 V_(L)53 53C11 V_(L)53 57D9 V_(L)87 61H5 V_(L)88 52B9 V_(L)88 63F5 V_(L)14 64A7 V_(L)17 65B7 V_(L)29 55E6 V_(L)99 55E4 914 V_(L)75 CDRL2-21 TASSLQS 49B11 V_(L)75 50H10 V_(L)75 53C1 V_(L)75 50G5v2 915 V_(L)94 CDRL2-22 KVSNWDS 65B7v2 55G5 916 V_(L)83 CDRL2-23 QDNKRPS 56A7 917 V_(L)52 CDRL2-24 DASTLQS 56E4 V_(L)52 56C11 918 V_(L)64 CDRL2-25 DDSDRPS 67A4 V_(L)20 65B4 V_(L)21 56G3.2 919 V_(L)85 CDRL2-26 GASSRDT 56G3.3 920 V_(L)81 CDRL2-27 GASARAT 55B10 V_(L)81 59A10 921 V_(L)48 CDRL2-28 GASSLQS 49H4 V_(L)48 59C9 922 V_(L)50 CDRL2-29 AASNLQR 58A5 V_(L)50 57A4 V_(L)50 57F9 V_(L)50 63G8v1 V_(L)1 63G8v2 V_(L)1 63G8v3 V_(L)1 64A8 V_(L)2 67B4 68D3 59D10 v2 923 V_(L)57 CDRL2-30 QNNKRPS 60F9 924 V_(L)58 CDRL2-31 GSSNRAT 48B4 V_(L)58 52D6 V_(L)58 60G5.2 925 V_(L)46 CDRL2-32 QDSKRPS 65D1 V_(L)27 65H11v2 61G5 926 V_(L)59 CDRL2-33 GASNRAT 64E6 927 V_(L)3 CDRL2-34 GAFSRAS 65E8 V_(L)3 65F11 V_(L)3 67G7 V_(L)3 63H11 V_(L)3 63B6 928 V_(L)4 CDRL2-35 GAFSRAT 64D4 V_(L)4 65C1 V_(L)16 66F6 V_(L)15 48G4 V_(L)89 53C3.1 V_(L)89 65C3 929 V_(L)5 CDRL2-36 GASNRAI 68D5 V_(L)5 64H5 930 V_(L)8 CDRL2-37 RDSKRPS 65G4 V_(L)8 67G8 V_(L)28 64H6 V_(L)37 67G10 v1 931 V_(L)9 CDRL2-38 SDSNRPS 65H11 V_(L)23 67G10 v2 932 V_(L)10 CDRL2-39 QDNERPS 66B4 933 V_(L)11 CDRL2-40 AASSLKS 66G2 934 V_(L)12 CDRL2-41 AASNLQS 68G5 935 V_(L)13 CDRL2-42 RDRNRPS 65E3 V_(L)25 65D4 V_(L)26 65B1 936 V_(L)19 CDRL2-43 TTSSLQS 53C3.2 937 V_(L)96 CDRL2-44 GTSIRAS 63A10v1 938 V_(L)22 CDRL2-45 CDSNRPS 63A10v2 V_(L)101 54H10.3 939 V_(L)97 CDRL2-46 SASSLQS 64C8 940 V_(L)24 CDRL2-47 KGSNWDS 64A6 941 V_(L)30 CDRL2-48 GTSTRAT 67F5 942 V_(L)32 CDRL2-49 GSSNRAI 64B10 943 V_(L)33 CDRL2-50 DNDKRPS 63F9 944 V_(L)38 CDRL2-51 ASSSLQS 67F6 945 V_(L)39 CDRL2-52 TLSFRAS 67F6v2 50D4 946 V_(L)92 CDRL2-53 AASTLLS 63A10v3 1878 V_(L)102 CDRL2-54 QDSERPS 48C9 947 V_(L)78 CDRL3-1 QQSDSIPRT 49A12 51E2 48F3 948 V_(L)77 CDRL3-2 QQSYSATFT 48F8 949 V_(L)49 CDRL3-3 HQSSDLPLT 53B9 V_(L)49 56B4 V_(L)49 57E7 V_(L)49 57F11 V_(L)49 48H11 950 V_(L)40 CDRL3-4 QQSYNTPCS 49A10 951 V_(L)65 CDRL3-5 MQRIEFPIT 48D4 V_(L)65 67C10 V_(L)36 67F6v1 V_(L)39 67F6v1 V_(L)39 49C8 952 V_(L)45 CDRL3-6 QQYDNLPFT 52H1 V_(L)45 49G2 953 V_(L)66 CDRL3-7 MQHIEFPST 50C12 V_(L)66 55G11 V_(L)66 49G3 954 V_(L)47 CDRL3-8 HQYDDLPLT 49H12 955 V_(L)43 CDRL3-9 QQYDNLPLT 54A1 V_(L)44 55G9 V_(L)44 51A8 956 V_(L)61 CDRL3-10 QSYDRNNHVV 51C10.1 957 V_(L)55 CDRL3-11 YSTDSSVNHVV 51C10.2 958 V_(L)70 CDRL3-12 QAWDSGTVV 51E5 959 V_(L)79 CDRL3-13 LQHSSYPLT 51G2 960 V_(L)51 CDRL3-14 QQTNSFPPWT 56A7 V_(L)52 56E4 V_(L)52 59A10 V_(L)48 49H4 V_(L)48 59C9 V_(L)50 58A5 V_(L)50 57A4 V_(L)50 57F9 V_(L)50 52A8 961 V_(L)41 CDRL3-15 QQSYSTPLT 65B1 V_(L)19 52B8 962 V_(L)82 CDRL3-16 QQYNNWPLT 56G3.2 V_(L)85 52C1 963 V_(L)67 CDRL3-17 GTWDSSLSAVV 64B10 V_(L)33 68C8 V_(L)34 52C5 964 V_(L)73 CDRL3-18 QQSSSIPWT 55E4 V_(L)75 49B11 V_(L)75 50H10 V_(L)75 53C1 V_(L)75 51C1 V_(L)95 60G5.1 V_(L)74 52F8 965 V_(L)42 CDRL3-19 MQALQTPFT 52H2 966 V_(L)84 CDRL3-20 QQYGSSPRS 53F6 967 V_(L)63 CDRL3-21 MQGLQTPPT 53H5.2 968 V_(L)62 CDRL3-22 LQHKSYPFT 53H5.3 969 V_(L)80 CDRL3-23 QQFSNSIT 54H10.1 970 V_(L)53 CDRL3-24 QQYGSSRT 55D1 V_(L)53 48H3 V_(L)53 53C11 V_(L)53 55D3 971 V_(L)71 CDRL3-25 QQYNIYPRT 55E9 972 V_(L)68 CDRL3-26 MQALQTLIT 55G5 973 V_(L)83 CDRL3-27 QAWDSATVI 56C11 974 V_(L)64 CDRL3-28 QVWDSSSDVV 56E7 975 V_(L)86 CDRL3-29 QQYAILPFT 56G1 976 V_(L)76 CDRL3-30 QQSSTIPWT 56G3.3 977 V_(L)81 CDRL3-31 QQYGRSLFT 55B10 V_(L)81 61H5 V_(L)88 52B9 V_(L)88 57B12 978 V_(L)72 CDRL3-32 QQYNTYPRT 57D9 979 V_(L)87 CDRL3-33 HQYGTSPCS 59D10 v1 980 V_(L)56 CDRL3-34 YSTDSSGNHVV 59D10 v2 981 V_(L)57 CDRL3-35 QAWDSSTAV 59G10.2 982 V_(L)60 CDRL3-36 QAWDSSTTWV 59G10.3 983 V_(L)54 CDRL3-37 GTWDSSLSVMV 60D7 984 V_(L)69 CDRL3-38 MQRIEFPLT 50G1 V_(L)90 60F9 985 V_(L)58 CDRL3-39 QQYGSSPPWT 48B4 V_(L)58 52D6 V_(L)58 61G5 V_(L)59 60G5.2 986 V_(L)46 CDRL3-40 QAWDSSTWV 63G8v1 987 V_(L)1 CDRL3-41 LQHNSYPLT 63G8v2 V_(L)1 64A8 V_(L)1 67B4 V_(L)1 68D3 V_(L)2 64E6 988 V_(L)3 CDRL3-42 QQFGSSLT 65E8 V_(L)3 65F11 V_(L)3 67G7 V_(L)3 63H11 V_(L3) 63F5 V_(L)14 65C1 V_(L)16 66F6 V_(L)15 63B6 989 V_(L)4 CDRL3-43 QQFGRSFT 64D4 V_(L)4 65C3 990 V_(L)5 CDRL3-44 QQYNNWPWT 68D5 V_(L)5 63E6 991 V_(L)6 CDRL3-45 QQSYSTSLT 66F7 V_(L)7 64H5 992 V_(L)8 CDRL3-46 QVWDSSSVV 65G4 V_(L)8 67G10 v1 993 V_(L)9 CDRL3-47 QVWDSSSDGV 67G10 v2 994 V_(L)10 CDRL3-48 QAWDSTTVV 64A10v3 64A7 995 V_(L)17 CDRL3-49 QQYGSSSLCS 66B4 996 V_(L)11 CDRL3-50 QQANSFPPT 66G2 997 V_(L)12 CDRL3-51 LQLNGYPLT 68G5 998 V_(L)13 CDRL3-52 QLWDSSTVV 66D4 999 V_(L)18 CDRL3-53 QQSYSSPLT 54H10.3 V_(L)97 55A7 1000 V_(L)98 CDRL3-54 QQTYSAPFT 67A4 1001 V_(L)20 CDRL3-55 QVWDSSSDHVV 65B4 V_(L)21 63A10 1002 V_(L)22 CDRL3-56 HACGSSSSDGV 65H11 1003 V_(L)23 CDRL3-57 QVWDSSCDGV 64C8 1004 V_(L)24 CDRL3-58 IQDTHWPTCS 65E3 1005 V_(L)25 CDRL3-59 QVWDSSTVV 67G8 V_(L)28 65D4 1006 V_(L)26 CDRL3-60 QVWDSNPVV 65D1 1007 V_(L)27 CDRL3-61 QAWDSRV 65B7v1 1008 V_(L)29 CDRL3-62 QQYGSSCS 64A6 1009 V_(L)30 CDRL3-63 QQYNTWPWT 65F9 V_(L)31 67F5 1010 V_(L)32 CDRL3-64 QQYEIWPWT 55E6 1011 V_(L)99 CDRL3-65 QQYGSSPWT 67A5 1012 V_(L)35 CDRL3-66 MQRLEFPIT 58C2 V_(L)91 61E1 1013 V_(L)100 CDRL3-67 QQSFSTPLT 64H6 1014 V_(L)37 CDRL3-68 QVWDSSPVV 63F9 1015 V_(L)38 CDRL3-69 LQRNSYPLT 53C3.2 1016 V_(L)96 CDRL3-70 HQYTNWPRT 48G4 1017 V_(L)89 CDRL3-71 QQYGTSPFT 53C3.1 V_(L)89 50G5 v1 1018 V_(L)93 CDRL3-72 LQHNSYPRT 50D4 1019 V_(L)92 CDRL3-74 QKYYSAPFT 50G5 v2 1020 V_(L)94 CDRL3-75 MEGTHWPRD 63G8v3 1879 V_(L)106 CDRL3-76 LQHNTYPLT 65B7v2 1880 V_(L)107 CDRL3-77 MQGTHWRGWT 65H11v2 1881 V_(L)103 CDRL3-78 QAWDSITVV 63A10v1 1882 V_(L)22 CDRL3-79 QVWDSSSDGV

TABLE 3C Coding Sequences for CDRHs SEQ Contained ID in Clone NO: Reference Designation Coding Sequences 48C9 1021 V_(H)73 CDRH1-1 GGTTACTACTGGACC 49A12 V_(H)73 51E2 V_(H)73 48F3 1022 V_(H)72 CDRH1-2 GGTTACTACTGGAGC 51E5 V_(H)74 52C5 V_(H)70 55E4 V_(H)70 60G50.1 V_(H)70 49B11 V_(H)70 50H10 V_(H)70 53C1 V_(H)70 56G1 V_(H)71 51C1 V_(H)89 48F8 1023 V_(H)48 CDRH1-3 AGCTATAGCATGAAC 51G2 V_(H)50 56A7 V_(H)51 53B9 V_(H)48 56B4 V_(H)48 57E7 V_(H)48 57F11 V_(H)48 56E4 V_(H)51 55E6 V_(H)93 48H11 1024 V_(H)39 CDRH1-4 GGCTACTATAAGCAC 48G4 1025 V_(H)83 CDRH1-5 GAATTATCCATACAC 49A10 1026 V_(H)62 CDRH1-6 AACTATGGCATGCAC 58C2 V_(H)85 59G10.2 V_(H)57 48D4 V_(H)62 49C8 1027 V_(H)44 CDRH1-7 AGTTATGATATCGAC 52H1 49G2 1028 V_(H)63 CDRH1-8 AACTATGGCATGCGC 50C12 V_(H)63 55G11 V_(H)63 49G3 1029 V_(H)46 CDRH1-9 AATCCTAGAATGGGTGTGAGC 49H12 1030 V_(H)42 CDRH1-10 AGTTACGATATCAAC 54A1 V_(H)43 55G9 V_(H)43 50G1 1031 V_(H)84 CDRH1-11 AGCTATGGCCTGCAC 51A8 1032 V_(H)58 CDRH1-12 AGCTATGGCATGCAC 52C1 V_(H)64 53H5.2 V_(H)59 56C11 V_(H)61 60D7 V_(H)66 64H5 V_(H)7 65G4 V_(H)8 66G2 V_(H)11 68G5 V_(H)12 64C8 V_(H)23 67G8 V_(H)27 68D3v2 V_(H)8 51C10.1 1033 V_(H)54 CDRH1-13 AACTATGCCATGAGC 59D10v1 V_(H)54 59D10v2 V_(H)54 51C10.2 1034 V_(H)67 CDRH1-14 AGTGGTGGTTACTACTGGAGC 64A6 V_(H)29 52A8 1035 V_(H)40 CDRH1-15 GGCTACTATTTGCAC 66B4 V_(H)10 52B8 1036 V_(H)77 CDRH1-16 TATTATTACTGGAGT 52F8 1037 V_(H)41 CDRH1-17 GGCTACTATACACAC 52H2 1038 V_(H)79 CDRH1-18 ACTTACTACTGGAGC 53F6 1039 V_(H)60 CDRH1-19 ACCTATGGCATGCAC 53H5.3 1040 V_(H)75 CDRH1-20 GATTACTACTGGAAC 54H10.1 1041 V_(H)52 CDRH1-21 AGCTATGCCATGAGC 60F9 V_(H)55 61G5 V_(H)56 55D1 V_(H)52 48H3 V_(H)52 53C11 V_(H)52 48B4 V_(H)55 52D6 V_(H)55 55D3 1042 V_(H)68 CDRH1-22 AGTGGTGTTTACTACTGGAAC 55E9 1043 V_(H)65 CDRH1-23 AGCTTTGGCATGCAC 55G5 1044 V_(H)78 CDRH1-24 AGTTACTACTGGAGC 65C3 V_(H)5 68D5 V_(H)5 67F5 V_(H)31 55A7 V_(H)92 56E7 1045 V_(H)81 CDRH1-25 AGCTACTGGATCGGC 67A5 V_(H)34 67C10 V_(H)35 64H6 V_(H)36 56G3.2 1046 V_(H)80 CDRH1-26 AGTTACTACTGGAAC 56G3.3 1047 V_(H)76 CDRH1-27 AGTAGTAGTTACTACTGGGGC 55B10 V_(H)76 61H5 V_(H)86 52B9 V_(H)86 57B12 1048 V_(H)69 CDRH1-28 AGTGGTGTTTACTACTGGAGC 57D9 1049 V_(H)82 CDRH1-29 AGCAACAGTGCTACTTGGAAC 59A10 1050 V_(H)47 CDRH1-30 GACTCCTACATGAGC 49H4 59C9 1051 V_(H)49 CDRH1-31 AGCTATAGCATGAGT 58A5 V_(H)49 57A4 V_(H)49 57F9 V_(H)49 59G10.3 1052 V_(H)53 CDRH1-32 CACTATGCCATGAGC 60G5.2 1053 V_(H)45 CDRH1-33 AACTATGGTATCAGC 63G8 1054 V_(H)1 CDRH1-34 AGCTATGGCATACAC 64A8 V_(H)1 67B4 V_(H)1 68D3 V_(H)1 64E6 1055 V_(H)2 CDRH1-35 AGTGGTGATTACTACTGGACC 65E8 V_(H)2 65F11 V_(H)2 67G7 V_(H)2 63H11 V_(H)3 63F5 V_(H)13 65C1 V_(H)15 66F6 V_(H)14 63B6 1056 V_(H)4 CDRH1-36 AGTGGTGATTACTACTGGAGC 64D4 V_(H)4 65F9 V_(H)30 64B10v1 V_(H)32 64B10v1 V_(H)32 63E6 1057 V_(H)6 CDRH1-37 AGTGGTGATTACTACTGGACC 66F7 V_(H)6 50G5 v1 V_(H)88 50G5 v2 V_(H)88 67G10v1 1058 V_(H)9 CDRH1-38 AACGCCTGGATGAGT 67G10v2 V_(H)9 63A10 V_(H)21 65H11 V_(H)22 53C3.2 1059 V_(H)90 CDRH1-39 AGTGGTAATTACTACTGGAGC 64A7 1060 V_(H)16 CDRH1-40 AGTGATACTTCCTACTGGGGC 50D4 1061 V_(H)87 CDRH1-41 AGTCATGATATCAAC 61E1 1062 V_(H)94 CDRH1-42 AGCAACAGTGCTGCTTGGAAC 66D4 1063 V_(H)17 CDRH1-43 GGCTACTATATACAC 54H10.3 V_(H)91 65B1 1064 V_(H)18 CDRH1-44 GGCTACTTTATGCAC 67A4 1065 V_(H)19 CDRH1-45 ACCTACGACATGCAC 65B4 1066 V_(H)20 CDRH1-46 AGTTACGACATGCAC 65E3 1067 V_(H)24 CDRH1-47 AACTATAACATGCAC 65D4 1068 V_(H)25 CDRH1-48 TTCTATGGCATGCAC 65D1 1069 V_(H)26 CDRH1-49 TACTATTACATTCAC 65B7 1070 V_(H)28 CDRH1-50 AGTGATGCTTACTACTGGAGC 68C8 1071 V_(H)33 CDRH1-51 AGTGGTGATAACTACTGGAGC 63F9 1072 V_(H)37 CDRH1-52 AGTGGTGGTTACTACTGGAAC 67F6 1073 V_(H)38 CDRH1-53 GGCTACTGGATCGGC 48C9 1074 V_(H)73 CDRH2-1 GAAATCAATCATAGTGAAAACACCAACT 52C5 V_(H)70 ACAACCCGTCCCTCAAGAGT 55E4 V_(H)70 56G1 V_(H)71 49A12 V_(H)73 51E2 V_(H)73 60G5.1 V_(H)70 49B11 V_(H)70 50H10 V_(H)70 53C1 V_(H)70 51C1 V_(H)89 48F3 1075 V_(H)72 CDRH2-2 GAAATCACTCATACTGGAAGCTCCAACT ACAACCCGTCCCTCAAGAGT 48F8 1076 V_(H)48 CDRH2-3 TCCATTAGTAGTAGTAGTAGTTACGAATA 53B9 V_(H)48 CTACGTAGACTCAGTGAAGGGC 56B4 V_(H)48 57E7 V_(H)48 57F11 V_(H)48 48H11 1077 V_(H)39 CDRH2-4 TGGATCAACCCTAACAGTGGTGCCACAA AGTATGCACAGAAGTTTCAGGGC 48G4 1078 V_(H)83 CDRH2-5 GGTTTTGATCCTGAAGATGGTGAAACAA 53C3.1 TCTACGCACAGAAGTTCCAGGGC 49A10 1079 V_(H)62 CDRH2-6 ATTATATGGTATGATGGAAGTAATAAAA 48D4 V_(H)62 ACTATGCAGACTCCGTGAAGGGC 49C8 1080 V_(H)44 CDRH2-7 TGGATGAACCCTAACGGTGGTAACACAG GCTATGCACAGAAGTTCCAGGGC 49G2 1081 V_(H)63 CDRH2-8 CTTATATGGTATGATGGAAGTAATAAGTT 50C12 V_(H)63 CTATGCAGACTCCGTGAAGGGC 55G11 V_(H)63 49G3 1082 V_(H)46 CDRH2-9 CACATTTTTTCGAATGACGAAAAATCCTA CAGCACATCTCTGAAGAGC 49H12 1083 V_(H)42 CDRH2-10 TGGATGAACCCCTACAGTGGGAGCACAG GCTATGCACAGAATTTCCAGGGC 50G1 1084 V_(H)84 CDRH2-11 GTTATATGGAATGATGGAAGTAATAAGC TTTATGCAGACTCCGTGAAGGGC 51A8 1085 V_(H)58 CDRH2-12 GTTATATCATATGATGGAAGTAATAAAT 63G8 V_(H)1 ACTATGCAGACTCCGTGAAGGGC 64A8 V_(H)1 67B4 V_(H)1 68D3 V_(H)1 51C10.1 1086 V_(H)54 CDRH2-13 GGTATTAGTGGTAGTAGTGCTGGCACAT 59D10v1 V_(H)54 ACTACGCAGACTCCGTGAAGGGC 59D10v2 V_(H)54 51C10.2 1087 V_(H)67 CDRH2-14 TACATCTATTACAATGGGAGTCCCTACGA CAACCCGTCCCTCAAGAGG 51E5 1088 V_(H)74 CDRH2-15 GAACTCGATCATAGTGGAAGTATCAACT ACAACCCGTCCCTCAAGAGT 51G2 1089 V_(H)50 CDRH2-16 TCCATTAGTAGTAGTAGTACTTACATATA 56A7 V_(H)51 CTACGCAGACTCAGTGAAGGGC 56E4 V_(H)51 52A8 1090 V_(H)40 CDRH2-17 TGGATCAACCCTAACAGTGCTGCCACAA ACTATGCACCGAAGTTTCAGGGC 52B8 1091 V_(H)77 CDRH2-18 TATATCTATTATAGTGGGAGCACCAACTA 55A7 V_(H)92 CAACCCCTCCCTCAAGAGT 52C1 1092 V_(H)64 CDRH2-19 GTTATATGGTATGATGGAAGTAATAACT ATTATGCAGACTCCGTGAAGGGC 52F8 1093 V_(H)41 CDRH2-20 TGGATCAACCCTAGCAGTGGTGACACAA AGTATGCACAGAAGTTTCAGGGC 52H2 1094 V_(H)79 CDRH2-21 TATATCTTTTACAATGGGAACGCCAACTA CAGCCCCTCCCTGAAGAGT 53F6 1095 V_(H)60 CDRH2-22 GTTATATGGTATGATGGAAGTAATAAAT 60D7 V_(H)66 ACTATGCAGACTCCGTGAAGGGC 65D4 V_(H)25 53H5.2 1096 V_(H)59 CDRH2-23 CTTATATCATATGATGGAAGTAATAAATA CTATGCAGACTCCGTGAAGGGC 53H5.3 1097 V_(H)75 CDRH2-24 GAAATCAATCATAGTGGAACCACCAACT ACAATCCGTCCCTCAAGAGT 54A1 1098 V_(H)43 CDRH2-25 TGGATGAACCCTCACAGTGGTAACACAG 55G9 V_(H)43 GCTATGCACAGAAGTTCCAGGGC 54H10.1 1099 V_(H)52 CDRH2-26 GCTATTAGTGGTAGTGGTCGTACCACATA 55D1 V_(H)52 CTCCGCAGACTCCGTGAAGGGC 48H3 V_(H)52 53C11 V_(H)52 55D3 1100 V_(H)68 CDRH2-27 TACCTCTATTACAGTGGGAGCACCTACTA CAACCCGTCCCTCAAGAGT 55E9 1101 V_(H)65 CDRH2-28 CTTATATGGTATGATGGAGATAATAAAT ACTATGCAGACTCCGTGAAGGGC 55G5 1102 V_(H)78 CDRH2-29 CGTATCTATATCAGTGGGAGCACCAACT ACAACCCCTCCCTCGAGAAT 56C11 1103 V_(H)61 CDRH2-30 GTTATATGGTATGATGGAAGTTATCAATT CTATGCAGACTCCGTGAAGGGC 56E7 1104 V_(H)81 CDRH2-31 ATCATCTATCCTGGTGACTCTGATACCAG 67A5 V_(H)34 ATACAGCCCGTCCTTCCAAGGC 67C10 V_(H)35 67F6 V_(H)38 56G3.2 1105 V_(H)80 CDRH2-32 CGTATCTATACCAGTGGGAGCACCAACT ACAATCCCTCCCTCAAGAGT 56G3.3 1106 V_(H)76 CDRH2-33 ATGATCTATTATAGTGGGACCACCTACTA CAACCCGTCCCTCAAGAGT 57B12 1107 V_(H)69 CDRH2-34 TACATCTATTACAGTGGGAGCACCTACTA 63H11 V_(H)3 CAACCCGTCCCTCAAGAGT 66F6 V_(H)14 65F9 V_(H)30 57D9 1108 V_(H)82 CDRH2-35 AGGACATACTACAGGTCCAAGTGGTATA 61E1 V_(H)94 ATGATTATGCAGTATCTGTGAAAAGT 58C2 1109 V_(H)85 CDRH2-36 GTTATATGGAATGATGGAAATAACAAAT ACTATGCAGACTCCGTGAAGGGC 59A10 1110 V_(H)47 CDRH2-37 TCCATTAGTAGTAGTGGTAGTATCGTATA 49H4 CTTCGCAGACTCTGTGAAGGGC 59C9 1111 V_(H)49 CDRH2-38 TCCATTAGTAGTAGTAGTACTTACATATA 58A5 V_(H)49 CTACGCAGACTCACTGAAGGGC 57A4 V_(H)49 57F9 V_(H)49 59G10.2 1112 V_(H)57 CDRH2-39 ATTACATCATATGGAGGAAGTAATAAAA ATTATGCAGACTCCGTGAAGGGC 59G10.3 1113 V_(H)53 CDRH2-40 GCTATTAGTGGTAGTGGTGCTGGCACATT CTACGCGGACTCCATGAAGGGC 60F9 1114 V_(H)55 CDRH2-41 GTTATTAGTGACAGTGGTGGTAGCACAT 48B4 V_(H)55 ACTACGCAGACTCCGTGAAGGGC 52D6 V_(H)55 60G5.2 1115 V_(H)45 CDRH2-42 TGGATCAGCGCTTACAATGGTTACTCAAA CTATGCACAGAAGTTCCAGGAC 61G5 1116 V_(H)56 CDRH2-43 GTTATTAGTGGTAGTGGTGGTGACACATA CTACGCAGACTCCGTGAAGGGC 64E6 1117 V_(H)2 CDRH2-44 TACATCTATTACACTGGGAGCACCTACTA 65E8 V_(H)2 CAACCCGTCCCTCAAGAGT 65F11 V_(H)2 67G7 V_(H)2 63B6 1118 V_(H)4 CDRH2-45 TACATCTATTACAGTGGGACCACCTACTA 64D4 V_(H)4 CAACCCGTCCCTCAAGAGT 65C3 1119 V_(H)5 CDRH2-46 TATATCTATTACACTGGGAGCACCAACTA 68D5 V_(H)5 CAACCCCTCCCTCAAGAGT 63E6 1120 V_(H)6 CDRH2-47 TGGATGAACCCTAATAGTGGTGCCACAA 66F7 V_(H)6 AGTATGCACAGAAGTTTCAGGGC 64H5 1121 V_(H)7 CDRH2-48 GTTATATGGGATGATGGAAGTAATAAAT 65G4 V_(H)8 ACTATGCAGACTCCGTGAAGGGC 67G10v1 1122 V_(H)9 CDRH2-49 CGTATTAAAAGCAAAACTGATGGTGGGA 67G10v2 V_(H)9 CAACAGAGTACGCTGCACCCGTGAAAGGC 63F5 1123 V_(H)13 CDRH2-50 TACATCTATTACAGTGGGAGCGCCTACTA CAACCCGTCCCTCAAGAGT 64A7 1124 V_(H)16 CDRH2-51 AATATCTATTATAGTGGGACCACCTACTT CAACCCGTCCCTCAAGAGT 65C1 1125 V_(H)15 CDRH2-52 TACATTTTTTACAGTGGGAGCACCTACTA 65B7 V_(H)28 CAACCCGTCCCTCAAGAGT 66B4 1126 V_(H)10 CDRH2-53 TGGATCAACCCTAACAGTGGTGGCACAG ACTATGCACAGAAGTTTCAGGGC 66G2 1127 V_(H)11 CDRH2-54 GGTATATCATATGATGGAAGTAATAAAA ACTATGCAGACTCCGTGAAGGGC 68G5 1128 V_(H)12 CDRH2-55 GTTATATGGTATGATGGAAGTAATAAAT ACCATGCAGACTCCGTGAAGGGC 66D4 1129 V_(H)17 CDRH2-56 TGGATCAACCCTCCCAGTGGTGCCACAA ACTATGCACAGAAGTTTCGGGGC 65B1 1130 V_(H)18 CDRH2-57 TGGATCAACCCTAACAGTGGTGCCACAA ACTATGCACAGAAGTTTCACGGC 67A4 1131 V_(H)19 CDRH2-58 GCTATTGGTATTGCTGGTGACACATACTA TTCAGACTCCGTGAAGGGC 65B4 1132 V_(H)20 CDRH2-59 ACTATTGATACTGCTGGTGACGCTTACTA TCCAGGCTCCGTGAAGGGC 63A10 1133 V_(H)21 CDRH2-60 CGTATTAAAAGCAAAACTGATGGTGGGA 67G10v1 V_(H)9 CAACAGACTACGCTGCACCCGTGAAAGGC 67G10v2 V_(H)9 65H11 1134 V_(H)22 CDRH2-61 CGTATTATAGGCAAAACTGATGGTGGGA CAACAGACTACGCTGCACCCGTGAAAGGC 64C8 1135 V_(H)23 CDRH2-62 GTTATATCATATGATGGAAGTAACAAAC ACTATGCAGACTCCGTGAAGGGC 65E3 1136 V_(H)24 CDRH2-63 GTTTTATGGTATGATGGAAATACTAAATA CTATGCAGACTCCGTGAAGGGC 65D1 1137 V_(H)26 CDRH2-64 CTTATATGGTATGATGGAAGTAATAAAG ACTATGCAGACTCCGTGAAGGGC 67G8 1138 V_(H)27 CDRH2-65 GTTATATGGTATGATGGAAGTAATAAAG ACTATGCAGACTCCGTGAAGGGC 64A6 1139 V_(H)29 CDRH2-66 TACATCTATTACAGTGGGGGCACCCACTA CAACCCGTCCCTCAAGAGT 67F5 1140 V_(H)31 CDRH2-67 TATATCTATTACAGTGGGAACACCAACTA CAACCCCTCCCTCAAGAGT 64B10 1141 V_(H)32 CDRH2-68 TTTATCTATTACAGTGGGGGCACCAACTA CAACCCCTCCCTCAAGAGT 68C8 1142 V_(H)33 CDRH2-69 TTCATGTTTTACAGTGGGAGTACCAACTA CAACCCCTCCCTCAAGAGT 64H6 1143 V_(H)36 CDRH2-70 ATCATCTATCCTGGTGACTCTGAAACCAG ATACAGCCCGTCCTTTCAAGGC 63F9 1144 V_(H)37 CDRH2-71 TACATCTATGACAGTGGGAGCACCTACT ACAACCCGTCCCTCAAGAGT 61H5 1145 V_(H)86 CDRH2-72 AGTATCTATTATAGTGGGACCACCTACTA 52B9 V_(H)86 CAACCCGTCCCTCAAGAGT 50G5 v1 1146 V_(H)88 CDRH2-73 TGGATCAACCCTGACAGTGGTGGCACAA 50G5 v2 V_(H)88 ACTATGCACAGAAGTTTCAGGGC 54H10.3 1147 V_(H)91 CDRH2-74 TGGATCAACCCTAACAGTGGTGGCACAA ACTATGCACAGAAGTTTCGGGGC 50D4 1148 V_(H)87 CDRH2-75 TGGATGAACCCTTACAGTGGTAGCACAG GCCTCGCACAGAGGTTCCAGGAC 55E6 1149 V_(H)93 CDRH2-76 TACATTAGTAGTGGTAGTAGTACCATATA CCACGCAGACTCTGTGAAGGGC 53C3.2 1150 V_(H)90 CDRH2-77 TACATCTATCACAGTGGGAGCGCCTACTA CAACCCGTCCCTCAAGAGT 64B10v2 1883 V_(H)96 CDRH2-78 TTTATTTATTACAGTGGGGGCACCAACTA CAACCCCCCCCTCAAGAGT 68D3v2 1884 V_(H)95 CDRH2-79 TTTATATCATATGCTGGAAGTAATAAATA CTATGCAGACTCCGTGAAGGGC 48C9 1151 V_(H)73 CDRH3-1 GAGAGTGGGAACTTCCCCTTTGACTAC 49A12 V_(H)73 51E2 V_(H)73 48F3 1152 V_(H)72 CDRH3-2 GGCGGGATTTTATGGTTCGGGGAGCAGG CTTTTGATATC 48F8 1153 V_(H)48 CDRH3-3 TCCCTAAGTATAGCAGTGGCTGCCTCTGA 53B9 V_(H)48 CTAC 56B4 V_(H)48 57E7 V_(H)48 57F11 V_(H)48 48H11 1154 V_(H)39 CDRH3-4 GAGGTACCCGACGGTATAGTAGTGGCTG GTTCAAATGCTTTTGATTTC 48G4 1155 V_(H)83 CDRH3-5 CATTCTGGTTCGGGGAGGTTTTACTACTA 53C3.1 CTACTACGGTATGGACGTC 49A10 1156 V_(H)62 CDRH3-6 GATCAGGATTACGATTTTTGGAGTGGTTA 48D4 V_(H)62 TCCTTACTTCTACTACTACGGTATGGACG TC 49C8 1157 V_(H)44 CDRH3-7 GGGAAGGAATTTAGCAGGGCGGAGTTTG ACTAC 49G2 1158 V_(H)63 CDRH3-8 GATCGGTATTACGATTTTTGGAGTGGTTA 50C12 V_(H)63 TCCATACTTCTTCTACTACGGTCTGGACG 55G11 V_(H)63 TC 49G3 1159 V_(H)46 CDRH3-9 GTAGATACCTTGAACTACCACTACTACGG TATGGACGTC 49H12 1160 V_(H)42 CDRH3-10 TATAATTGGAACTATGGGGCTTTTGATTTC 54A1 V_(H)43 55G9 V_(H)43 50G1 1161 V_(H)84 CDRH3-11 GATCAGTATTACGATTTTTGGAGCGGTTA CCCATACTATCACTACTACGGTATGGACG TC 51A8 1162 V_(H)58 CDRH3-12 GCGGACGGTGACTACCCATATTACTACTA CTACTACGGTATGGACGTC 51C10.1 1163 V_(H)54 CDRH3-13 GATTGGAGTATAGCAGTGGCTGGTACTTT 59D10 V_(H)54 TGACTAC v1 V_(H)54 59D10 v2 51C10.2 1164 V_(H)67 CDRH3-14 GGGGCCCTCTACGGTATGGACGTC 51E5 1165 V_(H)74 CDRH3-15 GTCCTGGGATCTACTCTTGACTAT 51G2 1166 V_(H)50 CDRH3-16 GATACTTATATCAGTGGCTGGAACTACG GTATGGACGTC 52A8 1167 V_(H)40 CDRH3-17 GAGGGTGGAACTTACAACTGGTTCGACC CC 52B8 1168 V_(H)77 CDRH3-18 GGAACTAGGGCTTTTGATATC 52C1 1169 V_(H)64 CDRH3-19 GATCGGGCGGGAGCCTCTCCCGGAATGG ACGTC 52C5 1170 V_(H)70 CDRH3-20 GTAACTGGAACGGATGCTTTTGATTTC 60G5.1 V_(H)70 49B11 V_(H)70 50H10 V_(H)70 53C1 V_(H)70 51C1 V_(H)89 55E4 V_(H)70 56G1 V_(H)71 52F8 1171 V_(H)41 CDRH3-21 AGTGGCTGGTACCCGTCCTACTACTACGG TATGGACGTC 52H2 1172 V_(H)79 CDRH3-22 GAAACGGACTACGGTGACTACGCACGTC CTTTTGAATAC 53F6 1173 V_(H)60 CDRH3-23 GGCCACTATGATAGTAGTGGTCCCAGGG ACTAC 53H5.2 1174 V_(H)59 CDRH3-24 GAGGCTAACTGGGGCTACAACTACTACG GTATGGACGTC 53H5.3 1175 V_(H)75 CDRH3-25 ATATTACGATATTTTGACTGGTTAGAATA CTACTTTGACTAC 61E1 1176 V_(H)94 CDRH3-26 GAGGGCAGCTGGTCCTCCTTCTTTGACTAC 54H10.1 1177 V_(H)52 CDRH3-27 GAACAGCAGTGGCTGGTTTATTTTGACTAC 55D1 V_(H)52 48H3 V_(H)52 53C11 V_(H)52 55D3 1178 V_(H)68 CDRH3-28 GATGGTATTACTATGGTTCGGGGAGTTAC 57B12 V_(H)69 TCACTACTACGGTATGGACGTC 55E6 1179 V_(H)93 CDRH3-29 GAAGGGTACTATGATAGTAGTGGTTATT ACTACAACGGTATGGACGTC 55E9 1180 V_(H)65 CDRH3-30 AACAGTGGCTGGGATTACTTCTACTACTA CGGTATGGACGTC 55G5 1181 V_(H)78 CDRH3-31 AGTGGGAGCTACTCCTTTGACTAC 56A7 1182 V_(H)51 CDRH3-32 GATATCTATAGCAGTGGCTGGAGCTACG 56E4 V_(H)51 GTATGGACGTC 56C11 1183 V_(H)61 CDRH3-33 GATCACGTTTGGAGGACTTATCGTTATAT CTTTGACTAC 56E7 1184 V_(H)81 CDRH3-34 GCACAACTGGGGATCTTTGACTAC 50G5 v1 1185 V_(H)88 CDRH3-35 GGCGGATACAGCTATGGTTACGAGGACT 50G5 v2 V_(H)88 ACTACGGTATGGACGTC 56G3.2 1186 V_(H)80 CDRH3-36 GGCCCTCTTTGGTTTGACTAC 56G3.3 1187 V_(H)76 CDRH3-37 GTGGCAGCAGTTTACTGGTATTTCGATCTC 55B10 V_(H)76 61H5 V_(H)86 52B9 V_(H)86 55A7 1188 V_(H)92 CDRH3-38 GGGATAACTGGAACTATTGACTTC 57D9 1189 V_(H)82 CDRH3-39 ATTGTAGTAGTACCAGCTGTTCTCTTTGA CTAC 58C2 1190 V_(H)85 CDRH3-40 GATCAGAATTACGATTTTTGGAATGGTTA TCCCTACTACTTCTACTACGGTATGGACG TC 59A10 1191 V_(H)47 CDRH3-41 GAGACGTTTAGCAGTGGCTGGTTCGATG 49H4 CTTTTGATATC 59C9 1192 V_(H)49 CDRH3-42 GATCGATGGAGCAGTGGCTGGAACGAAG 58A5 V_(H)49 GTTTTGACTAT 57A4 V_(H)49 57F9 V_(H)49 53C3.2 1193 V_(H)90 CDRH3-43 ACTACGGGTGCTTCTGATATC 59G10.2 1194 V_(H)57 CDRH3-44 GAGGCCGGGTATAGCTTTGACTAC 59G10.3 1195 V_(H)53 CDRH3-45 GATCTTAGAATAGCAGTGGCTGGTTCATT TGACTAC 60D7 1196 V_(H)66 CDRH3-46 GATCTTAGAATAGCAGTGGCTGGTTCATT TGACTAC 60F9 1197 V_(H)55 CDRH3-47 GATCAGTATTTCGATTTTTGGAGTGGTTA 48B4 V_(H)55 TCCTTTCTTCTACTACTACGGTATGGACG 52D6 V_(H)55 TC 60G5.2 1198 V_(H)45 CDRH3-48 GATCATAGCAGTGGCTGGTACTACTACG GTATGGACGTC 61G5 1199 V_(H)56 CDRH3-49 GATCATACCAGTGGCTGGTACTACTACG GTATGGACGTC 63G8 1200 V_(H)1 CDRH3-50 ACGGTGACTAAGGAGGACTACTACTACT 64A8 V_(H)1 ACGGTATGGACGTC 67B4 V_(H)1 68D3 V_(H)1 66G2 V_(H)11 64E6 1201 V_(H)2 CDRH3-51 ATGACTACCCCTTACTGGTACTTCGATCTC 65E8 V_(H)2 65F11 V_(H)2 67G7 V_(H)2 63H11 V_(H)3 63F5 V_(H)13 66F6 V_(H)14 63B6 1202 V_(H)4 CDRH3-52 ATGACTACTCCTTACTGGTACTTCGGTCTC 64D4 V_(H)4 65C3 1203 V_(H)5 CDRH3-53 GAATATTACTATGGTTCGGGGAGTTATTA 68D5 V_(H)5 TCCT 67F5 V_(H)5 63E6 1204 V_(H)6 CDRH3-54 GAACTCGGTGACTACCCCTTTTTTGACTAC 66F7 V_(H)6 64H5 1205 V_(H)7 CDRH3-55 GAATACGTAGCAGAAGCTGGTTTTGACT 65G4 V_(H)8 AC 67G10v1 1206 V_(H)9 CDRH3-56 GATAGTAGTGGGAGCTACTACGTGGAGG 67G10v2 V_(H)9 ACTACTTTGACTAC 63A10 V_(H)21 65H11 V_(H)22 64A7 1207 V_(H)16 CDRH3-57 CTCCGAGGGGTCTACTGGTACTTCGATCTC 65C1 1208 V_(H)15 CDRH3-58 ATGACTTCCCCTTACTGGTACTTCGATCTC 66B4 1209 V_(H)10 CDRH3-59 GACGCAGCAACTGGTCGCTACTACTTTGA CAAC 68G5 1210 V_(H)12 CDRH3-60 GATCCTGGATACAGCTATGGTCACTTTGA CTAC 66D4 1211 V_(H)17 CDRH3-61 GAGACTGGAACTTGGAGCTTCTTTGACTAC 65B1 1212 V_(H)18 CDRH3-62 GAACTGGGGATCTTCAACTGGTTCGACCCC 67A4 1213 V_(H)19 CDRH3-63 GATCGGAGCAGTGGCCGGTTCGGGGACT ACTACGGTATGGACGTC 65B4 1214 V_(H)20 CDRH3-64 GATCGGAGCAGTGGCCGGTTCGGGGACT TCTACGGTATGGACGTC 64C8 1215 V_(H)23 CDRH3-65 GAATTACTATGGTTCGGGGAGTATGGGG TAGACCACGGTATGGACGTC 65E3 1216 V_(H)24 CDRH3-66 GATGTCTACGGTGACTATTTTGCGTAC 65D4 1217 V_(H)25 CDRH3-67 GCCCTCAACTGGAACTTTTTTGACTAC 65D1 1218 V_(H)26 CDRH3-68 GAAGGGACAACTCGACGGGGATTTGACT AC 67G8 1219 V_(H)27 CDRH3-69 TCAGCAGTGGCTTTGTACAACTGGTTCGA CCCC 65B7 1220 V_(H)28 CDRH3-70 GAGTCTAGGATATTGTACTTCAACGGGTA CTTCCAGCAC 64A6 1221 V_(H)29 CDRH3-71 GTCCTCCATTACTCTGATAGTCGTGGTTA CTCGTACTACTCTGACTTC 65F9 1222 V_(H)30 CDRH3-72 GTCCTCCATTACTATGATAGTAGTGGTTA CTCGTACTACTTTGACTAC 64B10 1223 V_(H)32 CDRH3-73 TATAGCAGCACCTGGGACTACTATTACG GTGTGGACGTC 68C8 1224 V_(H)33 CDRH3-74 TATAGGAGTGACTGGGACTACTACTACG GTATGGACGTC 67A5 1225 V_(H)34 CDRH3-75 CGGGCCTCACGTGGATACAGATTTGGTCT TGCTTTTGCGATC 67C10 1226 V_(H)35 CDRH3-76 CGGGCCTCACGTGGATACAGATATGGTC TTGCTTTTGCTATC 64H6 1227 V_(H)36 CDRH3-77 GTAGCAGTGTCTGCCTTCAACTGGTTCGA CCCC 63F9 1228 V_(H)37 CDRH3-78 GATGTTCTAATGGTGTATACTAAAGGGG GCTACTACTATTACGGTGTGGACGTC 67F6 1229 V_(H)38 CDRH3-79 CGGGCCTCACGTGGATACAGCTATGGTC ATGCTTTTGATTTC 50D4 1230 V_(H)87 CDRH3-80 GACCTTAGCAGTGGCTACTACTACTACGG TTTGGACGTG 54H10.3 1231 V_(H)91 CDRH3-81 GAGGAAGACTACAGTGACCACCACTACT TTGACTAC 66D4 1885 V_(H)17 CDRH3-82 GAGACTGGAACTTGGAACTTCTTTGACTAC 68D3v2 1886 V_(H)95 CDRH3-83 ACGGTGACTGAGGAGGACTACTACTACT ACGGTATGGACGTC

TABLE 3D Coding Sequences for CDRLs SEQ Contained ID in Clone NO: Reference Designation Coding Sequence 48C9 1232 V_(L)78 CDRL1-1 CGGGCAAGTCAGAACATTAGGACCT 49A12 ATTTAAAT 51E2 48F3 1233 V_(L)77 CDRL1-2 CGGGCAAGTCAGAGGATTAGCAGTT ATTTAAAT 48F8 1234 V_(L)49 CDRL1-3 CGGGCCAGTCAGGACATTGGTAATA 53B9 GCTTACAC 56B4 57E7 57F11 48H11 1235 V_(L)40 CDRL1-4 CGGGCAAGTCAGAACATTAGGAGCT ATTTAAAT 49A10 1236 V_(L)65 CDRL1-5 AGGTCTAGTCAGAGCCTCTTGGATAG 48D4 TGATGATGGAAACACCTATTTGGAC 49C8 1237 V_(L)45 CDRL1-6 CAGGCGAGTCAGGACATTAACATCTA 52H1 TTTAAAT 49G2 1238 V_(L)66 CDRL1-7 AGGTCTAGTCAGAGCCTCTTGGATAG 50C12 V_(L)66 TGATGATGGAGACACCTATTTGGAC 55G11 V_(L)66 50G1 V_(L)90 60D7 V_(L)69 49G3 1239 V_(L)47 CDRL1-8 CAGGCGAGTCAGGGCATTAGCAACT ATTTAAAT 49H12 1240 V_(L)43 CDRL1-9 CAGGCGAGTCAAGACATTACCAAAT ATTTAAAT 51A8 1241 V_(L)61 CDRL1-10 ACCCGCAGCAGTGGCAGCATTGCCA GCGACTATGTGCAG 51C10.1 1242 V_(L)55 CDRL1-11 TCTGGAGATGCATTGCCAAAAAAATA TGCTTAT 51C10.2 1243 V_(L)70 CDRL1-12 TCTGGAGATAAATTGGGGGATAAAT ACGTTTGC 51E5 1244 V_(L)79 CDRL1-13 CGGGCAAGTCAGGACATTAGAAATG 63G8v1 V_(L)1 ATTTAGGC 64A8 V_(L)1 67B4 V_(L)1 68D3 V_(L)2 51G2 1245 V_(L)51 CDRL1-14 CGGGCGAGTCAGGGTATTAGCAGCT GGTTAGCC 52A8 1246 V_(L)41 CDRL1-15 CGGGCAAGTCAGACTATTAGCAGTTA TTTAAAT 52B8 1247 V_(L)82 CDRL1-16 AGGGCCAGTCAGAGTGTTAGCGACA TCTTAGCC 52C1 1248 V_(L)67 CDRL1-17 TCTGGAAGCAGCTCCAACATTGGGAT TAATTATGTATCC 52C5 1249 V_(L)73 CDRL1-18 CGGGCAAGTCAGAGCATTAGCAACT 55E4 V_(L)75 ATTTAAAT 49B11 V_(L)75 50H10 V_(L)75 53C1 V_(L)75 56G1 V_(L)76 51C1 V_(L)95 60G5.1 V_(L)74 52F8 1250 V_(L)42 CDRL1-19 AGGTCTAGTCAGAGCCTCCTGCATAG TAATGGATACAACTATTTGGAT 52H2 1251 V_(L)84 CDRL1-20 AGGGCCAGTCAGAGTGTTAGAAGCA GCTACTTAGCC 53F6 1252 V_(L)63 CDRL1-21 AGGTCTAGTCAGAGCCTCCAGCATAG TAATGGATACAACTATTTGGAT 53H5.2 1253 V_(L)62 CDRL1-22 CGGGCAAGTCAGGGCATTAGAAATG 50G5 v1 V_(L)93 ATTTAGGC 53H5.3 1254 V_(L)80 CDRL1-23 AGGGCCAGTCAGAGTGTTAGCAGCA ACGTCGCC 54A1 1255 V_(L)44 CDRL1-24 CAGGCGAGTCAGGACATTAGCATCTA 55G9 V_(L)44 TTTAAAT 54H10.1 1256 V_(L)53 CDRL1-25 AGGGCCAGTCAGAGTTTTAGCAGCA 55D1 V_(L)53 GTTACTTAGCC 48H3 V_(L)53 53C11 V_(L)53 55D3 1257 V_(L)71 CDRL1-26 CGGGCGAGTCAGGACATTAGCAATT 50D4 V_(L)92 ATTTAGCC 55E9 1258 V_(L)68 CDRL1-27 AGGTCTAGTCAGAGCCTCCTGCATAG TAACGGATTCAACTATTTGGAT 55G5 1259 V_(L)83 CDRL1-28 TCTGGAGACGAATTGGGGGATAAAT ATGCTTGC 56A7 1260 V_(L)52 CDRL1-29 CGGGCGAGTCAGGATATTAGCAGTTG 56E4 V_(L)52 GTTAGCC 56C11 1261 V_(L)64 CDRL1-30 GGGGGAAACGACATTGGAAGTAAAA GTGTGCAC 56E7 1262 V_(L)86 CDRL1-31 CAGGCGAGTCAGGACATTAAAAAAT TTTTAAAT 56G3.2 1263 V_(L)85 CDRL1-32

 AGGGCCAGGCAGAGTGTTGGCAGT AACTTAATC 56G3.3 1264 V_(L)81 CDRL1-33 AGGGCCAGTCAGAGTGTTAGCAGAG 55B10 V_(L)81 ACTACTTAGCC 61H5 V_(L)88 52B9 57B12 1265 V_(L)72 CDRL1-34 CGGGCGAGTCATGACATTAGCAATTA TTTAGCC 57D9 1266 V_(L)87 CDRL1-35 AGGGCCAGTCCGAGTGTTAGCAGCA GCTACTTAGCC 53C3.2 1267 V_(L)96 CDRL1-36 AGGGCCAGTCAGAGTATTAGCAGCA ATTTAGCC 59C9 1268 V_(L)50 CDRL1-37 CGGGCGAGTCAGGATATTGACAGCT 58A5 V_(L)50 GGTTAGTC 57A4 V_(L)50 57F9 V_(L)50 59D10 1269 V_(L)56 CDRL1-38 TCTGGAGATGCAGTGCCAAAAAAAT v1 ATGCTAAT 59D10 1270 V_(L)57 CDRL1-39 TCTGGAGATAATTTGGGGGATAAATA v2 V_(L)27 TGCTTGC 65D1 59G10.2 1271 V_(L)60 CDRL1-40 TCTGGAGATAATTTGGGGGATAAATA TGCTTTC 59G10.3 1272 V_(L)54 CDRL1-41 TCTGGAAGCAGCTCCAACATTGGGGA TAATTATGTATCC 54H10.3 1273 V_(L)97 CDRL1-42 CGGGCAAGTCAGACCATTAGCATCTA TTTAAAT 60F9 1274 V_(L)58 CDRL1-43 AGGGCCAGTCAGAGGGTTCCCAGCA 48B4 V_(L)58 GCTACATAGTC 52D6 V_(L)58 60G5.2 1275 V_(L)46 CDRL1-44 TCTGGAAATAAATTGGGGGATAAAT ATGTTTGC 61G5 1276 V_(L)59 CDRL1-45 AGGGCCAGTCAGAGAGTTCCCAGCA GCTACTTAGTC 64E6 1277 V_(L)3 CDRL1-46 AGGGCCAGTCAGAGTGTTAGGAACA 65E8 V_(L)3 GCTACTTAGCC 65F11 V_(L)3 67G7 V_(L)3 63H11 V_(L)3 66F6 V_(L)15 63B6 1278 V_(L)4 CDRL1-47 AGGGCCAGTCAGAGTGTTAGTAACA 64D4 V_(L)4 GCTACTTAGCC 65C3 1279 V_(L)5 CDRL1-48 AGGGCCAGTCAGAGTGTTAGCAGCC 68D5 V_(L)5 AGTTAGCC 63E6 1280 V_(L)6 CDRL1-49 CGGACAAGTCAGAGTATTAGCAGCT ATTTAAAT 66F7 1281 V_(L)7 CDRL1-50 CGGACAAGTCAGAGCATTAGCAACT ATTTAAAT 64H5 1282 V_(L)8 CDRL1-51 GGGGGAAACAACATTGGAAGTAAAA 65G4 V_(L)8 ATGTACAC 65E3 V_(L)25 64H6 V_(L)37 67G10 1283 V_(L)9 CDRL1-52 GGGGGAAACAACATTGGAAGTAAAG v1 CTGTGCAC 63A10 V_(L)22 63A10v2 V_(L)101 67G10 1284 V_(L)10 CDRL1-53 TCTGGAGATAAATTGGGGGATAAAT v2 ATGCTTGC 63F5 1285 V_(L)14 CDRL1-54 AGGGCCAGTCAGACTGTTAGGAACA ACTACTTAGCC 64A7 1286 V_(L)17 CDRL1-55 AGGGCCAGTCAGAGTGTTAGTCGCA ACTACTTAGCC 65C1 1287 V_(L)16 CDRL1-56 AGGGCCAGTCAGACTATTAGGAACA GCTACTTAGCC 66B4 1288 V_(L)11 CDRL1-57 CGGGCGAGTCAGGGTATTAGCAGGT GGTTAGCC 55A7 1289 V_(L)98 CDRL1-58 CGGGCAAGTCAGAGCATTAGCAGCT ATTTAAAT 68G5 1290 V_(L)13 CDRL1-59 GGGGGTAACAACATTGGAAGTATAA ATGTGCAC 66D4 1291 V_(L)18 CDRL1-60 CGGGCAAGTCAGATCATTAGCAGGT ATTTAAAT 65B1 1292 V_(L)19 CDRL1-61 CGGGCAAGTCAGAACATTAACAACT ATTTAAAT 67A4 1293 V_(L)20 CDRL1-62 GGGGGAAACAACATTGGAAGTAAAA GTGTGCAC 65B4 1294 V_(L)21 CDRL1-63 GGGGGAAACAACATTGGAAGTAAAA GTGTGCAG 55E6 1295 V_(L)99 CDRL1-64 AGGGCCAGTCAGAGTGTTAGTCGCA GCCACTTAGCC 65H11 1296 V_(L)23 CDRL1-65 GGGGGAAACAACATTGGAAGTAAAA CTGTGCAC 64C8 1297 V_(L)24 CDRL1-66 AGGTCTAGTCCAAGCCTCGTATACAG TGATGGAAACACCTACTTGAAT 65D4 1298 V_(L)26 CDRL1-67 GGGGGAAATGACATTGGAAGTAAAA ATGTGCAC 61E1 1299 V_(L)100 CDRL1-68 CGGGCAAGTCAGAGCATTGGCACCTT TTTAAAT 67G8 1300 V_(L)28 CDRL1-69 GGGGGAAACAACATTGGAAGTTACA ATGTGTTC 65B7 1301 V_(L)29 CDRL1-70 AGGGCCAGTCAGAGTGTTAGCAGCA TGTACTTAGCC 64A6 1302 V_(L)30 CDRL1-71 AGGGCCAGTCAGAGTGTTAACAGCA ACTTAGCC 65F9 1303 V_(L)31 CDRL1-72 AGGGCCAGTCAGAGTGTTAGCAGCA 67F5 V_(L)32 ACTTAGCC 64B10 1304 V_(L)33 CDRL1-73 TCTGGAAGCAGCTCCAATATTGGGAA TAATTATGTAGCC 68C8 1305 V_(L)34 CDRL1-74 TCTGGAAGCAGTTCCAACATTGGAAA TAATTATGTATCC 67A5 1306 V_(L)35 CDRL1-75 AGGTCTAGTCAGAGCCTCTTAAATAG 67C10 V_(L)36 TGATGATGGAAATACCTATTTGGAC 63F9 1307 V_(L)38 CDRL1-76 CGGGCAAGTCAGGACATTAGAAATG ATTTAGCC 67F6v1 1308 V_(L)39 CDRL1-77 AGGTCTAGTCAGAGCCTCTTAAATAG 67F6v2 V_(L)39 TGATGCTGGTACCACCTATTTGGAC 50G5 v2 1309 V_(L)94 CDRL1-78 AGGTCTAGTCAAAGACTCGTATACAG TGATGGAAACACCTACTTGAAT 48G4 1310 V_(L)89 CDRL1-79 AGGGCCAGTCAGAGTGTTGCCAGCA 53C3.1 V_(L)89 GTTACTTAGTC 58C2 1311 V_(L)91 CDRL1-81 AGGTCTAGTCAGAGCCTCTTCGATAA TGATGATGGAGACACCTATTTGGAC 65B7v1 1887 V_(L)29 CDRL1-82 AGGGCCAGTCAGAGTGTTAGCAGCA TCTACTTAGCC 65B7v2 1888 V_(L)107 CDRL1-83 AGGTCTAGTCAAAGCCTCGTATACAG TGATGGAGACACCTACTTGAAT 63G8v3 1889 V_(L)106 CDRL1-84 CGGGCAAGTCAGGGCATTAGAAGTG 63G8v2 V_(L)105 GTTTAGGC 63A10v3 1890 V_(L)102 CDRL1-85 TCTGGAGATAAATTGGGGAATAGAT ATACTTGC 65H11v2 1891 V_(L)23 CDRL1-86 TCTGGAGATAAATTGGGGGATAGAT ATGTTTGT 48C9 1312 V_(L)78 CDRL2-1 GTTGCATCCAGTTTGGAAAGT 49A12 V_(L)78 51E2 V_(L)78 48F3 1313 V_(L)77 CDRL2-2 GCTGTATCCAGTTTGCAAAGT 48F8 1314 V_(L)49 CDRL2-3 TTTGCTTCCCAGTCCTTCTCA 53B9 V_(L)49 56B4 V_(L)49 57E7 V_(L)49 57F11 V_(L)49 48H11 1315 V_(L)40 CDRL2-4 GGTGCATCTAATTTACAGAGT 49A10 1316 V_(L)65 CDRL2-5 ACGCTTTCCTATCGGGCCTCT 48D4 V_(L)65 49G2 V_(L)66 50C12 V_(L)66 55G11 V_(L)66 60D7 V_(L)69 67A5 V_(L)35 67C10 V_(L)36 50G1 V_(L)90 60D7 V_(L)36 58C2 V_(L)91 49C8 1317 V_(L)45 CDRL2-6 GATGTATCCAATTTGGAAACA 52H1 V_(L)45 54A1 V_(L)44 55G9 V_(L)44 49G3 1318 V_(L)47 CDRL2-7 GATGCATCCAATTTGGAAACA 56E7 V_(L)86 49H12 1319 V_(L)43 CDRL2-8 GATACATTCATTTTGGAAACA 51A8 1320 V_(L)61 CDRL2-9 GAGGATAAAGAAAGATCCTCT 51C10.1 1321 V_(L)55 CDRL2-10 GAGGACAGCAAACGACCCTCC 59D10 V_(L)56 v1 51C10.2 1322 V_(L)70 CDRL2-11 CAAAATAACAAGCGGCCCTCA 59G10.2 V_(L)60 51E5 1323 V_(L)79 CDRL2-12 GCTGCATCCAGTTTGCAATTT 51G2 1324 V_(L)51 CDRL2-13 GATGCATCCAGTTTGCAAAGT 52A8 1325 V_(L)41 CDRL2-14 GCTGCATCCAGTTTGCAAAGT 52C5 V_(L)73 53H5.2 V_(L)62 55D3 V_(L)71 56G1 V_(L)76 57B12 V_(L)72 63E6 V_(L)6 66F7 V_(L)7 66D4 V_(L)18 50G5 v1 V_(L)93 51C1 V_(L)95 55A7 V_(L)98 61E1 V_(L)100 60G5.1 V_(L)74 52B8 1326 V_(L)82 CDRL2-15 GGTGCATCCACCAGGGCCACT 53H5.3 V_(L)80 65F9 V_(L)31 52C1 1327 V_(L)67 CDRL2-16 GACAATAATAAGCGACCCTCA 59G10.3 V_(L)54 68C8 V_(L)34 52F8 1328 V_(L)42 CDRL2-17 TTGGGTTCTAATCGGGCCTCC 55E9 V_(L)68 52H2 1329 V_(L)84 CDRL2-18 GGTGCATCCAGGAGGGCCACT 53F6 1330 V_(L)63 CDRL2-19 TTGGATTCTAATCGGGCCTCC 54H10.1 1331 V_(L)53 CDRL2-20 GGTGCATCCAGCAGGGCCACT 55D1 V_(L)53 48H3 V_(L)53 53C11 V_(L)53 57D9 V_(L)87 61H5 V_(L)88 52B9 V_(L)88 63F5 V_(L)14 64A7 V_(L)17 65B7v1 V_(L)29 55E6 V_(L)99 55E4 1332 V_(L)75 CDRL2-21 ACAGCTTCCAGTTTGCAAAGT 49BG11 V_(L)75 50H10 V_(L)75 53C1 V_(L)75 50G5v2 1333 V_(L)94 CDRL2-22 AAGGTTTCTAACTGGGACTCT 65B7v2 V_(L)107 55G5 1334 V_(L)83 CDRL2-23 CAAGATACCAAGCGGCCCTCA 56A7 1335 V_(L)52 CDRL2-24 GATGCATCCACTTTGCAAAGT 56E4 V_(L)52 56C11 1336 V_(L)64 CDRL2-25 GATGATAGCGACCGGCCCTCA 67A4 V_(L)20 65B4 V_(L)21 56G3.2 1337 V_(L)85 CDRL2-26 GGTGCATCCAGCAGGGACACT 56G3.3 1338 V_(L)81 CDRL2-27 GGTGCATCCGCCAGGGCCACT 55B10 V_(L)81 59A10 1339 V_(L)48 CDRL2-28 GGTGCATCCAGTTTGCAAAGT 49H4 V_(L)48 59C9 1340 V_(L)50 CDRL2-29 GCTGCATCCAATTTGCAAAGA 58A5 V_(L)50 57A4 V_(L)50 57F9 V_(L)50 63G8v1 V_(L)104 63GBv2 V_(L)105 63G8v3 V_(L)106 64A8 V_(L)1 67B4 V_(L)1 68D3 V_(L)1 59D10 1341 V_(L)57 CDRL2-30 CAAGATACCAAGCGGCCCTCA v2 60F9 1342 V_(L)58 CDRL2-31 GGTTCATCCAACAGGGCCACT 48B4 V_(L)58 52D6 V_(L)58 60G5.2 1343 V_(L)46 CDRL2-32 CAAGATAGCAAGCGGCCCTCA 65D1 V_(L)27 65H11v2 V_(L)103 61G5 1344 V_(L)59 CDRL2-33 GGTGCATCCAACAGGGCCACA 64E6 1345 V_(L)3 CDRL2-34 GGTGCATTTAGCAGGGCCTCT 65E8 V_(L)3 65F11 V_(L)3 67G7 V_(L)3 63H11 V_(L)3 63B6 1346 V_(L)4 CDRL2-35 GGTGCATTCAGTAGGGCCACT 64D4 V_(L)4 65C1 V_(L)16 66F6 V_(L)15 48G4 V_(L)83 53C3.1 V_(L)83 65C3 1347 V_(L)5 CDRL2-36 GGTGCCTCCAACAGGGCCATT 68D5 V_(L)5 64H5 1348 V_(L)8 CDRL2-37 AGGGATAGCAAGCGGCCCTCT 65G4 V_(L)8 67G8 V_(L)28 64H6 V_(L)37 67G10 1349 V_(L)9 CDRL2-38 AGCGATAGCAACCGGCCCTCA v1 65H11 V_(L)23 67G10 1350 V_(L)10 CDRL2-39 CAAGATAACGAGCGGCCCTCA v2 66B4 1351 V_(L)11 CDRL2-40 GCTGCATCCAGTTTGAAAAGT 66G2 1352 V_(L)12 CDRL2-41 GCTGCATCCAATTTGCAAAGT 68G5 1353 V_(L)13 CDRL2-42 AGGGATAGGAACCGGCCCTCT 65E3 V_(L)25 65D4 V_(L)26 65B1 1354 V_(L)19 CDRL2-43 ACTACATCCAGTTTGCAAAGT 53C3.2 1355 V_(L)96 CDRL2-44 GGTACATCCATCAGGGCCAGT 63A10v1 1356 V_(L)22 CDRL2-45 TGTGATAGCAACCGGCCCTCA 63A10v2 V_(L)101 54H10.3 1357 V_(L)97 CDRL2-46 TCTGCATCCAGTTTGCAAAGT 64C8 1358 V_(L)24 CDRL2-47 AAGGGTTCTAACTGGGACTCA 64A6 1359 V_(L)30 CDRL2-48 GGTACATCCACCAGGGCCACT 67F5 1360 V_(L)32 CDRL2-49 GGTTCATCCAACAGGGCCATT 64B10 1361 V_(L)33 CDRL2-50 GACAATGATAAGCGACCCTCA 63F9 1362 V_(L)38 CDRL2-51 GCTTCATCCAGTTTGCAAAGT 67F6v2 1363 V_(L)39 CDRL2-52 ACGCTTTCCTTTCGGGCCTCT 50D4 1364 V_(L)92 CDRL2-53 GCTGCATCCACTTTGCTATCA 68A10v3 1892 V_(L)102 CDRL2-54 CAAGATAGCGAGCGGCCCTCA 48C9 1365 V_(L)78 CDRL3-1 CAACAGAGTGACAGTATCCCTCGGACG 49A12 51E2 48F3 1366 V_(L)77 CDRL3-2 CAACAGAGTTACAGTGCTACATTCACT 48F8 1367 V_(L)49 CDRL3-3 CATCAGAGTAGTGATTTACCGCTCACT 53B9 V_(L)49 56B4 V_(L)49 57E7 V_(L)49 57F11 V_(L)49 48H11 1368 V_(L)40 CDRL3-4 CAACAGAGTTACAATACCCCGTGCAGT 49A10 1369 V_(L)65 CDRL3-5 ATGCAACGTATAGAGTTTCCGATCACC 48D4 V_(L)65 67F6v2 V_(L)108 49C8 1370 V_(L)45 CDRL3-6 CAACAATATGATAATCTCCCATTCACT 52H1 V_(L)45 67C10 V_(L)36 67F6v1 V_(L)39 49G2 1371 V_(L)66 CDRL3-7 ATGCAACATATAGAATTTCCTTCGACC 50C12 V_(L)66 55G11 V_(L)66 49G3 1372 V_(L)47 CDRL3-8 CACCAGTATGATGATCTCCCGCTCACT 49H12 1373 V_(L)43 CDRL3-9 CAACAGTATGACAATTTACCGCTCACC 54A1 V_(L)44 55G9 V_(L)44 51A8 1374 V_(L)61 CDRL3-10 CAGTCTTATGATCGCAACAATCATGT GGTT 51C10.1 1375 V_(L)55 CDRL3-11 TACTCAACAGACAGCAGTGTTAATCA TGTGGTA 51C10.2 1376 V_(L)70 CDRL3-12 CAGGCGTGGGATAGTAGTACTGCGGTA 51E5 1377 V_(L)79 CDRL3-13 CTACAACATAGTAGTTACCCGCTCACT 51G2 1378 V_(L)51 CDRL3-14 CAACAGACTAACAGTTTCCCTCCGTG 56A7 V_(L)52 GACG 56E4 V_(L)52 59A10 V_(L)48 49H4 V_(L)48 59C9 V_(L)50 58A5 V_(L)50 57A4 V_(L)50 57F9 V_(L)50 52A8 1379 V_(L)41 CDRL3-15 CAGCAGAGTTACAGTACCCCGCTCACT 65B1 V_(L)19 52B8 1380 V_(L)82 CDRL3-16 CAGCAGTATAATAACTGGCCGCTCACT 56G3.2 V_(L)85 52C1 1381 V_(L)67 CDRL3-17 GGAACATGGGATAGCAGCCTGAGTG 64B10 V_(L)33 CTGTGGTA 68C8 V_(L)34 52C5 1382 V_(L)73 CDRL3-18 CAACAGAGTTCCAGTATCCCTTGGACG 55E4 V_(L)75 49B11 V_(L)75 50H10 V_(L)75 53C1 V_(L)75 51C1 V_(L)95 60G5.1 V_(L)74 52F8 1383 V_(L)42 CDRL3-19 ATGCAAGCTCTACAAACTCCATTCACT 52H2 1384 V_(L)84 CDRL3-20 CAGCAGTATGGTAGTTCACCTCGCAGT 53F6 1385 V_(L)63 CDRL3-21 ATGCAAGGTCTACAAACTCCTCCCACT 53H5.2 1386 V_(L)62 CDRL3-22 CTACAGCATAAGAGTTACCCATTCACT 53H5.3 1387 V_(L)80 CDRL3-23 CAGCAGTTTAGTAACTCAATCACC 54H10.1 1388 V_(L)53 CDRL3-24 CAGCAGTATGGTAGCTCACGGACG 55D1 V_(L)53 48H3 V_(L)53 53C11 V_(L)53 55D3 1389 V_(L)71 CDRL3-25 CAACAGTATAATATTTACCCTCGGACG 55E9 1390 V_(L)68 CDRL3-26 ATGCAAGCTCTACAAACTCTCATCACC 55G5 1391 V_(L)83 CDRL3-27 CAGGCGTGGGACAGCGGCACTGTGG TA 56C11 1392 V_(L)64 CDRL3-28 CAGGTGTGGGATAGTAGTAGTGATGT GGTA 56E7 1393 V_(L)86 CDRL3-29 CAACAATATGCTATTCTCCCATTCACT 56G1 1394 V_(L)76 CDRL3-30 CAACAGAGTTCCACTATCCCTTGGACG 56G3.3 1395 V_(L)81 CDRL3-31 CAGCAATATGGTAGATCACTATTCACT 55B10 V_(L)81 61H5 V_(L)88 52B9 V_(L)88 57B12 1396 V_(L)72 CDRL3-32 CAACAATATAATACTTACCCTCGGACG 57D9 1397 V_(L)87 CDRL3-33 CATCAGTATGGTACCTCACCGTGCAGT 59D10 1398 V_(L)56 CDRL3-34 TACTCAACAGACAGCAGTGGTAATCA v1 TGTGGTA 59D10 1399 V_(L)57 CDRL3-35 CAGGCGTGGGACAGCAGCACTACAT v2 GGGTG 59G10.2 1400 V_(L)60 CDRL3-36 CAGGCGTGGGACAGCGCCACTGTGA TT 59G10.3 1401 V_(L)54 CDRL3-37 GGAACATGGGACAGCAGCCTGAGTG TTATGGTT 60D7 1402 V_(L)69 CDRL3-38 ATGCAACGTATAGAGTTTCCGCTCACT 50G1 V_(L)90 60F9 1403 V_(L)58 CDRL3-39 CAGCAGTATGGTAGCTCACCTCCGTG 48B4 V_(L)58 GACG 52D6 V_(L)58 61G5 V_(L)59 60G5.2 1404 V_(L)46 CDRL3-40 CAGGCGTGGGACAGCAGCACTTGGG TG 63G8v1 1405 V_(L)104 CDRL3-41 CTCCAGCATAATAGTTACCCTCTCACT 63G8v2 V_(L)105 64A8 V_(L)1 67B4 V_(L)1 68D3 V_(L)2 64E6 1406 V_(L)3 CDRL3-42 CAGCAGTTTGGAAGCTCACTCACT 65E8 V_(L)3 65F11 V_(L)3 67G7 V_(L)3 63H11 V_(L) 63F5 V_(L)14 65C1 V_(L)16 66F6 V_(L)15 63B6 1407 V_(L)4 CDRL3-43 CAGCAGTTTGGTAGGTCATTCACT 64D4 V_(L)4 65C3 1408 V_(L)5 CDRL3-44 CAGCAGTATAATAACTGGCCGTGGACG 68D5 V_(L)5 63E6 1409 V_(L)6 CDRL3-45 CAACAGAGTTACAGTACCTCGCTCACT 66F7 V_(L)7 64H5 1410 V_(L)8 CDRL3-46 CAGGTGTGGGACAGCAGTAGTGTGG 65G4 V_(L)8 TA 67G10 1411 V_(L)9 CDRL3-47 CAGGTGTGGGACAGTAGTAGTGATG v1 GGGTA 67G10 1412 V_(L)10 CDRL3-48 CAGGCGTGGGACAGCACCACTGTGG v2 TA 63A10v2 V_(L)101 63A10v3 V_(L)102 64A7 1413 V_(L)17 CDRL3-49 CAGCAGTATGGTAGTTCATCTCTGTG CAGT 66B4 1414 V_(L)11 CDRL3-50 CAACAGGCTAACAGTTTCCCTCCGACG 66G2 1415 V_(L)12 CDRL3-51 CTACAACTTAATGGTTACCCTCTCACT 68G5 1416 V_(L)13 CDRL3-52 CAGTTGTGGGACAGCAGCACTGTGGTT 66D4 1417 V_(L)18 CDRL3-53 CAACAGAGTTACAGTTCCCCGCTCACT 54H10.3 V_(L)97 55A7 1418 V_(L)98 CDRL3-54 CAACAGACTTACAGTGCCCCATTCACT 67A4 1419 V_(L)20 CDRL3-55 CAGGTGTGGGATAGTAGTAGTGATCA 65B4 V_(L)21 TGTGGTA 63A10 1420 V_(L)22 CDRL3-56 CATGCGTGTGGGAGCAGTAGTAGCG ATGGGGTA 65H11 1421 V_(L)23 CDRL3-57 CAGGTGTGGGACAGTAGTTGTGATGG GGTA 64C8 1422 V_(L)24 CDRL3-58 ATACAAGATACACACTGGCCCACGTG CAGT 65E3 1423 V_(L)25 CDRL3-59 CAGGTGTGGGACAGCAGCACTGTGG 67G8 V_(L)28 TC 65D4 1424 V_(L)26 CDRL3-60 CAGGTGTGGGACAGCAACCCTGTGGTA 65D1 1425 V_(L)27 CDRL3-61 CAGGCGTGGGACAGCAGGGTA 65B7v1 1426 V_(L)29 CDRL3-62 CAGCAGTATGGTAGCTCGTGCAGT 64A6 1427 V_(L)30 CDRL3-63 CAGCAATATAATACCTGGCCGTGGACG 65F9 V_(L)31 67F5 1428 V_(L)32 CDRL3-64 CAGCAGTATGAAATTTGGCCGTGGACG 55E6 1429 V_(L)99 CDRL3-65 CAGCAGTATGGTAGTTCACCGTGGACG 67A5 1430 V_(L)35 CDRL3-66 ATGCAACGTCTAGAGTTTCCTATTACC 58C2 V_(L)91 61E1 1431 V_(L)100 CDRL3-67 CAACAGAGTTTCAGTACCCCGCTCACT 64H6 1432 V_(L)37 CDRL3-68 CAGGTGTGGGACAGCAGTCCTGTGGTA 63F9 1433 V_(L)38 CDRL3-69 CTACAGCGTAATAGTTACCCGCTCACT 53C3.2 1434 V_(L)96 CDRL3-70 CACCAGTATACTAACTGGCCTCGGACG 48G4 1435 V_(L)89 CDRL3-71 CAGCAGTATGGTACCTCACCATTTACT 53C3.1 V_(L)89 50G5 v1 1436 V_(L)93 CDRL3-72 CTACAGCATAATAGTTACCCTCGGACG 64B10v2 1893 V_(L)33 CDRL3-73 TATAGCAGCACCTGGGACTACTATTA CGGTGTGGACGTC 50D4 1437 V_(L)92 CDRL3-74 CAAAAGTATTACAGTGCCCCTTTCACT 50G5 v2 1438 V_(L)94 CDRL3-75 ATGGAAGGTACACACTGGCCTCGGG AC 63G8v3 1894 V_(L)106 CDRL3-76 CTCCAACATAATACTTACCCTCTCACT 65B7v2 1895 V_(L)107 CDRL3-77 ATGCAAGGTACACACTGGCGGGGTT GGACG 65H11v2 1896 V_(L)103 CDRL3-78 CAGGCGTGGGACAGCATCACTGTGGTA 63A10v1 1897 V_(H)21 CDRL3-79 CAGGTGTGGGACAGTAGTAGTGATG GGGTA

The structure and properties of CDRs within a naturally occurring antibody has been described, supra. Briefly, in a traditional antibody, the CDRs are embedded within a framework in the heavy and light chain variable region where they constitute the regions responsible for antigen binding and recognition. A variable region comprises at least three heavy or light chain CDRs, see, e.g., Kabat et al., (1991) “Sequences of Proteins of Immunological Interest”, 5^(th) Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242; see also Chothia and Lesk, (1987) J. Mol. Biol. 196:901-917; Chothia et al., (1989) Nature 342: 877-883), within a framework region (designated framework regions 1-4, FR1, FR2, FR3, and FR4, by Kabat et al., (1991); see also Chothia and Lesk, (1987) supra). The CDRs provided herein, however, can not only be used to define the antigen binding domain of a traditional antibody structure, but can be embedded in a variety of other polypeptide structures, as described herein.

In one aspect, the CDRs provided are (a) a CDRH selected from the group consisting of (i) a CDRH1 selected from the group consisting of SEQ ID NOS 603-655; (ii) a CDRH2 selected from the group consisting of SEQ ID NOS 656-732; (iii) a CDRH3 selected from the group consisting of SEQ ID NOS 733-813; and (iv) a CDRH of (i), (ii) and (iii) that contains one or more amino acid substitutions, deletions or insertions of no more than five, four, three, two, or one amino acids; (B) a CDRL selected from the group consisting of (i) a CDRL1 selected from the group consisting of SEQ ID NOS 814-893; (ii) a CDRL2 selected from the group consisting of SEQ ID NOS 894-946; (iii) a CDRL3 selected from the group consisting of SEQ ID NOS 947-1020; and (iv) a CDRL of (i), (ii) and (iii) that contains one or more amino acid substitutions, deletions or insertions of no more than 1, 2, 3, 4, or 5 amino acids amino acids.

In another aspect, an antigen binding protein comprises 1, 2, 3, 4, 5, or 6 variant forms of the CDRs listed in Tables 3A and 3B, infra, each having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a CDR sequence listed in Tables 3A and 3B, infra. Some antigen binding proteins comprise 1, 2, 3, 4, 5, or 6 of the CDRs listed in Tables 3A and 3B, infra, each differing by no more than 1, 2, 3, 4 or 5 amino acids from the CDRs listed in these tables.

In still another aspect, an antigen binding protein includes the following associations of CDRL1, CDRL2 and CDRL3, presented for convenience in tabular form and in reference to the clone source of the association:

TABLE 4 CDRL Associations Clone ID CDRL1 CDRL2 CDRL3 63G8 CDRL1-13 CDRL2-29 CDRL3-41 64A8 CDRL1-13 CDRL2-29 CDRL3-41 67B4 CDRL1-13 CDRL2-29 CDRL3-41 68D3 CDRL1-13 CDRL2-29 CDRL3-41 64E6 CDRL1-46 CDRL2-34 CDRL3-42 65E8 CDRL1-46 CDRL2-34 CDRL3-42 65F11 CDRL1-46 CDRL2-34 CDRL3-42 67G7 CDRL1-46 CDRL2-34 CDRL3-42 63B6 CDRL1-47 CDRL2-3 CDRL3-43 64D4 CDRL1-47 CDRL2-3 CDRL3-43 65C3 CDRL1-48 CDRL2-36 CDRL3-44 68D5 CDRL1-48 CDRL2-36 CDRL3-44 63E6 CDRL1-49 CDRL2-14 CDRL3-45 66F7 CDRL1-50 CDRL2-14 CDRL3-45 64H5 CDRL1-51 CDRL2-37 CDRL3-46 65G4 CDRL1-51 CDRL2-37 CDRL3-46 67G10v1 CDRL1-52 CDRL2-38 CDRL3-47 67G10v2 CDRL1-53 CDRL2-39 CDRL3-48 66B4 CDRL1-57 CDRL2-40 CDRL3-50 66G2 CDRL1-22 CDRL2-41 CDRL3-51 68G5 CDRL1-59 CDRL2-42 CDRL3-52 63F5 CDRL1-54 CDRL2-20 CDRL3-42 66F6 CDRL1-46 CDRL2-35 CDRL3-42 65C1 CDRL1-56 CDRL2-35 CDRL3-42 64A7 CDRL1-55 CDRL2-20 CDRL3-49 66D4 CDRL1-60 CDRL2-14 CDRL3-53 65B1 CDRL1-61 CDRL2-43 CDRL3-15 67A4 CDRL1-62 CDRL2-25 CDRL3-55 65B4 CDRL1-63 CDRL2-25 CDRL3-55 63A10 CDRL1-52 CDRL2-45 CDRL3-56 65H11 CDRL1-65 CDRL2-38 CDRL3-57 64C8 CDRL1-66 CDRL2-47 CDRL3-58 65E3 CDRL1-51 CDRL2-42 CDRL3-59 65D4 CDRL1-67 CDRL2-42 CDRL3-60 65D1 CDRL1-39 CDRL2-32 CDRL3-61 67G8 CDRL1-69 CDRL2-37 CDRL3-59 65B7 CDRL1-70 CDRL2-20 CDRL3-62 64A6 CDRL1-71 CDRL2-48 CDRL3-63 65F9 CDRL1-72 CDRL2-15 CDRL3-63 67F5 CDRL1-72 CDRL2-49 CDRL3-64 64B10 CDRL1-73 CDRL2-50 CDRL3-17 68C8 CDRL1-74 CDRL2-16 CDRL3-17 67A5 CDRL1-75 CDRL2-5 CDRL3-66 67C10 CDRL1-75 CDRL2-5 CDRL3-5 64H6 CDRL1-51 CDRL2-37 CDRL3-68 63F9 CDRL1-76 CDRL2-51 CDRL3-69 67F6 CDRL1-77 CDRL2-52 CDRL3-5 48H11 CDRL1-4 CDRL2-4 CDRL3-4 52A8 CDRL1-15 CDRL2-14 CDRL3-15 52F8 CDRL1-19 CDRL2-17 CDRL3-19 49H12 CDRL1-9 CDRL2-8 CDRL3-9 54A1 CDRL1-24 CDRL2-6 CDRL3-9 55G9 CDRL1-24 CDRL2-6 CDRL3-9 49C8 CDRL1-6 CDRL2-6 CDRL3-6 52H1 CDRL1-6 CDRL2-6 CDRL3-6 60G5.2 CDRL1-44 CDRL2-32 CDRL3-40 49G3 CDRL1-8 CDRL2-7 CDRL3-8 59A10 CDRL1-14 CDRL2-28 CDRL3-14 49H4 CDRL1-14 CDRL2-28 CDRL3-14 48F8 CDRL1-3 CDRL2-3 CDRL3-3 53B9 CDRL1-3 CDRL2-3 CDRL3-3 56B4 CDRL1-3 CDRL2-3 CDRL3-3 57E7 CDRL1-3 CDRL2-3 CDRL3-3 57F11 CDRL1-3 CDRL2-3 CDRL3-3 59C9 CDRL1-37 CDRL2-29 CDRL3-14 58A5 CDRL1-37 CDRL2-29 CDRL3-14 57A4 CDRL1-37 CDRL2-29 CDRL3-14 57F9 CDRL1-37 CDRL2-29 CDRL3-14 51G2 CDRL1-14 CDRL2-13 CDRL3-14 56A7 CDRL1-29 CDRL2-24 CDRL3-14 56E4 CDRL1-29 CDRL2-24 CDRL3-14 54H10.1 CDRL1-25 CDRL2-20 CDRL3-24 55D1 CDRL1-25 CDRL2-20 CDRL3-24 48H3 CDRL1-25 CDRL2-20 CDRL3-24 53C11 CDRL1-25 CDRL2-20 CDRL3-24 59G10.3 CDRL1-41 CDRL2-16 CDRL3-37 51C10.1 CDRL1-12 CDRL2-10 CDRL3-11 59D10 v1 CDRL1-38 CDRL2-10 CDRL3-34 59D10 v2 CDRL1-39 CDRL2-30 CDRL3-35 60F9 CDRL1-43 CDRL2-31 CDRL3-39 48B4 CDRL1-43 CDRL2-31 CDRL3-39 52D6 CDRL1-43 CDRL2-31 CDRL3-39 61G5 CDRL1-45 CDRL2-33 CDRL3-39 59G10.2 CDRL1-40 CDRL2-11 CDRL3-36 51A8 CDRL1-10 CDRL2-9 CDRL3-10 53H5.2 CDRL1-22 CDRL2-14 CDRL3-22 53F6 CDRL1-21 CDRL2-19 CDRL3-21 56C11 CDRL1-30 CDRL2-25 CDRL3-28 49A10 CDRL1-5 CDRL2-5 CDRL3-5 48D4 CDRL1-5 CDRL2-5 CDRL3-5 49G2 CDRL1-7 CDRL2-5 CDRL3-7 50C12 CDRL1-7 CDRL2-5 CDRL3-7 55G11 CDRL1-7 CDRL2-5 CDRL3-7 52C1 CDRL1-17 CDRL2-16 CDRL3-17 55E9 CDRL1-27 CDRL2-17 CDRL3-26 60D7 CDRL1-1 CDRL2-5 CDRL3-38 51C10.2 CDRL1-12 CDRL2-11 CDRL3-12 55D3 CDRL1-26 CDRL2-14 CDRL3-25 57B12 CDRL1-34 CDRL2-14 CDRL3-32 52C5 CDRL1-18 CDRL2-14 CDRL3-18 55E4 CDRL1-18 CDRL2-21 CDRL3-18 49B11 CDRL1-18 CDRL2-21 CDRL3-18 50H10 CDRL1-18 CDRL2-21 CDRL3-18 53C1 CDRL1-18 CDRL2-21 CDRL3-18 56G1 CDRL1-18 CDRL2-14 CDRL3-30 48F3 CDRL1-2 CDRL2-2 CDRL3-2 48C9 CDRL1-1 CDRL2-1 CDRL3-1 49A12 CDRL1-1 CDRL2-1 CDRL3-1 51E2 CDRL1-1 CDRL2-1 CDRL3-1 51E5 CDRL1-13 CDRL2-12 CDRL3-13 53H5.3 CDRL1-23 CDRL2-15 CDRL3-23 56G3.3 CDRL1-33 CDRL2-27 CDRL3-31 55B10 CDRL1-33 CDRL2-27 CDRL3-31 52B8 CDRL1-16 CDRL2-15 CDRL3-16 55G5 CDRL1-28 CDRL2-23 CDRL3-27 52H2 CDRL1-20 CDRL2-18 CDRL3-20 56G3.2 CDRL1-32 CDRL2-26 CDRL3-16 56E7 CDRL1-31 CDRL2-7 CDRL3-29 57D9 CDRL1-35 CDRL2-20 CDRL3-33 61H5 CDRL1-33 CDRL2-20 CDRL3-31 52B9 CDRL1-33 CDRL2-20 CDRL3-31 48G4 CDRL1-79 CDRL2-35 CDRL3-71 53C3.1 CDRL1-79 CDRL2-35 CDRL3-71 50G1 CDRL1-7 CDRL2-5 CDRL3-38 58C2 CDRL1-81 CDRL2-5 CDRL3-66 60G5.1 CDRL1-18 CDRL2-14 CDRL3-18 54H10.3 CDRL1-42 CDRL2-46 CDRL3-53 50G5 v1 CDRL1-22 CDRL2-14 CDRL3-72 50G5 v2 CDRL1-78 CDRL2-22 CDRL3-75 51C1 CDRL1-18 CDRL2-14 CDRL3-18 53C3.2 CDRL1-36 CDRL2-44 CDRL3-70 50D4 CDRL1-26 CDRL2-53 CDRL3-74 55A7 CDRL1-58 CDRL2-14 CDRL3-54 55E6 CDRL1-64 CDRL2-20 CDRL3-65 61E1 CDRL1-68 CDRL2-14 CDRL3-67 63H11 CDRL1-46 CDRL2-34 CDRL3-42

In an additional aspect, an antigen binding protein includes the following associations of CDRH1, CDRH2 and CDRH3, presented for convenience in tablular form and in reference to the clone source of the association:

TABLE 5 CDRH Associations Clone ID CDRH1 CDRH2 CDRH3 63G8 CDRH1-34 CDRH2-12 CDRH3-50 64A8 CDRH1-34 CDRH2-12 CDRH3-50 67B4 CDRH1-34 CDRH2-12 CDRH3-50 68D3 CDRH1-34 CDRH2-12 CDRH3-50 64E6 CDRH1-35 CDRH2-44 CDRH3-51 65E8 CDRH1-35 CDRH2-44 CDRH3-51 65F11 CDRH1-35 CDRH2-44 CDRH3-51 67G7 CDRH1-35 CDRH2-44 CDRH3-51 63B6 CDRH1-36 CDRH2-45 CDRH3-52 64D4 CDRH1-36 CDRH2-45 CDRH3-52 65C3 CDRH1-24 CDRH2-46 CDRH3-53 68D5 CDRH1-24 CDRH2-46 CDRH3-53 63E6 CDRH1-37 CDRH2-47 CDRH3-54 66F7 CDRH1-37 CDRH2-47 CDRH3-54 64H5 CDRH1-12 CDRH2-48 CDRH3-55 65G4 CDRH1-12 CDRH2-48 CDRH3-55 67G10v1 CDRH1-38 CDRH2-49 CDRH3-56 67G10v2 CDRH1-38 CDRH2-49 CDRH3-56 66B4 CDRH1-15 CDRH2-53 CDRH3-59 66G2 CDRH1-12 CDRH2-54 CDRH3-50 68G5 CDRH1-12 CDRH2-55 CDRH3-60 63F5 CDRH1-35 CDRH2-50 CDRH3-51 66F6 CDRH1-35 CDRH2-34 CDRH3-51 65C1 CDRH1-35 CDRH2-52 CDRH3-58 64A7 CDRH1-40 CDRH2-51 CDRH3-57 66D4 CDRH1-43 CDRH2-56 CDRH3-61 65B1 CDRH1-44 CDRH2-57 CDRH3-62 67A4 CDRH1-45 CDRH2-58 CDRH3-63 65B4 CDRH1-46 CDRH2-59 CDRH3-64 63A10 CDRH1-38 CDRH2-60 CDRH3-56 65H11 CDRH1-38 CDRH2-61 CDRH3-56 64C8 CDRH1-12 CDRH2-62 CDRH3-65 65E3 CDRH1-47 CDRH2-63 CDRH3-66 65D4 CDRH1-48 CDRH2-22 CDRH3-67 65D1 CDRH1-49 CDRH2-64 CDRH3-68 67G8 CDRH1-12 CDRH2-65 CDRH3-69 65B7 CDRH1-50 CDRH2-52 CDRH3-70 64A6 CDRH1-14 CDRH2-66 CDRH3-71 65F9 CDRH1-36 CDRH2-34 CDRH3-72 67F5 CDRH1-24 CDRH2-67 CDRH3-53 64B10 CDRH1-36 CDRH2-68 CDRH3-73 68C8 CDRH1-51 CDRH2-69 CDRH3-74 67A5 CDRH1-25 CDRH2-31 CDRH3-75 67C10 CDRH1-25 CDRH2-31 CDRH3-76 64H6 CDRH1-25 CDRH2-70 CDRH3-77 63F9 CDRH1-52 CDRH2-71 CDRH3-78 67F6 CDRH1-53 CDRH2-31 CDRH3-79 48H11 CDRH1-4 CDRH2-4 CDRH3-4 52A8 CDRH1-15 CDRH2-17 CDRH3-17 52F8 CDRH1-17 CDRH2-20 CDRH3-21 49H12 CDRH1-10 CDRH2-10 CDRH3-10 54A1 CDRH1-10 CDRH2-25 CDRH3-10 55G9 CDRH1-10 CDRH2-25 CDRH3-10 49C8 CDRH1-7 CDRH2-7 CDRH3-7 52H1 CDRH1-7 CDRH2-7 CDRH3-7 60G5.2 CDRH1-33 CDRH2-42 CDRH3-48 49G3 CDRH1-9 CDRH2-9 CDRH3-9 59A10 CDRH1-30 CDRH2-37 CDRH3-41 49H4 CDRH1-30 CDRH2-37 CDRH3-41 48F8 CDRH1-3 CDRH2-3 CDRH3-3 53B9 CDRH1-3 CDRH2-3 CDRH3-3 56B4 CDRH1-3 CDRH2-3 CDRH3-3 57E7 CDRH1-3 CDRH2-3 CDRH3-3 57F11 CDRH1-3 CDRH2-3 CDRH3-3 59C9 CDRH1-31 CDRH2-38 CDRH3-42 58A5 CDRH1-31 CDRH2-38 CDRH3-42 57A4 CDRH1-31 CDRH2-38 CDRH3-42 57F9 CDRH1-31 CDRH2-38 CDRH3-42 51G2 CDRH1-3 CDRH2-16 CDRH3-16 56A7 CDRH1-3 CDRH2-16 CDRH3-32 56E4 CDRH1-3 CDRH2-16 CDRH3-32 54H10.1 CDRH1-21 CDRH2-26 CDRH3-27 55D1 CDRH1-21 CDRH2-26 CDRH3-27 48H3 CDRH1-21 CDRH2-26 CDRH3-27 53C11 CDRH1-21 CDRH2-26 CDRH3-27 59G10.3 CDRH1-32 CDRH2-40 CDRH3-45 51C10.1 CDRH1-13 CDRH2-13 CDRH3-13 59D10 v1 CDRH1-13 CDRH2-13 CDRH3-13 59D10 v2 CDRH1-13 CDRH2-13 CDRH3-13 60F9 CDRH1-21 CDRH2-41 CDRH3-47 48B4 CDRH1-21 CDRH2-41 CDRH3-47 52D6 CDRH1-21 CDRH2-41 CDRH3-47 61G5 CDRH1-21 CDRH2-43 CDRH3-49 59G10.2 CDRH1-6 CDRH2-39 CDRH3-44 51A8 CDRH1-12 CDRH2-12 CDRH3-12 53H5.2 CDRH1-12 CDRH2-23 CDRH3-24 53F6 CDRH1-19 CDRH2-22 CDRH3-23 56C11 CDRH1-12 CDRH2-30 CDRH3-33 49A10 CDRH1-6 CDRH2-6 CDRH3-6 48D4 CDRH1-6 CDRH2-6 CDRH3-6 49G2 CDRH1-8 CDRH2-8 CDRH3-8 50C12 CDRH1-8 CDRH2-8 CDRH3-8 55G11 CDRH1-8 CDRH2-8 CDRH3-8 52C1 CDRH1-12 CDRH2-19 CDRH3-19 55E9 CDRH1-23 CDRH2-28 CDRH3-30 60D7 CDRH1-12 CDRH2-22 CDRH3-46 51C10.2 CDRH1-14 CDRH2-14 CDRH3-14 55D3 CDRH1-22 CDRH2-27 CDRH3-28 57B12 CDRH1-28 CDRH2-34 CDRH3-28 52C5 CDRH1-2 CDRH2-1 CDRH3-20 60G5.1 CDRH1-2 CDRH2-1 CDRH3-20 55E4 CDRH1-2 CDRH2-1 CDRH3-20 49B11 CDRH1-2 CDRH2-1 CDRH3-20 50H10 CDRH1-2 CDRH2-1 CDRH3-20 53C1 CDRH1-2 CDRH2-1 CDRH3-20 56G1 CDRH1-2 CDRH2-1 CDRH3-20 48F3 CDRH1-2 CDRH2-2 CDRH3-2 48C9 CDRH1-1 CDRH2-1 CDRH3-1 49A12 CDRH1-1 CDRH2-1 CDRH3-1 51E2 CDRH1-1 CDRH2-1 CDRH3-1 51E5 CDRH1-2 CDRH2-15 CDRH3-15 53H5.3 CDRH1-20 CDRH2-24 CDRH3-25 56G3.3 CDRH1-27 CDRH2-33 CDRH3-37 55B10 CDRH1-27 CDRH2-33 CDRH3-37 52B8 CDRH1-16 CDRH2-18 CDRH3-18 55G5 CDRH1-24 CDRH2-29 CDRH3-31 52H2 CDRH1-18 CDRH2-21 CDRH3-22 56G3.2 CDRH1-26 CDRH2-32 CDRH3-36 56E7 CDRH1-25 CDRH2-31 CDRH3-34 57D9 CDRH1-29 CDRH2-35 CDRH3-39 48G4 CDRH1-5 CDRH2-5 CDRH3-5 53C3.1 CDRH1-5 CDRH2-5 CDRH3-5 50G1 CDRH1-11 CDRH2-11 CDRH3-11 58C2 CDRH1-6 CDRH2-36 CDRH3-40 63H11 CDRH1-35 CDRH2-34 CDRH3-51 61H5 CDRH1-27 CDRH2-72 CDRH3-37 52B9 CDRH1-27 CDRH2-72 CDRH3-37 54H10.3 CDRH1-43 CDRH2-74 CDRH3-81 50G5 v1 CDRH1-37 CDRH2-73 CDRH3-35 50G5 v2 CDRH1-37 CDRH2-73 CDRH3-35 51C1 CDRH1-2 CDRH2-1 CDRH3-20 53C3.2 CDRH1-39 CDRH2-77 CDRH3-43 50D4 CDRH1-41 CDRH2-75 CDRH3-80 55A7 CDRH1-24 CDRH2-18 CDRH3-38 55E6 CDRH1-3 CDRH2-76 CDRH3-29 61E1 CDRH1-42 CDRH2-35 CDRH3-26

In an additional aspect, an antigen binding protein includes the following associations of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 presented for convenience in tablular form and in reference to the clone source of the association:

TABLE 6 CDRH and CDRL Associations Clone ID CDRL1 CDRL2 CDRL3 CDRH1 CDRH2 CDRH3 63G8 CDRL1-13 CDRL2-29 CDRL3-41 CDRH1-34 CDRH2-12 CDRH3-50 64A8 CDRL1-13 CDRL2-29 CDRL3-41 CDRH1-34 CDRH2-12 CDRH3-50 67B4 CDRL1-13 CDRL2-29 CDRL3-41 CDRH1-34 CDRH2-12 CDRH3-50 68D3 CDRL1-13 CDRL2-29 CDRL3-41 CDRH1-34 CDRH2-12 CDRH3-50 64E6 CDRL1-46 CDRL2-34 CDRL3-42 CDRH1-35 CDRH2-44 CDRH3-51 65E8 CDRL1-46 CDRL2-34 CDRL3-42 CDRH1-35 CDRH2-44 CDRH3-51 65F11 CDRL1-46 CDRL2-34 CDRL3-42 CDRH1-35 CDRH2-44 CDRH3-51 67G7 CDRL1-46 CDRL2-34 CDRL3-42 CDRH1-35 CDRH2-44 CDRH3-51 63B6 CDRL1-47 CDRL2-3 CDRL3-43 CDRH1-36 CDRH2-45 CDRH3-52 64D4 CDRL1-47 CDRL2-3 CDRL3-43 CDRH1-36 CDRH2-45 CDRH3-52 65C3 CDRL1-48 CDRL2-36 CDRL3-44 CDRH1-24 CDRH2-46 CDRH3-53 68D5 CDRL1-48 CDRL2-36 CDRL3-44 CDRH1-24 CDRH2-46 CDRH3-53 63E6 CDRL1-49 CDRL2-14 CDRL3-45 CDRH1-37 CDRH2-47 CDRH3-54 66F7 CDRL1-50 CDRL2-14 CDRL3-45 CDRH1-37 CDRH2-47 CDRH3-54 64H5 CDRL1-51 CDRL2-37 CDRL3-46 CDRH1-12 CDRH2-48 CDRH3-55 65G4 CDRL1-51 CDRL2-37 CDRL3-46 CDRH1-12 CDRH2-48 CDRH3-55 67G10v1 CDRL1-52 CDRL2-38 CDRL3-47 CDRH1-38 CDRH2-49 CDRH3-56 67G10v2 CDRL1-53 CDRL2-39 CDRL3-48 CDRH1-38 CDRH2-49 CDRH3-56 66B4 CDRL1-57 CDRL2-40 CDRL3-50 CDRH1-15 CDRH2-53 CDRH3-59 66G2 CDRL1-22 CDRL2-41 CDRL3-51 CDRH1-12 CDRH2-54 CDRH3-50 68G5 CDRL1-59 CDRL2-42 CDRL3-52 CDRH1-12 CDRH2-55 CDRH3-60 63F5 CDRL1-54 CDRL2-20 CDRL3-42 CDRH1-35 CDRH2-50 CDRH3-51 66F6 CDRL1-46 CDRL2-35 CDRL3-42 CDRH1-35 CDRH2-34 CDRH3-51 65C1 CDRL1-56 CDRL2-35 CDRL3-42 CDRH1-35 CDRH2-52 CDRH3-58 64A7 CDRL1-55 CDRL2-20 CDRL3-49 CDRH1-40 CDRH2-51 CDRH3-57 66D4 CDRL1-60 CDRL2-14 CDRL3-53 CDRH1-43 CDRH2-56 CDRH3-61 65B1 CDRL1-61 CDRL2-43 CDRL3-15 CDRH1-44 CDRH2-57 CDRH3-62 67A4 CDRL1-62 CDRL2-25 CDRL3-55 CDRH1-45 CDRH2-58 CDRH3-63 65B4 CDRL1-63 CDRL2-25 CDRL3-55 CDRH1-46 CDRH2-59 CDRH3-64 63A10 CDRL1-52 CDRL2-45 CDRL3-56 CDRH1-38 CDRH2-60 CDRH3-56 65H11 CDRL1-65 CDRL2-38 CDRL3-57 CDRH1-38 CDRH2-61 CDRH3-56 64C8 CDRL1-66 CDRL2-47 CDRL3-58 CDRH1-12 CDRH2-62 CDRH3-65 65E3 CDRL1-51 CDRL2-42 CDRL3-59 CDRH1-47 CDRH2-63 CDRH3-66 65D4 CDRL1-67 CDRL2-42 CDRL3-60 CDRH1-48 CDRH2-22 CDRH3-67 65D1 CDRL1-39 CDRL2-32 CDRL3-61 CDRH1-49 CDRH2-64 CDRH3-68 67G8 CDRL1-69 CDRL2-37 CDRL3-59 CDRH1-12 CDRH2-65 CDRH3-69 65B7 CDRL1-70 CDRL2-20 CDRL3-62 CDRH1-50 CDRH2-52 CDRH3-70 64A6 CDRL1-71 CDRL2-48 CDRL3-63 CDRH1-14 CDRH2-66 CDRH3-71 65F9 CDRL1-72 CDRL2-15 CDRL3-63 CDRH1-36 CDRH2-34 CDRH3-72 67F5 CDRL1-72 CDRL2-49 CDRL3-64 CDRH1-24 CDRH2-67 CDRH3-53 64B10 CDRL1-73 CDRL2-50 CDRL3-17 CDRH1-36 CDRH2-68 CDRH3-73 68C8 CDRL1-74 CDRL2-16 CDRL3-17 CDRH1-51 CDRH2-69 CDRH3-74 67A5 CDRL1-75 CDRL2-5 CDRL3-66 CDRH1-25 CDRH2-31 CDRH3-75 67C10 CDRL1-75 CDRL2-5 CDRL3-5 CDRH1-25 CDRH2-31 CDRH3-76 64H6 CDRL1-51 CDRL2-37 CDRL3-68 CDRH1-25 CDRH2-70 CDRH3-77 63F9 CDRL1-76 CDRL2-51 CDRL3-69 CDRH1-52 CDRH2-71 CDRH3-78 67F6 CDRL1-77 CDRL2-52 CDRL3-5 CDRH1-53 CDRH2-31 CDRH3-79 48H11 CDRL1-4 CDRL2-4 CDRL3-4 CDRH1-4 CDRH2-4 CDRH3-4 52A8 CDRL1-15 CDRL2-14 CDRL3-15 CDRH1-15 CDRH2-17 CDRH3-17 52F8 CDRL1-19 CDRL2-17 CDRL3-19 CDRH1-17 CDRH2-20 CDRH3-21 49H12 CDRL1-9 CDRL2-8 CDRL3-9 CDRH1-10 CDRH2-10 CDRH3-10 54A1 CDRL1-24 CDRL2-6 CDRL3-9 CDRH1-10 CDRH2-25 CDRH3-10 55G9 CDRL1-24 CDRL2-6 CDRL3-9 CDRH1-10 CDRH2-25 CDRH3-10 49C8 CDRL1-6 CDRL2-6 CDRL3-6 CDRH1-7 CDRH2-7 CDRH3-7 52H1 CDRL1-6 CDRL2-6 CDRL3-6 CDRH1-7 CDRH2-7 CDRH3-7 60G5.2 CDRL1-44 CDRL2-32 CDRL3-40 CDRH1-33 CDRH2-42 CDRH3-48 49G3 CDRL1-8 CDRL2-7 CDRL3-8 CDRH1-9 CDRH2-9 CDRH3-9 59A10 CDRL1-14 CDRL2-28 CDRL3-14 CDRH1-30 CDRH2-37 CDRH3-41 49H4 CDRL1-14 CDRL2-28 CDRL3-14 CDRH1-30 CDRH2-37 CDRH3-41 48F8 CDRL1-3 CDRL2-3 CDRL3-3 CDRH1-3 CDRH2-3 CDRH3-3 53B9 CDRL1-3 CDRL2-3 CDRL3-3 CDRH1-3 CDRH2-3 CDRH3-3 56B4 CDRL1-3 CDRL2-3 CDRL3-3 CDRH1-3 CDRH2-3 CDRH3-3 57E7 CDRL1-3 CDRL2-3 CDRL3-3 CDRH1-3 CDRH2-3 CDRH3-3 57F11 CDRL1-3 CDRL2-3 CDRL3-3 CDRH1-3 CDRH2-3 CDRH3-3 59C9 CDRL1-37 CDRL2-29 CDRL3-14 CDRH1-31 CDRH2-38 CDRH3-42 58A5 CDRL1-37 CDRL2-29 CDRL3-14 CDRH1-31 CDRH2-38 CDRH3-42 57A4 CDRL1-37 CDRL2-29 CDRL3-14 CDRH1-31 CDRH2-38 CDRH3-42 57F9 CDRL1-37 CDRL2-29 CDRL3-14 CDRH1-31 CDRH2-38 CDRH3-42 51G2 CDRL1-14 CDRL2-13 CDRL3-14 CDRH1-3 CDRH2-16 CDRH3-16 56A7 CDRL1-29 CDRL2-24 CDRL3-14 CDRH1-3 CDRH2-16 CDRH3-32 56E4 CDRL1-29 CDRL2-24 CDRL3-14 CDRH1-3 CDRH2-16 CDRH3-32 54H10.1 CDRL1-25 CDRL2-20 CDRL3-24 CDRH1-21 CDRH2-26 CDRH3-27 55D1 CDRL1-25 CDRL2-20 CDRL3-24 CDRH1-21 CDRH2-26 CDRH3-27 48H3 CDRL1-25 CDRL2-20 CDRL3-24 CDRH1-21 CDRH2-26 CDRH3-27 53C11 CDRL1-25 CDRL2-20 CDRL3-24 CDRH1-21 CDRH2-26 CDRH3-27 59G10.3 CDRL1-41 CDRL2-16 CDRL3-37 CDRH1-32 CDRH2-40 CDRH3-45 51C10.1 CDRL1-12 CDRL2-10 CDRL3-11 CDRH1-13 CDRH2-13 CDRH3-13 59D10 CDRL1-38 CDRL2-10 CDRL3-34 CDRH1-13 CDRH2-13 CDRH3-13 v1 59D10 CDRL1-39 CDRL2-30 CDRL3-35 CDRH1-13 CDRH2-13 CDRH3-13 v2 60F9 CDRL1-43 CDRL2-31 CDRL3-39 CDRH1-21 CDRH2-41 CDRH3-47 48B4 CDRL1-43 CDRL2-31 CDRL3-39 CDRH1-21 CDRH2-41 CDRH3-47 52D6 CDRL1-43 CDRL2-31 CDRL3-39 CDRH1-21 CDRH2-41 CDRH3-47 61G5 CDRL1-45 CDRL2-33 CDRL3-39 CDRH1-21 CDRH2-43 CDRH3-49 59G10.2 CDRL1-40 CDRL2-11 CDRL3-36 CDRH1-6 CDRH2-39 CDRH3-44 51A8 CDRL1-10 CDRL2-9 CDRL3-10 CDRH1-12 CDRH2-12 CDRH3-12 53H5.2 CDRL1-22 CDRL2-14 CDRL3-22 CDRH1-12 CDRH2-23 CDRH3-24 53F6 CDRL1-21 CDRL2-19 CDRL3-21 CDRH1-19 CDRH2-22 CDRH3-23 56C11 CDRL1-30 CDRL2-25 CDRL3-28 CDRH1-12 CDRH2-30 CDRH3-33 49A10 CDRL1-5 CDRL2-5 CDRL3-5 CDRH1-6 CDRH2-6 CDRH3-6 48D4 CDRL1-5 CDRL2-5 CDRL3-5 CDRH1-6 CDRH2-6 CDRH3-6 49G2 CDRL1-7 CDRL2-5 CDRL3-7 CDRH1-8 CDRH2-8 CDRH3-8 50C12 CDRL1-7 CDRL2-5 CDRL3-7 CDRH1-8 CDRH2-8 CDRH3-8 55G11 CDRL1-7 CDRL2-5 CDRL3-7 CDRH1-8 CDRH2-8 CDRH3-8 52C1 CDRL1-17 CDRL2-16 CDRL3-17 CDRH1-12 CDRH2-19 CDRH3-19 55E9 CDRL1-27 CDRL2-17 CDRL3-26 CDRH1-23 CDRH2-28 CDRH3-30 60D7 CDRL1-1 CDRL2-5 CDRL3-38 CDRH1-12 CDRH2-22 CDRH3-46 51C10.2 CDRL1-12 CDRL2-11 CDRL3-12 CDRH1-14 CDRH2-14 CDRH3-14 55D3 CDRL1-26 CDRL2-14 CDRL3-25 CDRH1-22 CDRH2-27 CDRH3-28 57B12 CDRL1-34 CDRL2-14 CDRL3-32 CDRH1-28 CDRH2-34 CDRH3-28 52C5 CDRL1-18 CDRL2-14 CDRL3-18 CDRH1-2 CDRH2-1 CDRH3-20 60G5.1 CDRL1-18 CDRL2-14 CDRL3-18 CDRH1-2 CDRH2-1 CDRH3-20 55E4 CDRL1-18 CDRL2-21 CDRL3-18 CDRH1-2 CDRH2-1 CDRH3-20 49B11 CDRL1-18 CDRL2-21 CDRL3-18 CDRH1-2 CDRH2-1 CDRH3-20 50H10 CDRL1-18 CDRL2-21 CDRL3-18 CDRH1-2 CDRH2-1 CDRH3-20 53C1 CDRL1-18 CDRL2-21 CDRL3-18 CDRH1-2 CDRH2-1 CDRH3-20 56G1 CDRL1-18 CDRL2-14 CDRL3-30 CDRH1-2 CDRH2-1 CDRH3-20 48F3 CDRL1-2 CDRL2-2 CDRL3-2 CDRH1-2 CDRH2-2 CDRH3-2 48C9 CDRL1-1 CDRL2-1 CDRL3-1 CDRH1-1 CDRH2-1 CDRH3-1 49A12 CDRL1-1 CDRL2-1 CDRL3-1 CDRH1-1 CDRH2-1 CDRH3-1 51E2 CDRL1-1 CDRL2-1 CDRL3-1 CDRH1-1 CDRH2-1 CDRH3-1 51E5 CDRL1-13 CDRL2-12 CDRL3-13 CDRH1-2 CDRH2-15 CDRH3-15 53H5.3 CDRL1-23 CDRL2-15 CDRL3-23 CDRH1-20 CDRH2-24 CDRH3-25 56G3.3 CDRL1-33 CDRL2-27 CDRL3-31 CDRH1-27 CDRH2-33 CDRH3-37 55B10 CDRL1-33 CDRL2-27 CDRL3-31 CDRH1-27 CDRH2-33 CDRH3-37 52B8 CDRL1-16 CDRL2-15 CDRL3-16 CDRH1-16 CDRH2-18 CDRH3-18 55G5 CDRL1-28 CDRL2-23 CDRL3-27 CDRH1-24 CDRH2-29 CDRH3-31 52H2 CDRL1-20 CDRL2-18 CDRL3-20 CDRH1-18 CDRH2-21 CDRH3-22 56G3.2 CDRL1-32 CDRL2-26 CDRL3-16 CDRH1-26 CDRH2-32 CDRH3-36 56E7 CDRL1-31 CDRL2-7 CDRL3-29 CDRH1-25 CDRH2-31 CDRH3-34 57D9 CDRL1-35 CDRL2-20 CDRL3-33 CDRH1-29 CDRH2-35 CDRH3-39 61H5 CDRL1-33 CDRL2-20 CDRL3-31 CDRH1-27 CDRH2-72 CDRH3-37 52B9 CDRL1-33 CDRL2-20 CDRL3-31 CDRH1-27 CDRH2-72 CDRH3-37 48G4 CDRL1-79 CDRL2-35 CDRL3-71 CDRH1-5 CDRH2-5 CDRH3-5 53C3.1 CDRL1-79 CDRL2-35 CDRL3-71 CDRH1-5 CDRH2-5 CDRH3-5 50G1 CDRL1-7 CDRL2-5 CDRL3-38 CDRH1-11 CDRH2-11 CDRH3-11 58C2 CDRL1-81 CDRL2-5 CDRL3-66 CDRH1-6 CDRH2-36 CDRH3-40 54H10.3 CDRL1-42 CDRL2-46 CDRL3-53 CDRH1-43 CDRH2-74 CDRH3-81 50G5 v1 CDRL1-22 CDRL2-14 CDRL3-72 CDRH1-37 CDRH2-73 CDRH3-35 50G5 v2 CDRL1-78 CDRL2-22 CDRL3-75 CDRH1-37 CDRH2-73 CDRH3-35 51C1 CDRL1-18 CDRL2-14 CDRL3-18 CDRH1-2 CDRH2-1 CDRH3-20 53C3.2 CDRL1-36 CDRL2-44 CDRL3-70 CDRH1-39 CDRH2-77 CDRH3-43 50D4 CDRL1-26 CDRL2-53 CDRL3-74 CDRH1-41 CDRH2-75 CDRH3-80 55A7 CDRL1-58 CDRL2-14 CDRL3-54 CDRH1-24 CDRH2-18 CDRH3-38 55E6 CDRL1-64 CDRL2-20 CDRL3-65 CDRH1-3 CDRH2-76 CDRH3-29 61E1 CDRL1-68 CDRL2-14 CDRL3-67 CDRH1-42 CDRH2-35 CDRH3-26 63H11 CDRL1-46 CDRL2-34 CDRL3-42 CDRH1-35 CDRH2-34 CDRH3-51

Consensus Sequences

In yet another aspect, the CDRs disclosed herein include consensus sequences derived from groups of related monoclonal antibodies. As described herein, a “consensus sequence” refers to amino acid sequences having conserved amino acids common among a number of sequences and variable amino acids that vary within a given amino acid sequences. The CDR consensus sequences provided include CDRs corresponding to each of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3.

Consensus sequences were determined using standard analyses of the CDRs corresponding to the V_(H) and V_(L) of the disclosed antigen binding proteins shown in Tables 3A and 3B, some of which specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. The consensus sequences can be determined by keeping the CDRs contiguous within the same sequence corresponding to a V_(H) or V_(L).

Light Chain CDR3 Group 1 QQFGSSLT (SEQ ID NO: 1439) Group 2 QQS Y S T S LT (SEQ ID NO: 1440) QQS Y S S P LT (SEQ ID NO: 1441) QQS F S T P LT (SEQ ID NO: 1442) QQS X ₁ S X ₂ X ₃ LT (SEQ ID NO: 1443) wherein X₁ is Y or F; X₂ is T or S; and X₃ is P or S. Group 3 LQ R N SYP L T (SEQ ID NO: 1444) LQ H N SYP R T (SEQ ID NO: 1445) LQ H S SYP L T (SEQ ID NO: 1446) LQ X ₄ X ₅ SYP X ₆ T (SEQ ID NO: 1447) wherein X₄ is H or R; X₅ is N or S; and X₆ is L or R. Group 4 MQR I EFP L T (SEQ ID NO: 1448) MQR I EFP I T (SEQ ID NO: 1449) MQR L EFP I T (SEQ ID NO: 1450) MQR X ₇ EFP X ₈ T (SEQ ID NO: 1451) wherein X₇ is I or L; and X₈ us I or L. Group 5 Q V WDS N P VV (SEQ ID NO: 1452) Q L WDS S T VV (SEQ ID NO: 1453) Q V WDS S S VV (SEQ ID NO: 1454) Q V WDS S P VV (SEQ ID NO: 1455) Q V WDS S T VV (SEQ ID NO: 1456) Q X ₉ WDS X ₁₀ X ₁₁ VV (SEQ ID NO: 1457) wherein X₉ is V or L; X₁₀ is S or N; and X₁₁ is T, P or S. Group 6 QQYN N WP L T (SEQ ID NO: 1458) QQYN N WP W T (SEQ ID NO: 1459) QQYN T WP W T (SEQ ID NO: 1460) QQYN X ₁₂ WP X ₁₃ T (SEQ ID NO: 1461) wherein X₁₂ is N or T; and X₁₃ is W or L. Group 7 QVWDSS S D H V V (SEQ ID NO: 1462) QVWDSS S D V V (SEQ ID NO: 1463) QVWDSS C D G V (SEQ ID NO: 1464) QVWDSS S D G V (SEQ ID NO: 1465) QVWDSS X ₁₄ D X ₁₅ V X ₁₆ (SEQ ID NO: 1466) wherein X₁₄ is S or C; X₁₅ is H, V or G; and X₁₆ is V or absent. Group 8 QQSS S IPWT (SEQ ID NO: 1467) QQSS T IPWT (SEQ ID NO: 1468) QQSS X ₁₇ IPWT (SEQ ID NO: 1469) wherein X₁₇ is S or T. Group 9 QQTNSFPPWT (SEQ ID NO: 1470) Group 10 GTWDSSLS A V V (SEQ ID NO: 1471) GTWDSSLS V V V (SEQ ID NO: 1472) GTWDSSLS A M V (SEQ ID NO: 1473) GTWDSSLS X ₁₈ X ₁₉ V (SEQ ID NO: 1474) wherein X₁₈ is A or V; and X₁₉ is V or M. Group 11 QQYDNLP L T (SEQ ID NO: 1475) QQYDNLP F T (SEQ ID NO: 1476) QQYDNLP X ₂₀ T (SEQ ID NO: 1477) wherein X₂₀ is L or F. Group 12 QQYGSS P PWT (SEQ ID NO: 1478) QQYGSS PWT (SEQ ID NO: 1479) QQYGSS X ₂₁ PWT (SEQ ID NO: 1480) wherein X₂₁ is P or absent. Group 13 QQYG R S L FT (SEQ ID NO: 1481) QQYG T S P FT (SEQ ID NO: 1482) QQYG X ₂₂ S X ₂₃ FT (SEQ ID NO: 1483) wherein X₂₂ is R or T; and X₂₃ is L or P. Group 14 QQYGSS R S (SEQ ID NO: 1484) QQYGSS P R S (SEQ ID NO: 1485) QQYGSS R T (SEQ ID NO: 1486) QQYGSS C S (SEQ ID NO: 1487) QQYGSS X ₂₄ X ₂₅ X ₂₆ (SEQ ID NO: 1488) wherein X₂₄ is P or absent; X₂₅ is R or C and X₂₆ is S or T. Group 15 QADWSS T T W V (SEQ ID NO: 1489) QADWSS T A V (SEQ ID NO: 1490) QADWSS T W V (SEQ ID NO: 1491) QAWDSS X ₂₇ T X ₂₈ V (SEQ ID NO: 1492) wherein X₂₇ is T or absent; and X₂₈ is W or A. Group 16 QADWS G TV V (SEQ ID NO: 1493) QADWS T TV V (SEQ ID NO: 1494) QAWDS A TV I (SEQ ID NO: 1495) QAWDS X ₂₉ TV X ₃₀ (SEQ ID NO: 1496) wherein X₂₉ is G, T, A or absent; and X₃₀ is V or I. Group 17 QQ S YSA T FT (SEQ ID NO: 1497) QQ T YSA P FT (SEQ ID NO: 1498) QQ X ₃₁ YSA X ₃₂ FT (SEQ ID NO: 1499) wherein X₃₁ is S or T; and X₃₂ is T or P. Group 18 QQYN I YPRT (SEQ ID NO: 1500) QQYN T YPRT (SEQ ID NO: 1501) QQYN X ₃₃ YPRT (SEQ ID NO: 1502) wherein X₃₃ is I or T. Group 19 HQ S S DLPLT (SEQ ID NO: 1503) HQ Y D DLPLT (SEQ ID NO: 1504) HQ X ₃₄ X ₃₅ DLPLT (SEQ ID NO: 1505) wherein X₃₄ is S or Y; and X₃₅ is S or D. Group 20 MQALQT P F T (SEQ ID NO: 1506) MQALQT L I T (SEQ ID NO: 1507) MQALQT X ₃₆ X ₃₇ T (SEQ ID NO: 1508) wherein X₃₆ is P or L; and X₃₇ is F or I. Group 21 QQFGRSFT (SEQ ID NO: 1509) Group 22 YSTDSS V NHVV (SEQ ID NO: 1510) YSTDSS G NHVV (SEQ ID NO: 1511) YSTDSS X ₃₈ NHVV (SEQ ID NO: 1512) wherein X₃₈ is V or G.

Light Chain CDR2 Group 1 A ASSL Q S (SEQ ID NO: 1513) S ASSL Q S (SEQ ID NO: 1514) A ASSL Q F (SEQ ID NO: 1515) A ASSL K S (SEQ ID NO: 1516) X ₃₉ ASSL X ₄₀ X ₄₁ (SEQ ID NO: 1517) wherein X₃₉ is A or S; X₄₀ is Q or K; and X₄₁ is S or F. Group 2 G A S S R A T (SEQ ID NO: 1518) G A S S R D T (SEQ ID NO: 1519) G T S T R A T (SEQ ID NO: 1520) G A S T R A T (SEQ ID NO: 1521) G A S A R A T (SEQ ID NO: 1522) G A S R R A T (SEQ ID NO: 1523) G A S N R A T (SEQ ID NO: 1524) G X ₄₂ S X ₄₃ R X ₄₄ T (SEQ ID NO: 1525) wherein X₄₂ is A or T; X₄₃ is S, T, A, R or N; and X₄₄ is A or D. Group 3 GAFSRA S (SEQ ID NO: 1526) GAFSRA T (SEQ ID NO: 1527) GAFSRA X ₄₅ (SEQ ID NO: 1528) wherein X₄₅ is S or T. Group 4 Q D T KRPS (SEQ ID NO: 1529) R D S KRPS (SEQ ID NO: 1530) E D S KRPS (SEQ ID NO: 1531) Q D S KRPS (SEQ ID NO: 1532) X ₄₆ D X ₄₇ KRPS (SEQ ID NO: 1533) wherein X₄₆ is Q, R or E; and X₄₇ is T or S. Group 5 TLS Y RAS (SEQ ID NO: 1534) TLS F RAS (SEQ ID NO: 1535) TLS X ₄₈ RAS (SEQ ID NO: 1536) wherein X₄₈ is Y or F. Group 6 AASNLQ R (SEQ ID NO: 1537) AASNLQ S (SEQ ID NO: 1538) AASNLQ X ₄₉ (SEQ ID NO: 1539) wherein X49 is R or S. Group 7 G A SNRA I (SEQ ID NO: 1540) G S SNRA I (SEQ ID NO: 1541) G S SNRA T (SEQ ID NO: 1542) G X ₅₀ SNRA X ₅₁ (SEQ ID NO: 1543) wherein X₅₀ is A or S; and X₅₁ is I or T. Group 8 D A S S LQS (SEQ ID NO: 1544) D A S T LQS (SEQ ID NO: 1545) G A S S LQS (SEQ ID NO: 1546) G A S N LQS (SEQ ID NO: 1547) X ₅₂ A S X ₅₃ LQS (SEQ ID NO: 1548) wherein X₅₂ is D or G; and X₅₃ is S, T or N. Group 9 DN N KRPS (SEQ ID NO: 1549) DN D KRPS (SEQ ID NO: 1550) DN X ₅₃ KRPS (SEQ ID NO: 1551) wherein X₅₃ is N or D. Group 10 D A SNLET (SEQ ID NO: 1552) D V SNLET (SEQ ID NO: 1553) D X ₅₄ SNLET (SEQ ID NO: 1554) wherein X₅₄ is A or V. Group 11 L G SNRAS (SEQ ID NO: 1555) L D SNRAS (SEQ ID NO: 1556) L X ₅₅ SNRAS (SEQ ID NO: 1557) wherein X₅₅ is G or D. Group 12 Q D N K RPS (SEQ ID NO: 1558) Q N N K RPS (SEQ ID NO: 1559) Q D N E RPS (SEQ ID NO: 1560) Q X ₅₆ N X ₅₇ RPS (SEQ ID NO: 1561) wherein X₅₆ is D or N; and X₅₇ is K or E. Group 13 RDRNRPS (SEQ ID NO: 1562) Group 14 S DSNRPS (SEQ ID NO: 1563) C DSNRPS (SEQ ID NO: 1564) X ₅₈ DSNRPS (SEQ ID NO: 1565) wherein X₅₈ is S or C. Group 15 DDSDRPS (SEQ ID NO: 1566) Group 16 A V SSLQS (SEQ ID NO: 1567) A S SSLQS (SEQ ID NO: 1568) A X ₅₉ SSLQS (SEQ ID NO: 1569) wherein X₅₉ is S or V. Group 17 T A SSLQS (SEQ ID NO: 1570) T T SSLQS (SEQ ID NO: 1571) T X ₆₀ SSLQS (SEQ ID NO: 1572) wherein X₆₀ is A or T. Group 18 K V SNWDS (SEQ ID NO: 1573) K G SNWDS (SEQ ID NO: 1574) K X ₆₁ SNWDS (SEQ ID NO: 1575) wherein X₆₁ is V or G.

Light Chain CDR1 Group 1 RAS Q S V S D I L A (SEQ ID NO: 1576) RAS P 5 V S S S Y L A (SEQ ID NO: 1577) RAS Q S F S S S Y L A (SEQ ID NO: 1578) RAS Q S V S R S H L A (SEQ ID NO: 1579) RAS Q S V S R D Y L A (SEQ ID NO: 1580) RAS Q S V S R N Y L A (SEQ ID NO: 1581) RAS Q S V S S M Y L A (SEQ ID NO: 1582) RAS Q S V S S Q L A (SEQ ID NO: 1583) RAS Q S I S S N L A (SEQ ID NO: 1584) RAS Q S V S S N L A (SEQ ID NO: 1585) RAS Q S V S S N V A (SEQ ID NO: 1586) RAS Q S V N S N L A (SEQ ID NO: 1587) RAS Q S V R S S S L A (SEQ ID NO: 1588) RAS Q S V S N S S L A (SEQ ID NO: 1589) RAS Q S V R N S S L A (SEQ ID NO: 1590) RAS X ₆₂ S X ₆₃ X ₆₄ X ₆₅ X ₆₆ X ₆₇ X ₆₈ A (SEQ ID NO: 1591) wherein X₆₂ is P or Q; X₆₃ is V, I or F; X₆₄ is S, R or absent; X₆₅ is S, R or N; X₆₆ is D, S, N or M; X₆₇ is I, Y, H, Q, N or S; and X₆₈ is L or V. Group 2 R A SQ I I S R YLN (SEQ ID NO: 1592) R T SQ S I S S YLN (SEQ ID NO: 1593) R A SQ S I S N YLN (SEQ ID NO: 1594) R T SQ S I S S YLN (SEQ ID NO: 1595) R A SQ T I S I YLN (SEQ ID NO: 1596) R A SQ R I S S YLN (SEQ ID NO: 1597) R A SQ S I S S YLN (SEQ ID NO: 1598) R A SQ N I R T YLN (SEQ ID NO: 1599) R A SQ N I R S YLN (SEQ ID NO: 1600) R A SQ N I N N YLN (SEQ ID NO: 1601) R X ₆₉ SQ X ₇₀ I X ₇₁ X ₇₂ YLN (SEQ ID NO: 1602) wherein X₆₉ is A or T; X₇₀ is I, S, T or N; X₇₁ is R, S or N; and X₇₂ is R, S, N, or I. Group 3 GGN N IGS Y N V H (SEQ ID NO: 1603) GGN N IGS I N V H (SEQ ID NO: 1604) GGN N IGS K S V Q (SEQ ID NO: 1605) GGN D IGS K S V H (SEQ ID NO: 1606) GGN N IGS K S V H (SEQ ID NO: 1607) GGN N IGS K T V H (SEQ ID NO: 1608) GGN N IGS K A V H (SEQ ID NO: 1609) GGN N IGS K N V H (SEQ ID NO: 1610) GGN D IGS K N V H (SEQ ID NO: 1611) GGN X ₇₃ IGS X ₇₄ X ₇₅ V X ₇₆ (SEQ ID NO: 1612) wherein X₇₃ is N, or D; X₇₄ is Y, I or K; X₇₅ is N, S, T or A; and X₇₆ is H or Q. Group 4 RASQ D IRNDL G (SEQ ID NO: 1613) RASQ D IRNDL A (SEQ ID NO: 1614) RASQ G IRNDL G (SEQ ID NO: 1615) RASQ X ₇₇ IRNDL X ₇₈ (SEQ ID NO: 1616) wherein X₇₇ is D or G; and X₇₈ is G or A. Group 5 RSSQSL L N S D A G T TYLD (SEQ ID NO: 1617) RSSQSL F D N D D G D TYLD (SEQ ID NO: 1618) RSSQSL L N S D D G N TYLD (SEQ ID NO: 1619) RSSQSL L D S D D G D TYLD (SEQ ID NO: 1620) RSSQSL L D S D D G N TYLD (SEQ ID NO: 1621) RSSQSL X ₇₉ X ₈₀ X ₈₁ D X ₈₂ G X ₈₃ TYLD (SEQ ID NO: 1622) wherein X₇₉ is L or F; X₈₀ is N or D; X₈₁ is S or N; X₈₂ is A or D; and X₈₃ is T, D or N. Group 6 SG N K LGDKY V C (SEQ ID NO: 1623) SG D K LGDKY V C (SEQ ID NO: 1624) SG D K LGDKY A C (SEQ ID NO: 1625) SG D E LGDKY A C (SEQ ID NO: 1626) SG D N LGDKY A F (SEQ ID NO: 1627) SG D N LGDKY A C (SEQ ID NO: 1628) SG X ₈₄ X ₈₅ LGDKY X ₈₆ X ₈₇ (SEQ ID NO: 1629) wherein X₈₄ is N or D; X₈₅ is K, E or N; X₈₆ is V or A; and X₈₇ is C or F. Group 7 QASQ G I S N Y LN (SEQ ID NO: 1630) QASQ D I K K F LN (SEQ ID NO: 1631) QASQ D I N I Y LN (SEQ ID NO: 1632) QASQ D I S I Y LN (SEQ ID NO: 1633) QASQ D I T K Y LN (SEQ ID NO: 1634) QASQ X ₈₈ I X ₈₉ X ₉₀ X ₉₁ LN (SEQ ID NO: 1635) wherein X₈₈ is G or D; X₈₉ is S, K N or T; X₉₀ is N, K or I; and X₉₁ is Y or F. Group 8 RASQ D I D S WL V (SEQ ID NO: 1636) RASQ G I S R WL A (SEQ ID NO: 1637) RASQ D I S S WL A (SEQ ID NO: 1638) RASQ G I S S WL A (SEQ ID NO: 1639) RASQ X ₉₂ I X ₉₃ X ₉₄ WL X ₉₅ (SEQ ID NO: 1640) wherein X₉₂ is D or G; X₉₃ is D or S; X₉₄ is R or S; and X₉₅ is V or A. Group 9 SGSSSNIG N NYV A (SEQ ID NO: 1641) SGSSSNIG I NYV S (SEQ ID NO: 1642) SGSSSNIG D NYV S (SEQ ID NO: 1643) SGSSSNIG N NYV S (SEQ ID NO: 1644) SGSSSNIG X ₉₆ NYV X ₉₇ (SEQ ID NO: 1645) wherein X₉₆ is N, I or D; and X₉₇ is A or S. Group 10 RAS Q DISNYLA (SEQ ID NO: 1646) RAS H DISNYLA (SEQ ID NO: 1647) RAS X ₉₈ DISNYLA (SEQ ID NO: 1648) wherein X₉₈ is Q or H. Group 11 RASQ R V P SSY I V (SEQ ID NO: 1649) RASQ R V P SSY L V (SEQ ID NO: 1650) RASQ S V A SSY L V (SEQ ID NO: 1651) RASQ X ₉₉ V X ₁₀₀ SSY X ₁₀₁ V (SEQ ID NO: 1652) wherein X₉₉ is R or S; X₁₀₀ is P or A; and X₁₀₁ is I or L. Group 12 RSSQSL L HSNG Y NYLD (SEQ ID NO: 1653) RSSQSL L HSNG F NYLD (SEQ ID NO: 1654) RSSQSL Q HSNG Y NYLD (SEQ ID NO: 1655) RSSQSL X ₁₀₂ HSNG X ₁₀₃ NYLD (SEQ ID NO: 1656) wherein X₁₀₂ is L or Q; and X₁₀₃ is Y or F. Group 13 RASQT V RN N YLA (SEQ ID NO: 1657) RASQT I RN S YLA (SEQ ID NO: 1658) RASQT X ₁₀₄ RN X ₁₀₅ YLA (SEQ ID NO: 1659) wherein X₁₀₄ is V or I; and X₁₀₅ is N or S. Group 14 RSS Q R LVYSDGNTYLN (SEQ ID NO: 1660) RSS P S LVYSDGNTYLN (SEQ ID NO: 1661) RSS X ₁₀₆ X ₁₀₇ LVYSDGNTYLN (SEQ ID NO: 1662) wherein X₁₀₆ is Q or P; and X₁₀₇ is R or S. Group 15 SGDA L PKKYA Y (SEQ ID NO: 1663) SGDA V PKKYA N (SEQ ID NO: 1664) SGDA X ₁₀₈ PKKYA X ₁₀₉ (SEQ ID NO: 1665) wherein X₁₀₈ is L or V; and X₁₀₉ is Y or N.

Heavy Chain CDR3 Group 1 MT T PYWYF D L (SEQ ID NO: 1666) MT S PYWYF D L (SEQ ID NO: 1667) MT T PYWYF G L (SEQ ID NO: 1668) MT X ₁₁₀ PYWYF X ₁₁₁ L (SEQ ID NO: 1669) wherein X₁₁₀ is T or S; and X₁₁₁ is D or G. Group 2 D R Y Y DFW S GYP Y F R YYG L DV (SEQ ID NO: 1670) D Q Y F DFW S GYP F F Y YYG M DV (SEQ ID NO: 1671) D Q D Y DFW S GYP Y F Y YYG M DV (SEQ ID NO: 1672) D Q N Y DFW N GYP Y Y F YYG M DV (SEQ ID NO: 1673) D Q Y Y DFW S GYP Y Y H YYG M DV (SEQ ID NO: 1674) D X ₁₁₂ X ₁₁₃ X ₁₁₄ DFW X ₁₁₅ GYP X ₁₁₆ X ₁₁₇ X ₁₁₈ YYG X ₁₁₉ DV (SEQ ID NO: 1675) wherein X₁₁₂ is R or Q; X₁₁₃ is Y, D or N; X₁₁₄ is Y or F; X₁₁₅ is S or N; X₁₁₆ is Y or F; X₁₁₇ is F or Y; X₁₁₈ is R, Y, F or H; and X₁₁₉ is L or M. Group 3 VTGTDAFDF (SEQ ID NO: 1676) Group 4 TVTKEDYYYYGMDV (SEQ ID NO: 1677) Group 5 DSSGSYYVEDYFDY (SEQ ID NO: 1678) Group 6 D W S IAVAG T FDY (SEQ ID NO: 1679) D L R IAVAG S FDY (SEQ ID NO: 1680) D X ₁₁₉ X ₁₂₀ IAVAG X ₁₂₁ FDY (SEQ ID NO: 1681) wherein X₁₁₉ is W or L; X₁₂₀ is S or R; and X₁₂₁ is T or S. Group 7 EYYYGSGSYYP (SEQ ID NO: 1682) Group 8 ELGDYPFFDY (SEQ ID NO: 1683) Group 9 EYVAEAGFDY (SEQ ID NO: 1684) Group 10 VAAVYWYFDL (SEQ ID NO: 1685) Group 11 YNWNYGAFDF (SEQ ID NO: 1686) Group 12 RASRGYR F GLAFAI (SEQ ID NO: 1687) RASRGYR Y GLAFAI (SEQ ID NO: 1688) RASRGYR X ₁₂₂ GLAFAI (SEQ ID NO: 1689) wherein X₁₂₂ is F or Y. Group 13 DGITMVRGVTHYYGMDV (SEQ ID NO: 1690) Group 14 DH S SGWYYYGMDV (SEQ ID NO: 1691) DH T SCWYYYGMDV (SEQ ID NO: 1692) DH X ₁₂₃ SCWYYYGMDV (SEQ ID NO: 1693) wherein X₁₂₃ is S or T. Group 15 Y S T WDYYYG V DV (SEQ ID NO: 1694) Y R D WDYYYG M DV (SEQ ID NO: 1695) Y X ₁₂₄ X ₁₂₅ WDYYYG X ₁₂₆ DV (SEQ ID NO: 1696) wherein X₁₂₄ is S or R; X₁₂₅ is T or D; and X₁₂₆ is V or M. Group 16 VLHY S DS R GYSYY S D F (SEQ ID NO: 1697) VLHY Y DS S GYSYY F D Y (SEQ ID NO: 1698) VLHY X ₁₂₇ DS X ₁₂₈ GYSYY X ₁₂₉ D X ₁₃₀ (SEQ ID NO: 1699) wherein X₁₂₇ is S or Y; X₁₂₈ is R or S; X₁₂₉ is S or F; and X₁₃₀ is F or Y.

Heavy Chain CDR2 Group 1 N I Y Y S G T T Y F NPSLKS (SEQ ID NO: 1700) F I Y Y S G G T N Y NPSLKS (SEQ ID NO: 1701) Y I Y Y S G G T H Y NPSLKS (SEQ ID NO: 1702) Y I Y H S G S A Y Y NPSLKS (SEQ ID NO: 1703) Y I Y D S G S T Y Y NPSLKS (SEQ ID NO: 1704) S I Y Y S G T T Y Y NPSLKS (SEQ ID NO: 1705) M I Y Y S G T T Y Y NPSLKS (SEQ ID NO: 1706) Y I Y Y S G T T Y Y NPSLKS (SEQ ID NO: 1707) Y I Y Y S G S A Y Y NPSLKS (SEQ ID NO: 1708) Y I F Y S G S T Y Y NPSLKS (SEQ ID NO: 1709) Y L Y Y S G S T Y Y NPSLKS (SEQ ID NO: 1710) Y I Y Y S G S T Y Y NPSLKS (SEQ ID NO: 1711) Y I Y Y T G S T Y Y NPSLKS (SEQ ID NO: 1712) Y I Y Y T G S T N Y NPSLKS (SEQ ID NO: 1713) Y I Y Y S G N T N Y NPSLKS (SEQ ID NO: 1714) Y I Y Y S G S T N Y NPSLKS (SEQ ID NO: 1715) X ₁₃₁ X ₁₃₂ X ₁₃₃ X ₁₃₄ X ₁₃₅ G X ₁₃₆ X ₁₃₇ X ₁₃₈ X ₁₃₉ NPSLKS (SEQ ID NO: 1716) wherein X₁₃₁ is N, F, Y, S or M; X₁₃₂ is I or L; X₁₃₃ is Y or F; X₁₃₄ is Y, H or D; X₁₃₅ is S or T; X₁₃₆ is T, G, S or T; X₁₃₇ is T or A; X₁₃₈ is Y, N or H; and X₁₃₉ is F or Y. Group 2 L I W Y DG D N K Y Y ADSVKG (SEQ ID NO: 1717) G I S Y DG S N K N Y ADSVKG (SEQ ID NO: 1718) I I W Y DG S N K N Y ADSVKG (SEQ ID NO: 1719) L I W Y DG S N K N Y ADSVKG (SEQ ID NO: 1720) L I W Y DG S N K D Y ADSVKG (SEQ ID NO: 1721) V I W Y DG S N K D Y ADSVKG (SEQ ID NO: 1722) L I S Y DG S N K Y Y ADSVKG (SEQ ID NO: 1723) V I S Y DG S N K H Y ADSVKG (SEQ ID NO: 1724) V I S Y DG S N K Y Y ADSVKG (SEQ ID NO: 1725) V I W D DG S N K Y Y ADSVKG (SEQ ID NO: 1726) V I W D DG S N N Y Y ADSVKG (SEQ ID NO: 1727) V I W Y DG S N K Y H ADSVKG (SEQ ID NO: 1728) V I W Y DG S N K Y Y ADSVKG (SEQ ID NO: 1729) V I W N DG N N K Y Y ADSVKG (SEQ ID NO: 1730) V I W N DG S N K N Y ADSVKG (SEQ ID NO: 1731) X ₁₄₀ I X ₁₄₁ X ₁₄₂ DG X ₁₄₃ N X ₁₄₄ X ₁₄₅ X ₁₄₆ ADSVKG (SEQ ID NO: 1732) wherein X₁₄₀ is L, G, I or V; X₁₄₁ is W or S; X₁₄₂ is Y, D or N; X₁₄₃ is S or D; X₁₄₄ is K or N; X₁₄₅ is Y, N, D, or H; and X₁₄₆ is Y or H. Group 3 W I NP P SG A T N YAQKF R G (SEQ ID NO: 1733) W I NP N SG G T N YAQKF R G (SEQ ID NO: 1734) W I NP N SG A T N YAQKF H G (SEQ ID NO: 1735) W I NP S SG D T K YAQKF Q G (SEQ ID NO: 1736) W M NP N SG A T K YAQKF Q G (SEQ ID NO: 1737) W I NP N SG A T K YAQKF Q G (SEQ ID NO: 1738) W I NP D SG G T N YAQKF Q G (SEQ ID NO: 1739) W I NP N SG G T D YAQKF Q G (SEQ ID NO: 1740) W X ₁₄₇ NP X ₁₄₈ SG X ₁₄₉ T X ₁₅₀ YAQKF X ₁₅₁ G (SEQ ID NO: 1741) wherein X₁₄₇ is I or M; X₁₄₈ is P, N, S or D; X₁₄₉ is A, G or D; X₁₅₀ is N, K, or D; X₁₅₁ is R, H or Q. Group 4 EINHS E N TNYNPSLKS (SEQ ID NO: 1742) EINHS G T TNYNPSLKS (SEQ ID NO: 1743) EINHS X ₁₅₂ X ₁₅₃ TNYNPSLKS (SEQ ID NO: 1744) wherein X₁₅₂ is E or G; and X₁₅₃ is N or T. Group 5 IIYPGDS D TRYSPSFQG (SEQ ID NO: 1745) IIYPGDS E TRYSPSFQG (SEQ ID NO: 1746) IIYPGDS X ₁₅₄ TRYSPSFQG (SEQ ID NO: 1747) wherein X₁₅₄ is D or E. Group 6 SISSSS T Y I YY A DS V KG (SEQ ID NO: 1748) SISSSS T Y I YY A DS L KG (SEQ ID NO: 1749) SISSSS S Y E YY V DS V KG (SEQ ID NO: 1750) SISSSS X ₁₅₅ Y X ₁₅₆ YY X ₁₅₇ DS X ₁₅₈ KG (SEQ ID NO: 1751) wherein X₁₅₅ is T or S; X₁₅₆ is I or E; X₁₅₇ is A or V; and X₁₅₈ is V or L. Group 7 RI K S KTDGGTT D YAAPVKG (SEQ ID NO: 1752) RI K S KTDGGTT E YAAPVKG (SEQ ID NO: 1753) RI I G KTDGGTT D YAAPVKG (SEQ ID NO: 1754) RI X ₁₅₉ X ₁₆₀ KTDGGTT X ₁₆₁ YAAPVKG (SEQ ID NO: 1755) wherein X₁₅₉ is K or I; X₁₆₀ is S or G; and X₁₆₁ is D or E. Group 8 GISGSSAGTYYADSVGK (SEQ ID NO: 1756) Group 9 VIS D SGG S TYYADSVKG (SEQ ID NO: 1757) VIS G SGG D TYYADSVKG (SEQ ID NO: 1758) VIS X ₁₆₂ SGG X ₁₆₃ TYYADSVKG (SEQ ID NO: 1759) wherein X₁₆₂ is D or G; and X₁₆₃ is S or D. Group 10 RTYYRSKWYNDYAVSVKS (SEQ ID NO: 1760) Group 11 RIY I SGSTNYNPSL E N (SEQ ID NO: 1761) RIY T SGSTNYNPSL K S (SEQ ID NO: 1762) RIY X ₁₆₄ SGSTNYNPSL X ₁₆₅ X ₁₆₆ (SEQ ID NO: 1763) wherein X₁₆₄ is I or T; X₁₆₅ is E or K; and X₁₆₆ is N or S. Group 12 WMNPYSGSTG Y AQ N FQ G (SEQ ID NO: 1764) WMNPYSGSTG L AQ R FQ D (SEQ ID NO: 1765) WMNPYSGSTG X ₁₆₇ AQ X ₁₆₈ FQ X ₁₆₉ (SEQ ID NO: 1766) wherein X₁₆₇ is Y or L; X₁₆₈ is N or R; and X₁₆₉ is G or D.

Heavy Chain CDR1 Group 1 SG V Y YW N (SEQ ID NO: 1767) SG V Y YW S (SEQ ID NO: 1768) SG G Y YW N (SEQ ID NO: 1769) SG G Y YW S (SEQ ID NO: 1770) SG D N TW S (SEQ ID NO: 1771) SG N Y TW S (SEQ ID NO: 1772) SG D Y TW T (SEQ ID NO: 1773) SG D Y TW S (SEQ ID NO: 1774) SG X ₁₇₀ X ₁₇₁ TW X ₁₇₂ (SEQ ID NO: 1775) wherein X₁₇₀ is V, G, N or D; X₁₇₁ is Y or N; and X₁₇₂ is N, S or T. Group 2 T YYW S (SEQ ID NO: 1776) Y YYW S (SEQ ID NO: 1777) S YYW S (SEQ ID NO: 1778) G YYW S (SEQ ID NO: 1779) G YYW T (SEQ ID NO: 1780) X ₁₇₃ YYW X ₁₇₄ (SEQ ID NO: 1781) wherein X₁₇₃ is T, S or G; and X₁₇₄ is S or T. Group 3 S Y GMH (SEQ ID NO: 1782) S F GMH (SEQ ID NO: 1783) T Y GMH (SEQ ID NO: 1784) F Y GMH (SEQ ID NO: 1785) X ₁₇₅ X ₁₇₆ GMH (SEQ ID NO: 1786) wherein X₁₇₅ is S, T or F; and X₁₇₆ is Y or F. Group 4 SY A M S (SEQ ID NO: 1787) SY S M N (SEQ ID NO: 1788) SY S M S (SEQ ID NO: 1789) SY X ₁₇₇ M X ₁₇₈ (SEQ ID NO: 1790) wherein X₁₇₇ is A or S; and X₁₇₈ is S, N or M. Group 5 Y YY I H (SEQ ID NO: 1791) G YY L H (SEQ ID NO: 1792) G YY K H (SEQ ID NO: 1793) G YY T H (SEQ ID NO: 1794) G YY I H (SEQ ID NO: 1795) X ₁₇₉ YY X ₁₈₀ H (SEQ ID NO: 1796) wherein X₁₇₉ is Y or G; and X₁₈₀ is I, L, K or T. Group 6 SYG I H (SEQ ID NO: 1797) SYG L H (SEQ ID NO: 1798) SYG X ₁₈₁ H (SEQ ID NO: 1799) wherein X₁₈₁ is L or I. Group 7 NY G M H (SEQ ID NO: 1800) NY G M R (SEQ ID NO: 1801) NY N M H (SEQ ID NO: 1802) NY X ₁₈₂ M X ₁₈₃ (SEQ ID NO: 1803) wherein X₁₈₂ is G or N; and X₁₈₃ is H, R or M. Group 8 S YWIG (SEQ ID NO: 1804) G YWIG (SEQ ID NO: 1805) X ₁₈₄ YWIG (SEQ ID NO: 1806) wherein X₁₈₄ is S or G. Group 9 GY Y MH (SEQ ID NO: 1807) GY F MH (SEQ ID NO: 1808) GY X ₁₈₅ MH (SEQ ID NO: 1809) wherein X₁₈₅ is Y or F. Group 10 S Y DI N (SEQ ID NO: 1810) S H DI N (SEQ ID NO: 1811) S Y DI D (SEQ ID NO: 1812) S X ₁₈₆ DI X ₁₈₇ (SEQ ID NO: 1813) wherein X₁₈₆ is Y or H; and X₁₈₇ is N or D. Group 11 N YAMS (SEQ ID NO: 1814) H YAMS (SEQ ID NO: 1815) X ₁₈₈ YAMS (SEQ ID NO: 1816) wherein X₁₈₈ is N or H. Group 12 NAWMS (SEQ ID NO: 1817) Group 13 SSSYYWG (SEQ ID NO: 1818) Group 14 D YYWN (SEQ ID NO: 1819) S YYWN (SEQ ID NO: 1820) X ₁₈₉ YYWN (SEQ ID NO: 1821) wherein X₁₈₉ is D or S. Group 15 SNSA T WN (SEQ ID NO: 1822) SNSA A WN (SEQ ID NO: 1823) SNSA X ₁₉₀ WN (SEQ ID NO: 1824) wherein X₁₉₀ is T or A. Group 16 S YDMH (SEQ ID NO: 1825) T YDMH (SEQ ID NO: 1826) X ₁₉₁ YDMH (SEQ ID NO: 1827) wherein X₁₉₁ is S or T.

In some cases an antigen binding protein comprises at least one heavy chain CDR1, CDR2, or CDR3 having one of the above consensus sequences. In some cases, an antigen binding protein comprises at least one light chain CDR1, CDR2, or CDR3 having one of the above consensus sequences. In other cases, the antigen binding protein comprises at least two heavy chain CDRs according to the determined consensus sequences, and/or at least two light chain CDRs according to the determined consensus sequences. In still other cases, the antigen binding protein comprises at least three heavy chain CDRs according to the determined consensus sequences, and/or at least three light chain CDRs according to the determined consensus sequences.

Exemplary Antigen Binding Proteins

According to one aspect, an isolated antigen binding protein comprising (a) one or more heavy chain complementary determining regions (CDRHs) comprising one or more of: (i) a CDRH1 selected from the group consisting of SEQ ID NOS 603-655; (ii) a CDRH2 selected from the group consisting of SEQ ID NOS 656-732; (iii) a CDRH3 selected from the group consisting of SEQ ID NOS 733-813; and (iv) a CDRH of (i), (ii) and (iii) that comprises ten, nine, eight, seven, six, five, four, three, two or one amino acid substitutions, deletions, insertions and combinations thereof; (b) one or more light chain complementary determining regions (CDRLs) comprising one or more of: (i) a CDRL1 selected from the group consisting of SEQ ID NOS 814-893; (ii) a CDRL2 comprising one or more of SEQ ID NOS 894-946; (iii) a CDRL3 comprising one or more of SEQ ID NOS 947-1020; and (iv) a CDRL of (i), (ii) and (iii) that comprises ten, nine, eight, seven, six, five, four, three, four, two or one amino acid substitutions, deletions or insertions and combinations thereof; or (c) one or more heavy chain CDRHs of (a) and one or more light chain CDRLs of (b).

In another embodiment, the CDRHs have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOS 603-813, and/or the CDRLs have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOS 814-1020. In a further embodiment, the VH is selected from the group consisting of SEQ ID NOS 316-409, and/or the V_(L) is selected from the group consisting of SEQ ID NOS 217-315.

According to one aspect, an isolated antigen binding protein comprising (a) one or more variable heavy chains (V_(H)s) comprising one or more of: (i) SEQ ID NOS 316-409; and (ii) a V_(H) of (i) that comprises ten, nine, eight, seven, six, five, four, three, two or one amino acid substitutions, deletions, insertions and combinations thereof; (b) one or more variable light chains (V_(L)s) selected from the group consisting of: (i) SEQ ID NOS 217-315, and (ii) a V_(L) of (i) that comprises ten, nine, eight, seven, six, five, four, three, two or one amino acid substitutions, deletions, insertions and combinations thereof; or (c) one or more variable heavy chains of (a) and one or more variable light chains of (b).

In another embodiment, the variable heavy chain (V_(H)) has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOS 36-409, and/or the variable light chain (V_(L)) has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%. 98% or 99% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOS 217-315.

In one aspect, also provided is an antigen binding protein that specifically binds to a linear or three-dimensional epitope comprising one or more amino acid residues from FGFR1c, FGRF2c and FGFR3c.

In one aspect, also provided is an antigen binding protein that specifically binds to a linear or three-dimensional epitope comprising one or more amino acid residues from 13-Klotho.

In another aspect, also provided is an isolated antigen binding protein that specifically binds to a linear or three-dimensional epitope comprising one or more amino acid residues from both β-Klotho and one or more amino acid residues from FGFR1c, FGFR2c and FGFR3c.

In yet another embodiment, the isolated antigen binding protein described hereinabove comprises a first amino acid sequence comprising at least one of the CDRH consensus sequences disclosed herein, and a second amino acid sequence comprising at least one of the CDRL consensus sequences disclosed herein.

In one aspect, the first amino acid sequence comprises at least two of the CDRH consensus sequences, and/or the second amino acid sequence comprises at least two of the CDRL consensus sequences. In certain embodiments, the first and the second amino acid sequence are covalently bonded to each other.

In a further embodiment, the first amino acid sequence of the isolated antigen binding protein comprises the CDRH3, the CDRH2 and the CDRH1 parings shown in Table 5 for each clone, and/or the second amino acid sequence of the isolated antigen binding protein comprises the CDRL3, the CDRL2 and the CDRL1 pairings shown in Table 4 or each clone.

In a further embodiment, the antigen binding protein comprises at least two CDRH sequences of heavy chain sequences H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17 or H18, H19, H20, H21, H22, H23, H24, H25, H26, H27, H28, H29, H30, H31, H32, H33, H34, H35, H36, H37, H38, H39, H40, H41, H42, H43, H44, H45, H146, H46, H48, H49, H50, H51, H52, H53, H54, H55, H56, H57, H58, H59, H60, H61, H62, H63, H64, H65, H66, H67, H68, H69, H70, H71, H72, H73, H74, H75, H76, H77, H78, H79, H80, H81, H82, H83, H84, H85, H86, H87, H88, H89, H90, H91, H92, H93 and H94, as shown in Tables 3A and 4A.

In again a further embodiment, the antigen binding protein comprises at least two CDRL sequences of light chain sequences L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, L21, L22, L23, L24, L25, L26, L27, L28, L29, L30, L31, L32, L33, L34, L35, L36, L37, L38, L39, L40, L41, L42, L43, L44, L45, L46, L47, L48, L49, L50, L51, L52, L53, L54, L55, L56, L57, L58, L59, L60, L61, L62, L63, L64, L65, L66, L67, L68, L69, L70, L71, L72, L73, L74, L75, L76, L77, L78, L79, L80, L81, L82, L83, L84, L85, L86, L87, L88, L89, L90, L91, L92, L93, L94, L95, L96, L97, L98, L99 and L100, as shown in Tables 3B and 4B.

In still a further embodiment, the antigen binding protein comprises at least two CDRH sequences of heavy chain sequences H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17 or H18, H19, H20, H21, H22, H23, H24, H25, H26, H27, H28, H29, H30, H31, H32, H33, H34, H35, H36, H37, H38, H39, H40, H41, H42, H43, H44, H45, H146, H46, H48, H49, H50, H51, H52, H53, H54, H55, H56, H57, H58, H59, H60, H61, H62, H63, H64, H65, H66, H67, H68, H69, H70, H71, H72, H73, H74, H75, H76, H77, H78, H79, H80, H81, H82, H83, H84, H85, H86, H87, H88, H89, H90, H91, H92, H93 and H94, as shown in Tables 3A and 4A, and at least two CDRLs of light chain sequences L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, L21, L22, L23, L24, L25, L26, L27, L28, L29, L30, L31, L32, L33, L34, L35, L36, L37, L38, L39, L40, L41, L42, L43, L44, L45, L46, L47, L48, L49, L50, L51, L52, L53, L54, L55, L56, L57, L58, L59, L60, L61, L62, L63, L64, L65, L66, L67, L68, L69, L70, L71, L72, L73, L74, L75, L76, L77, L78, L79, L80, L81, L82, L83, L84, L85, L86, L87, L88, L89, L90, L91, L92, L93, L94, L95, L96, L97, L98, L99 and L100, as shown in Tables 3B and 4B.

In again another embodiment, the antigen binding protein comprises the CDRH1, CDRH2, and CDRH3 sequences of heavy chain sequences H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17 or H18, H19, H20, H21, H22, H23, H24, H25, H26, H27, H28, H29, H30, H31, H32, H33, H34, H35, H36, H37, H38, H39, H40, H41, H42, H43, H44, H45, H146, H46, H48, H49, H50, H51, H52, H53, H54, H55, H56, H57, H58, H59, H60, H61, H62, H63, H64, H65, H66, H67, H68, H69, H70, H71, H72, H73, H74, H75, H76, H77, H78, H79, H80, H81, H82, H83, H84, H85, H86, H87, H88, H89, H90, H91, H92, H93 and H94, as shown in Tables 3A and 4A.

In yet another embodiment, the antigen binding protein comprises the CDRL1, CDRL2, and CDRL3 sequences of light chain sequences L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, L21, L22, L23, L24, L25, L26, L27, L28, L29, L30, L31, L32, L33, L34, L35, L36, L37, L38, L39, L40, L41, L42, L43, L44, L45, L46, L47, L48, L49, L50, L51, L52, L53, L54, L55, L56, L57, L58, L59, L60, L61, L62, L63, L64, L65, L66, L67, L68, L69, L70, L71, L72, L73, L74, L75, L76, L77, L78, L79, L80, L81, L82, L83, L84, L85, L86, L87, L88, L89, L90, L91, L92, L93, L94, L95, L96, L97, L98, L99 and L100, as shown in Tables 3B and 4B.

In yet another embodiment, the antigen binding protein comprises all six CDRs of an antigen binding protein comprising the following V_(H) and V_(L) pairs: V_(L)1 with V_(H)1; V_(L)2 with V_(H)1; V_(L)3 with V_(H)2 or V_(H)3; V_(L)4 with V_(H)4; V_(L)5 with V_(H)5; V_(L)6 with V_(H)6; V_(L)7 with V_(H)6; V_(L)8 with V_(H)7 or V_(H)8; V_(L)9 with V_(H)9; V_(L)10 with V_(H)9; V_(L)11 with V_(H) 10; V_(L)12 with V_(H)11; V_(L)13 with V_(H)12; V_(L)13 with V_(H)14; V_(L)14 with V_(H)13; V_(L)15 with V_(H)14; V_(L)16 with V_(H)15; V_(L)17 with V_(H)16; V_(L)18 with V_(H)17; V_(L)19 with V_(H)18; V_(L)20 with V_(H)19; V_(L)21 with V_(H)20; V_(L)22 with V_(H)21; V_(L)23 with V_(H)22; V_(L)24 with V_(H)23; V_(L)25 with V_(H)24; V_(L)26 with V_(H)25; V_(L)27 with V_(H)26; V_(L)28 with V_(H)27; V_(L)29 with V_(H)28; V_(L)30 with V_(H)29; V_(L)31 with V_(H)30; V_(L)32 with V_(H)31; V_(L)33 with V_(H)32; V_(L)34 with V_(H)33; V_(L)35 with V_(H)34; V_(L)36 with V_(H)35; V_(L)37 with V_(H)36; V_(L)38 with V_(H)37; V_(L)39 with V_(H)38; V_(L)40 with V_(H)39; V_(L)41 with V_(H)40; V_(L)42 with V_(H)41; V_(L)43 with V_(H)42; V_(L)44 with V_(H)43; V_(L)45 with V_(H)44; V_(L)46 with V_(H)45; V_(L)47 with V_(H)46; V_(L)48 with V_(H)47; V_(L)49 with V_(H)48; V_(L)50 with V_(H)49; V_(L)51 with V_(H)50; V_(L)52 with V_(H)51; V_(L)53 with V_(H)52; V_(L)54 with V_(H)53; V_(L)55 with V_(H)54; V_(L)56 with V_(H)54; V_(L)57 with V_(H)54; V_(L)58 with V_(H)55; V_(L)59 with V_(H)56; V_(L)60 with V_(H)57; V_(L)61 with V_(H)58; V_(L)62 with V_(H)59; V_(L)63 with V_(H)60; V_(L)64 with V_(H)1; V_(L)65 with V_(H)62; V_(L)66 with V_(H)63; V_(L)67 with V_(H)64; V_(L)68 with V_(H)65; V_(L)69 with V_(H)66; V_(L)70 with V_(H)67; V_(L)71 with V_(H)68; V_(L)72 with V_(H)69; V_(L)73 with V_(H)70; V_(L)74 with V_(H)70; V_(L)75 with V_(H)70; V_(L)76 with V_(H)71; V_(L)77 with V_(H)72; V_(L)78 with V_(H)73; V_(L)79 with V_(H)74; V_(L)80 with V_(H)75; V_(L)81 with V_(H)76; V_(L)82 with V_(H)77; V_(L)83 with V_(H)78; V_(L)84 with V_(H)79; V_(L)85 with V_(H)80; V_(L)86 with V_(H)81; V_(L)87 with V_(H)82; V_(L)88 with V_(H)86; V_(L)89 with V_(H)83; V_(L)90 with V_(H)84; V_(L)91 with V_(H)85; V_(L) 92 with V_(H) 87; V_(L) 93 with V_(H) 88; V_(L) 94 with V_(H) 88; V_(L) 95 with V_(H) 89; V_(L) 96 with V_(H) 90; V_(L) 97 with V_(H) 91; V_(L) 98 with V_(H) 92; V_(L) 99 with V_(H) 93; and V_(L) 100 with V_(H) 94; as shown in Tables 2A and 2B and Tables 4A and 4B.

TABLE 7A Heavy Chain Sequences Full Heavy Full Heavy Variable Heavy Variable Heavy CDRH1 CDRH2 CDRH3 Ref (H#) SEQ ID NO (VH#) SEQ ID NO SEQ ID NO SEQ ID NO SEQ ID NO 63G8 H1 123 V_(H)1 326 636 667 782 68D3 64A8 67B4 64E6 H2 136 V_(H)2 339 637 699 783 65E8 65F11 67G7 63H11 H3 135 V_(H)3 338 637 689 783 63B6 H4 133 V_(H)4 336 638 700 784 64D4 65C3 H5 142 V_(H)5 345 626 701 785 68D5 63E6 H6 113 V_(H)6 316 639 702 786 66F7 64H5 H7 126 V_(H)7 329 614 703 787 65G4 H8 129 V_(H)8 332 614 703 787 67G10v1 H9 121 V_(H)9 324 640 704 788 67G10v2 66B4 H10 115 V_(H)10 318 617 708 791 66G2 H11 124 V_(H)11 327 614 709 782 68G5 H12 130 V_(H)12 333 614 710 792 63F5 H13 134 V_(H)13 337 637 705 783 66F6 H14 138 V_(H)14 341 637 689 783 65C1 H15 137 V_(H)15 340 637 707 790 64A7 H16 141 V_(H)16 344 642 706 789 66D4 H17 114 V_(H)17 317 645 711 793 65B1 H18 116 V_(H)18 319 646 712 794 67A4 H19 118 V_(H)19 321 647 713 795 65B4 H20 117 V_(H)20 320 648 714 796 63A10 H21 119 V_(H)21 322 640 715 788 65H11 H22 120 V_(H)22 323 640 716 788 64C8 H23 122 V_(H)23 325 614 717 797 65E3 H24 128 V_(H)24 331 649 718 798 65D4 H25 127 V_(H)25 330 650 677 799 65D1 H26 125 V_(H)26 328 651 719 800 67G8 H27 131 V_(H)27 334 614 720 801 65B7 H28 132 V_(H)28 335 652 707 802 64A6 H29 139 V_(H)29 342 616 721 803 65F9 H30 140 V_(H)30 343 638 689 804 67F5 H31 143 V_(H)31 346 626 722 785 64B10 H32 144 V_(H)32 347 638 723 805 68C8 H33 145 V_(H)33 348 653 724 806 67A5 H34 146 V_(H)34 349 627 686 807 67C10 H35 147 V_(H)35 350 627 686 808 64H6 H36 148 V_(H)36 351 627 725 809 63F9 H37 149 V_(H)37 352 654 726 810 67F6 H38 150 V_(H)38 353 655 686 811 48H11 H39 154 V_(H)39 357 606 659 736 52A8 H40 164 V_(H)40 368 617 672 749 52F8 H41 167 V_(H)41 371 619 675 753 49H12 H42 159 V_(H)42 362 612 665 742 54A1 H43 172 V_(H)43 376 612 680 742 55G9 49C8 H44 156 V_(H)44 359 609 662 739 52H1 60G5.2 H45 193 V_(H)45 397 635 697 780 49G3 H46 158 V_(H)46 361 611 664 741 59A10 H47 187 V_(H)47 391 632 692 773 49H4 48F8 H48 153 V_(H)48 356 605 658 735 53B9 56B4 57E7 57F11 59C9 H49 188 V_(H)49 392 633 693 774 58A5 57A4 57F9 51G2 H50 163 V_(H)50 367 605 671 748 56A7 H51 179 V_(H)51 383 605 671 764 56E4 54H10 H52 173 V_(H)52 377 623 681 759 55D1 48H3 53C11 59G10.3 H53 190 V_(H)53 394 634 695 777 59D10v1 H54 195 V_(H)54 364 615 668 745 59D10v2 51C10.1 60F9 H55 192 V_(H)55 396 623 696 779 48B4 52D6 61G5 H56 194 V_(H)56 398 623 698 781 59G10.2 H57 189 V_(H)57 393 608 694 776 51A8 H58 160 V_(H)58 363 614 667 744 53H5.2 H59 170 V_(H)59 374 614 678 756 53F6 H60 169 V_(H)60 373 621 677 755 56C11 H61 180 V_(H)61 384 614 685 765 49A10 H62 155 V_(H)62 358 608 661 738 48D4 49G2 H63 157 V_(H)63 360 610 663 740 50C12 55G11 52C1 H64 166 V_(H)64 370 614 674 751 55E9 H65 176 V_(H)65 380 625 683 762 60D7 H66 191 V_(H)66 395 614 677 778 51C10.2 H67 161 V_(H)67 365 616 669 746 55D3 H68 174 V_(H)68 378 624 682 760 57B12 H69 184 V_(H)69 388 630 689 760 55E4 H70 175 V_(H)70 379 604 656 752 52C5 60G5.1 55E4 49B11 50H10 53C1 56G1 H71 182 V_(H)71 386 604 656 752 48F3 H72 152 V_(H)72 355 604 657 734 48C9 H73 151 V_(H)73 354 603 656 733 49A12 51E2 51E5 H74 162 V_(H)74 366 604 670 747 53H5.3 H75 171 V_(H)75 375 622 679 757 56G3.3 H76 183 V_(H)76 387 629 688 769 55B10 52B8 H77 165 V_(H)77 369 618 673 750 55G5 H78 177 V_(H)78 381 626 684 763 52H2 H79 168 V_(H)79 372 620 676 754 56G3.2 H80 196 V_(H)80 399 628 687 768 56E7 H81 181 V_(H)81 385 627 686 766 57D9 H82 185 V_(H)82 389 631 690 771 48G4 H83 197 V_(H)83 400 607 660 737 53C3.1 50G1 H84 178 V_(H)84 382 613 666 743 58C2 H85 186 V_(H)85 390 608 691 772 61H5 H86 198 V_(H)86 401 629 727 769 52B9 50D4 H87 199 V_(H)87 402 643 730 812 50G5v1 H88 200 V_(H)88 403 639 728 767 50G5v2 51C1 H89 201 V_(H)89 404 604 656 752 53C3.2 H90 202 V_(H)90 405 641 732 775 54H10.3 H91 203 V_(H)91 406 645 729 813 55A7 H92 204 V_(H)92 407 626 673 770 55E6 H93 205 V_(H)93 408 605 731 761 61E1 H94 206 V_(H)94 409 644 690 758

TABLE 7B Light Chain Sequences Full Light Full Light Variable Light Variable Light CDRL1 CDRL2 CDRL3 Ref (L#) SEQ ID NO (VH#) SEQ ID NO SEQ ID NO SEQ ID NO SEQ ID NO 63G8 L1 26 V_(L)1 229 826 922 987 64A8 67B4 68D3 L2 28 V_(L)2 231 826 922 987 65E8 L3 37 V_(L)3 241 859 927 988 63H11 64E6 67G7 65F11 63B6 L4 35 V_(L)4 239 860 928 989 64D4 65C3 L5 43 V_(L)5 247 861 929 990 68D5 63E6 L6 14 V_(L)6 217 862 907 991 66F7 L7 15 V_(L)7 218 863 907 991 64H5 L8 30 V_(L)8 233 864 930 992 65G4 67G10v1 L9 23 V_(L)9 226 865 931 993 67G10v2 L10 24 V_(L)10 227 866 932 994 66B4 L11 17 V_(L)11 220 870 933 996 66G2 L12 27 V_(L)12 230 835 934 997 68G5 L13 100 V_(L)13 236 872 935 998 63F5 L14 36 V_(L)14 240 867 913 988 66F6 L15 39 V_(L)15 243 859 928 988 65C1 L16 38 V_(L)16 242 869 928 988 64A7 L17 42 V_(L)17 246 868 913 995 66D4 L18 16 V_(L)18 219 873 907 999 65B1 L19 18 V_(L)19 221 874 936 961 67A4 L20 20 V_(L)20 223 875 918 1001 65B4 L21 19 V_(L)21 222 876 918 1001 63A10 L22 21 V_(L)22 224 865 938 1002 65H11 L23 22 V_(L)23 225 878 931 1003 64C8 L24 25 V_(L)24 228 879 940 1004 65E3 L25 32 V_(L)25 235 864 935 1005 65D4 L26 31 V_(L)26 234 880 935 1006 65D1 L27 29 V_(L)27 232 852 925 1007 67G8 L28 33 V_(L)28 237 882 930 1005 65B7 L29 34 V_(L)29 238 883 913 1008 64A6 L30 40 V_(L)30 244 884 941 1009 65F9 L31 41 V_(L)31 245 885 908 1009 67F5 L32 44 V_(L)32 248 885 942 1010 64B10 L33 45 V_(L)33 249 886 943 963 68C8 L34 46 V_(L)34 250 887 909 963 67A5 L35 47 V_(L)35 251 888 898 1012 67C10 L36 48 V_(L)36 252 888 898 951 64H6 L37 49 V_(L)37 253 864 930 1014 63F9 L38 50 V_(L)38 254 889 944 1015 67F6 L39 51 V_(L)39 255 890 945 951 48H11 L40 55 V_(L)40 259 817 897 950 52A8 L41 66 V_(L)41 270 828 907 961 52F8 L42 69 V_(L)42 273 832 910 965 49H12 L43 60 V_(L)43 264 822 901 955 54A1 L44 74 V_(L)44 278 837 899 955 55G9 49C8 L45 57 V_(L)45 261 819 899 952 52H1 60G5.2 L46 93 V_(L)46 297 857 925 986 49G3 L47 59 V_(L)47 263 821 900 954 59A10 L48 87 V_(L)48 291 827 921 960 49H4 48F8 L49 54 V_(L)49 258 816 896 949 53B9 56B4 57E7 57F11 59C9 L50 88 V_(L)50 292 850 922 960 58A5 57A4 57F9 51G2 L51 65 V_(L)51 269 827 906 960 56A7 L52 80 V_(L)52 284 842 917 960 56E4 54H10.1 L53 75 V_(L)53 279 838 913 970 55D1 48H3 53C11 59G10.3 L54 90 V_(L)54 294 854 909 983 51C10.1 L55 62 V_(L)55 266 824 903 957 59D10v1 L56 97 V_(L)56 301 851 903 980 59D10v2 L57 98 V_(L)57 302 852 923 981 60F9 L58 92 V_(L)58 296 856 924 985 48B4 52D6 61G5 L59 94 V_(L)59 298 858 926 985 59G10.2 L60 89 V_(L)60 293 853 904 982 51A8 L61 61 V_(L)61 265 823 902 956 53H5.2 L62 72 V_(L)62 276 835 907 968 53F6 L63 71 V_(L)63 275 834 912 967 56C11 L64 81 V_(L)64 285 843 918 974 49A10 L65 56 V_(L)65 260 818 898 951 48D4 49G2 L66 58 V_(L)66 262 820 898 953 50C12 55G11 52C1 L67 68 V_(L)67 272 830 909 963 55E9 L68 78 V_(L)68 282 840 910 972 60D7 L69 91 V_(L)69 295 820 898 984 51C10.2 L70 63 V_(L)70 267 825 904 958 55D3 L71 76 V_(L)71 280 839 907 971 57B12 L72 85 V_(L)72 289 847 907 978 52C5 L73 95 V_(L)73 299 831 907 964 60G5.1 L74 V_(L)74 55E4 L75 77 V_(L)75 281 831 914 964 49B11 50H10 53C1 56G1 L76 83 V_(L)76 287 831 907 976 48F3 L77 53 V_(L)77 257 815 895 948 48C9 L78 52 V_(L)78 256 814 894 947 49A12 51E2 51E5 L79 64 V_(L)79 268 826 905 959 53H5.3 L80 73 V_(L)80 277 836 908 969 56G3.3 L81 84 V_(L)81 288 846 920 977 55B10 52B8 L82 67 V_(L)82 271 829 908 962 55G5 L83 79 V_(L)83 283 841 916 973 52H2 L84 70 V_(L)84 274 833 911 966 56G3.2 L85 99 V_(L)85 303 845 919 962 56E7 L86 82 V_(L)86 286 844 900 975 57D9 L87 86 V_(L)87 290 848 913 976 61H5 L88 96 V_(L)88 300 846 913 977 52B9 48G4 L89 101 V_(L)89 304 892 928 1017 53C3.1 50G1 L90 102 V_(L)90 305 820 898 984 58C2 L91 103 V_(L)91 306 893 898 1012 50D4 L92 104 V_(L)92 307 839 946 1019 50G5v1 L93 105 V_(L)93 308 835 907 1018 50G5v2 L94 106 V_(L)94 309 891 915 1020 51C1 L95 107 V_(L)95 310 831 907 964 53C3.2 L96 108 V_(L)96 311 849 937 1016 54H10.3 L97 109 V_(L)97 312 855 939 999 55A7 L98 110 V_(L)98 313 871 907 1000 55E6 L99 111 V_(L)99 314 877 913 1011 61E1 L100 112 V_(L)100 315 881 907 1013

In one aspect, the isolated antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c provided herein can be a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof.

In another embodiment, the antibody fragment of the isolated antigen-binding proteins provided herein can be a Fab fragment, a Fab′ fragment, an F(ab′)₂ fragment, an Fv fragment, a diabody, or a single chain antibody molecule.

In a further embodiment, an isolated antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c provided herein is a human antibody and can be of the IgG1-, IgG2- IgG3- or IgG4-type.

In another embodiment, an isolated antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c comprises a light or a heavy chain polypeptide as set forth in Tables 1A-1B. In some embodiments, an antigen binding protein that specifically binds to a complex comprising 13-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c comprises a variable light or variable heavy domain such as those listed in Tables 2A-2B. In still other embodiments, an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c comprises one, two or three CDRHs or one, two or three CDRLs as set forth in Tables 3A-3B, 4A-4B, infra. Such antigen binding proteins, and indeed any of the antigen binding proteins disclosed herein, can be PEGylated with one or more PEG molecules, for examples PEG molecules having a molecular weight selected from the group consisting of 5K, 10K, 20K, 40K, 50K, 60K, 80K, 100K or greater than 100K.

In yet another aspect, any antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c provided herein can be coupled to a labeling group and can compete for binding to the extracellular portion of the individual protein components of a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c with an antigen binding protein of one of the isolated antigen binding proteins provided herein. In one embodiment, the isolated antigen binding protein provided herein can reduce blood glucose levels, decrease triglyceride and cholesterol levels or improve other glycemic parameters and cardiovascular risk factors when administered to a patient.

As will be appreciated, for any antigen binding protein comprising more than one CDR provided in Tables 3A-3B, and 4A-4B, any combination of CDRs independently selected from the depicted sequences may be useful. Thus, antigen binding proteins with one, two, three, four, five or six of independently selected CDRs can be generated. However, as will be appreciated by those in the art, specific embodiments generally utilize combinations of CDRs that are non-repetitive, e.g., antigen binding proteins are generally not made with two CDRH2 regions, etc.

Some of the antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c that are provided herein are discussed in more detail below.

Antigen Binding Proteins and Binding Epitopes and Binding Domains

When an antigen binding protein is said to bind an epitope on a complex β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, or the extracellular domain of a protein component of such a complex, what is meant is that the antigen binding protein specifically binds to a specified portion of the complex comprising β-Klotho and an FGFR (e.g., FGFR1c, FGFR2c or FGFR3c) or to the extracellular domain of such a complex. In some embodiments, e.g., in certain cases where the antigen binding protein binds only β-Klotho, the antigen binding protein can specifically bind to a polypeptide consisting of specified residues (e.g., a specified segment of β-Klotho). In other embodiments, e.g., in certain cases where an antigen binding protein interacts with both β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, the antigen binding protein can bind residues, sequences of residues, or regions in both β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, depending on which receptor the antigen binding protein recognizes. In still other embodiments the antigen binding protein will bind residues, sequences or residues or regions of a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, for example FGFR1c.

In any of the foregoing embodiments, such an antigen binding protein does not need to contact every residue of β-Klotho or a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, or the extracellular domain of the recited proteins or complexes. Nor does every single amino acid substitution or deletion within β-Klotho or a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, or the extracellular domain of the recited proteins or complexes, necessarily significantly affect binding affinity.

Epitope specificity and the binding domain(s) of an antigen binding protein can be determined by a variety of methods. Some methods, for example, can use truncated portions of an antigen. Other methods utilize antigen mutated at one or more specific residues, such as by employing an alanine scanning or arginine scanning-type approach or by the generation and study of chimeric proteins in which various domains, regions or amino acids are swapped between two proteins (e.g., mouse and human forms of one or more of the antigens or target proteins), or by protease protection assays.

Competing Antigen Binding Proteins

In another aspect, antigen binding proteins are provided that compete with one of the exemplified antibodies or functional fragments for binding to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Such antigen binding proteins can also bind to the same epitope as one of the herein exemplified antigen binding proteins, or an overlapping epitope. Antigen binding proteins and fragments that compete with or bind to the same epitope as the exemplified antigen binding proteins are expected to show similar functional properties. The exemplified antigen binding proteins and fragments include those with the heavy and light chains H1-H94 and L1-L100, variable region domains V_(L)1-V_(L)100 and V_(H)1-V_(H)94, and CDRs provided herein, including those in Tables 1, 2, 3, and 4. Thus, as a specific example, the antigen binding proteins that are provided include those that compete with an antibody comprising:

(a) 1, 2, 3, 4, 5 or all 6 of the CDRs listed for an antigen binding protein listed in Tables 3A and 3B, and 4A and 4B, infra;

(b) a V_(H) and a V_(L) selected from V_(L)1-V_(L)100 and V_(H)1-V_(H)94 and listed for an antigen binding protein listed in Tables 2A and 2B; or

(c) two light chains and two heavy chains as specified for an antigen binding protein listed in Tables 1A and 1B, infra.

Thus, in one embodiment, the present disclosure provides antigen binding proteins, including human antibodies, that competes for binding to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c with a reference antibody, wherein the reference antibody comprises a combination of light chain and heavy chain variable domain sequences selected from the group consisting of V_(L)1 with V_(H)1, V_(L)2 with V_(H)1, V_(L)3 with V_(H)2 or V_(H)3, V_(L)4 with V_(H)4, V_(L)5 with V_(H)5, V_(L)6 with V_(H)6, V_(L)7 with V_(H)6, V_(L)8 with V_(H)7 or V_(H)8, V_(L)9 with V_(H)9, V_(L)10 with V_(H)9, V_(L)11 with V_(H) 10, V_(L)12 with V_(H)11, V_(L)13 with V_(H)12, V_(L)13 with V_(H)14, V_(L)14 with V_(H)13, V_(L)15 with V_(H)14, V_(L)16 with V_(H)15, V_(L)17 with V_(H)16, V_(L)18 with V_(H)17, V_(L)19 with V_(H)18, V_(L)20 with V_(H)19, V_(L)21 with V_(H)20, V_(L)22 with V_(H)21, V_(L)23 with V_(H)22, V_(L)24 with V_(H)23, V_(L)25 with V_(H)24, V_(L)26 with V_(H)25, V_(L)27 with V_(H)26, V_(L)28 with V_(H)27, V_(L)29 with V_(H)28, V_(L)30 with V_(H)29, V_(L)31 with V_(H)30, V_(L)32 with V_(H)31, V_(L)33 with V_(H)32, V_(L)34 with V_(H)33, V_(L)35 with V_(H)34, V_(L)36 with V_(H)35, V_(L)37 with V_(H)36, V_(L)38 with V_(H)37, V_(L)39 with V_(H)38, V_(L)40 with V_(H)39, V_(L)41 with V_(H)40, V_(L)42 with V_(H)41, V_(L)43 with V_(H)42, V_(L)44 with V_(H)43, V_(L)45 with V_(H)44, V_(L)46 with V_(H)45, V_(L)47 with V_(H)46, V_(L)48 with V_(H)47, V_(L)49 with V_(H)48, V_(L)50 with V_(H)49, V_(L)51 with V_(H)50, 52 with V_(H)51, V_(L)53 with V_(H)52, V_(L)54 with V_(H)53, V_(L)55 with 54, and V_(L)56 with V_(H)54, V_(L)57 with V_(H)54, V_(L)58 with V_(H)55, V_(L)59 with V_(H)56, V_(L)60 with V_(H)57, V_(L)61 with V_(H)58, V_(L)62 with V_(H)59, V_(L)63 with V_(H)60, V_(L)64 with V_(H)1, V_(L)65 with V_(H)62, V_(L)66 with V_(H)63, V_(L)67 with V_(H)64, V_(L)68 with V_(H)65, V_(L)69 with V_(H)66, V_(L)70 with V_(H)67, V_(L)71 with V_(H)68, V_(L)72 with V_(H)69, V_(L)73 with V_(H)70, V_(L)74 with V_(H)70, and V_(L)75 with V_(H)70, V_(L)76 with V_(H)71, V_(L)77 with V_(H)72, V_(L)78 with V_(H)73, V_(L)79 with V_(H)74, V_(L)80 with V_(H)75, V_(L)81 with V_(H)76, V_(L)82 with V_(H)77, V_(L)83 with V_(H)78, V_(L)84 with V_(H)79, V_(L)85 with V_(H)80, V_(L)86 with V_(H)81, V_(L)87 with V_(H)82, V_(L)88 with V_(H)86, V_(L)89 with V_(H)83, V_(L)90 with V_(H)84, V_(L)91 with V_(H)85, V_(L) 92 with V_(H) 87, V_(L) 93 with V_(H) 88, V_(L) 94 with V_(H) 88, V_(L) 95 with V_(H) 89, V_(L) 96 with V_(H) 90, V_(L) 97 with V_(H) 91, V_(L) 98 with V_(H) 92, V_(L) 99 with V_(H) 93, and V_(L) 100 with V_(H) 94.

In another embodiment, the present disclosure provides antigen binding proteins, including human antibodies, that compete for binding to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c with a reference antibody, wherein the reference antibody is 63G8, 64A8, 67B4, 68D3, 64E6, 65E8, 65F11, 67G7, 63B6, 64D4, 65C3, 68D5, 63E6, 66F7, 64H5, 65G4, 67G10v1, 67G10v2, 66B4, 66G2, 68G5, 63F5, 66F6, 65C1, 64A7, 66D4, 65B1, 67A4, 65B4, 63A10, 65H11, 64C8, 65E3, 65D4, 65D1, 67G8, 65B7, 64A6, 65F9, 67F5, 64B10, 68C8, 67A5, 67C10, 64H6, 63F9, 67F6, 48H11, 52A8, 52F8, 49H12, 54A1, 55G9, 49C8, 52H1, 60G5.2, 49G3, 59A10, 48F8, 53B9, 56B4, 57E7, 57F11, 59C9, 58A5, 57A4, 57F9, 51G2, 56A7, 56E4, 54H10, 55D1, 48H3, 53C11, 59G10.3, 51C10.1, 59D10v1, 59D10v2, 60F9, 48B4, 52D6, 61G5, 59G10.2, 51A8, 53H5.2, 53F6, 56C11, 49A10, 48D4, 49G2, 50C12, 55G11, 52C1, 55E9, 60D7, 51C10.2, 55D3, 57B12, 52C5, 60G5.1, 55E4, 49B11, 50H10, 53C1, 56G1, 48F3, 48C9, 49A12, 51E2, 51E5, 53H5.3, 56G3.3, 55B10, 52B8, 55G5, 52H2, 56G3.2, 6E7, 57D9, 61H5, 48G4, 50G1, 58C2, 50D4, 50G5v1, 50G5v2, 51C1, 53C3.2, 54H10.3, 55A7, 55E6, 61E1, 53C3.1, 49H4, and 51E2.

In a further embodiment, an isolated antigen binding protein, such as a human antibody, is provided that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c with substantially the same Kd as a reference antibody; initiates FGF21-like signaling in an in vitro ELK-Luciferase assay to the same degree as a reference antibody; lowers blood glucose; lowers serum lipid levels; and/or competes for binding with said reference antibody to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, wherein the reference antibody is selected from the group consisting of 63G8, 64A8, 67B4, 68D3, 64E6, 65E8, 65F11, 67G7, 63B6, 64D4, 65C3, 68D5, 63E6, 66F7, 64H5, 65G4, 67G10v1, 67G10v2, 66B4, 66G2, 68G5, 63F5, 66F6, 65C1, 64A7, 66D4, 65B1, 67A4, 65B4, 63A10, 65H11, 64C8, 65E3, 65D4, 65D1, 67G8, 65B7, 64A6, 65F9, 67F5, 64B10, 68C8, 67A5, 67C10, 64H6, 63F9, 67F6, 48H11, 52A8, 52F8, 49H12, 54A1, 55G9, 49C8, 52H1, 60G5.2, 49G3, 59A10, 48F8, 53B9, 56B4, 57E7, 57F11, 59C9, 58A5, 57A4, 57F9, 51G2, 56A7, 56E4, 54H10, 55D1, 48H3, 53C11, 59G10.3, 51C10.1, 59D10v1, 59D10v2, 60F9, 48B4, 52D6, 61G5, 59G10.2, 51A8, 53H5.2, 53F6, 56C11, 49A10, 48D4, 49G2, 50C12, 55G11, 52C1, 55E9, 60D7, 51C10.2, 55D3, 57B12, 52C5, 60G5.1, 55E4, 49B11, 50H10, 53C1, 56G1, 48F3, 48C9, 49A12, 51E2, 51E5, 53H5.3, 56G3.3, 55B10, 52B8, 55G5, 52H2, 56G3.2, 6E7, 57D9, 61H5, 48G4, 50G1, 58C2, 50D4, 50G5v1, 50G5v2, 51C1, 53C3.2, 54H10.3, 55A7, 55E6, 61E1, 53C3.1, 49H4, and 51E2.

The ability to compete with an antibody can be determined using any suitable assay, such as those described herein, in which antigen binding proteins 63G8, 64A8, 67B4, 68D3, 64E6, 65E8, 65F11, 67G7, 63B6, 64D4, 65C3, 68D5, 63E6, 66F7, 64H5, 65G4, 67G10v1, 67G10v2, 66B4, 66G2, 68G5, 63F5, 66F6, 65C1, 64A7, 66D4, 65B1, 67A4, 65B4, 63A10, 65H11, 64C8, 65E3, 65D4, 65D1, 67G8, 65B7, 64A6, 65F9, 67F5, 64B10, 68C8, 67A5, 67C10, 64H6, 63F9, 67F6, 48H11, 52A8, 52F8, 49H12, 54A1, 55G9, 49C8, 52H1, 60G5.2, 49G3, 59A10, 48F8, 53B9, 56B4, 57E7, 57F11, 59C9, 58A5, 57A4, 57F9, 51G2, 56A7, 56E4, 54H10, 55D1, 48H3, 53C11, 59G10.3, 51C10.1, 59D10v1, 59D10v2, 60F9, 48B4, 52D6, 61G5, 59G10.2, 51A8, 53H5.2, 53F6, 56C11, 49A10, 48D4, 49G2, 50C12, 55G11, 52C1, 55E9, 60D7, 51C10.2, 55D3, 57B12, 52C5, 60G5.1, 55E4, 49B11, 50H10, 53C1, 56G1, 48F3, 48C9, 49A12, 51E2, 51E5, 53H5.3, 56G3.3, 55B10, 52B8, 55G5, 52H2, 56G3.2, 6E7, 57D9, 61H5, 48G4, 50G1, 58C2, 50D4, 50G5v1, 50G5v2, 51C1, 53C3.2, 54H10.3, 55A7, 55E6, 61E1, 53C3.1, 49H4, and 51E2 can be used as the reference antibody.

Monoclonal Antibodies

The antigen binding proteins that are provided include monoclonal antibodies that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, and induce FGF21-like signaling to various degrees. Monoclonal antibodies can be produced using any technique known in the art, e.g., by immortalizing spleen cells harvested from the transgenic animal after completion of the immunization schedule. The spleen cells can be immortalized using any technique known in the art, e.g., by fusing them with myeloma cells to produce hybridomas. Myeloma cells for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas). Examples of suitable cell lines for use in mouse fusions include Sp-20, P3-X63/Ag8, P3-X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XXO Bul; examples of cell lines used in rat fusions include R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210. Other cell lines useful for cell fusions are U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6.

In some instances, a hybridoma cell line is produced by immunizing an animal (e.g., a transgenic animal having human immunoglobulin sequences) with an immunogen comprising (1) cell-bound receptor of CHO transfectants expressing full length human FGFR1c and β-Klotho at the cell surface, obtained by transfecting CHO cells with cDNA encoding a human full length FGFR1c polypeptide of SEQ ID NO: 4 and cDNA encoding a human β-Klotho polypeptide of SEQ ID NO: 7 with cells incubated with FGF21 prior to freezing (as shown in Example 2); or (2) cell-bound receptor of 293T transfectants expressing full length human (3-Klotho and an N-terminal truncated form of human FGFR1c encompassing amino acid residue #141 to #822 polypeptide of SEQ ID NO: 4 (as shown in Example 2); harvesting spleen cells from the immunized animal; fusing the harvested spleen cells to a myeloma cell line, thereby generating hybridoma cells; establishing hybridoma cell lines from the hybridoma cells, and identifying a hybridoma cell line that produces an antibody that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c and can induce FGF21-like signaling (e.g., as described in Example 4). Such hybridoma cell lines, and the monoclonal antibodies produced by them, form aspects of the present disclosure.

Monoclonal antibodies secreted by a hybridoma cell line can be purified using any technique known in the art. Hybridomas or mAbs can be further screened to identify mAbs with particular properties, such as the ability to induce FGF21-like signaling. Examples of such screens are provided herein.

Chimeric and Humanized Antibodies

Chimeric and humanized antibodies based upon the foregoing sequences can readily be generated. One example is a chimeric antibody, which is an antibody composed of protein segments from different antibodies that are covalently joined to produce functional immunoglobulin light or heavy chains or immunologically functional portions thereof. Generally, a portion of the heavy chain and/or light chain is identical with or homologous to a corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is/are identical with or homologous to a corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass. For methods relating to chimeric antibodies, see, for example, U.S. Pat. No. 4,816,567; and Morrison et al., (1985) Proc. Natl. Acad. Sci. USA 81:6851-6855, which are hereby incorporated by reference. CDR grafting is described, for example, in U.S. Pat. No. 6,180,370, No. 5,693,762, No. 5,693,761, No. 5,585,089, and No. 5,530,101.

Generally, a goal of making a chimeric antibody is to create a chimera in which the number of amino acids from the intended patient/recipient species is maximized. One example is the “CDR-grafted” antibody, in which the antibody comprises one or more complementarity determining regions (CDRs) from a particular species or belonging to a particular antibody class or subclass, while the remainder of the antibody chain(s) is/are identical with or homologous to a corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass. For use in humans, the variable region or selected CDRs from a rodent antibody often are grafted into a human antibody, replacing the naturally-occurring variable regions or CDRs of the human antibody.

One useful type of chimeric antibody is a “humanized” antibody. Generally, a humanized antibody is produced from a monoclonal antibody raised initially in a non-human animal. Certain amino acid residues in this monoclonal antibody, typically from non-antigen recognizing portions of the antibody, are modified to be homologous to corresponding residues in a human antibody of corresponding isotype. Humanization can be performed, for example, using various methods by substituting at least a portion of a rodent variable region for the corresponding regions of a human antibody (see, e.g., U.S. Pat. No. 5,585,089, and No. 5,693,762; Jones et al., (1986) Nature 321:522-525; Riechmann et al., (1988) Nature 332:323-27; Verhoeyen et al., (1988) Science 239:1534-1536).

In one aspect, the CDRs of the light and heavy chain variable regions of the antibodies provided herein (e.g., in Tables 3-4 and 21-23) are grafted to framework regions (FRs) from antibodies from the same, or a different, phylogenetic species. For example, the CDRs of the heavy and light chain variable regions V_(H)1, V_(H)2, V_(H)3, V_(H)4, V_(H)5, V_(H)6, V_(H)7, V_(H)8, V_(H)9, V_(H)10, V_(H)11, V_(H)12, V_(H)13, V_(H)14, V_(H)15, V_(H)16, V_(H)17, V_(H)18, V_(H)19, V_(H)20, V_(H)21 V_(H)22, V_(H)23, V_(H)24, V_(H)25, V_(H)26, V_(H)27, V_(H)28, V_(H)29, V_(H)30, V_(H)31, V_(H)32, V_(H)33, V_(H)34, V_(H)35, V_(H)36, V_(H)37, V_(H)38, V_(H)39, V_(H)40, V_(H)41, V_(H)42, V_(H)43, V_(H)44, V_(H)45, V_(H)46, V_(H)47, V_(H)48, V_(H)49, V_(H)50, V_(H)51, V_(H)52, V_(H)53, V_(H)54, V_(H)55, V_(H)56, V_(H)57, V_(H)58, V_(H)59, V_(H)60, V_(H)61, V_(H)62, V_(H)63, V_(H)64, V_(H)65, V_(H)66, V_(H)67, V_(H)68, V_(H)69, V_(H)70, V_(H)71, V_(H)72, V_(H)73, V_(H)74, V_(H)75, V_(H)76, V_(H)77, V_(H)78, V_(H)79, V_(H)80, 81, V_(H)82, V_(H)83, V_(H)84, V_(H)85, V_(H) 86, V_(H) 87, V_(H)88, V_(H)89, V_(H)90, V_(H)91, V_(H)92, V_(H)93, and V_(H)94 and/or V_(L)1, V_(L)2, V_(L)3, V_(L)4, V_(L)5, V_(L)6, V_(L)7, V_(L)8, V_(L)9, V_(L)10, V_(L)11, V_(L)12, V_(L)13, V_(L)14, V_(L)15, V_(L)16, V_(L)17, V_(L)18, V_(L)19, V_(L)20, V_(L)21, V_(L)22, V_(L)23, V_(L)24, V_(L)25, V_(L)26, V_(L)27, V_(L)28, V_(L)29, V_(L)30, V_(L)31, V_(L)32, V_(L)33, V_(L)34, V_(L)35, V_(L)36, V_(L)37, V_(L)38, V_(L)39, V_(L)40, V_(L)41, V_(L)42, V_(L)43, V_(L)44, V_(L)45, V_(L)46, V_(L)47, V_(L)48, V_(L)49, V_(L)50, V_(L)51, V_(L)52, V_(L)53, V_(L)54, V_(L)55, V_(L)56, V_(L)57, V_(L)58, V_(L)59, V_(L)60, V_(L)61, V_(L)62, V_(L)63, V_(L)64, V_(L)65, V_(L)66, V_(L)67, V_(L)68, V_(L)69, V_(L)70, V_(L)71, V_(L)72, V_(L)73, V_(L)74, V_(L)75, V_(L)76, V_(L)77, V_(L)78, V_(L)79, V_(L)80, V_(L)81, V_(L)82, V_(L)83, V_(L)84, V_(L)85, V_(L)86, V_(L)87, V_(L)88, V_(L)89, V_(L)90, V_(L)91, V_(L)92, V_(L)93, V_(L)94, V_(L)95, V_(L)96, V_(L)97, V_(L)98, V_(L)99 and V_(L)100 can be grafted to consensus human FRs. To create consensus human FRs, FRs from several human heavy chain or light chain amino acid sequences can be aligned to identify a consensus amino acid sequence. In other embodiments, the FRs of a heavy chain or light chain disclosed herein are replaced with the FRs from a different heavy chain or light chain. In one aspect, rare amino acids in the FRs of the heavy and light chains of an antigen binding protein (e.g., an antibody) that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c are not replaced, while the rest of the FR amino acids are replaced. A “rare amino acid” is a specific amino acid that is in a position in which this particular amino acid is not usually found in an FR. Alternatively, the grafted variable regions from the one heavy or light chain can be used with a constant region that is different from the constant region of that particular heavy or light chain as disclosed herein. In other embodiments, the grafted variable regions are part of a single chain Fv antibody.

In certain embodiments, constant regions from species other than human can be used along with the human variable region(s) to produce hybrid antibodies.

Fully Human Antibodies

Fully human antibodies are provided by the instant disclosure. Methods are available for making fully human antibodies specific for a given antigen without exposing human beings to the antigen (“fully human antibodies”). One specific means provided for implementing the production of fully human antibodies is the “humanization” of the mouse humoral immune system. Introduction of human immunoglobulin (Ig) loci into mice in which the endogenous Ig genes have been inactivated is one means of producing fully human monoclonal antibodies (mAbs) in mouse, an animal that can be immunized with any desirable antigen. Using fully human antibodies can minimize the immunogenic and allergic responses that can sometimes be caused by administering mouse or mouse-derived mAbs to humans as therapeutic agents.

Fully human antibodies can be produced by immunizing transgenic animals (typically mice) that are capable of producing a repertoire of human antibodies in the absence of endogenous immunoglobulin production. Antigens for this purpose typically have six or more contiguous amino acids, and optionally are conjugated to a carrier, such as a hapten. See, e.g., Jakobovits et al., (1993) Proc. Natl. Acad. Sci. USA 90:2551-2555; Jakobovits et al., (1993) Nature 362:255-258; and Bruggermann et al., (1993) Year in Immunol. 7:33. In one example of such a method, transgenic animals are produced by incapacitating the endogenous mouse immunoglobulin loci encoding the mouse heavy and light immunoglobulin chains therein, and inserting into the mouse genome large fragments of human genome DNA containing loci that encode human heavy and light chain proteins. Partially modified animals, which have less than the full complement of human immunoglobulin loci, are then cross-bred to obtain an animal having all of the desired immune system modifications. When administered an immunogen, these transgenic animals produce antibodies that are immunospecific for the immunogen but have human rather than murine amino acid sequences, including the variable regions. For further details of such methods, see, e.g., WO96/33735 and WO94/02602. Additional methods relating to transgenic mice for making human antibodies are described in U.S. Pat. No. 5,545,807; No. 6,713,610; No. 6,673,986; No. 6,162,963; No. 5,545,807; No. 6,300,129; No. 6,255,458; No. 5,877,397; No. 5,874,299 and No. 5,545,806; in PCT publications WO91/10741, WO90/04036, and in EP 546073 and EP 546073.

According to certain embodiments, antibodies of the invention can be prepared through the utilization of a transgenic mouse that has a substantial portion of the human antibody producing genome inserted but that is rendered deficient in the production of endogenous, murine antibodies. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving this result are disclosed in the patents, applications and references disclosed in the specification, herein. In certain embodiments, one can employ methods such as those disclosed in PCT Published Application No. WO 98/24893 or in Mendez et al., (1997) Nature Genetics, 15:146-156, which are hereby incorporated by reference for any purpose.

Generally, fully human monoclonal antibodies specific for a complex comprising 13-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR1c can be produced as follows. Transgenic mice containing human immunoglobulin genes are immunized with the antigen of interest, e.g. those described herein, lymphatic cells (such as B-cells) from the mice that express antibodies are obtained. Such recovered cells are fused with a myeloid-type cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. In certain embodiments, the production of a hybridoma cell line that produces antibodies specific to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR1c is provided.

In certain embodiments, fully human antibodies can be produced by exposing human splenocytes (B or T cells) to an antigen in vitro, and then reconstituting the exposed cells in an immunocompromised mouse, e.g. SCID or nod/SCID. See, e.g., Brams et al., J. Immunol. 160: 2051-2058 (1998); Carballido et al., Nat. Med., 6: 103-106 (2000). In certain such approaches, engraftment of human fetal tissue into SCID mice (SCID-hu) results in long-term hematopoiesis and human T-cell development. See, e.g., McCune et al., Science, 241:1532-1639 (1988); Ifversen et al., Sem. Immunol., 8:243-248 (1996). In certain instances, humoral immune response in such chimeric mice is dependent on co-development of human T-cells in the animals. See, e.g., Martensson et al., Immunol., 83:1271-179 (1994). In certain approaches, human peripheral blood lymphocytes are transplanted into SCID mice. See, e.g., Mosier et al., Nature, 335:256-259 (1988). In certain such embodiments, when such transplanted cells are treated either with a priming agent, such as Staphylococcal Enterotoxin A (SEA), or with anti-human CD40 monoclonal antibodies, higher levels of B cell production is detected. See, e.g., Martensson et al., Immunol., 84: 224-230 (1995); Murphy et al., Blood, 86:1946-1953 (1995).

Thus, in certain embodiments, fully human antibodies can be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells. In other embodiments, antibodies can be produced using the phage display techniques described herein.

The antibodies described herein were prepared through the utilization of the XENOMOUSE® technology, as described herein. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in the patents, applications, and references disclosed in the background section herein. In particular, however, a preferred embodiment of transgenic production of mice and antibodies therefrom is disclosed in U.S. patent application Ser. No. 08/759,620, filed Dec. 3, 1996 and International Patent Application Nos. WO 98/24893, published Jun. 11, 1998 and WO 00/76310, published Dec. 21, 2000, the disclosures of which are hereby incorporated by reference. See also Mendez et al., Nature Genetics, 15:146-156 (1997), the disclosure of which is hereby incorporated by reference.

Through the use of such technology, fully human monoclonal antibodies to a variety of antigens have been produced. Essentially, XENOMOUSE® lines of mice are immunized with an antigen of interest (e.g. an antigen provided herein), lymphatic cells (such as B-cells) are recovered from the hyper-immunized mice, and the recovered lymphocytes are fused with a myeloid-type cell line to prepare immortal hybridoma cell lines. These hybridoma cell lines are screened and selected to identify hybridoma cell lines that produced antibodies specific to the antigen of interest. Provided herein are methods for the production of multiple hybridoma cell lines that produce antibodies specific to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR1c. Further, provided herein are characterization of the antibodies produced by such cell lines, including nucleotide and amino acid sequence analyses of the heavy and light chains of such antibodies.

The production of the XENOMOUSE® strains of mice is further discussed and delineated in U.S. patent application Ser. Nos. 07/466,008, filed Jan. 12, 1990, 07/610,515, filed Nov. 8, 1990, 07/919,297, filed Jul. 24, 1992, 07/922,649, filed Jul. 30, 1992, 08/031,801, filed Mar. 15, 1993, 08/112,848, filed Aug. 27, 1993, 08/234,145, filed Apr. 28, 1994, 08/376,279, filed Jan. 20, 1995, 08/430, 938, filed Apr. 27, 1995, 08/464,584, filed Jun. 5, 1995, 08/464,582, filed Jun. 5, 1995, 08/463,191, filed Jun. 5, 1995, 08/462,837, filed Jun. 5, 1995, 08/486,853, filed Jun. 5, 1995, 08/486,857, filed Jun. 5, 1995, 08/486,859, filed Jun. 5, 1995, 08/462,513, filed Jun. 5, 1995, 08/724,752, filed Oct. 2, 1996, 08/759,620, filed Dec. 3, 1996, U.S. Publication 2003/0093820, filed Nov. 30, 2001 and U.S. Pat. Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181, and 5,939,598 and Japanese Patent Nos. 3 068 180 B2, 3 068 506 B2, and 3 068 507 B2. See also European Patent No., EP 0 463 151 B1, grant published Jun. 12, 1996, International Patent Application No., WO 94/02602, published Feb. 3, 1994, International Patent Application No., WO 96/34096, published Oct. 31, 1996, WO 98/24893, published Jun. 11, 1998, WO 00/76310, published Dec. 21, 2000. The disclosures of each of the above-cited patents, applications, and references are hereby incorporated by reference in their entirety.

Using hybridoma technology, antigen-specific human mAbs with the desired specificity can be produced and selected from the transgenic mice such as those described herein. Such antibodies can be cloned and expressed using a suitable vector and host cell, or the antibodies can be harvested from cultured hybridoma cells.

Fully human antibodies can also be derived from phage-display libraries (as described in Hoogenboom et al., (1991) J. Mol. Biol. 227:381; and Marks et al., (1991) J. Mol. Biol. 222:581). Phage display techniques mimic immune selection through the display of antibody repertoires on the surface of filamentous bacteriophage, and subsequent selection of phage by their binding to an antigen of choice. One such technique is described in PCT Publication No. WO 99/10494 (hereby incorporated by reference), which describes the isolation of high affinity and functional agonistic antibodies for MPL- and msk-receptors using such an approach.

Bispecific or Bifunctional Antigen Binding Proteins

Also provided are bispecific and bifunctional antibodies that include one or more CDRs or one or more variable regions as described above. A bispecific or bifunctional antibody in some instances can be an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including, but not limited to, fusion of hybridomas or linking of Fab′ fragments. See, e.g., Songsivilai & Lachmann, (1990) Clin. Exp. Immunol. 79:315-321; Kostelny et al., (1992) J. Immunol. 148:1547-1553. When an antigen binding protein of the instant disclosure binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, the binding may lead to the activation of FGF21-like activity as measured by the FGF21-like functional and signaling assays described in Examples 4-6; when such an antigen binding protein is an antibody it is referred to as an agonistic antibody.

Various Other Forms

Some of the antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c that are provided in the present disclosure include variant forms of the antigen binding proteins disclosed herein (e.g., those having the sequences listed in Tables 1-4 and 6-23).

In various embodiments, the antigen binding proteins disclosed herein can comprise one or more non-naturally occurring/encoded amino acids. For instance, some of the antigen binding proteins have one or more non-naturally occurring/encoded amino acid substitutions in one or more of the heavy or light chains, variable regions or CDRs listed in Tables 1-23. Examples of non-naturally occurring/encoded amino acids (which can be substituted for any naturally-occurring amino acid found in any sequence disclosed herein, as desired) include: 4-hydroxyproline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, α-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl-terminal direction, in accordance with standard usage and convention. A non-limiting lists of examples of non-naturally occurring/encoded amino acids that can be inserted into an antigen binding protein sequence or substituted for a wild-type residue in an antigen binding sequence include β-amino acids, homoamino acids, cyclic amino acids and amino acids with derivatized side chains. Examples include (in the L-form or D-form; abbreviated as in parentheses): citrulline (Cit), homocitrulline (hCit), Nα-methylcitrulline (NMeCit), Nα-methylhomocitrulline (Nα-MeHoCit), ornithine (Orn), Nα-Methylornithine (Nα-MeOrn or NMeOrn), sarcosine (Sar), homolysine (hLys or hK), homoarginine (hArg or hR), homoglutamine (hQ), Nα-methylarginine (NMeR), Nα-methylleucine (Nα-MeL or NMeL), N-methylhomolysine (NMeHoK), Nα-methylglutamine (NMeQ), norleucine (Nle), norvaline (Nva), 1,2,3,4-tetrahydroisoquinoline (Tic), Octahydroindole-2-carboxylic acid (Oic), 3-(1-naphthyl)alanine (1-Nal), 3-(2-naphthyl)alanine (2-Nal), 1,2,3,4-tetrahydroisoquinoline (Tic), 2-indanylglycine (IgI), para-iodophenylalanine (pI-Phe), para-aminophenylalanine (4AmP or 4-Amino-Phe), 4-guanidino phenylalanine (Guf), glycyllysine (abbreviated “K(Nε-glycyl)” or “K(glycyl)” or “K(gly)”), nitrophenylalanine (nitrophe), aminophenylalanine (aminophe or Amino-Phe), benzylphenylalanine (benzylphe), γ-carboxyglutamic acid (γ-carboxyglu), hydroxyproline (hydroxypro), p-carboxyl-phenylalanine (Cpa), α-aminoadipic acid (Aad), Nα-methyl valine (NMeVal), N-α-methyl leucine (NMeLeu), Nα-methylnorleucine (NMeNle), cyclopentylglycine (Cpg), cyclohexylglycine (Chg), acetylarginine (acetylarg), α,β-diaminopropionoic acid (Dpr), α,γ-diaminobutyric acid (Dab), diaminopropionic acid (Dap), cyclohexylalanine (Cha), 4-methyl-phenylalanine (MePhe), β,β-diphenyl-alanine (BiPhA), aminobutyric acid (Abu), 4-phenyl-phenylalanine (or biphenylalanine; 4Bip), α-amino-isobutyric acid (Aib), beta-alanine, beta-aminopropionic acid, piperidinic acid, aminocaprioic acid, aminoheptanoic acid, aminopimelic acid, desmosine, diaminopimelic acid, N-ethylglycine, N-ethylaspargine, hydroxylysine, allo-hydroxylysine, isodesmosine, allo-isoleucine, N-methylglycine, N-methylisoleucine, N-methylvaline, 4-hydroxyproline (Hyp), γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω-methylarginine, 4-Amino-O-Phthalic Acid (4APA), and other similar amino acids, and derivatized forms of any of those specifically listed.

Additionally, the antigen binding proteins can have one or more conservative amino acid substitutions in one or more of the heavy or light chains, variable regions or CDRs listed in Tables 1-4 and 6-23. Naturally-occurring amino acids can be divided into classes based on common side chain properties:

1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;

2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

3) acidic: Asp, Glu;

4) basic: H is, Lys, Arg;

5) residues that influence chain orientation: Gly, Pro; and

6) aromatic: Trp, Tyr, Phe.

Conservative amino acid substitutions can involve exchange of a member of one of these classes with another member of the same class. Conservative amino acid substitutions can encompass non-naturally occurring/encoded amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. See Table 8, infra. These include peptidomimetics and other reversed or inverted forms of amino acid moieties.

Non-conservative substitutions can involve the exchange of a member of one of the above classes for a member from another class. Such substituted residues can be introduced into regions of the antibody that are homologous with human antibodies, or into the non-homologous regions of the molecule.

In making such changes, according to certain embodiments, the hydropathic index of amino acids can be considered. The hydropathic profile of a protein is calculated by assigning each amino acid a numerical value (“hydropathy index”) and then repetitively averaging these values along the peptide chain. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).

The importance of the hydropathic profile in conferring interactive biological function on a protein is understood in the art (see, e.g., Kyte et al., 1982, J. Mol. Biol. 157:105-131). It is known that certain amino acids can be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, in certain embodiments, the substitution of amino acids whose hydropathic indices are within ±2 is included. In some aspects, those which are within ±1 are included, and in other aspects, those within ±0.5 are included.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functional protein or peptide thereby created is intended for use in immunological embodiments, as in the present case. In certain embodiments, the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigen-binding or immunogenicity, that is, with a biological property of the protein.

The following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5±1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5) and tryptophan (−3.4). In making changes based upon similar hydrophilicity values, in certain embodiments, the substitution of amino acids whose hydrophilicity values are within ±2 is included, in other embodiments, those which are within ±1 are included, and in still other embodiments, those within ±0.5 are included. In some instances, one can also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. These regions are also referred to as “epitopic core regions.”

Exemplary conservative amino acid substitutions are set forth in Table 8.

TABLE 8 Conservative Amino Acid Substitutions Original Residue Exemplary Substitutions Ala Ser Arg Lys Asn Gln, His Asp Glu Cys Ser Gln Asn Glu Asp Gly Pro His Asn, Gln Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe Val Ile, Leu

A skilled artisan will be able to determine suitable variants of polypeptides as set forth herein using well-known techniques coupled with the information provided herein. One skilled in the art can identify suitable areas of the molecule that can be changed without destroying activity by targeting regions not believed to be important for activity. The skilled artisan also will be able to identify residues and portions of the molecules that are conserved among similar polypeptides. In further embodiments, even areas that can be important for biological activity or for structure can be subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.

Additionally, one skilled in the art can review structure-function studies identifying residues in similar polypeptides that are important for activity or structure. In view of such a comparison, one can predict the importance of amino acid residues in a protein that correspond to amino acid residues important for activity or structure in similar proteins. One skilled in the art can opt for chemically similar amino acid substitutions for such predicted important amino acid residues.

One skilled in the art can also analyze the three-dimensional structure and amino acid sequence in relation to that structure in similar polypeptides. In view of such information, one skilled in the art can predict the alignment of amino acid residues of an antibody with respect to its three dimensional structure. One skilled in the art can choose not to make radical changes to amino acid residues predicted to be on the surface of the protein, since such residues can be involved in important interactions with other molecules. Moreover, one skilled in the art can generate test variants containing a single amino acid substitution at each desired amino acid residue. These variants can then be screened using assays for FGF21-like signaling, (including those described in the Examples provided herein) thus yielding information regarding which amino acids can be changed and which must not be changed. In other words, based on information gathered from such routine experiments, one skilled in the art can readily determine the amino acid positions where further substitutions should be avoided either alone or in combination with other mutations.

A number of scientific publications have been devoted to the prediction of secondary structure. See, Moult, (1996) Curr. Op. in Biotech. 7:422-427; Chou et al., (1974) Biochem. 13:222-245; Chou et al., (1974) Biochemistry 113:211-222; Chou et al., (1978) Adv. Enzymol. Relat. Areas Mol. Biol. 47:45-148; Chou et al., (1979) Ann. Rev. Biochem. 47:251-276; and Chou et al., (1979) Biophys. J. 26:367-384. Moreover, computer programs are currently available to assist with predicting secondary structure. One method of predicting secondary structure is based upon homology modeling. For example, two polypeptides or proteins that have a sequence identity of greater than 30%, or similarity greater than 40% can have similar structural topologies. The growth of the protein structural database (PDB) has provided enhanced predictability of secondary structure, including the potential number of folds within a polypeptide's or protein's structure. See, Holm et al., (1999) Nucl. Acid. Res. 27:244-247. It has been suggested (Brenner et al., (1997) Curr. Op. Struct. Biol. 7:369-376) that there are a limited number of folds in a given polypeptide or protein and that once a critical number of structures have been resolved, structural prediction will become dramatically more accurate.

Additional methods of predicting secondary structure include “threading” (Jones, (1997) Curr. Opin. Struct. Biol. 7:377-387; Sippl et al., (1996) Structure 4:15-19), “profile analysis” (Bowie et al., (1991) Science 253:164-170; Gribskov et al., (1990) Meth. Enzym. 183:146-159; Gribskov et al., (1987) Proc. Nat. Acad. Sci. 84:4355-4358), and “evolutionary linkage” (See, Holm, (1999) supra; and Brenner, (1997) supra).

In some embodiments, amino acid substitutions are made that: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter ligand or antigen binding affinities, and/or (4) confer or modify other physicochemical or functional properties on such polypeptides. For example, single or multiple amino acid substitutions (in some embodiments, conservative amino acid substitutions) can be made in the naturally-occurring sequence. Substitutions can be made in that portion of the antibody that lies outside the domain(s) forming intermolecular contacts. In such embodiments, conservative amino acid substitutions can be used that do not substantially change the structural characteristics of the parent sequence (e.g., one or more replacement amino acids that do not disrupt the secondary structure that characterizes the parent or native antigen binding protein). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton, Proteins: Structures and Molecular Properties 2^(nd) edition, 1992, W. H. Freeman & Company; Creighton, Proteins: Structures and Molecular Principles, 1984, W. H. Freeman & Company; Introduction to Protein Structure (Branden and Tooze, eds.), 2^(nd) edition, 1999, Garland Publishing; Petsko & Ringe, Protein Structure and Function, 2004, New Science Press Ltd; and Thornton et al., (1991) Nature 354:105, which are each incorporated herein by reference.

Additional preferred antibody variants include cysteine variants wherein one or more cysteine residues in the parent or native amino acid sequence are deleted from or substituted with another amino acid (e.g., serine). Cysteine variants are useful, inter alia when antibodies must be refolded into a biologically active conformation. Cysteine variants can have fewer cysteine residues than the native antibody, and typically have an even number to minimize interactions resulting from unpaired cysteines.

The heavy and light chains, variable regions domains and CDRs that are disclosed can be used to prepare polypeptides that contain an antigen binding region that can specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c and may induce FGF21-like signaling. For example, one or more of the CDRs listed in Tables 3-4 and 21-23 can be incorporated into a molecule (e.g., a polypeptide) covalently or noncovalently to make an immunoadhesion. An immunoadhesion can incorporate the CDR(s) as part of a larger polypeptide chain, can covalently link the CDR(s) to another polypeptide chain, or can incorporate the CDR(s) noncovalently. The CDR(s) enable the immunoadhesion to bind specifically to a particular antigen of interest (e.g., to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c or an epitope thereon).

The heavy and light chains, variable regions domains and CDRs that are disclosed can be used to prepare polypeptides that contain an antigen binding region that can specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c and may induce FGF21-like signaling. For example, one or more of the CDRs listed in Tables 3-4 and 21-23 can be incorporated into a molecule (e.g., a polypeptide) that is structurally similar to a “half” antibody comprising the heavy chain, the light chain of an antigen binding protein paired with a Fc fragment so that the antigen binding region is monovalent (like a Fab fragment) but with a dimeric Fc moiety.

Mimetics (e.g., “peptide mimetics” or “peptidomimetics”) based upon the variable region domains and CDRs that are described herein are also provided. These analogs can be peptides, non-peptides or combinations of peptide and non-peptide regions. Fauchere, (1986) Adv. Drug Res. 15:29; Veber and Freidinger, (1985) TINS p. 392; and Evans et al., (1987) J. Med. Chem. 30:1229, which are incorporated herein by reference for any purpose. Peptide mimetics that are structurally similar to therapeutically useful peptides can be used to produce a similar therapeutic or prophylactic effect. Such compounds are often developed with the aid of computerized molecular modeling. Generally, peptidomimetics are proteins that are structurally similar to an antibody displaying a desired biological activity, such as here the ability to specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, but have one or more peptide linkages optionally replaced by a linkage selected from: —CH₂NH—, —CH₂S—, —CH₂—CH₂—, —CH—CH-(cis and trans), —COCH₂—, —CH(OH)CH₂—, and —CH₂SO—, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) can be used in certain embodiments to generate more stable proteins. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation can be generated by methods known in the art (Rizo and Gierasch, (1992) Ann. Rev. Biochem. 61:387), incorporated herein by reference), for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

Derivatives of the antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c that are described herein are also provided. The derivatized antigen binding proteins can comprise any molecule or substance that imparts a desired property to the antibody or fragment, such as increased half-life in a particular use. The derivatized antigen binding protein can comprise, for example, a detectable (or labeling) moiety (e.g., a radioactive, colorimetric, antigenic or enzymatic molecule, a detectable bead (such as a magnetic or electrodense (e.g., gold) bead), or a molecule that binds to another molecule (e.g., biotin or streptavidin), a therapeutic or diagnostic moiety (e.g., a radioactive, cytotoxic, or pharmaceutically active moiety), or a molecule that increases the suitability of the antigen binding protein for a particular use (e.g., administration to a subject, such as a human subject, or other in vivo or in vitro uses). Examples of molecules that can be used to derivatize an antigen binding protein include albumin (e.g., human serum albumin) and polyethylene glycol (PEG). Albumin-linked and PEGylated derivatives of antigen binding proteins can be prepared using techniques well known in the art. Certain antigen binding proteins include a PEGylated single chain polypeptide as described herein. In one embodiment, the antigen binding protein is conjugated or otherwise linked to transthyretin (“TTR”) or a TTR variant. The TTR or TTR variant can be chemically modified with, for example, a chemical selected from the group consisting of dextran, poly(n-vinyl pyrrolidone), polyethylene glycols, propropylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols and polyvinyl alcohols.

Other derivatives include covalent or aggregative conjugates of the antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c that are disclosed herein with other proteins or polypeptides, such as by expression of recombinant fusion proteins comprising heterologous polypeptides fused to the N-terminus or C-terminus of an antigen binding protein that induces FGF21-like signaling. For example, the conjugated peptide can be a heterologous signal (or leader) polypeptide, e.g., the yeast alpha-factor leader, or a peptide such as an epitope tag. An antigen binding protein-containing fusion protein of the present disclosure can comprise peptides added to facilitate purification or identification of an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c (e.g., a poly-His tag) and that can induce FGF21-like signaling. An antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c also can be linked to the FLAG peptide as described in Hopp et al., (1988) Bio/Technology 6:1204; and U.S. Pat. No. 5,011,912. The FLAG peptide is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody (mAb), enabling rapid assay and facile purification of expressed recombinant protein. Reagents useful for preparing fusion proteins in which the FLAG peptide is fused to a given polypeptide are commercially available (Sigma, St. Louis, Mo.).

Multimers that comprise one or more antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c form another aspect of the present disclosure. Multimers can take the form of covalently-linked or non-covalently-linked dimers, trimers, or higher multimers. Multimers comprising two or more antigen binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c and which may induce FGF21-like signaling are contemplated for use as therapeutics, diagnostics and for other uses as well, with one example of such a multimer being a homodimer. Other exemplary multimers include heterodimers, homotrimers, heterotrimers, homotetramers, heterotetramers, etc.

One embodiment is directed to multimers comprising multiple antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c joined via covalent or non-covalent interactions between peptide moieties fused to an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Such peptides can be peptide linkers (spacers), or peptides that have the property of promoting multimerization. Leucine zippers and certain polypeptides derived from antibodies are among the peptides that can promote multimerization of antigen binding proteins attached thereto, as described in more detail herein.

In particular embodiments, the multimers comprise from two to four antigen binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. The antigen binding protein moieties of the multimer can be in any of the forms described above, e.g., variants or fragments. Preferably, the multimers comprise antigen binding proteins that have the ability to specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.

In one embodiment, an oligomer is prepared using polypeptides derived from immunoglobulins. Preparation of fusion proteins comprising certain heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain) has been described, e.g., by Ashkenazi et al., (1991) Proc. Natl. Acad. Sci. USA 88:10535; Byrn et al., (1990) Nature 344:677; and Hollenbaugh et al., (1992) Current Protocols in Immunology, Suppl. 4, pages 10.19.1-10.19.11.

One embodiment comprises a dimer comprising two fusion proteins created by fusing an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c to the Fc region of an antibody. The dimer can be made by, for example, inserting a gene fusion encoding the fusion protein into an appropriate expression vector, expressing the gene fusion in host cells transformed with the recombinant expression vector, and allowing the expressed fusion protein to assemble much like antibody molecules, whereupon interchain disulfide bonds form between the Fc moieties to yield the dimer.

The term “Fc polypeptide” as used herein includes native and mutein forms of polypeptides derived from the Fc region of an antibody. Truncated forms of such polypeptides containing the hinge region that promotes dimerization also are included. Fusion proteins comprising Fc moieties (and oligomers formed therefrom) offer the advantage of facile purification by affinity chromatography over Protein A or Protein G columns.

One suitable Fc polypeptide, described in PCT application WO 93/10151 and U.S. Pat. No. 5,426,048 and No. 5,262,522, is a single chain polypeptide extending from the N-terminal hinge region to the native C-terminus of the Fc region of a human IgG1 antibody. Another useful Fc polypeptide is the Fc mutein described in U.S. Pat. No. 5,457,035, and in Baum et al., (1994) EMBO J. 13:3992-4001. The amino acid sequence of this mutein is identical to that of the native Fc sequence presented in WO 93/10151, except that amino acid 19 has been changed from Leu to Ala, amino acid 20 has been changed from Leu to Glu, and amino acid 22 has been changed from Gly to Ala. The mutein exhibits reduced affinity for Fc receptors.

In other embodiments, the variable portion of the heavy and/or light chains of a antigen binding protein such as disclosed herein can be substituted for the variable portion of an antibody heavy and/or light chain.

Alternatively, the oligomer is a fusion protein comprising multiple antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c with or without peptide linkers (spacer peptides). Among the suitable peptide linkers are those described in U.S. Pat. No. 4,751,180 and U.S. Pat. No. 4,935,233.

Another method for preparing oligomeric derivatives comprising that antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c involves use of a leucine zipper. Leucine zipper domains are peptides that promote oligomerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschultz et al., (1988) Science 240:1759-64), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble oligomeric proteins are described in PCT application WO 94/10308, and the leucine zipper derived from lung surfactant protein D (SPD) described in Hoppe et al., (1994) FEBS Letters 344:191, hereby incorporated by reference. The use of a modified leucine zipper that allows for stable trimerization of a heterologous protein fused thereto is described in Fanslow et al., (1994) Semin. Immunol. 6:267-278. In one approach, recombinant fusion proteins comprising an antigen binding protein fragment or derivative that specifically binds to a complex comprising β-Klotho and an FGFR (e.g., FGFR1c, FGFR2c or FGFR3c) is fused to a leucine zipper peptide are expressed in suitable host cells, and the soluble oligomeric antigen binding protein fragments or derivatives that form are recovered from the culture supernatant.

In certain embodiments, the antigen binding protein has a K_(D) (equilibrium binding affinity) of less than 1 μM, 10 μM, 100 μM, 1 nM, 2 nM, 5 nM, 10 nM, 25 nM or 50 nM.

In another aspect the instant disclosure provides an antigen binding protein having a half-life of at least one day in vitro or in vivo (e.g., when administered to a human subject). In one embodiment, the antigen binding protein has a half-life of at least three days. In another embodiment, the antibody or portion thereof has a half-life of four days or longer. In another embodiment, the antibody or portion thereof has a half-life of eight days or longer. In another embodiment, the antibody or portion thereof has a half-life of ten days or longer. In another embodiment, the antibody or portion thereof has a half-life of eleven days or longer. In another embodiment, the antibody or portion thereof has a half-life of fifteen days or longer. In another embodiment, the antibody or antigen-binding portion thereof is derivatized or modified such that it has a longer half-life as compared to the underivatized or unmodified antibody. In another embodiment, an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c contains point mutations to increase serum half life, such as described in WO 00/09560, published Feb. 24, 2000, incorporated by reference.

Glycosylation

An antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c can have a glycosylation pattern that is different or altered from that found in the native species. As is known in the art, glycosylation patterns can depend on both the sequence of the protein (e.g., the presence or absence of particular glycosylation amino acid residues, discussed below), or the host cell or organism in which the protein is produced. Particular expression systems are discussed below.

Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tri-peptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine can also be used.

Addition of glycosylation sites to the antigen binding protein is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tri-peptide sequences (for N-linked glycosylation sites). The alteration can also be made by the addition of, or substitution by, one or more serine or threonine residues to the starting sequence (for O-linked glycosylation sites). For ease, the antigen binding protein amino acid sequence can be altered through changes at the DNA level, particularly by mutating the DNA encoding the target polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the antigen binding protein is by chemical or enzymatic coupling of glycosides to the protein. These procedures are advantageous in that they do not require production of the protein in a host cell that has glycosylation capabilities for N- and O-linked glycosylation. Depending on the coupling mode used, the sugar(s) can be attached to (a) arginine and histidine; (b) free carboxyl groups; (c) free sulfhydryl groups such as those of cysteine; (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline; (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan; or (f) the amide group of glutamine. These methods are described in WO 87/05330 and in Aplin & Wriston, (1981) CRC Crit. Rev. Biochem. 10:259-306.

Removal of carbohydrate moieties present on the starting antigen binding protein can be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the protein to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin et al., (1987) Arch. Biochem. Biophys. 259:52-57 and by Edge et al., (1981) Anal. Biochem. 118:131-37. Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., (1987) Meth. Enzymol. 138:350-59. Glycosylation at potential glycosylation sites can be prevented by the use of the compound tunicamycin as described by Duskin et al., (1982) J. Biol. Chem. 257:3105-09. Tunicamycin blocks the formation of protein-N-glycoside linkages.

Hence, aspects of the present disclosure include glycosylation variants of antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c wherein the number and/or type of glycosylation site(s) has been altered compared to the amino acid sequences of the parent polypeptide. In certain embodiments, antibody protein variants comprise a greater or a lesser number of N-linked glycosylation sites than the native antibody. An N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue designated as X can be any amino acid residue except proline. The substitution of amino acid residues to create this sequence provides a potential new site for the addition of an N-linked carbohydrate chain. Alternatively, substitutions that eliminate or alter this sequence will prevent addition of an N-linked carbohydrate chain present in the native polypeptide. For example, the glycosylation can be reduced by the deletion of an Asn or by substituting the Asn with a different amino acid. In other embodiments, one or more new N-linked sites are created. Antibodies typically have a N-linked glycosylation site in the Fc region.

Labels and Effector Groups

In some embodiments, an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c comprises one or more labels. The term “labeling group” or “label” means any detectable label. Examples of suitable labeling groups include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I) fluorescent groups (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent groups, biotinyl groups, or predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, the labeling group is coupled to the antigen binding protein via spacer arms of various lengths to reduce potential steric hindrance. Various methods for labeling proteins are known in the art and can be used as is seen fit.

The term “effector group” means any group coupled to an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c and that acts as a cytotoxic agent. Examples for suitable effector groups are radioisotopes or radionuclides (e.g., ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I). Other suitable groups include toxins, therapeutic groups, or chemotherapeutic groups. Examples of suitable groups include calicheamicin, auristatins, geldanamycin and cantansine. In some embodiments, the effector group is coupled to the antigen binding protein via spacer arms of various lengths to reduce potential steric hindrance.

In general, labels fall into a variety of classes, depending on the assay in which they are to be detected: a) isotopic labels, which can be radioactive or heavy isotopes; b) magnetic labels (e.g., magnetic particles); c) redox active moieties; d) optical dyes; enzymatic groups (e.g. horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase); e) biotinylated groups; and f) predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags, etc.). In some embodiments, the labeling group is coupled to the antigen binding protein via spacer arms of various lengths to reduce potential steric hindrance. Various methods for labeling proteins are known in the art.

Specific labels include optical dyes, including, but not limited to, chromophores, phosphors and fluorophores, with the latter being specific in many instances. Fluorophores can be either “small molecule” fluores, or proteinaceous fluores.

By “fluorescent label” is meant any molecule that can be detected via its inherent fluorescent properties. Suitable fluorescent labels include, but are not limited to, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosin, coumarin, methyl-coumarins, pyrene, Malacite green, stilbene, Lucifer Yellow, Cascade Blue, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, the Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cascade Yellow and R-phycoerythrin (PE) (Molecular Probes, Eugene, Oreg.), FITC, Rhodamine, and Texas Red (Pierce, Rockford, Ill.), Cy5, Cy5.5, Cy7 (Amersham Life Science, Pittsburgh, Pa.). Suitable optical dyes, including fluorophores, are described in Molecular Probes Handbook by Richard P. Haugland and in subsequent editions, including Molecular Probes Handbook, A Guide to Fluorescent Probes and Labeling Technologies, 11^(th) edition, Johnson and Spence (eds), hereby expressly incorporated by reference.

Suitable proteinaceous fluorescent labels also include, but are not limited to, green fluorescent protein, including a Renilla, Ptilosarcus, or Aequorea species of GFP (Chalfie et al., (1994) Science 263:802-805), eGFP (Clontech Labs., Inc., Genbank Accession Number U55762), blue fluorescent protein (BFP, Quantum Biotechnologies, Inc., Quebec, Canada; Stauber, (1998) Biotechniques 24:462-71; Heim et al., (1996) Curr. Biol. 6:178-82), enhanced yellow fluorescent protein (EYFP, Clontech Labs., Inc.), luciferase (Ichiki et al., (1993) J. Immunol. 150:5408-17), β-galactosidase (Nolan et al., (1988) Proc. Natl. Acad. Sci. U.S.A. 85:2603-07) and Renilla (WO92/15673, WO95/07463, WO98/14605, WO98/26277, WO99/49019, U.S. Pat. Nos. 5,292,658, 5,418,155, 5,683,888, 5,741,668, 5,777,079, 5,804,387, 5,874,304, 5,876,995 and 5925558).

Preparing of Antigen Binding Proteins

Non-human antibodies that are provided can be, for example, derived from any antibody-producing animal, such as a mouse, rat, rabbit, goat, donkey, or non-human primate (such as a monkey, (e.g., cynomolgus or rhesus monkey) or an ape (e.g., chimpanzee)). Non-human antibodies can be used, for instance, in in vitro cell culture and cell-culture based applications, or any other application where an immune response to the antibody does not occur or is insignificant, can be prevented, is not a concern, or is desired. In certain embodiments, the antibodies can be produced by immunizing with cell bound receptor from CHO transfectants expressing full length human FGFR1c and β-Klotho at the cell surface following incubated with FGF21; or with cell bound receptor of 293T transfectants expressing full length human β-Klotho and an N-terminal truncated version of human FGFR1c encompassing amino acid residues 141 to 822 of the polypeptide of SEQ ID NO: 4; or with full-length β-Klotho, FGFR1c, FGFR2c or FGFR3c; or with the extracellular domain of β-Klotho, FGFR1c, FGFR2c or FGFR3c; or with two of β-Klotho, FGFR1c, FGFR2c, and FGFR3c; or with whole cells expressing FGFR1c, β-Klotho or both FGFR1c and β-Klotho; or with membranes prepared from cells expressing FGFR1c, β-Klotho or both FGFR1c and β-Klotho; or with fusion proteins, e.g., Fc fusions comprising FGFR1c, β-Klotho or FGFR1c and β-Klotho (or extracellular domains thereof) fused to Fc, and other methods known in the art, e.g., as described in the Examples presented herein. Alternatively, the certain non-human antibodies can be raised by immunizing with amino acids which are segments of one or more of β-Klotho, FGFR1c, FGFR2c or FGFR3c that form part of the epitope to which certain antibodies provided herein bind. The antibodies can be polyclonal, monoclonal, or can be synthesized in host cells by expressing recombinant DNA.

Fully human antibodies can be prepared as described above by immunizing transgenic animals containing human immunoglobulin loci or by selecting a phage display library that is expressing a repertoire of human antibodies.

The monoclonal antibodies (mAbs) can be produced by a variety of techniques, including conventional monoclonal antibody methodology, e.g., the standard somatic cell hybridization technique of Kohler & Milstein, (1975) Nature 256:495-97. Alternatively, other techniques for producing monoclonal antibodies can be employed, for example, the viral or oncogenic transformation of B-lymphocytes. One suitable animal system for preparing hybridomas is the murine system, which is a very well established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art. For such procedures, B cells from immunized mice are fused with a suitable immortalized fusion partner, such as a murine myeloma cell line. If desired, rats or other mammals besides can be immunized instead of mice and B cells from such animals can be fused with the murine myeloma cell line to form hybridomas. Alternatively, a myeloma cell line from a source other than mouse can be used. Fusion procedures for making hybridomas also are well known. SLAM technology can also be employed in the production of antibodies.

The single chain antibodies that are provided can be formed by linking heavy and light chain variable domain (Fv region) fragments via an amino acid bridge (short peptide linker), resulting in a single polypeptide chain. Such single-chain Fvs (scFvs) can be prepared by fusing DNA encoding a peptide linker between DNAs encoding the two variable domain polypeptides (V_(L) and V_(H)). The resulting polypeptides can fold back on themselves to form antigen-binding monomers, or they can form multimers (e.g., dimers, trimers, or tetramers), depending on the length of a flexible linker between the two variable domains (Kortt et al., (1997) Prot. Eng. 10:423; Kortt et al., (2001) Biomol. Eng. 18:95-108). By combining different V_(L) and V_(H)-comprising polypeptides, one can form multimeric scFvs that bind to different epitopes (Kriangkum et al., (2001) Biomol. Eng. 18:31-40). Techniques developed for the production of single chain antibodies include those described in U.S. Pat. No. 4,946,778; Bird et al., (1988) Science 242:423-26; Huston et al., (1988) Proc. Natl. Acad. Sci. U.S.A. 85:5879-83; Ward et al., (1989) Nature 334:544-46, de Graaf et al., (2002) Methods Mol. Biol. 178:379-387. Single chain antibodies derived from antibodies provided herein include, but are not limited to scFvs comprising the variable domain combinations of the heavy and light chain variable regions depicted in Table 2, or combinations of light and heavy chain variable domains which include the CDRs depicted in Tables 3-4 and 6-23.

Antibodies provided herein that are of one subclass can be changed to antibodies from a different subclass using subclass switching methods. Thus, IgG antibodies can be derived from an IgM antibody, for example, and vice versa. Such techniques allow the preparation of new antibodies that possess the antigen binding properties of a given antibody (the parent antibody), but also exhibit biological properties associated with an antibody isotype or subclass different from that of the parent antibody. Recombinant DNA techniques can be employed. Cloned DNA encoding particular antibody polypeptides can be employed in such procedures, e.g., DNA encoding the constant domain of an antibody of the desired isotype. See, e.g., Lantto et al., (2002) Methods Mol. Biol. 178:303-16.

Accordingly, the antibodies that are provided include those comprising, for example, the variable domain combinations described, supra., having a desired isotype (for example, IgA, IgG1, IgG2, IgG3, IgG4, IgE, and IgD) as well as Fab or F(ab′)₂ fragments thereof. Moreover, if an IgG4 is desired, it can also be desired to introduce a point mutation (e.g., a mutation from CPSCP to CPPCP (SEQ ID NOs 1828 and 1829, respectively, in order of appearance) in the hinge region as described in Bloom et al., (1997) Protein Science 6:407-15, incorporated by reference herein) to alleviate a tendency to form intra-H chain disulfide bonds that can lead to heterogeneity in the IgG4 antibodies.

Moreover, techniques for deriving antibodies having different properties (i.e., varying affinities for the antigen to which they bind) are also known. One such technique, referred to as chain shuffling, involves displaying immunoglobulin variable domain gene repertoires on the surface of filamentous bacteriophage, often referred to as phage display. Chain shuffling has been used to prepare high affinity antibodies to the hapten 2-phenyloxazol-5-one, as described by Marks et al., (1992) Nature Biotechnology 10:779-83.

Conservative modifications can be made to the heavy and light chain variable regions described in Table 2, or the CDRs described in Tables 3A and 3B, 4A and 4B, and Tables 6-23 (and corresponding modifications to the encoding nucleic acids) to produce an antigen binding protein having functional and biochemical characteristics. Methods for achieving such modifications are described herein.

Antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c can be further modified in various ways. For example, if they are to be used for therapeutic purposes, they can be conjugated with polyethylene glycol (PEGylated) to prolong the serum half-life or to enhance protein delivery. PEG can be attached directly to the antigen binding protein or it can be attached via a linker, such as a glycosidic linkage.

Alternatively, the V region of the subject antibodies or fragments thereof can be fused with the Fc region of a different antibody molecule. The Fc region used for this purpose can be modified so that it does not bind complement, thus reducing the likelihood of inducing cell lysis in the patient when the fusion protein is used as a therapeutic agent. In addition, the subject antibodies or functional fragments thereof can be conjugated with human serum albumin to enhance the serum half-life of the antibody or fragment thereof. Another useful fusion partner for the antigen binding proteins or fragments thereof is transthyretin (TTR). TTR has the capacity to form a tetramer, thus an antibody-TTR fusion protein can form a multivalent antibody which can increase its binding avidity.

Alternatively, substantial modifications in the functional and/or biochemical characteristics of the antigen binding proteins described herein can be achieved by creating substitutions in the amino acid sequence of the heavy and light chains that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulkiness of the side chain. A “conservative amino acid substitution” can involve a substitution of a native amino acid residue with a normative residue that has little or no effect on the polarity or charge of the amino acid residue at that position. See, Table 8, supra. Furthermore, any native residue in the polypeptide can also be substituted with alanine, as has been previously described for alanine scanning mutagenesis.

Amino acid substitutions (whether conservative or non-conservative) of the subject antibodies can be implemented by those skilled in the art by applying routine techniques. Amino acid substitutions can be used to identify important residues of the antibodies provided herein, or to increase or decrease the affinity of these antibodies for a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c or for modifying the binding affinity of other antigen-binding proteins described herein.

Methods of Expressing Antigen Binding Proteins

Expression systems and constructs in the form of plasmids, expression vectors, transcription or expression cassettes that comprise at least one polynucleotide as described above are also provided herein, as well host cells comprising such expression systems or constructs.

The antigen binding proteins provided herein can be prepared by any of a number of conventional techniques. For example, antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c can be produced by recombinant expression systems, using any technique known in the art. See, e.g., Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, (Kennet et al., eds.) Plenum Press (1980) and subsequent editions; and Harlow & Lane, (1988) supra.

Antigen binding proteins can be expressed in hybridoma cell lines (e.g., in particular antibodies can be expressed in hybridomas) or in cell lines other than hybridomas. Expression constructs encoding the antibodies can be used to transform a mammalian, insect or microbial host cell. Transformation can be performed using any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus or bacteriophage and transducing a host cell with the construct by transfection procedures known in the art, as exemplified by U.S. Pat. Nos. 4,399,216; 4,912,040; 4,740,461; and 4,959,455. The optimal transformation procedure used will depend upon which type of host cell is being transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, mixing nucleic acid with positively-charged lipids, and direct microinjection of the DNA into nuclei.

Recombinant expression constructs typically comprise a nucleic acid molecule encoding a polypeptide comprising one or more of the following: one or more CDRs provided herein; a light chain constant region; a light chain variable region; a heavy chain constant region (e.g., C_(H)1, C_(H)2 and/or C_(H)3); and/or another scaffold portion of an antigen binding protein. These nucleic acid sequences are inserted into an appropriate expression vector using standard ligation techniques. In one embodiment, the heavy or light chain constant region is appended to the C-terminus of the anti-β-Klotho/FGFR (e.g., FGFR1c, FGFR2c or FGFR3c) complex-specific heavy or light chain variable region and is ligated into an expression vector. The vector is typically selected to be functional in the particular host cell employed (i.e., the vector is compatible with the host cell machinery, permitting amplification and/or expression of the gene can occur). In some embodiments, vectors are used that employ protein-fragment complementation assays using protein reporters, such as dihydrofolate reductase (see, for example, U.S. Pat. No. 6,270,964, which is hereby incorporated by reference). Suitable expression vectors can be purchased, for example, from Invitrogen Life Technologies or BD Biosciences. Other useful vectors for cloning and expressing the antibodies and fragments include those described in Bianchi and McGrew, (2003) Biotech. Biotechnol. Bioeng. 84:439-44, which is hereby incorporated by reference. Additional suitable expression vectors are discussed, for example, in “Gene Expression Technology,” Methods Enzymol., vol. 185, (Goeddel et al., ed.), (1990), Academic Press.

Typically, expression vectors used in any of the host cells will contain sequences for plasmid maintenance and for cloning and expression of exogenous nucleotide sequences. Such sequences, collectively referred to as “flanking sequences” in certain embodiments will typically include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, a complete intron sequence containing a donor and acceptor splice site, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element.

Optionally, an expression vector can contain a “tag”-encoding sequence, i.e., an oligonucleotide molecule located at the 5′ or 3′ end of an antigen binding protein coding sequence; the oligonucleotide sequence encodes polyHis (such as hexaHis, HHHHHH (SEQ ID NO: 1830)), or another “tag” such as FLAG, HA (hemaglutinin influenza virus), or myc, for which commercially available antibodies exist. This tag is typically fused to the polypeptide upon expression of the polypeptide, and can serve as a means for affinity purification or detection of the antigen binding protein from the host cell. Affinity purification can be accomplished, for example, by column chromatography using antibodies against the tag as an affinity matrix. Optionally, the tag can subsequently be removed from the purified antigen binding protein by various means such as using certain peptidases for cleavage.

Flanking sequences can be homologous (i.e., from the same species and/or strain as the host cell), heterologous (i.e., from a species other than the host cell species or strain), hybrid (i.e., a combination of flanking sequences from more than one source), synthetic or native. As such, the source of a flanking sequence can be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequence is functional in, and can be activated by, the host cell machinery.

Flanking sequences useful in the vectors can be obtained by any of several methods well known in the art. Typically, flanking sequences useful herein will have been previously identified by mapping and/or by restriction endonuclease digestion and can thus be isolated from the proper tissue source using the appropriate restriction endonucleases. In some cases, the full nucleotide sequence of a flanking sequence can be known. Here, the flanking sequence can be synthesized using the methods described herein for nucleic acid synthesis or cloning.

Whether all or only a portion of the flanking sequence is known, it can be obtained using polymerase chain reaction (PCR) and/or by screening a genomic library with a suitable probe such as an oligonucleotide and/or flanking sequence fragment from the same or another species. Where the flanking sequence is not known, a fragment of DNA containing a flanking sequence can be isolated from a larger piece of DNA that can contain, for example, a coding sequence or even another gene or genes. Isolation can be accomplished by restriction endonuclease digestion to produce the proper DNA fragment followed by isolation using agarose gel purification, column chromatography or other methods known to the skilled artisan. The selection of suitable enzymes to accomplish this purpose will be readily apparent to one of ordinary skill in the art.

An origin of replication is typically a part of those prokaryotic expression vectors purchased commercially, and the origin aids in the amplification of the vector in a host cell. If the vector of choice does not contain an origin of replication site, one can be chemically synthesized based on a known sequence, and ligated into the vector. For example, the origin of replication from the plasmid pBR322 (GenBank Accession # J01749, New England Biolabs, Beverly, Mass.) is suitable for most gram-negative bacteria, and various viral origins (e.g., SV40, polyoma, adenovirus, vesicular stomatitus virus (VSV), or papillomaviruses such as HPV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (for example, the SV40 origin is often used only because it also contains the virus early promoter).

A transcription termination sequence is typically located 3′ to the end of a polypeptide coding region and serves to terminate transcription. Usually, a transcription termination sequence in prokaryotic cells is a G-C rich fragment followed by a poly-T sequence. While the sequence is easily cloned from a library or even purchased commercially as part of a vector, it can also be readily synthesized using methods for nucleic acid synthesis such as those described herein.

A selectable marker gene encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium. Typical selection marker genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, tetracycline, or kanamycin for prokaryotic host cells; (b) complement auxotrophic deficiencies of the cell; or (c) supply critical nutrients not available from complex or defined media. Specific selectable markers are the kanamycin resistance gene, the ampicillin resistance gene, and the tetracycline resistance gene. Advantageously, a neomycin resistance gene can also be used for selection in both prokaryotic and eukaryotic host cells.

Other selectable genes can be used to amplify the gene that will be expressed. Amplification is the process wherein genes that are required for production of a protein critical for growth or cell survival are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Examples of suitable selectable markers for mammalian cells include dihydrofolate reductase (DHFR) and promoterless thymidine kinase genes. Mammalian cell transformants are placed under selection pressure wherein only the transformants are uniquely adapted to survive by virtue of the selectable gene present in the vector. Selection pressure is imposed by culturing the transformed cells under conditions in which the concentration of selection agent in the medium is successively increased, thereby leading to the amplification of both the selectable gene and the DNA that encodes another gene, such as an antigen binding protein that binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. As a result, increased quantities of a polypeptide such as an antigen binding protein are synthesized from the amplified DNA.

A ribosome-binding site is usually necessary for translation initiation of mRNA and is characterized by a Shine-Dalgarno sequence (prokaryotes) or a Kozak sequence (eukaryotes). The element is typically located 3′ to the promoter and 5′ to the coding sequence of the polypeptide to be expressed.

In some cases, such as where glycosylation is desired in a eukaryotic host cell expression system, one can manipulate the various pre- or pro-sequences to improve glycosylation or yield. For example, one can alter the peptidase cleavage site of a particular signal peptide, or add prosequences, which also can affect glycosylation. The final protein product can have, in the −1 position (relative to the first amino acid of the mature protein), one or more additional amino acids incident to expression, which may not have been totally removed. For example, the final protein product can have one or two amino acid residues found in the peptidase cleavage site, attached to the amino-terminus. Alternatively, use of some enzyme cleavage sites can result in a slightly truncated form of the desired polypeptide, if the enzyme cuts at such area within the mature polypeptide.

Expression and cloning will typically contain a promoter that is recognized by the host organism and operably linked to the molecule encoding an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Promoters are untranscribed sequences located upstream (i.e., 5′) to the start codon of a structural gene (generally within about 100 to 1000 bp) that control transcription of the structural gene. Promoters are conventionally grouped into one of two classes: inducible promoters and constitutive promoters. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as the presence or absence of a nutrient or a change in temperature. Constitutive promoters, on the other hand, uniformly transcribe a gene to which they are operably linked, that is, with little or no control over gene expression. A large number of promoters, recognized by a variety of potential host cells, are well known. A suitable promoter is operably linked to the DNA encoding heavy chain or light chain comprising an antigen binding protein by removing the promoter from the source DNA by restriction enzyme digestion and inserting the desired promoter sequence into the vector.

Suitable promoters for use with yeast hosts are also well known in the art. Yeast enhancers are advantageously used with yeast promoters. Suitable promoters for use with mammalian host cells are well known and include, but are not limited to, those obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retroviruses, hepatitis-B virus, and Simian Virus 40 (SV40). Other suitable mammalian promoters include heterologous mammalian promoters, for example, heat-shock promoters and the actin promoter.

Additional promoters which can be of interest include, but are not limited to: SV40 early promoter (Benoist & Chambon, (1981) Nature 290:304-310); CMV promoter (Thomsen et al., (1984) Proc. Natl. Acad. U.S.A. 81:659-663); the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus (Yamamoto et al., (1980) Cell 22:787-97); herpes thymidine kinase promoter (Wagner et al., (1981) Proc. Natl. Acad. Sci. U.S.A. 78:1444-45); promoter and regulatory sequences from the metallothionine gene (Prinster et al., (1982) Nature 296:39-42); and prokaryotic promoters such as the beta-lactamase promoter (Villa-Kamaroff et al., (1978) Proc. Natl. Acad. Sci. U.S.A. 75:3727-31); or the tac promoter (DeBoer et al., (1983) Proc. Natl. Acad. Sci. U.S.A. 80:21-25). Also of interest are the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: the elastase I gene control region that is active in pancreatic acinar cells (Swift et al., (1984) Cell 38:639-46; Ornitz et al., (1986) Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, (1987) Hepatology 7:425-515); the insulin gene control region that is active in pancreatic beta cells (Hanahan, (1985) Nature 315:115-22); the immunoglobulin gene control region that is active in lymphoid cells (Grosschedl et al., (1984) Cell 38:647-58; Adames et al., (1985) Nature 318:533-38; Alexander et al., (1987) Mol. Cell. Biol. 7:1436-44); the mouse mammary tumor virus control region that is active in testicular, breast, lymphoid and mast cells (Leder et al., (1986) Cell 45:485-95); the albumin gene control region that is active in liver (Pinkert et al., (1987) Genes and Devel. 1:268-76); the alpha-feto-protein gene control region that is active in liver (Krumlauf et al., (1985) Mol. Cell. Biol. 5:1639-48; Hammer et al., (1987) Science 253:53-58); the alpha 1-antitrypsin gene control region that is active in liver (Kelsey et al., (1987) Genes and Devel. 1:161-71); the beta-globin gene control region that is active in myeloid cells (Mogram et al., (1985) Nature 315:338-40; Kollias et al., (1986) Cell 46:89-94); the myelin basic protein gene control region that is active in oligodendrocyte cells in the brain (Readhead et al., (1987) Cell 48:703-12); the myosin light chain-2 gene control region that is active in skeletal muscle (Sani, (1985) Nature 314:283-86); and the gonadotropic releasing hormone gene control region that is active in the hypothalamus (Mason et al., (1986) Science 234:1372-78).

An enhancer sequence can be inserted into the vector to increase transcription of DNA encoding light chain or heavy chain comprising an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c by higher eukaryotes, e.g., a human antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Enhancers are cis-acting elements of DNA, usually about 10-300 bp in length, that act on the promoter to increase transcription. Enhancers are relatively orientation and position independent, having been found at positions both 5′ and 3′ to the transcription unit. Several enhancer sequences available from mammalian genes are known (e.g., globin, elastase, albumin, alpha-feto-protein and insulin). Typically, however, an enhancer from a virus is used. The SV40 enhancer, the cytomegalovirus early promoter enhancer, the polyoma enhancer, and adenovirus enhancers known in the art are exemplary enhancing elements for the activation of eukaryotic promoters. While an enhancer can be positioned in the vector either 5′ or 3′ to a coding sequence, it is typically located at a site 5′ from the promoter. A sequence encoding an appropriate native or heterologous signal sequence (leader sequence or signal peptide) can be incorporated into an expression vector, to promote extracellular secretion of the antibody. The choice of signal peptide or leader depends on the type of host cells in which the antibody is to be produced, and a heterologous signal sequence can replace the native signal sequence. Examples of signal peptides that are functional in mammalian host cells include the following: the signal sequence for interleukin-7 (IL-7) described in U.S. Pat. No. 4,965,195; the signal sequence for interleukin-2 receptor described in Cosman et al., (1984) Nature 312:768-71; the interleukin-4 receptor signal peptide described in EP Patent No. 0367 566; the type I interleukin-1 receptor signal peptide described in U.S. Pat. No. 4,968,607; the type II interleukin-1 receptor signal peptide described in EP Patent No. 0 460 846.

Expression vectors can be constructed from a starting vector such as a commercially available vector. Such vectors can but need not contain all of the desired flanking sequences. Where one or more of the flanking sequences are not already present in the vector, they can be individually obtained and ligated into the vector. Methods used for obtaining each of the flanking sequences are well known to one skilled in the art.

After the vector has been constructed and a nucleic acid molecule encoding light chain, a heavy chain, or a light chain and a heavy chain comprising an antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c has been inserted into the proper site of the vector, the completed vector can be inserted into a suitable host cell for amplification and/or polypeptide expression. The transformation of an expression vector for an antigen binding protein into a selected host cell can be accomplished by well known methods including transfection, infection, calcium phosphate co-precipitation, electroporation, microinjection, lipofection, DEAE-dextran mediated transfection, or other known techniques. The method selected will in part be a function of the type of host cell to be used. These methods and other suitable methods are well known to the skilled artisan, and are set forth, for example, in Sambrook et al., (2001), supra.

A host cell, when cultured under appropriate conditions, synthesizes an antigen binding protein that can subsequently be collected from the culture medium (if the host cell secretes it into the medium) or directly from the host cell producing it (if it is not secreted). The selection of an appropriate host cell will depend upon various factors, such as desired expression levels, polypeptide modifications that are desirable or necessary for activity (such as glycosylation or phosphorylation) and ease of folding into a biologically active molecule.

Mammalian cell lines available as hosts for expression are well known in the art and include, but are not limited to, immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to HeLa cells, Human Embryonic Kidney 293 cells (HEK293 cells), Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines. In certain embodiments, cell lines can be selected through determining which cell lines have high expression levels and constitutively produce antigen binding proteins with desirable binding properties (e.g., the ability to bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c). In another embodiment, a cell line from the B cell lineage that does not make its own antibody but has a capacity to make and secrete a heterologous antibody can be selected. The ability to induce FGF21-like signaling can also form a selection criterion.

Uses of Antigen Binding Proteins for Diagnostic and Therapeutic Purposes

The antigen binding proteins disclosed herein are useful for detecting to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c in biological samples and identification of cells or tissues that produce one or more of β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. For instance, the antigen binding proteins disclosed herein can be used in diagnostic assays, e.g., binding assays to detect and/or quantify a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c expressed in a tissue or cell.

Antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c can also be used in treatment of diseases related to FGF21-like signaling in a patient in need thereof, such as type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease, and metabolic syndrome. By forming a signaling complex comprising an antigen binding protein and a complex comprising 13-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, the natural in vivo activity of FGF21, which associates with a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c in vivo to initiate signaling, can be mimicked and/or enhanced, leading to therapeutic effects.

Indications

A disease or condition associated with human FGF21 includes any disease or condition whose onset in a patient is influenced by, at least in part, the lack of or therapeutically insufficient induction of FGF21-like signaling, which is initiated in vivo by the formation of a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. The severity of the disease or condition can also be decreased by the induction of FGF21-like signaling. Examples of diseases and conditions that can be treated with the antigen binding proteins provided herein include type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease, and metabolic syndrome.

The antigen binding proteins described herein can be used to treat type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease, and metabolic syndrome, or can be employed as a prophylactic treatment administered, e.g., daily, weekly, biweekly, monthly, bimonthly, biannually, etc to prevent or reduce the frequency and/or severity of symptoms, e.g., elevated plasma glucose levels, elevated triglycerides and/or cholesterol levels, thereby providing an improved glycemic and cardiovascular risk factor profile.

Diagnostic Methods

The antigen binding proteins described herein can be used for diagnostic purposes to detect, diagnose, or monitor diseases and/or conditions associated with FGFR1c, FGFR2c, FGFR3c, β-Klotho, FGF21 and/or complexes comprising combinations thereof. Also provided are methods for the detection of the presence of to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c in a sample using classical immunohistological methods known to those of skill in the art (e.g., Tijssen, (1985) “Practice and Theory of Enzyme Immunoassays” in Laboratory Techniques in Biochemistry and Molecular Biology, 15 (Burdon & van Knippenberg, eds.), Elsevier Biomedical); Zola, (1987) Monoclonal Antibodies: A Manual of Techniques, pp. 147-58 (CRC Press, Inc.); Jalkanen et al., (1985) J. Cell. Biol. 101:976-85; Jalkanen et al., (1987) J. Cell Biol. 105:3087-96). The detection of a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c can be performed in vivo or in vitro.

Diagnostic applications provided herein include use of the antigen binding proteins to detect expression/formation of a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c, and/or binding to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Examples of methods useful in the detection of the presence of a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA).

For diagnostic applications, the antigen binding protein typically will be labeled with a detectable labeling group. Suitable labeling groups include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I), fluorescent groups (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent groups, biotinyl groups, or predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, the labeling group is coupled to the antigen binding protein via spacer arms of various lengths to reduce potential steric hindrance. Various methods for labeling proteins are known in the art and can be used.

In another aspect, an antigen binding protein can be used to identify a cell or cells that express a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In a specific embodiment, the antigen binding protein is labeled with a labeling group and the binding of the labeled antigen binding protein to a complex comprising 13-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c is detected. In a further specific embodiment, the binding of the antigen binding protein to a complex comprising 13-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c detected in vivo. In a further specific embodiment, the antigen binding protein is isolated and measured using techniques known in the art. See, for example, Harlow & Lane, (1988) supra; Current Protocols In Immunology (John E. Coligan, ed), John Wiley & Sons (1993 ed., and supplements and/or updates).

Another aspect provides for detecting the presence of a test molecule that competes for binding to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c with the antigen binding proteins provided, as disclosed herein. An example of one such assay could involve detecting the amount of free antigen binding protein in a solution containing an amount of a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c in the presence or absence of the test molecule. An increase in the amount of free antigen binding protein (i.e., the antigen binding protein not bound to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c) would indicate that the test molecule is capable of competing for binding to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c with the antigen binding protein. In one embodiment, the antigen binding protein is labeled with a labeling group. Alternatively, the test molecule is labeled and the amount of free test molecule is monitored in the presence and absence of an antigen binding protein.

Methods of Treatment: Pharmaceutical Formulations and Routes of Administration

Methods of using the disclosed antigen binding proteins are also provided. In some methods, an antigen binding protein is provided to a patient, which induces FGF21-like signaling.

Pharmaceutical compositions that comprise a therapeutically effective amount of one or a plurality of the antigen binding proteins and a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative, and/or adjuvant are also provided. In addition, methods of treating a patient by administering such pharmaceutical composition are included. The term “patient” includes human patients.

Acceptable formulation materials are nontoxic to recipients at the dosages and concentrations employed. In specific embodiments, pharmaceutical compositions comprising a therapeutically effective amount of human antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c are provided.

In certain embodiments, acceptable formulation materials preferably are nontoxic to recipients at the dosages and concentrations employed. In certain embodiments, the pharmaceutical composition can contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. In such embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring, flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as Pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (such as sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants. See, e.g., Remington's Pharmaceutical Sciences, 18th Edition, (A. R. Gennaro, ed.), 1990, Mack Publishing Company, and subsequent editions.

In certain embodiments, the optimal pharmaceutical composition will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format and desired dosage. See, for example, Remington's Pharmaceutical Sciences, supra. In certain embodiments, such compositions can influence the physical state, stability, rate of in vivo release and rate of in vivo clearance of the antigen binding proteins disclosed. In certain embodiments, the primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier can be water for injection, physiological saline solution or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. In specific embodiments, pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, and can further include sorbitol or a suitable substitute. In certain embodiments, compositions comprising antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents (see, Remington's Pharmaceutical Sciences, supra for examples of suitable formulation agents) in the form of a lyophilized cake or an aqueous solution. Further, in certain embodiments, antigen binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c can be formulated as a lyophilizate using appropriate excipients such as sucrose.

The pharmaceutical compositions can be selected for parenteral delivery. Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. Preparation of such pharmaceutically acceptable compositions is within the skill of the art.

The formulation components are present preferably in concentrations that are acceptable to the site of administration. In certain embodiments, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

When parenteral administration is contemplated, the therapeutic compositions can be provided in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising the desired antigen binding protein in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which the antigen binding protein is formulated as a sterile, isotonic solution, properly preserved. In certain embodiments, the preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads or liposomes, that can provide controlled or sustained release of the product which can be delivered via depot injection. In certain embodiments, hyaluronic acid can also be used, which can have the effect of promoting sustained duration in the circulation. In certain embodiments, implantable drug delivery devices can be used to introduce the desired antigen binding protein.

Certain pharmaceutical compositions are formulated for inhalation. In some embodiments, antigen binding proteins that bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c are formulated as a dry, inhalable powder. In specific embodiments, antigen binding protein inhalation solutions can also be formulated with a propellant for aerosol delivery. In certain embodiments, solutions can be nebulized. Pulmonary administration and formulation methods therefore are further described in International Patent Application No. PCT/US94/001875, which is incorporated by reference and describes pulmonary delivery of chemically modified proteins. Some formulations can be administered orally. Antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c that are administered in this fashion can be formulated with or without carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. In certain embodiments, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of an antigen binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

Some pharmaceutical compositions comprise an effective quantity of one or a plurality of human antigen binding proteins that specifically bind to a complex comprising 13-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

Additional pharmaceutical compositions will be evident to those skilled in the art, including formulations involving antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. See, for example, International Patent Application No. PCT/US93/00829, which is incorporated by reference and describes controlled release of porous polymeric microparticles for delivery of pharmaceutical compositions. Sustained-release preparations can include semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides (as disclosed in U.S. Pat. No. 3,773,919 and European Patent Application Publication No. EP 058481, each of which is incorporated by reference), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., (1983) Biopolymers 2:547-556), poly (2-hydroxyethyl-inethacrylate) (Langer et al., (1981) J. Biomed. Mater. Res. 15:167-277 and Langer, (1982) Chem. Tech. 12:98-105), ethylene vinyl acetate (Langer et al., (1981) supra) or poly-D(−)-3-hydroxybutyric acid (European Patent Application Publication No. EP 133988). Sustained release compositions can also include liposomes that can be prepared by any of several methods known in the art. See, e.g., Eppstein et al., (1985) Proc. Natl. Acad. Sci. U.S.A. 82:3688-3692; European Patent Application Publication Nos. EP 036676; EP 088046 and EP 143949, incorporated by reference.

Pharmaceutical compositions used for in vivo administration are typically provided as sterile preparations. Sterilization can be accomplished by filtration through sterile filtration membranes. When the composition is lyophilized, sterilization using this method can be conducted either prior to or following lyophilization and reconstitution. Compositions for parenteral administration can be stored in lyophilized form or in a solution. Parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

In certain embodiments, cells expressing a recombinant antigen binding protein as disclosed herein are encapsulated for delivery (see, Tao et al., Invest. Ophthalmol V is Sci (2002) 43:3292-3298 and Sieving et al., Proc. Natl. Acad. Sciences USA (2006) 103:3896-3901).

In certain formulations, an antigen binding protein has a concentration of between 10 mg/ml and 150 mg/ml. Some formulations contain a buffer, sucrose and polysorbate. An example of a formulation is one containing 50-100 mg/ml of antigen binding protein, 5-20 mM sodium acetate, 5-10% w/v sucrose, and 0.002-0.008% w/v polysorbate. Certain, formulations, for instance, contain 1-100 mg/ml of an antigen binding protein in 9-11 mM sodium acetate buffer, 8-10% w/v sucrose, and 0.005-0.006% w/v polysorbate. The pH of certain such formulations is in the range of 4.5-6. Other formulations can have a pH of 5.0-5.5.

Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, crystal, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) that is reconstituted prior to administration. Kits for producing a single-dose administration unit are also provided. Certain kits contain a first container having a dried protein and a second container having an aqueous formulation. In certain embodiments, kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lyosyringes) are provided. The therapeutically effective amount of an antigen binding protein-containing pharmaceutical composition to be employed will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will vary depending, in part, upon the molecule delivered, the indication for which the antigen binding protein is being used, the route of administration, and the size (body weight, body surface or organ size) and/or condition (the age and general health) of the patient. In certain embodiments, the clinician can titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.

A typical dosage can range from about 1 μg/kg to up to about 30 mg/kg or more, depending on the factors mentioned above. In specific embodiments, the dosage can range from 10 μg/kg up to about 35 mg/kg, optionally from 0.1 mg/kg up to about 35 mg/kg, alternatively from 0.3 mg/kg up to about 20 mg/kg. In some applications, the dosage is from 0.5 mg/kg to 20 mg/kg and in other applications the dosage is from 21-100 mg/kg. In some instances, an antigen binding protein is dosed at 0.3-20 mg/kg. The dosage schedule in some treatment regimes is at a dose of 0.3 mg/kg qW-20 mg/kg qW.

Dosing frequency will depend upon the pharmacokinetic parameters of the particular antigen binding protein in the formulation used. Typically, a clinician administers the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, or as two or more doses (which can but need not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Appropriate dosages can be ascertained through use of appropriate dose-response data. In certain embodiments, the antigen binding proteins can be administered to patients throughout an extended time period. Chronic administration of an antigen binding protein minimizes the adverse immune or allergic response commonly associated with antigen binding proteins that are not fully human, for example an antibody raised against a human antigen in a non-human animal, for example, a non-fully human antibody or non-human antibody produced in a non-human species.

The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally, through injection by intravenous, intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial, intraportal, or intralesional routes; by sustained release systems or by implantation devices. In certain embodiments, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

The composition also can be administered locally via implantation of a membrane, sponge or another appropriate material onto which the desired molecule has been absorbed or encapsulated. In certain embodiments, where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

It also can be desirable to use antigen binding protein pharmaceutical compositions ex vivo. In such instances, cells, tissues or organs that have been removed from the patient are exposed to antigen binding protein pharmaceutical compositions after which the cells, tissues and/or organs are subsequently implanted back into the patient.

In particular, antigen binding proteins that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c can be delivered by implanting certain cells that have been genetically engineered, using methods such as those described herein and known in the art, to express and secrete the polypeptide. In certain embodiments, such cells can be animal or human cells, and can be autologous, heterologous, or xenogeneic. In certain embodiments, the cells can be immortalized. In other embodiments, in order to decrease the chance of an immunological response, the cells can be encapsulated to avoid infiltration of surrounding tissues. In further embodiments, the encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissues.

Combination Therapies

In another aspect, the present disclosure provides a method of treating a subject for diabetes with a therapeutic antigen binding protein of the present disclosure, such as the fully human therapeutic antibodies described herein, together with one or more other treatments. In one embodiment, such a combination therapy achieves an additive or synergistic effect. The antigen binding proteins can be administered in combination with one or more of the type 2 diabetes or obesity treatments currently available. These treatments for diabetes include biguanide (metaformin), and sulfonylureas (such as glyburide, glipizide). Additional treatments directed at maintaining glucose homeostasis include PPAR gamma agonists (pioglitazone, rosiglitazone); glinides (meglitinide, repaglinide, and nateglinide); DPP-4 inhibitors (Januvia® and Onglyza®) and alpha glucosidase inhibitors (acarbose, voglibose).

Additional combination treatments for diabetes include injectable treatments such as insulin and incretin mimetics (Byetta®, Exenatide®), other GLP-1 (glucagon-like peptide) analogs such as Victoza® (liraglutide), other GLP-1R agonists and Symlin® (pramlintide).

Additional combination treatments directed at weight loss include Meridia® and Xenical®.

EXAMPLES

The following examples, including the experiments conducted and the results achieved, are provided for illustrative purposes only and are not to be construed as limiting.

Example 1 Preparation of FGFR1c and (3-Klotho Over Expressing Cells For Use as an Antigen

Nucleic acid sequences encoding the full length human FGFR1c polypepetide (SEQ ID NO: 4; FIGS. 1A-1B) and a separate sequence encoding the full length human β-Klotho polypeptide (SEQ ID NO: 7; FIGS. 2A-2C) were subcloned into suitable mammalian cell expression vectors (e.g., pcDNA3.1 Zeo, pcDNA3.1 Hyg (Invitrogen, Carlsbad, Calif.) or pDSRα24. The pDSRα24 vector contains SV40 early promoter/enhancer for expressing the gene of interest and a mouse DHFR expression cassette for selection in CHO DHFR (−) host cells such as AM1/D CHO (a derivative of DG44, CHO DHFR (−)).

AM-1/D CHO cells were transfected with linearized DNAs of huFGFR1c and huβ-Klotho in standard mammalian cell expression vectors e.g. pcDNA3.1 puro and pcDNA3.1 Hyg with Lipofectamine 2000 (Invitrogen, Carlsbad Calif.). The transfected cells were trypsinized 2 days after transfection and seeded into media containing the corresponding selection drugs i.e. puromycin and hygromycin. After 2 weeks, the resulting transfected colonies were trypsinized and pooled. Single cell clones from the pools were isolated and screened with antibodies to huFGFR1c and huβKlotho in FACS and Clone 16 was selected due to the high level and balanced expression of the two receptor components.

2×10e9 fresh cells from Clone 16 were harvested from roller bottles into a smaller volume in PBS and incubated with 10 μg/ml recombinant FGF21 (Amgen, Thousand Oaks Calif.) at 4C for 1 hours to form complex with the cell surface receptors. The cells were washed twice with cold PBS, pelleted by centrifugation and frozen in individual vials at 2×10e8 cells for immunization.

HEK 293T cells were transfected with DNA expressing a truncated version of huFGFR1c (a signal peptide VH21 was joined to the remaining FGFR1c from amino acid residue #141 to #822 (in SEQ ID NO: 4) with a deletion that removed both the D1 domain and the acidic box (AB) and DNA expressing the full length huβ-Klotho in pcDNA3.1 series or pTT5 (an expression vector developed by Durocher, NRCC, with CMV promoter and EBV ori) based vector for transient expression. The removal of the D1-AB on FGFR1c was designed to expose epitopes on FGFR1c (e.g., in the D2 and D3 domains) that may be masked by this auto-inhibitory domain (see Mohammadi et al., (2005) Cytokine Growth Factor Reviews, 16, 107-137; Gupte et al., (2011) J. Mol. Biol. 408:491-502).

The expression of β-Klotho and truncated FGFR1c in the transfected 293T cells was verified by the respective specific antibodies in FACS and cells were harvested on day 3 post-transfection and frozen as cell pellet into aliquots for immunization.

Stable CHO or transiently transfected HEK 293T cells expressing FGFR1c and β-Klotho individually or together were also generated and used for titering mouse sera by FACS after immunization and for binding screens of the hybridoma supernatants by FMAT (see Example 3).

Example 2 Preparation of Monoclonal Antibodies

Immunizations were conducted using one or more suitable forms of FGF21 receptor antigen, including: (1) cell-bound receptor of CHO transfectants expressing full length human FGFR1c and β-Klotho at the cell surface, obtained by transfecting CHO cells with cDNA encoding a human full length FGFR1c polypeptide of SEQ ID NO: 4 (see also FIGS. 1 a-b) and cDNA encoding a human β-Klotho polypeptide of SEQ ID NO: 7 (see also FIGS. 2 a-c) in a balanced ratio with cells and incubated with FGF21 prior to freezing; (2) cell-bound receptor of 293T transfectants expressing full length human β-Klotho and an N-terminal truncated form of human FGFR1c encompassing amino acid residues 141-822 polypeptide of SEQ ID NO: 4 (D1 domain of FGFR1c deleted).

A suitable amount of immunogen (i.e., 3−4×10⁶ cells/mouse of stably transfected CHO cells or transiently transfected 293T cells mentioned above was used for initial immunization in XENOMOUSE® according to the methods disclosed in U.S. patent application Ser. No. 08/759,620, filed Dec. 3, 1996 and International Patent Application Nos. WO 98/24893, and WO 00/76310, the disclosures of which are incorporated by reference. Following the initial immunization, subsequent boost immunizations of immunogen (1.7×10⁶ FGF21R transfected cells/mouse) were administered on a schedule and for the duration necessary to induce a suitable anti-FGF21R titer in the mice. Titers were determined by a suitable method, for example, by enzyme immunoassay, fluorescence activated cell sorting (FACS), or by other methods (including combinations of enzyme immunoassays and FACS).

Animals exhibiting suitable titers were identified, and lymphocytes were obtained from draining lymph nodes and, if necessary, pooled for each cohort. Lymphocytes were dissociated from lymphoid tissue by grinding in a suitable medium (for example, Dulbecco's Modified Eagle Medium; DMEM; obtainable from Invitrogen, Carlsbad, Calif.) to release the cells from the tissues, and suspended in DMEM. B cells were selected and/or expanded using standard methods, and fused with suitable fusion partner, for example, nonsecretory myeloma P3X63Ag8.653 cells (American Type Culture Collection CRL 1580; Kearney et al, (1979) J. Immunol. 123:1548-1550), using techniques that were known in the art.

In one suitable fusion method, lymphocytes were mixed with fusion partner cells at a ratio of 1:4. The cell mixture was gently pelleted by centrifugation at 400×g for 4 minutes, the supernatant decanted, and the cell mixture gently mixed (for example, by using a 1 ml pipette). Fusion was induced with PEG/DMSO (polyethylene glycol/dimethyl sulfoxide; obtained from Sigma-Aldrich, St. Louis Mo.; 1 ml per million of lymphocytes). PEG/DMSO was slowly added with gentle agitation over one minute followed, by one minute of mixing. IDMEM (DMEM without glutamine; 2 ml per million of B cells), was then added over 2 minutes with gentle agitation, followed by additional IDMEM (8 ml per million B-cells) which was added over 3 minutes.

The fused cells were pelleted (400×g 6 minutes) and resuspended in 20 ml Selection media (for example, DMEM containing Azaserine and Hypoxanthine [HA] and other supplemental materials as necessary) per million B-cells. Cells were incubated for 20-30 minutes at 37° C. and then resuspended in 200 ml selection media and cultured for three to four days in T175 flasks prior to 96 well plating.

Cells were distributed into 96-well plates using standard techniques to maximize clonality of the resulting colonies. An alternative method was also employed and the fused cells were directly plated clonally into 384-well plates to ensure monoclonality from the start. After several days of culture, supernatants were collected and subjected to screening assays as detailed in the examples below, including confirmation of binding to human FGF21 receptor, specificity and/or cross-species reactivity. Positive cells were further selected and subjected to standard cloning and subcloning techniques. Clonal lines were expanded in vitro, and the secreted human antibodies obtained for analysis.

In this manner, mice were immunized with cells expressing full length FGF21R cells mixed with FGF21, or cells expressing a truncated FGFR1c and full length β-Klotho, with a range of 11-17 immunizations over a period of approximately one to three and one-half months. Several cell lines secreting FGF21R-specific antibodies were obtained, and the antibodies were further characterized. The sequences thereof are presented herein and in the Sequence Listing, and results of various tests using these antibodies are provided.

Example 3 Selection of Binding Antibodies by FMAT

After 14 days of culture, hybridoma supernatants were screened for FGF21R-specific monoclonal antibodies by Fluorometric Microvolume Assay Technology (FMAT) by screening against either the CHO AM1/D/huFGF21R cell line or recombinant HEK293 cells that were transfected with human FGF21R and counter-screening against parental CHO or HEK293 cells. Briefly the cells in Freestyle media (Invitrogen) were seeded into 384-well FMAT plates in a volume of 50 μL/well at a density of 4,000 cells/well for the stable transfectants, and at a density of 16,000 cells/well for the parental cells, and cells were incubated overnight at 37° C. 10 μL/well of supernatant was then added, and the plates were incubated for approximately one hour at 4° C., after which 10 μL/well of anti-human IgG-Cy5 secondary antibody was added at a concentration of 2.8 μg/ml (400 ng/ml final concentration). Plates were then incubated for one hour at 4° C., and fluorescence was read using an FMAT Cellular Detection System (Applied Biosystems).

In total, over 1,500 hybridoma supernatants were identified as binding to the FGF21 receptor expressing cells but not to parental cells by the FMAT method. These supernatants were then tested in the FGF21 functional assays as described below.

Example 4 Selection of Antibodies that Induce FGF21-Like Signaling

Experiments were performed to identify functional antibodies that mimic wild-type FGF21 activity (e.g., the ability to induce FGF21-like signaling) using a suitable FGF21 reporter assay. The disclosed FGF21 reporter assay measures activation of FGFR signaling via a MAPK pathway readout. β-Klotho is a co-receptor for FGF21 signaling, and although it is believed not to have any inherent signaling capability due to its very short cytoplasmic domain, it is required for FGF21 to induce signaling through FGFRs.

Example 4.1 ELK-Luciferase Reporter Assay

ELK-luciferase assays were performed using a recombinant human 293T kidney cell or CHO cell system. Specifically, the host cells were engineered to over-express β-Klotho and luciferase reporter constructs. The reporter constructs contain sequences encoding GAL4-ELK1 and 5×UAS-Luc, a luciferase reporter driven by a promoter containing five tandem copies of the Ga14 binding site. Activation of the FGF21 receptor complex in these recombinant reporter cell lines induces intracellular signal transduction, which in turn leads to ERK and ELK phosphorylation. Luciferase activity is regulated by the level of phosphorylated ELK, and is used to indirectly monitor and quantify FGF21 activity.

In one example, CHO cells were transfected sequentially using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's protocol with the receptor constructs expressing β-Klotho, FGFR1c and the reporter plasmids: 5×Ga14-Luciferase (minimal TK promoter with 5×Gal4 binding sites upstream of luciferase) and Ga14-ELK1. Ga14-ELK1 binds to the Ga14 binding sites and activates transcription when it is phosphorylated by ERK. Luciferase transcription, and thereby the corresponding enzymatic activity in this context is regulated by the level of phosphorylated ELK1, and is used to indirectly monitor and quantify FGF21 activity.

Clone 16 was selected as the FGF21 luciferase reporter cell line based on the optimal assay window of 10-20 fold with native FGF21 exhibiting an EC50 in the single nM range.

For the assay, the ELK-luciferase reporter cells were plated in 96 well assay plates, and serum starved overnight. FGF21 or test samples were added for 6 hours at 37 degrees. The plates were then allowed to cool to room temperature and the luciferase activity in the cell lysates was measured with Bright-Glo (Promega).

Example 4.2 ERK-Phosphorylation Assay

Alternative host cell lines specifically L6 (a rat myoblastic cell line) was developed and applied to identify antibodies with FGF21-like signaling activity. The rat L6 cell line is a desirable host cell line for the activity assay because it is known to express minimal levels of endogeneous FGF receptors. The L6 cells do not respond to FGF21 even when transfected with β-Klotho expression vector and therefore provides a cleaner background. (Kurosu et al., (2007) J. Biol. Chem. 282, 26687-26695).

Human primary preadipocytes isolated from subcutaneous adipose tissues of multiple healthy nondiabetic donors were purchased from Zen-Bio, Inc. The preadipocytes were plated in 24-well plates and differentiated for 18 days into mature adipocytes. After a 3-hour starvation period, adipocytes were treated with different concentrations of test molecules for 10 minutes. Following treatment, the media was aspirated and cells were snap-frozen in liquid nitrogen. Cell lysates were prepared and ERK phosphorylation was measured using the Phospho-ERK1/2(Thr202/Tyr204;Thr185/Tyr187)/Total ERK1/2 Assay Whole Cell Lysate Kit from Meso Scale Discovery.

L6 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells were transfected with plasmids expressing β-Klotho and individual FGFR using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's protocol.

Analysis of FGF signaling in L6 cells was performed as described in the literature (Kurosu et al., (2007) J. Biol. Chem. 282, 26687-26695). Cell cultures were collected 10 min after the treatment of FGF21 or test molecules and snap frozen in liquid nitrogen, homogenized in the lysis buffer and ERK phosphorylation was measured using the Phospho-ERK1/2(Thr202/Tyr204;Thr185/Tyr187)/Total ERK1/2 Assay Whole Cell Lysate Kit from Meso Scale Discovery.”

In addition, the factor-dependent mouse BaF3 cell-based proliferation assay used frequently for cytokine receptors can also be developed and applied.

Among the hybridoma supernatants tested in the CHO cell (Clone 16) based human FGF21 ELK-luciferase reporter assay, over 140 were identified as positive (>20% of the activity of FGF21) when compared to 20 nM FGF21 as the positive control (FIGS. 3 and 4). Antibodies can be purified from the conditioned media of the hybridoma cultures of these positives and tested again in the CHO cell based ELK-luciferase reporter assay to assess the potency of the representative antibodies in the dose-responsive assay and determine the EC50. The activities and potency can be confirmed in the L6 cell based ERK1/2-phosphrylation assay. The EC50 is expected to be consistent to the ELK-luciferase assay in the CHO stable cell line Clone 16.

Example 5 Determining that Induction of FGF21-Like Signaling is Specific to the FGFR/βKlotho Complex

FGF21 has been reported to signal through multiple receptor complexes including FGFR1c, 2c, 3c, and 4 when paired with β-Klotho. The selectivity of the FGF21 agonistic antibodies can be determined in the rat myoblastic L6 cells transfected with vectors expressing the respective FGFRs and β-Klotho as described in Example 4.2.

Observed selectivity would be strongly suggestive that the action of these antibodies is β-Klotho-dependent yet it must also involve the FGFR component of the signaling complex. The results are set forth in Table 6 below.

TABLE 9 FGFR Selectivity Molecule FGFR1c FGFR2c FGFR3c FGFR4 Fgf21 + + + − FGF19 + + + + 16H7 D58A + − − − 49H12.1 + − − − 51A8.1 + − − − 51E5.1 + − − − 54A1.1 + − − − 60D7.1 + − − − 63A10.1 + − − − 64B10.1 + − − − 65C3.1 + − − − 66G2.1 + − − − 67F5.1 + − − − 67C10.1 + − − − 68C8.1 + − − − 49C8.1 + − − − 49G3.3 + − − − 56E7.3 + − − − 52A8.1 + − − −

Example 5.1 Binding Specificity is Exclusively β-Klotho Dependent

The binding specificity of the reporter assay positive antibodies in the hybridoma supernatants was determined by FACS using 293T cells transiently transfected to express full length FGFR1c alone, β-Klotho alone or FGFR1c and β-Klotho together. Over 98% (141 out of 143 hybridomas) bind β-Klotho alone whereas none bind FGFR1c alone.

Example 6 Activity in Primary Human Adipocytes

FGF21 stimulates glucose uptake and lipolysis in cultured adipocytes, and adipocytes are considered to be more physiologically relevant than the recombinant reporter cell system.

A panel of the antibodies were tested in the human adipocyte assay for Erk-phosphorylation activity as described in Example 4.2 and compared with FGF21 for their EC₅₀. The results are set forth below in Table 10 below.

TABLE 10 Activity of Antibodies on pERK Human Adipocyte Assay Molecule EC₅₀ Fgf21 0.623 16H7 0.280 49H12.1 0.254 51A8.1 0.213 51E5.1 3.221 54A1.1 0.206 60D7.1 0.496 63A10.1 0.435 64B10.1 0.955 65C3.1 6.387 66G2.1 3.529 67F5.1 1.438 67C10.1 5.789 68C8.1 1.216 49C8.1 0.243 49G3.3 1.424 56E7.3 0.916 58C2.1 0.317

Example 7 Competition Binding and Epitope Binning

To compare the similarity of the binding sites of the antibodies on the FGF21 receptor, a series of competition binding experiments can be performed and measured by Biacore. In one example, representative agonistic FGF21 receptor antibodies (and any controls) can be immobilized on the sensor chip surface. Soluble human FGFR1c/β-Klotho ECD-Fc complex or β-Klotho can then be captured on the immobilized antibody surfaces. Finally, several of the test FGF21 receptor antibodies can be injected individually over the captured soluble human FGF21 receptor or β-Klotho. If the injected antibody recognizes a distinct binding site relative to that recognized by the immobilized antibody, a second binding event will be observed. If the antibodies recognize very similar binding site, no more binding will be observed.

Alternatively or additionally, a Biacore analysis can be carried out with biotinylated-FGF21 immobilized on the sensor ship. 10 nM soluble β-Klotho is then passed over the chip alone or mixed with the individual test antibodies at 100 nM. The results are set forth below in Table 11 below.

TABLE 11 Epitope Binning Summary Bin 1: 2 ^(nd) Campaign—24H11, 17C3, 16H7, 20D4, 21B4, 22H5, 23F8, 21H2, 18B11; 3 ^(rd) Campaign—40D2, 46D11 Current—49H12, 51A8, 54A1, 60D7, 49C8, 49G3, 56E7, 63A10, 64B10 (64B10.1), 67C8, 68C8.1 Bin 2: 2 ^(nd) Campaign—17D8, 12C11, 26H11, 12E4, 18G1; 3 ^(rd) Campaign—37D3 Bin 3: 3 ^(rd) Campaign—39F7, 38F2, 39F11, 39G5 Bin 4: 3 ^(rd) Campaign—20E8 Bin 5: current—51E5 Bin 6: current—52A8 (52A8.1), 67F5 (67F5.1), 67C10 (67C10.1), 65C3.1, 66G2.1 Bold samples in bold are recombinant mAbs Italicized samples are from hybridoma supernatants.

Example 8 Recognition of Native and Denatured Structures

The ability of disclosed antigen binding proteins to recognize denatured and native structures was investigated. The procedure and results were as follows.

Example 8.1 FGF21 Receptor Agonistic Antibodies do not Recognize Denatured Structures

Cell lysates from CHO cells stably expressing FGF21 receptor (FGFR1c and β-Klotho) or CHO parental cells were diluted with sample buffer without beta-mercaptoethanol (non-reducing conditions). 20 μl of cell lysate were loaded per lane on adjacent lanes separated with a molecular weight marker lane on 4-20% SDS-PAGE gels. Following electrophoresis, the gels were blotted onto 0.2μ nitrocellulose filters. The blots were treated with Tris-buffered saline/Triton-X (TBST) plus 5% non-fat milk (blocking buffer) for 30 minutes. The blots were then cut along the molecular weight marker lanes. The strips were probed with commercial goat anti-murine βKlotho or mouse anti-huFGFR1 (R&D Diagnostics) in TBST/5% milk. Blots were incubated with the antibodies for one hour at room temperature, followed by three washes with TBST+1% milk. The blots were then probed with anti-human or anti-goat IgG-HRP secondary antibodies for 20 min. Blots were given three 15 minute washes with TBST followed by treatment with Pierce Supersignal West Dura developing reagent (1 minute) and exposure to Kodak Biomax X-ray film.

The commercial anti-β-Klotho and anti-FGFR1 antibodies detected the corresponding receptor proteins in the SDS-PAGE indicating they bind to denatured receptor proteins.

Example 8.2 FGF21 Receptor Agonistic Antibodies Bind To Native Receptor Structure

A FACS binding assay was performed with several commercially available FGFR1c and β-Klotho antibodies, and several of the disclosed FGF21 receptor agonistic antibodies. The experiments were performed as follows.

CHO cells stably expressing FGF21 receptor were treated with R&D Systems mouse anti-huFGFR1, goat anti-mu β-Klotho (1 μg per 1×10⁶ cells in 100 μl PBS/0.5% BSA). Cells were incubated with the antibodies at 4° C. followed by two washes with PBS/BSA. Cells were then treated with FITC-labeled secondary antibodies at 4° C. followed by two washes. The cells were resuspended in 1 ml PBS/BSA and antibody binding was analyzed using a FACSCalibur™ instrument.

None of the commercial anti-β-Klotho or anti-FGFR1 antibodies tested bind well to cell surface FGF21 receptor, as determined by FACS. This observation further confirmed that the commercial antibodies to the receptor components bind to denatured and non-native structure whereas all of the agonistic antibodies described herein bind receptors on cell surface as shown by FACS or FMAT which were the initial screens.

Example 9 Arginine Scanning

As described above, antigen binding proteins that bind a complex comprising b-Klotho and one of FGFR1c, FGFR2c and FGFR3c can be created and characterized. To determine the neutralizing determinants on human FGFR1c and/or β-Klotho that these various antigen binding proteins bound, a number of mutant FGFR1c and/or β-Klotho proteins can be constructed having arginine substitutions at select amino acid residues of human FGFR1c and/or β-Klotho. Arginine scanning is an art-recognized method of evaluating where antibodies, or other proteins, bind to another protein, see, e.g., Nanevicz et al., (1995) J. Biol. Chem., 270:37, 21619-25 and Zupnick et al., (2006) J. Biol. Chem., 281:29, 20464-73. In general, the arginine sidechain is positively charged and relatively bulky as compared to other amino acids, which can disrupt antibody binding to a region of the antigen where the mutation is introduced. Arginine scanning is a method that determines if a residue is part of a neutralizing determinant and/or an epitope.

Various amino acids distributed throughout the human FGFR1c and/or β-Klotho extracellular domains can be selected for mutation to arginine. The selection can be biased towards charged or polar amino acids to maximize the possibility of the residue being on the surface and reduce the likelihood of the mutation resulting in misfolded protein. Using standard techniques known in the art, sense and anti-sense oligonucleotides containing the mutated residues can be designed based on criteria provided by Stratagene Quickchange® II protocol kit (Stratagene/Agilent, Santa Clara, Calif.). Mutagenesis of the wild-type (WT) FGFR1c and/or β-Klotho sequences can be performed using a Quickchange® II kit (Stratagene). Chimeric constructs can be engineered to encode a FLAG-histidine tag (six histidines (SEQ ID NO: 1830)) on the carboxy terminus of the extracellular domain to facilitate purification via the poly-His tag.

Multiplex analysis using the Bio-Plex Workstation and software (BioRad, Hercules, Calif.) can be performed to determine neutralizing determinants on human FGFR1c and/or β-Klotho by analyzing exemplary human FGFR1c and/or β-Klotho mAbs differential binding to arginine mutants versus wild-type FGFR1c and/or β-Klotho proteins. Any number of bead codes of pentaHis-coated beads (“penta-His” disclosed as SEQ ID NO: 1831) (Qiagen, Valencia, Calif.) can be used to capture histidine-tagged protein. The bead codes can allow the multiplexing of FGFR1c and/or β-Klotho arginine mutants and wild-type human FGFR1c and/or β-Klotho.

To prepare the beads, 100 ul of wild-type FGFR1c and/or β-Klotho and FGFR1c and/or β-Klotho arginine mutant supernatants from transient expression culture are bound to penta-His-coated beads (“penta-His” disclosed as SEQ ID NO: 1831) overnight at 4° C. or 2 hours at room temperature with vigorous shaking. The beads are then washed as per the manufacturer's protocol and the bead set pooled and aliquoted into 2 or 3 columns of a 96-well filter plate (Millipore, Bellerica, Mass., product #MSBVN1250) for duplicate or triplicate assay points, respectively. 100 μl anti-FGFR1c and/or anti-β-Klotho antibodies in 4-fold dilutions are added to the wells, incubated for 1 hour at room temperature, and washed. 100 μl of a 1:100 dilution of PE-conjugated anti-human IgG Fc (Jackson Labs., Bar Harbor, Me.) is added to each well, incubated for 1 hour at room temperature and washed. Beads are resuspended in 1% BSA, shaken for 3 minutes, and read on the Bio-Plex workstation. Antibody binding to FGFR1c and/or β-Klotho arginine mutant protein is compared to antibody binding to the human FGFR1c and/or β-Klotho wild-type from the same pool. A titration of antibody over approximately a 5 log scale can be performed. Median Fluorescence Intensity (MFI) of FGFR1c and/or β-Klotho arginine mutant proteins can be graphed as a percent of maximum wild-type human FGFR1c and/or β-Klotho signal. Those mutants for which signal from all the antibodies are below a cut-off value, e.g., 30% of wild-type FGFR1c and/or β-Klotho can be deemed to be either of too low a protein concentration on the bead due to poor expression in the transient culture or possibly misfolded and can be excluded from analysis. Mutations (i.e., arginine substitutions) that increase the EC50 for the FGFR1c and/or β-Klotho mAb by a cut-off value, e.g., 3-fold or greater (as calculated by, e.g., GraphPad Prism®) can be considered to have negatively affected FGFR1c and/or 13-Klotho mAb binding. Through these methods, neutralizing determinants and epitopes for various FGFR1c and/or β-Klotho antibodies are elucidated.

Example 10 Protease Protection Analysis

Regions of the human FGF21 receptor bound by the antigen binding proteins that bind human FGF21 receptor, e.g., FGFR1c, β-Klotho or FGFR1c and β-Klotho complex can be identified by fragmenting human FGF21 receptor into peptides with specific proteases, e.g., AspN, Lys-C, chymotrypsin or trypsin. The sequence of the resulting human FGF21 receptor peptides (i.e., both disulfide- and non-disulfide-containing peptide fragments from FGFR1c and β-Klotho portions) can then be determined. In one example, soluble forms of a human FGF21 receptor, e.g., a complex comprising the FGFR1c ECD-Fc and β-Klotho ECD-Fc heterodimer described herein can be digested with AspN (which cleaves after aspartic acid and some glutamic acid residues at the amino end) by incubating about 100 μg of soluble FGF21 receptor at 1.0 mg/ml in 0.1M sodium phosphate (pH 6.5) for 20 hrs at 37° C. with 2 μg of AspN.

A peptide profile of the AspN digests can then be generated on HPLC chromatography while a control digestion with a similar amount of antibody is expected to be essentially resistant to AspN endoprotease. A protease protection assay can then be performed to determine the proteolytic digestion of human FGF21 receptor in the presence of the antigen binding proteins. The general principle of this assay is that binding of an antigen binding protein to the FGF21 receptor can result in protection of certain specific protease cleavage sites and this information can be used to determine the region or portion of FGF21 receptor where the antigen binding protein binds.

Briefly, the peptide digests can be subjected to HPLC peptide mapping; the individual peaks are collected, and the peptides are identified and mapped by on-line electrospray ionization LC-MS (ESI-LC-MS) analyses and/or by N-terminal sequencing. HPLC analyses for these studies can be performed using a narrow bore reverse-phase C18 column (Agilent Technologies) for off-line analysis and using a capillary reverse phase C18 column (The Separation Group) for LC-MS. HPLC peptide mapping can be performed with a linear gradient from 0.05% trifluoroacetic acid (mobile phase A) to 90% acetonitrile in 0.05% trifluoroacetic acid. Columns can be developed at desirable flow rate for narrow bore HPLC for off-line or on-line LC-MS analyses, and for capillary HPLC for on-line LC-MS analyses.

Sequence analyses can be conducted by on-line LC-MS/MS and by Edman sequencing on the peptide peaks recovered from HPLC. On-line ESI LC-MS analyses of the peptide digest can be performed to determine the precise mass and sequence of the peptides that are separated by HPLC. The identities of selected peptides present in the peptide peaks from the protease digestion can thus be determined.

Example 11 Construction of Chimeric Receptors

An additional method of determining activation determinants on which these various antigen binding proteins bind is as follows. Specific chimeric FGFR1c and/or β-Klotho proteins between human and mouse species can be constructed, expressed in transient or stable 293 or CHO cells (as described herein) and tested. For example, a chimeric FGF21 receptor can be constructed comprising native human FGFR1c, FGFR2c, FGFR3c or FGFR4 receptors. By way of example, FGFR1c can be paired with chimeric human/mouse β-Klotho in which selected regions or sequences on the human β-Klotho are systematically replaced by the corresponding mouse-specific residues (see, e.g., FIG. 2A-2C). Similarly, native human β-Klotho can be paired with chimeric human/mouse FGFR1c, FGFR2c, FGFR3c or FGFR4. Here, selected regions or sequences on the human FGFR1c are systematically replaced by the corresponding mouse-specific residues (see, e.g., the alignments of FIGS. 1A-1B). The critical sequences involved in the binding and/or activity of the antigen binding proteins can be derived through binding assay or activity measurements described in previous Examples 4, 5, 6, and 7 based on the chimeric FGF21 receptors.

Example 11.1 Construction of Specific Chimeras

Human-mouse β-Klotho chimeras were constructed using the methodology described above. A schematic of the chimeras constructed is presented in FIG. 4. In summary, the chimeras generated comprised (from N- to C-terminus) a fusion of a human β-Klotho sequence fused to a murine β-Klotho sequence fused to a human β-Klotho sequence. Human β-Klotho (SEQ ID NO:8) was used as a framework into which regions of murine β-Klotho (full length sequence shown in SEQ ID NO:468) were inserted. The regions of murine 13-Klotho that were inserted were as follows:

Murine Residues 82P-520P PKNFSWGVGTGAFQVEGSWKTDGRGPSIWDRYVYSHLRGVNGTDRSTDSY IFLEKDLLALDFLGVSFYQFSISWPRLFPNGTVAAVNAQGLRYYRALLDS LVLRNIEPIVTLYHWDLPLTLQEEYGGWKNATMIDLFNDYATYCFQTFGD RVKYWI Murine Residues 416G-519P (SEQ ID NO: 476) GWFTDSYIKTEDTTAIYMMKNFLNQVLQAIKFDEIRVFGYTAWTLLDGFE WQDAYTTRRGLFYVDFNSEQKERKPKSSAHYYKQIIQDNGFPLKESTPDM KGRF Murine Residues 507P-632G (SEQ ID NO: 477) PLKESTPDMKGRFPCDFSWGVTESVLKPEFTVSSPQFTDPHLYVWNVTGN RLLYRVEGVRLKTRPSQCTDYVSIKKRVEMLAKMKVTHYQFALDWTSILP TGNLSKVNRQVLRYYRCVVSEGLKLG Murine Residues 520P-735A (SEQ ID NO: 478) PCDFSWGVTESVLKPEFTVSSPQFTDPHLYVWNVTGNRLLYRVEGVRLKT RPSQCTDYVSIKKRVEMLAKMKVTHYQFALDWTSILPTGNLSKVNRQVLR YYRCVVSEGLKLGVFPMVTLYHPTHSHLGLPLPLLSSGGWLNMNTAKAFQ DYAELCFRELGDLVKLWITINEPNRLSDMYNRTSNDTYRAAHNLMIAHA QVWHLYDRQYRPVQHGA Murine Residues 632G-849Q (SEQ ID NO: 479) GVFPMVTLYHPTHSHLGLPLPLLSSGGWLNMNTAKAFQDYAELCFRELGD LVKLWITINEPNRLSDMYNRTSNDTYRAAHNLMIAHAQVWHLYDRQYRPV QHGAVSLSLHCDWAEPANPFVDSHWKAAERFLQFEIAWFADPLFKTGDYP SVMKEYIASKNQRGLSSSVLPRFTAKESRLVKGTVDFYALNHFTTRFVIH KQLNTNRSVADRDVQFLQ Murine Residues 735A-963S (SEQ ID NO: 480) AVSLSLHCDWAEPANPFVDSHWKAAERFLQFEIAWFADPLFKTGDYPSVM KEYIASKNQRGLSSSVLPRFTAKESRLVKGTVDFYALNHFTTRFVIHKQL NTNRSVADRDVQFLQDITRLSSPSRLAVTPWGVRKLLAWIRRNYRDRDIY ITANGIDDLALEDDQIRKYYLEKYVQEALKAYLIDKVKIKGYYAFKLTEE KSKPRFGFFTSDFRAKSSVQFYSKLISSS Murine Residues 1M-81F (SEQ ID NO: 481) MKTGCAAGSPGNEWIFFSSDERNTRSRKTMSNRALQRSAVLSAFVLLRAV TGFSGDGKAIWDKKQYVSPVNPSQLFLYDTF Murine Residues 82P-193L (SEQ ID NO: 482) PKNFSWGVGTGAFQVEGSWKTDGRGPSIWDRYVYSHLRGVNGTDRSTDSY IFLEKDLLALDFLGVSFYQFSISWPRLFPNGTVAAVNAQGLRYYRALLDS LVLRNIEPIVTL

The chimeras that were generated using the murine β-Klotho sequences comprised the following:

TABLE 12 N-terminal C-terminal SEQ. Human β- Mouse β- Human β- Con- Construct ID Klotho Klotho Klotho struct Identifier NO. Residues Residues Residues 1 huBeta_Klotho (1- 1-81   82-520 523-1044 81, 523-1044) (muBetaKLOTHO 82-520) 2 huBeta_Klotho (1- 1-507  506-1043 507) (muBetaKLOTHO 506F-1045S) 3 huBeta_Klotho  1-193 194-1044 (194-1044) (muBetaKLOTHO 1-L193) 4 huBeta_Klotho (1- 1-81   82-302 303-1044 81, 303-1044) (muBetaKLOTHO 82P-302S) 5 huBeta_Klotho (1- 1-193 194-416 419-1044 193, 419-1044) (muBetaKLOTHO Y194-416G) 6 huBeta_Klotho(1- 1-301 302-506 509-1044 301, 509-1044) (muBetaKLOTHO S302-F506) 7 huBeta_Klotho(1- 1-417 416-519 522-1044 417, 522-1044) (muBetaKLOTHO G416-F519) 8 huBeta_Klotho (1- 1-508 507-632 635-1044 507, 635-1044) (muBeta KLOTHO F06-G632) 9 huBeta_Klotho (1- 1-521 520-735 738-1044 521, 738-1044) (muBeta KLOTHO 520P-735A) 10 huBeta_Klotho (1- 1-633 632-849 852-1044 633, 852-1044) (muBeta KLOTHO 632G-849Q) 11 huBeta_Klotho (1- 1-736 735-963 967-1044 736, 967-1044) (muBeta KLOTHO 735A-963S) 12 huBeta_Klotho  1-81  82-1044 (82-1044) (muBeta KLOTHO 1-81F) 13 huBeta_Klotho (1- 1-81   82-193 194-1044 81, 194-1044) (muBeta KLOTHO 82P-193L) 14 huBeta_Klotho (1- 1-301  302-506, 967-1044 301, 509-743, 967- 742-964 1044) (muBeta KLOTHO 302- 506, 742-964)

The generated chimeras comprised the following amino acid sequences:

(i) huBeta_Klotho(1-81, 523-1044) (muBetaKLOTHO 82-520) (SEQ ID NO: 455) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFSWGVGTGAFQVEGSW KTDGRGPSIWDRYVYSHLRGVNGTDRSTDSYIFLEKDLLALDFLGVSFYQ FSISWPRLFPNGTVAAVNAQGLRYYRALLDSLVLRNIEPIVTLYHWDLPL TLQEEYGGWKNATMIDLFNDYATYCFQTFGDRVKYWITIHNPYLVAWHGF GTGMHAPGEKGNLTAVYTVGHNLIKAHSKVWHNYDKNFRPHQKGWLSITL GSHWIEPNRTDNMEDVINCQHSMSSVLGWFANPIHGDGDYPEFMKTGAMI PEFSEAEKEEVRGTADFFAFSFGPNNFRPSNTVVKMGQNVSLNLRQVLNW IKLEYDDPQILISENGWFTDSYIKTEDTTAIYMMKNFLNQVLQAIKFDEI RVFGYTAWTLLDGFEWQDAYTTRRGLFYVDFNSEQKERKPKSSAHYYKQI IQDNGFPLKESTPDMKGRFPCDFSWGVTESVLKPESVASSPQFSDPHLYV WNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFALD WASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLP EPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYN RSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPANP YADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSSSA LPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFLQD ITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDDRL RKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFKAK SSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFLGC CFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (ii) huBeta_Klotho(1-507) (muBetaKLOTHO 506F-10455) (SEQ ID NO: 456) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFPLKESTPDMKGRFPCDFSWGVTESVLKPEFTVSSPQFTDPHL YVWNVTGNRLLYRVEGVRLKTRPSQCTDYVSIKKRVEMLAKMKVTHYQFA LDWTSILPTGNLSKVNRQVLRYYRCVVSEGLKLGVFPMVTLYHPTHSHLG LPLPLLSSGGWLNMNTAKAFQDYAELCFRELGDLVKLWITINEPNRLSDM YNRTSNDTYRAAHNLMIAHAQVWHLYDRQYRPVQHGAVSLSLHCDWAEPA NPFVDSHWKAAERFLQFEIAWFADPLFKTGDYPSVMKEYIASKNQRGLSS SVLPRFTAKESRLVKGTVDFYALNHFTTRFVIHKQLNTNRSVADRDVQFL QDITRLSSPSRLAVTPWGVRKLLAWIRRNYRDRDIYITANGIDDLALEDD QIRKYYLEKYVQEALKAYLIDKVKIKGYYAFKLTEEKSKPRFGFFTSDFR AKSSVQFYSKLISSSGLPAENRSPACGQPAEDTDCTICSFLVEKKPLIFF GCCFISTLAVLLSITVFHHQKRRKFQKARNLQNIPLKKGHSRVFS (iii) huBeta_Klotho(194-1044) (muBetaKLOTHO 1-L193) (SEQ ID NO: 457) MKTGCAAGSPGNEWIFFSSDERNTRSRKTMSNRALQRSAVLSAFVLLRAV TGFSGDGKAIWDKKQYVSPVNPSQLFLYDTFPKNFSWGVGTGAFQVEGSW KTDGRGPSIWDRYVYSHLRGVNGTDRSTDSYIFLEKDLLALDFLGVSFYQ FSISWPRLFPNGTVAAVNAQGLRYYRALLDSLVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHL YVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFA LDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLG LPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDI YNRSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPA NPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSS SALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFL QDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDD RLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFK AKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (iv) huBeta_Klotho(1-81, 303-1044) (muBetaKLOTHO 82P-302S) (SEQ ID NO: 458) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFSWGVGTGAFQVEGSW KTDGRGPSIWDRYVYSHLRGVNGTDRSTDSYIFLEKDLLALDFLGVSFYQ FSISWPRLFPNGTVAAVNAQGLRYYRALLDSLVLRNIEPIVTLYHWDLPL TLQEEYGGWKNATMIDLFNDYATYCFQTFGDRVKYWITIHNPYLVAWHGF GTGMHAPGEKGNLTAVYTVGHNLIKAHSKVWHNYDKNFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHL YVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFA LDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLG LPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDI YNRSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPA NPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSS SALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFL QDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDD RLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFK AKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (v) huBeta_Klotho(1-193, 419-1044) (muBetaKLOTHO Y194-416G) (SEQ ID NO: 459) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL TLQEEYGGWKNATMIDLFNDYATYCFQTFGDRVKYWITIHNPYLVAWHGF GTGMHAPGEKGNLTAVYTVGHNLIKAHSKVWHNYDKNFRPHQKGWLSITL GSHWIEPNRTDNMEDVINCQHSMSSVLGWFANPIHGDGDYPEFMKTGAMI PEFSEAEKEEVRGTADFFAFSFGPNNFRPSNTVVKMGQNVSLNLRQVLNW IKLEYDDPQILISENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLDEI RVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYKQI IRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHLYV WNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFALD WASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLP EPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYN RSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPANP YADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSSSA LPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFLQD ITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDDRL RKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFKAK SSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFLGC CFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (vi) huBeta_Klotho(1-301, 509-1044) (muBetaKLOTHO S302-F506) (SEQ ID NO: 460) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRTDNMEDVINCQHSMSSVLGWFANPIHGDGDYPEFMKTGAMI PEFSEAEKEEVRGTADFFAFSFGPNNFRPSNTVVKMGQNVSLNLRQVLNW IKLEYDDPQILISENGWFTDSYIKTEDTTAIYMMKNFLNQVLQAIKFDEI RVFGYTAWTLLDGFEWQDAYTTRRGLFYVDFNSEQKERKPKSSAHYYKQI IQDNGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHLYV WNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFALD WASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLP EPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYN RSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPANP YADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSSSA LPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFLQD ITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDDRL RKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFKAK SSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFLGC CFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (vii) huBeta_Klotho(1-417, 522-1044) (muBetaKLOTHO G416-F519) (SEQ ID NO: 461) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSYIKTEDTTAIYMMKNFLNQVLQAIKFD EIRVFGYTAWTLLDGFEWQDAYTTRRGLFYVDFNSEQKERKPKSSAHYYK QIIQDNGFPLKESTPDMKGRFPCDFSWGVTESVLKPESVASSPQFSDPHL YVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFA LDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLG LPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDI YNRSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPA NPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSS SALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFL QDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDD RLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFK AKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (viii) huBeta_Klotho(1-507, 635-1044) (muBeta KLOTHO F06-G632) (SEQ ID NO: 462) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFPLKESTPDMKGRFPCDFSWGVTESVLKPEFTVSSPQFTDPHL YVWNVTGNRLLYRVEGVRLKTRPSQCTDYVSIKKRVEMLAKMKVTHYQFA LDWTSILPTGNLSKVNRQVLRYYRCVVSEGLKLGISAMVTLYYPTHAHLG LPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDI YNRSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPA NPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSS SALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFL QDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDD RLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFK AKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (ix) huBeta_Klotho(1-521, 738-1044) (muBeta KLOTHO 520P-735A) (SEQ ID NO: 463) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPEFTVSSPQFTDPHL YVWNVTGNRLLYRVEGVRLKTRPSQCTDYVSIKKRVEMLAKMKVTHYQFA LDWTSILPTGNLSKVNRQVLRYYRCVVSEGLKLGVFPMVTLYHPTHSHLG LPLPLLSSGGWLNMNTAKAFQDYAELCFRELGDLVKLWITINEPNRLSDM YNRTSNDTYRAAHNLMIAHAQVWHLYDRQYRPVQHGAVSLSLHADWAEPA NPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSS SALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFL QDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDD RLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFK AKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (x) huBeta_Klotho(1-633, 852-1044) (muBeta KLOTHO 632G-849Q) (SEQ ID NO: 464) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHL YVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFA LDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGVFPMVTLYHPTHSHLG LPLPLLSSGGWLNMNTAKAFQDYAELCFRELGDLVKLWITINEPNRLSDM YNRTSNDTYRAAHNLMIAHAQVWHLYDRQYRPVQHGAVSLSLHCDWAEPA NPFVDSHWKAAERFLQFEIAWFADPLFKTGDYPSVMKEYIASKNQRGLSS SVLPRFTAKESRLVKGTVDFYALNHFTTRFVIHKQLNTNRSVADRDVQFL QDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDD RLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFK AKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (xi) huBeta_Klotho(1-736, 967-1044) (muBeta KLOTHO 735A-963S) (SEQ ID NO: 465) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHL YVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFA LDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLG LPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDI YNRSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHCDWAEPA NPFVDSHWKAAERFLQFEIAWFADPLFKTGDYPSVMKEYIASKNQRGLSS SVLPRFTAKESRLVKGTVDFYALNHFTTRFVIHKQLNTNRSVADRDVQFL QDITRLSSPSRLAVTPWGVRKLLAWIRRNYRDRDIYITANGIDDLALEDD QIRKYYLEKYVQEALKAYLIDKVKIKGYYAFKLTEEKSKPRFGFFTSDFR AKSSVQFYSKLISSSGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (xii) huBeta_Klotho(82-1044) (muBeta KLOTHO 1-81F) (SEQ ID NO: 466) MKTGCAAGSPGNEWIFFSSDERNTRSRKTMSNRALQRSAVLSAFVLLRAV TGFSGDGKAIWDKKQYVSPVNPSQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHL YVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFA LDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLG LPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDI YNRSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPA NPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSS SALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFL QDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDD RLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFK AKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (xiii) huBeta_Klotho(1-81, 194-1044) (muBeta KLOTHO 82P-193L) (SEQ ID NO: 467) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFSWGVGTGAFQVEGSW KTDGRGPSIWDRYVYSHLRGVNGTDRSTDSYIFLEKDLLALDFLGVSFYQ FSISWPRLFPNGTVAAVNAQGLRYYRALLDSLVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFS VLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREAL NWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLD EIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYK QIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHL YVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFA LDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLG LPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDI YNRSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHADWAEPA NPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSS SALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFL QDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDD RLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFK AKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFL GCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS (xiv) huBeta_Klotho (1-301, 509-743, 967-1044) (muBetaKLOTHO 302-506, 742-964) MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAV TGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSW KKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQ FSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPL ALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGY GTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITL GSHWIEPNRTDNMEDVINCQHSMSSVLGWFANPIHGDGDYPEFMKTGAMI PEFSEAEKEEVRGTADFFAFSFGPNNFRPSNTVVKMGQNVSLNLRQVLNW IKLEYDDPQILISENGWFTDSYIKTEDTTAIYMMKNFLNQVLQAIKFDEI RVFGYTAWTLLDGFEWQDAYTTRRGLFYVDFNSEQKERKPKSSAHYYKQI IQDNGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHLYV WNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFALD WASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLP EPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYN RSGNDTYGAAHNLLVAHALAWRLYDQQFRPSQRGAVSLSLHCDWAEPANP FVDSHWKAAERFLQFEIAWFADPLFKTGDYPSVMKEYIASKNQRGLSSSV LPRFTAKESRLVKGTVDFYALNHFTTRFVIHKQLNTNRSVADRDVQFLQD ITRLSSPSRLAVTPWGVRKLLAWIRRNYRDRDIYITANGIDDLALEDDQI RKYYLEKYVQEALKAYLIDKVKIKGYYAFKLTEEKSKPRFGFFTSDFRAK SSVQFYSKLISSSGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFLGC CFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS

Various antigen binding proteins provided herein, as well as human FGF21, were tested for the ability to activate chimeras in L6 cells. FIG. 5 shows the observed results with each tested molecule.

These data indicate that while human FGF21 was able to activate FGFR1c combined with all of the human/mouse β-Klotho chimeras (the “+” sign indicates activity on the receptor), the substitutions of mouse sequences into human β-Klotho affected the activities of 16H7, 37D3, and 39F7 (See FIG. 5). These results suggest that β-Klotho sequences 1-81, 302-522, and 849-1044 are important for the activities of agonistic antigen binding proteins and may represent an important epitope for their function.

In addition, various antigen binding proteins were also tested for binding to the various human/mouse β-Klotho chimeras transiently expressed on the surface of HEK-293T cells by flow cytometry. Transfection and flow-cytometry was performed as described in Example 12. It will be appreciated that antibodies which do not have the ability to cross-bind full length murine β-Klotho are unable to bind the human/mouse β-Klotho chimera if the chimera spans a region of the antibody's binding site. In this manner, the binding profile of each antibody on the panel of chimeras reveals epitope information for the antibody. Data is shown below in Table 10. The anti-β-Klotho antibody 2G10 (which binds both human and mouse β-Klotho) was used as the positive control for expression of each human/mouse chimera. Using this positive control it was determine the expression level of chimeras 7 and 8 were not high enough to provide robust data and therefore they were eliminated from the analysis. One antibody, 26H11, was found to bind to full-length mouse β-Klotho and therefore could not be assigned an epitope in this analysis. Other antibodies which did not cross-bind to mouse β-Klotho could be group into epitope clusters. The first cluster included antibodies 16H7, 46D11, and 49G3.3, which antibodies did not bind to chimera #3 and chimera #12, indicating that the epitope includes the 1-81 region. Additionally, this group of antibodies also lacked observed binding to chimeras 1, 5, 6 and 14, which indicates that the epitope also includes the 294-506 region. Taken together, this data suggests that these antibodies have a complex non-linear type of epitope.

A second cluster included only antibody 65C3.1. This antibody lacked binding to chimeras #2, #11, and #14, indicating an epitope in the region of 849-936. A third cluster, including antibodies 49H12.1, 54A1.1, 49C8.1, 51A8.1, 63A10.1, 64B10.1, 68C8.1 and 39F7, lacked binding to chimera #1, #5, and #6, indicating that their epitope is in the 302-416 region. The forth cluster included antibodies 67C10.1, 51E5.1, 52A8.1, 66G2, 167F5.1, which lacked binding on chimeras #2, #8, #9, #10, #11, and #14 indicating that the epitope for these antibodies lies within region 506-1045. A “+” or “−” symbol in the chart below indicates binding of the respective antibody (“+”), or lack of binding (“−”) to the chimera and/or the respective ortholog of β-Klotho, or Mock Cells (negative control).

TABLE 13 Chimera Binding Mock cells CHIMERA # hu β- mu β- (Neg. Epitope 1 2 3 4 5 6 9 10 11 12 13 14 Klotho klotho Cont.) Region 2G10 + + + + + + + + + + + + + + − 26H11 + + + + + + + + + + + + + + − 16H7 − + − + − − + + + − + − + − − 1-81 & 49G3.3 − + − + − − + + + − + − + − − 302-416 46D11 − + − + − − + + + − + − + − − 49H12.1 − + + + − − + + + + + − + − − 302-416 54A1.1 − + + + − − + + + + + − + − − 49C8.1 − + + + − − + + + + + − + − − 51A8.1 − + + + − − + + + + + − + − − 63A10.1 − + + + − − + + + + + − + − − 64B10.1 − + + + − − + + + + + − + − − 68C8.1 − + + + − − + + + + + − + − − 39F7 − + + + − − + + + + + − + − − 65C3.1 + − + + + + + + − + + − + − − 849-936 67C10.1 + − + + + + − − − + + − + − − 506-1045 51E5.1 + − + + + + − − − + + − + − − 52A8.1 + − + + + + − − − + + − + − − 66G2.1 + − + + + + − − − + + − + − − 67F5.1 + − + + + + − − − + + − + − − IgG2/K − − − − − − − − − − − − − − − Control IgG4/K − − − − − − − − − − − − − − − Control Secondary − − − − − − − − − − − − − − − Only

Example 12 FGF21 Receptor Agonistic Antibodies Binding Selectivity

A panel of FGF21 receptor agonistic antibodies were assayed using flow cytometry for the binding to human FGFR1/human β-klotho transiently co-transfected HEK293T cells, human FGFR1c transiently transfected HEK293T cells and β-klotho transiently transfected HEK293T cells. In addition, binding was also tested on HEK-293T cells transiently transfected with cynomologous monkey orthologs of FGFR1c and β-klotho. Cells were transfected by preparing 10 ug plasmid DNA in 500 μl OptiMEM™ media (Invitrogen™) and mixing this with 10 ul of 293fectin™ in 500 μl OptiMEM™ media, and then incubating the solution for 5 minutes at room temperature. This solution was then added dropwise to 10 million HEK293T cells in 10 ml of media. 24 hours following transfection, the cells were washed and 50,000 cells were stained with each primary antibody, 50 μl of unpurified hybridoma supernatant was diluted 1:2 and used for staining cells. After a one hour incubation at 4° c., the cells were washed and an anti-Human Fc-specific secondary was added. Stained cells were then analyzed on a flow cytometer. The panel of hybridoma supernatants tested all bound specifically to human β-Klotho/human FGFR1c co-transfected cells as well as human β-Klotho transfected alone. Data is shown below in Table 11. No staining was detected for any of the antibodies on cells transfected with FGFR1c alone. All antibodies except 64B10.1 and 68C8.1 specifically detected cynomologous β-Klotho/cynoFGFR1c co-transfected cells.

TABLE 14 FGFR Antibody Selectivity Human Human β- HuFGFR1c/Hu Mock FGFR1c Klotho β-Klotho Co- Cyno FGFR1c/Cyno Transfected Transfect Tranfected transfected β-Klotho Co- 293T cells 293T cells 293T Cells 293T Cells transfected Cells Antibody GeoMean GeoMean GeoMean GeoMean GeoMean 49G3.3 648 706 14891 17919 25947 49H12.1 581 719 16213 21731 20870 51E5.1 723 747 16900 20951 36536 51A8.1 728 795 17799 22826 18476 54A1.1 709 770 14317 18701 11106 59G10.3 686 780 15669 21105 33464 63A10.1 648 834 17442 20432 32558 64B10.1 624 691 14939 19850 701 65C3.1 705 719 13720 18835 24564 66G2.1 695 780 12671 16715 21566 67F5.1 632 757 13482 13948 15784 67C10.1 688 780 15114 18896 4063 68C8.1 592 798 15905 20622 750 16H7 @ 723 869 16335 20686 31319 5 ug/ml

Example 13 Hotspot/Covariant Mutants

A total of 17 antibodies were analyzed for potential hotspots and covariance violations. The designed variants (shown below) outline amino acid substitutions capable of reducing and/or avoiding isomerization, deamidation, oxidation, covariance violations, and the like. In the data below, “02 49C8.1_VKL[F21I]” refers to a variant of the parental antibody 49C8.1 that has a mutation at position 21, from F (Phe) to I (Isoleucine). Note that a structure-based numbering scheme is followed for designating amino acid positions. It will be appreciated that these single point mutations can be combined in any combinatorial manner in order to arrive at a final desired molecule. The data are shown below in Table 15 and Table 16.

TABLE 15 Antibody 49C8.1 02 49C8.1_VK: [F21I] 03 49C8.1_VK: [F91L] 04 49C8.1_VK: [I101F] 05 49C8.1_VK: [I101V] 06 49C8.1_VK: [P141Q] 07 49C8.1_VK: [P141G] 08 49C8.1_VH: [T48P] 09 49C8.1_VH: [N61Q] 10 49C8.1_VH: [G65T] Antibody 49H12_N83D 01 49H12_N83D_VK: [F91L] 02 49H12_N83D_VK: [I101F] 03 49H12_N83D_VK: [I101V] 04 49H12_N83D_VH: [M24K] 05 49H12_N83D_VH: [I30T] 06 49H12_N83D_VH: [T48P] 07 49H12_N83D_VH: [W57Y] 08 49H12_N83D_VH: [W111Y] Antibody 49G3.3 01 49G3.3_VK: [F91L] 02 49G3.3_VK: [I101F] 03 49G3.3_VK: [I101V] 04 49G3.3_VK: [G141Q] 05 49G3.3_VH: [E17Q] 06 49G3.3_VH: [V25F] 07 49G3.3_VH: [T56A] 08 49G3.3_VH: [T56G] 09 49G3.3_VH: [T144L] 10 49G3.3_VH: [T144M] Antibody 51A8.1 01 51A8.1_VL: [I98T] 02 51A8.1_VL: [I98A] 03 51A8.1_VH: [R17G] 04 51A8.1_VH: [D61E] 05 51A8.1_VH: [D72E] 06 51A8.1_VH: [D110E] Antibody 51E5.1 01 51E5.1_VK: [N53K] 02 51E5.1_VK: [R54L] 03 51E5.1_VK: [R54S] 04 51E5.1_VK: [G141Q] 05 51E5.1_VH: [D59E] 06 51E5.1_VH: [H60T] Antibody 52A8.1 01 52A8.1_VK: [F10S] 02 52A8.1_VK: [H44Y] 03 52A8.1_VK: [H44F] 04 52A8.1_VK: [G141Q] 05 52A8.1_VH: [W57Y] 06 52A8.1_VH: [R95S] 07 52A8.1_VH: [W135Y] Antibody 54A1.1_N83D 01 54A1.1_N83D_VK: [A5T] 02 54A1.1_N83D_VK: [L46Q] 03 54A1.1_N83D_VK: [G81S] 04 54A1.1_N83D_VK: [F91L] 05 54A1.1_N83D_VK: [I101F] 06 54A1.1_N83D_VK: [I101V] 07 54A1.1_N83D_VK: [P141G] 08 54A1.1_N83D_VK: [P141Q] 09 54A1.1_N83D_VH: [T48P] 10 54A1.1_N83D_VH: [W57Y] 11 54A1.1_N83D_VH: [W111Y] Antibody 56E7.3 01 56E7.3_VK: [N53K] 02 56E7.3_VK: [F91L] 03 56E7.3_VK: [I101F] 04 56E7.3_VK: [P141Q] 05 56E7.3_VK: [P141G] 06 56E7.3_VK: [T144K] 07 56E7.3_VK: [T144R] 08 56E7.3_VH: [L31F] 09 56E7.3_VH: [D65E] 10 56E7.3_VH: [T84K] 11 56E7.3_VH: [R95S] Antibody 58C2.1 01 58C2.1_VK: [D36E] 02 58C2.1_VH: [R17G] 03 58C2.1_VH: [D61E] 04 58C2.1_VH: [D72E] 05 58C2.1_VH: [N116Q] Antibody 60D7.1_N30T 01 60D7.1_N30T_VK: [D33E] 02 60D7.1_N30T_VK: [D36E] 03 60D7.1_N30T_VH: [R17G] 04 60D7.1_N30T_VH: [D61E] 05 60D7.1_N30T_VH: [D72E] 06 60D7.1_N30T_VH: [W115Y] Antibody 63A10.1_C58S 01 63A10.1_C58S_VL: [H9L] 02 63A10.1_C58S_VL: [H9P] 03 63A10.1_C58S_VL: [T15L] 04 63A10.1_C58S_VL: [T15P] 05 63A10.1_C58S_VL: [A16G] 06 63A10.1_C58S_VL: [M18T] 07 63A10.1_C58S_VL: [D51A] 08 63A10.1_C58S_VL: [D51S] 09 63A10.1_C58S_VL: [D51F] 10 63A10.1_C58S_VL: [D67E] 11 63A10.1_C58S_VL: [P83S] 12 63A10.1_C58S_VL: [E97Q] 13 63A10.1_C58S_VL: [D110E] 14 63A10.1_C58S_VL: [D136E] 15 63A10.1_C58S_VH: [D11G] 16 63A10.1_C58S_VH: [K14Q] 17 63A10.1_C58S_VH: [I29F] 18 63A10.1_C58S_VH: [G56S] 19 63A10.1_C58S_VH: [D64E] 20 63A10.1_C58S_VH: [G84D] 21 63A10.1_C58S_VH: [G84N] 22 63A10.1_C58S_VH: [T98A] 23 63A10.1_C58S_VH: [T107A] 24 63A10.1_C58S_VH: [T108R] 25 63A10.1_C58S_VH: [D109E] 26 63A10.1_C58S_VL: [W109Y] Antibody 63A10.3_N20R_C42S 01 63A10.3_N20R_C42S_VL: [W109Y] 02 63A10.3_N20R_C42S_VL: [D67E] 03 63A10.3_N20R_C42S_VL: [D110E] 04 63A10.3_N20R_C42S_VH: [D11G] 05 63A10.3_N20R_C42S_VH: [K14Q] 06 63A10.3_N20R_C42S_VH: [I29F] 07 63A10.3_N20R_C42S_VH: [G56S] 08 63A10.3_N20R_C42S_VH: [D64E] 09 63A10.3_N20R_C42S_VH: [G84N] 10 63A10.3_N20R_C42S_VH: [T98A] 11 63A10.3_N20R_C42S_VH: [T107A] 12 63A10.3_N20R_C42S_VH: [T108R] 13 63A10.3_N20R_C42S_VH: [D109E] 14 63A10.3_N20R_C42S_VL: [W109Y] Antibody 64B10.1 01 64B10.1_VL: [G92A] 02 64B10.1_VL: [G99E] 03 64B10.1_VL: [D110E] 04 64B10.1_VH: [L5Q] 05 64B10.1_VH: [T144L] 06 64B10.1_VH: [T144M] 07 64B10.1_VL: [W109Y] 08 64B10.1_VH: [W113Y] Antibody 66G2 01 66G2_VK: [R54L] 02 66G2_VK: [K88E] 03 66G2_VK: [K88D] 04 66G2_VK: [N110Q] 05 66G2_VH: [R17G] 06 66G2_VH: [D61E] 07 66G2_VH: [D72E] 08 66G2_VH: [I78F] 09 66G2_VH: [T108K] 10 66G2_VH: [T108R] Antibody 67F5 1. 01 67F5_VK: [H57Y] 2. 02 67F5_VK: [Q97E] 3. 03 67F5_VK: [S98P] 4. 04 67F5_VK: [A99E] 5. 05 67F5_VK: [N105Y] 6. 06 67F5_VH: [K5Q] 7. 07 67F5_VK: [W135Y] 8. 08 67F5_VK: [W137Y] Antibody 67C10 1. 01 67C10_VK: [F2I] 2. 02 67C10_VK: [D36E] 3. 03 67C10_VH: [Q24K] 4. 04 67C10_VH: [D65E] Antibody 68C8 1. 01 68C8_VL: [G92A] 2. 02 68C8_VL: [G99E] 3. 03 68C8_VL: [D110E] 4. 04 68C8_VH: [D29G] 5. 05 68C8_VH: [H83D] 6. 06 68C8_VH: [G107A] 7. 07 68C8_VH: [T144L] 8. 08 68C8_VH: [T144M] 9. 09 68C8_VL: [W109Y] 10. 10  68C8_VH: [W113Y]

TABLE 16 Exemplary Substitutions >49C8.1_VK DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDNLPFTFGPGTKVDLKR >49C8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPN GGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49H12_N83D_VK DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH QVQLVQSGAEVKKPGASVKVSCMASGYIFTSYDINWVRQATGQGPEWMGWMNPY SGSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >49G3.3_VK DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >51A8.1_VL NFILTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDKERSSGV PDRFSGSIDSSSNSASLTISGLKIEDEADYYCQSYDRNNHVVFGGGTKLTVLG >51A8.1_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADGDYPYYYYYY GMDVWGQGTTVTVSS >51E5.1_VK DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPNRLIYAASSLQFG VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPLTFGGGTRVEIKR >51E5.1_VH QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGELDHSGSI NYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARVLGSTLDYWGQGTLVT VSS >52A8.1_VK DIQMTQSPSFLSASVGDRVTITCRASQTISSYLNWHQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKR >52A8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGWINPN SAATNYAPKFQGRVTVTRDTSISTAYMELSRLRSDDTAVYYCAREGGTYNWFDPWG QGTLVTVSS >54A1.1_N83D_VK DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >56E7.3_VK DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGPGTTVDIKR >56E7.3_VH EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >58C2.1_VK EIVMTQTPLSLPVTPGEPASISCRSSQSLFDNDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRLEFPITFGQGTRLEIKR >58C2.1_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWND GNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQNYDFWNGYP YYFYYGMDVWGQGTTVTVSS >60D7.1_N30T_VK DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIKR >60D7.1_N30T_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCARDQYFDFWSGYPFF YYYGMDVWGQGTTVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.3_N20R_C42S_VL SYELTQPPSVSVSPGQTARITCSGDKLGNRYTSWYQQKSGQSPVLVIYQDSERPSGIP ERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSTTVVFGGGTKLTVLG >63A10.3_N20R_C42S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >64B10.1_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >64B10.1_VH QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTWDYYYGVDVWG QGTTVTVSS >66G2_VK DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTKFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGM DVWGQGTTVTVSS >67F5_VK EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIHGSSNRAIGIP ARFSGSGSGTEFTLTISSLQSADFAVYNCQQYEIWPWTFGQGTKVEIKR >67F5_VH QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67C10_VK DFVMTQTPLSLPVTPGEPASISCRSSQSLLNSDDGNTYLDWYLQKPGQSPQLLIYTLS YRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPITFGQGTRLEIKR >67C10_VH EVQLVQSGAEVKKPGESLKISCQGSGYSFSSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCARRASRGYRYGLAFAIW GQGTMVTVSS >68C8_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTTVTVSS >49C8.1_VK.02 DIQMTQSPSSLSASVGDRVTITCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETGV PSRFSGSGSGTDFTLTISSLQPEDIATYFCQQYDNLPFTFGPGTKVDLKR >49C8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPN GGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49C8.1_VK.03 DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTLTISSLQPEDIATYFCQQYDNLPFTFGPGTKVDLKR >49C8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPN GGNTGYAQKFQGRVTMTRDTS INTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYWGQGTLVTVSS >49C8.1_VK.04 DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTFTISSLQPEDFATYFCQQYDNLPFTFGPGTKVDLKR >49C8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPN GGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49C8.1_VK.05 DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTFTISSLQPEDVATYFCQQYDNLPFTFGPGTKVDLKR >49C8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPN GGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49C8.1_VK.06 DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDNLPFTFGQGTKVDLKR >49C8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPN GGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49C8.1_VK.07 DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDNLPFTFGGGTKVDLKR >49C8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPN GGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49C8.1_VK DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDNLPFTFGPGTKVDLKR >49C8.1_VH.08 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQAPGQGLEWMGWMNPN GGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49C8.1_VK DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDNLPFTFGPGTKVDLKR >49C8.1_VH.09 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPQ GGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49C8.1_VK DIQMTQSPSSLSASVGDRVTFTCQASQDINIYLNWYQQKPGKAPKLLIYDVSNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDNLPFTFGPGTKVDLKR >49C8.1_VH.10 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDIDWVRQATGQGLEWMGWMNPN TGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAIYYCARGKEFSRAEFDYW GQGTLVTVSS >49H12_N83D_VK.01 DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTLTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH QVQLVQSGAEVKKPGASVKVSCMASGYIFTSYDINWVRQATGQGPEWMGWMNPY SGSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >49H12_N83D_VK.02 DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH QVQLVQSGAEVKKPGASVKVSCMASGYIFTSYDINWVRQATGQGPEWMGWMNPY SGSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >49H12_N83D_VK.03 DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTFTISSLQPEDVATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH QVQLVQSGAEVKKPGASVKVSCMASGYIFTSYDINWVRQATGQGPEWMGWMNPY SGSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >49H12_N83D_VK DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH.04 QVQLVQSGAEVKKPGASVKVSCKASGYIFTSYDINWVRQATGQGPEWMGWMNPYS GSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFWG QGTMVTVSS >49H12_N83D_VK DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH.05 QVQLVQSGAEVKKPGASVKVSCMASGYTFTSYDINWVRQATGQGPEWMGWMNPY SGSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >49H12_N83D_VK DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH.06 QVQLVQSGAEVKKPGASVKVSCMASGYIFTSYDINWVRQAPGQGPEWMGWMNPY SGSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >49H12_N83D_VK DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH.07 QVQLVQSGAEVKKPGASVKVSCMASGYIFTSYDINWVRQATGQGPEWMGYMNPYS GSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFWG QGTMVTVSS >49H12_N83D_VK DIQMTQSPSSLSASVGDRVTITCQASQDITKYLNWYQQKPGKAPKLLIYDTFILETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIKR >49H12_N83D_VH.08 QVQLVQSGAEVKKPGASVKVSCMASGYIFTSYDINWVRQATGQGPEWMGWMNPY SGSTGYAQNFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNYNYGAFDFW GQGTMVTVSS >49G3.3_VK.01 DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTLTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >49G3.3_VK.02 DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDFATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >49G3.3_VK.03 DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDVATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >49G3.3_VK.04 DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDDLPLTFGQGTKVEIRR >49G3.3_VH QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >49G3.3_VK DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH.05 QVTLKESGPVLVKPTQTLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >49G3.3_VK DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH.06 QVTLKESGPVLVKPTETLTLTCTFSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >49G3.3_VK DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH.07 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLAHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >49G3.3_VK DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH.08 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLGHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTTVTVSS >49G3.3_VK DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH.09 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTLVTVSS >49G3.3_VK DIQMTQSPSSLSASIGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDDLPLTFGGGTKVEIRR >49G3.3_VH.10 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLTHIFSNDE KSYSTSLKSRLTISKDTSKSQVVLSMTNMDPVDTATYYCVRVDTLNYHYYGMDVW GQGTMVTVSS >51A8.1_VL.01 NFILTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDKERSSGV PDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDRNNHVVFGGGTKLTVLG >51A8.1_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADGDYPYYYYYY GMDVWGQGTTVTVSS >51A8.1_VL.02 NFILTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDKERSSGV PDRFSGSIDSSSNSASLTISGLKAEDEADYYCQSYDRNNHVVFGGGTKLTVLG >51A8.1_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADGDYPYYYYYY GMDVWGQGTTVTVSS >51A8.1_VL NFILTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDKERSSGV PDRFSGSIDSSSNSASLTISGLKIEDEADYYCQSYDRNNHVVFGGGTKLTVLG >51A8.1_VH.03 QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADGDYPYYYYYY GMDVWGQGTTVTVSS >51A8.1_VL NFILTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDKERSSGV PDRFSGSIDSSSNSASLTISGLKIEDEADYYCQSYDRNNHVVFGGGTKLTVLG >51A8.1_VH.04 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEGS NKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADGDYPYYYYYYG MDVWGQGTTVTVSS >51A8.1_VL NFILTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDKERSSGV PDRFSGSIDSSSNSASLTISGLKIEDEADYYCQSYDRNNHVVFGGGTKLTVLG >51A8.1_VH.05 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDG SNKYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADGDYPYYYYYY GMDVWGQGTTVTVSS >51A8.1_VL NFILTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDKERSSGV PDRFSGSIDSSSNSASLTISGLKIEDEADYYCQSYDRNNHVVFGGGTKLTVLG >51A8.1_VH.06 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAEGDYPYYYYYY GMDVWGQGTTVTVSS >51E5.1_VK.01 DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYAASSLQFG VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPLTFGGGTRVEIKR >51E5.1_VH QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGELDHSGSI NYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARVLGSTLDYWGQGTLVT VSS >51E5.1_VK.02 DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPNLLIYAASSLQFGV PSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPLTFGGGTRVEIKR >51E5.1_VH QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGELDHSGSI NYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARVLGSTLDYWGQGTLVT VSS >51E5.1_VK.03 DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPNSLIYAASSLQFGV PSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPLTFGGGTRVEIKR >51E5.1_VH QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGELDHSGSI NYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARVLGSTLDYWGQGTLVT VSS >51E5.1_VK.04 DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPNRLIYAASSLQFG VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPLTFGQGTRVEIKR >51E5.1_VH QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGELDHSGSI NYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARVLGSTLDYWGQGTLVT VSS >51E5.1_VK DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPNRLIYAASSLQFG VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPLTFGGGTRVEIKR >51E5.1_VH.05 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGELEHSGSI NYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARVLGSTLDYWGQGTLVT VSS >51E5.1_VK DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPNRLIYAASSLQFG VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPLTFGGGTRVEIKR >51E5.1_VH.06 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGELDTSGSI NYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARVLGSTLDYWGQGTLVT VSS >52A8.1_VK.01 DIQMTQSPSSLSASVGDRVTITCRASQTISSYLNWHQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKR >52A8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGWINPN SAATNYAPKFQGRVTVTRDTSISTAYMELSRLRSDDTAVYYCAREGGTYNWFDPWG QGTLVTVSS >52A8.1_VK.02 DIQMTQSPSFLSASVGDRVTITCRASQTISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKR >52A8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGWINPN SAATNYAPKFQGRVTVTRDTSISTAYMELSRLRSDDTAVYYCAREGGTYNWFDPWG QGTLVTVSS >52A8.1_VK.03 DIQMTQSPSFLSASVGDRVTITCRASQTISSYLNWFQQKPGKAPKLLIYAASSLQSGVP SRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKR >52A8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGWINPN SAATNYAPKFQGRVTVTRDTSISTAYMELSRLRSDDTAVYYCAREGGTYNWFDPWG QGTLVTVSS >52A8.1_VK.04 DIQMTQSPSFLSASVGDRVTITCRASQTISSYLNWHQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKR >52A8.1_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGWINPN SAATNYAPKFQGRVTVTRDTSISTAYMELSRLRSDDTAVYYCAREGGTYNWFDPWG QGTLVTVSS >52A8.1_VK DIQMTQSPSFLSASVGDRVTITCRASQTISSYLNWHQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKR >52A8.1_VH.05 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGYINPNS AATNYAPKFQGRVTVTRDTSISTAYMELSRLRSDDTAVYYCAREGGTYNWFDPWG QGTLVTVSS >52A8.1_VK DIQMTQSPSFLSASVGDRVTITCRASQTISSYLNWHQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKR >52A8.1_VH.06 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGWINPN SAATNYAPKFQGRVTVTRDTSISTAYMELSSLRSDDTAVYYCAREGGTYNWFDPWG QGTLVTVSS >52A8.1_VK DIQMTQSPSFLSASVGDRVTITCRASQTISSYLNWHQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKR >52A8.1_VH.07 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGWINPN SAATNYAPKFQGRVTVTRDTSISTAYMELSRLRSDDTAVYYCAREGGTYNYFDPWG QGTLVTVSS >54A1.1_N83D_VK.01 DIQMTQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK.02 DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQQKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK.03 DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK.04 DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTLTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK.05 DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDFATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK.06 DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDVATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK.07 DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGGGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK.08 DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGQGTKVDIKR >54A1.1_N83D_VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH.09 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH.10 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGYMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNWNYGAFDFW GQGTMVTVSS >54A1.1_N83D_VK DIQMAQSPSSLSASVGDRVTITCQASQDISIYLNWYQLKPGKAPKLLIYDVSNLETGV PSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGPGTKVDIKR >54A1.1_N83D_VH.11 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPH SGNTGYAQKFQGRVTMTRDTSINTAYMELSSLRSEDTAVYYCAKYNYNYGAFDFW GQGTMVTVSS >58C2.1_VK.01 EIVMTQTPLSLPVTPGEPASISCRSSQSLFDNDEGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRLEFPITFGQGTRLEIKR >58C2.1_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWND GNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQNYDFWNGYP YYFYYGMDVWGQGTTVTVSS >58C2.1_VK EIVMTQTPLSLPVTPGEPASISCRSSQSLFDNDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRLEFPITFGQGTRLEIKR >58C2.1_VH.02 QVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWND GNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQNYDFWNGYP YYFYYGMDVWGQGTTVTVSS >58C2.1_VK EIVMTQTPLSLPVTPGEPASISCRSSQSLFDNDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRLEFPITFGQGTRLEIKR >58C2.1_VH.03 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWNEG NNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQNYDFWNGYPY YFYYGMDVWGQGTTVTVSS >58C2.1_VK EIVMTQTPLSLPVTPGEPASISCRSSQSLFDNDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRLEFPITFGQGTRLEIKR >58C2.1_VH.04 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWND GNNKYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQNYDFWNGYP YYFYYGMDVWGQGTTVTVSS >58C2.1_VK EIVMTQTPLSLPVTPGEPASISCRSSQSLFDNDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRLEFPITFGQGTRLEIKR >58C2.1_VH.05 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWND GNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQNYDFWQGYP YYFYYGMDVWGQGTTVTVSS >56E7.3_VK.01 DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPKLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGPGTTVDIKR >56E7.3_VH EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >56E7.3_VK.02 DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQYAILPFTFGPGTTVDIKR >56E7.3_VH EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >56E7.3_VK.03 DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYAILPFTFGPGTTVDIKR >56E7.3_VH EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >56E7.3_VK.04 DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGGGTTVDIKR >56E7.3_VH EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >56E7.3_VK.05 DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGQGTTVDIKR >56E7.3_VH EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >56E7.3_VK.06 DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGPGTKVDIKR >56E7.3_VH EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >56E7.3_VK.07 DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGPGTRVDIKR >56E7.3_VH EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >56E7.3_VK DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGPGTTVDIKR >56E7.3_VH.08 EVQLVQSGPEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSD TRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLVT VSS >56E7.3_VK DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGPGTTVDIKR >56E7.3_VH.09 EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGESD TRYSPSFQGQVTISADTSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLVT VSS >56E7.3_VK DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGPGTTVDIKR >56E7.3_VH.10 EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADKSISTAYLQWSRLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >56E7.3_VK DLQMTQSPSSLSASVGDRVTITCQASQDIKKFLNWYQQKPGKAPNLLIYDASNLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYAILPFTFGPGTTVDIKR >56E7.3_VH.11 EVQLVQSGPEVKKPGESLKISCKGSGYSLTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADTSISTAYLQWSSLKASDTAVYYCARAQLGIFDYWGQGTLV TVSS >60D7.1_N30T_VK.01 DIVLTQTPLSLPVTPGEPASISCRSSQSLLESDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIKR >60D7.1_N30T_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCARDQYFDFWSGYPFF YYYGMDVWGQGTTVTVSS >60D7.1_N30T_VK.02 DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSDEGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIKR >60D7.1_N30T_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCARDQYFDFWSGYPFF YYYGMDVWGQGTTVTVSS >60D7.1_N30T_VK DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIKR >60D7.1_N30T_VH.03 QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCARDQYFDFWSGYPFF YYYGMDVWGQGTTVTVSS >60D7.1_N30T_VK DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIKR >60D7.1_N30T_VH.04 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYEG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCARDQYFDFWSGYPFF YYYGMDVWGQGTTVTVSS >60D7.1_N30T_VK DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIKR >60D7.1_N30T_VH.05 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDG SNKYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCARDQYFDFWSGYPFF YYYGMDVWGQGTTVTVSS >60D7.1_N30T_VK DIVLTQTPLSLPVTPGEPASISCRSSQSLLDSDDGDTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIKR >60D7.1_N30T_VH.06 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDG SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCARDQYFDFYSGYPFF YYYGMDVWGQGTTVTVSS >63A10.1_C58S_VL.01 SYELTQPLSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.02 SYELTQPPSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.03 SYELTQPHSVSVALAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.04 SYELTQPHSVSVAPAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.05 SYELTQPHSVSVATGQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.06 SYELTQPHSVSVATAQTARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGIP ERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.07 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQAPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.08 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQSPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.09 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQFPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.10 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSESNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.11 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNSGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.12 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIQAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.13 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWESSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.14 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSEGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.15 EVQLVESGGGLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.16 EVQLVESGGDLVQPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.17 EVQLVESGGDLVKPGGSLRLSCAVSGFTFSNAWMSWVRQAPGKGLEWVGRIKSKT DGGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVED YFDYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.18 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVSRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.19 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTE GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.20 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDDSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.21 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDNSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.22 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKAEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.23 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCATDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.24 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTRDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVWDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH.25 EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTESSGSYYVEDYF DYWGQGTLVTVSS >63A10.1_C58S_VL.26 SYELTQPHSVSVATAQMARITCGGNNIGSKAVHWYQQKPGQDPVLVIYSDSNRPSGI PERFSGSNPGNTATLTISRIEAGDEADYYCQVYDSSSDGVFGGGTKLTVLG >63A10.1_C58S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.3_N20R_C42S_VL.01 SYELTQPPSVSVSPGQTARITCSGDKLGNRYTSWYQQKPGQSPVLVIYQDSERPSGIP ERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSTTVVFGGGTKLTVLG >63A10.3_N20R_C42S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.3_N20R_C42S_VL.02 SYELTQPPSVSVSPGQTARITCSGDKLGNRYTSWYQQKSGQSPVLVIYQESERPSGIPE RFSGSNSGNTATLTISGTQAMDEADYYCQAWDSTTVVFGGGTKLTVLG >63A10.3_N20R_C42S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >63A10.3_N20R_C42S_VL.03 SYELTQPPSVSVSPGQTARITCSGDKLGNRYTSWYQQKSGQSPVLVIYQDSERPSGIP ERFSGSNSGNTATLTISGTQAMDEADYYCQAWESTTVVFGGGTKLTVLG >63A10.3_N20R_C42S_VH EVQLVESGGDLVKPGGSLRLSCAVSGITFSNAWMSWVRQAPGKGLEWVGRIKSKTD GGTTDYAAPVKGRFTVSRDGSKNTLYLQMNSLKTEDTAVYYCTTDSSGSYYVEDYF DYWGQGTLVTVSS >64B10.1_VL.01 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >64B10.1_VH QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTWDYYYGVDVWG QGTTVTVSS >64B10.1_VL.02 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLGITGLQTEDEADYYCGTWDSSLSAVVFGGGTKLTVLG >64B10.1_VH QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTWDYYYGVDVWG QGTTVTVSS >64B10.1_VL.03 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWESSLSAVVFGGGTKLTVLG >64B10.1_VH QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTWDYYYGVDVWG QGTTVTVSS >64B10.1_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >64B10.1_VH.04 QIQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTWDYYYGVDVWG QGTTVTVSS >64B10.1_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >64B10.1_VH.05 QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTWDYYYGVDVWG QGTLVTVSS >64B10.1_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >64B10.1_VH.06 QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTWDYYYGVDVWG QGTMVTVSS >64B10.1_VL.07 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTYDSSLSAVVFGGGTKLTVLG >64B10.1_VH QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTWDYYYGVDVWG QGTTVTVSS >64B10.1_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVAWYQQLPGTAPKLLIYDNDKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >64B10.1_VH.08 QIQLLESGPGLVKPSETLSLTCTVSGGSVSSGDYYWSWIRQPPGKGLEWIGFIYYSGG TNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADTAVYYCARYSSTYDYYYGVDVWG QGTTVTVSS >66G2_VK.01 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASNLQSG VPSRFSGSGSGTKFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGM DVWGQGTTVTVSS >66G2_VK.02 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTEFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGM DVWGQGTTVTVSS >66G2_VK.03 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTDFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGM DVWGQGTTVTVSS >66G2_VK.04 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTKFTLTINSLQPEDFATYYCLQLQGYPLTFGGGTKVEIKR >66G2_VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGM DVWGQGTTVTVSS >66G2_VK DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTKFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH.05 QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGM DVWGQGTTVTVSS >66G2_VK DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTKFTLTI NSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH.06 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYEGS NKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGMD VWGQGTTVTVSS >66G2_VK DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTKFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH.07 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYAESVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGMD VWGQGTTVTVSS >66G2_VK DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTKFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH.08 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRFTISRDNPKNTLYLQMNSLRAEDTAVYYCATTVTKEDYYYYGM DVWGQGTTVTVSS >66G2_VK DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTKFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH.09 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCAKTVTKEDYYYYGM DVWGQGTTVTVSS >66G2_VK DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTKFTLTINSLQPEDFATYYCLQLNGYPLTFGGGTKVEIKR >66G2_VH.10 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAGISYDG SNKNYADSVKGRITISRDNPKNTLYLQMNSLRAEDTAVYYCARTVTKEDYYYYGM DVWGQGTTVTVSS >67F5_VK.01 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIYGSSNRAIGIP ARFSGSGSGTEFTLTISSLQSADFAVYNCQQYEIWPWTFGQGTKVEIKR >67F5_VH QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67F5_VK.02 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIHGSSNRAIGIP ARFSGSGSGTEFTLTISSLESADFAVYNCQQYEIWPWTFGQGTKVEIKR >67F5_VH QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67F5_VK.03 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIHGSSNRAIGIP ARFSGSGSGTEFTLTISSLQPADFAVYNCQQYEIWPWTFGQGTKVEIKR >67F5_VH QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67F5_VK.04 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIHGSSNRAIGIP ARFSGSGSGTEFTLTISSLQSEDFAVYNCQQYEIWPWTFGQGTKVEIKR >67F5_VH QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67F5_VK.05 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIHGSSNRAIGIP ARFSGSGSGTEFTLTISSLQSADFAVYYCQQYEIWPWTFGQGTKVEIKR >67F5_VH QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67F5_VK EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIHGSSNRAIGIP ARFSGSGSGTEFTLTISSLQSADFAVYNCQQYEIWPWTFGQGTKVEIKR >67F5_VH.06 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67F5_VK.07 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIHGSSNRAIGIP ARFSGSGSGTEFTLTISSLQSADFAVYNCQQYEIYPWTFGQGTKVEIKR >67F5_VH QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67F5_VK.08 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIHGSSNRAIGIP ARFSGSGSGTEFTLTISSLQSADFAVYNCQQYEIWPYTFGQGTKVEIKR >67F5_VH QVQLKESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGNTN YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREYYYGSGSYYPWGQGTL VTVSS >67C10_VK.01 DIVMTQTPLSLPVTPGEPASISCRSSQSLLNSDDGNTYLDWYLQKPGQSPQLLIYTLSY RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPITFGQGTRLEIKR >67C10_VH EVQLVQSGAEVKKPGESLKISCQGSGYSFSSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCARRASRGYRYGLAFAIW GQGTMVTVSS >67C10_VK.02 DFVMTQTPLSLPVTPGEPASISCRSSQSLLNSDEGNTYLDWYLQKPGQSPQLLIYTLS YRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPITFGQGTRLEIKR >67C10_VH EVQLVQSGAEVKKPGESLKISCQGSGYSFSSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCARRASRGYRYGLAFAIW GQGTMVTVSS >67C10_VK DFVMTQTPLSLPVTPGEPASISCRSSQSLLNSDDGNTYLDWYLQKPGQSPQLLIYTLS YRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPITFGQGTRLEIKR >67C10_VH.03 EVQLVQSGAEVKKPGESLKISCKGSGYSFSSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCARRASRGYRYGLAFAIW GQGTMVTVSS >67C10_VK DFVMTQTPLSLPVTPGEPASISCRSSQSLLNSDDGNTYLDWYLQKPGQSPQLLIYTLS YRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPITFGQGTRLEIKR >67C10_VH.04 EVQLVQSGAEVKKPGESLKISCQGSGYSFSSYWIGWVRQMPGKGLEWMGIIYPGESD TRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCARRASRGYRYGLAFAIWG QGTMVTVSS >68C8_VL.01 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTTVTVSS >68C8_VL.02 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTEDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTTVTVSS >68C8_VL.03 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWESSLSAVVFGGGTKLTVLG >68C8_VH QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTTVTVSS >68C8_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH.04 QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTTVTVSS >68C8_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH.05 QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLDTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTTVTVSS >68C8_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH.06 QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCARYRSDWDYYYGMDVW GQGTTVTVSS >68C8_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH.07 QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTLVTVSS >68C8_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH.08 QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTMVTVSS >68C8_VL.09 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTYDSSLSAVVFGGGTKLTVLG >68C8_VH QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDWDYYYGMDVW GQGTTVTVSS >68C8_VL QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLG >68C8_VH.10 QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGDNYWSWIRQPPGKGLEWIGFMFYSG STNYNPSLKSRVTISLHTSKNQFSLRLSSVTAADTAVYYCGRYRSDYDYYYGMDVW GQGTTVTVSS

Example 14 Immunogenicity Prediction

Immune responses against proteins are enhanced by antigen processing and presentation in the major histocompatability complex (MHC) class II binding site. This interaction is required for T cell help in maturation of antibodies that recognize the protein. Since the binding sites of MHC class II molecules have been characterized, it is possible to predict whether proteins have specific sequences that can bind to a series of common human alleles. Computer algorithms have been created based on literature references and MHC class II crystal structures to determine whether linear 9 amino acid peptide sequences have the potential to break immune tolerance. We used the TEPITOPE™ program called to determine if point mutations of FGF21 are predicted to increase antigen specific T-cells in a majority of humans. Based on the linear protein sequence, none of the mutations examined are expected enhance immunogenicity. Results are shown in Table 17A and Table 17B below.

TABLE 17A Protein Predicted Immunogenicity Met-FGF21 Low Met-hFGF21(N106D) Low Met-FGF21 (N122D) Low hFc(R4).L15.hFGF21(G170E) Low hFc(R4).L15.hFGF21(P171A) Low hFc(R4).L15.hFGF21(S172L) Low p30.hFc.L15.hFGF21(A45K, G170E) Low p30.hFc.L15.hFGF21 (L98R, P171G) Low

TABLE 17B LC HC Non- Non- LC LC Non- Tolerant HC HC Non- tolerant Predicted LC Total Tolerant Tolerant HLA HC Total Tolerant tolerant HLA Clone immunogenicity Agretopes Agretopes Agretopes DRB1 Agretopes Agretopes Agretopes DRB1 68C8 Tier 1 3 3 0 NA 12 12 0 NA 63A10 Tier 1 1 1 0 NA 12 12 0 NA 51A8 Tier 2 3 2 1 0101 16 16 0 NA 0701 51E5 Tier 2 6 6 0 NA 11 10 1 0401 0701 64B10 Tier 2 2 2 0 NA 12 11 1 0801 49H12 Tier 3 7 5 2 0101 13 13 0 NA 0701 0801 1301 1501 54A1 Tier 3 6 4 2 0301 14 14 0 NA 0801 1501 52A8 Tier 3 6 5 1 0701 13 12 1 1301 60D7 Tier 4 8 7 1 0301 16 14 2 0401 0401 1501 1101 49C8 Tier 4 7 5 2 0801 14 13 1 0401 1501 67C10 Tier 4 8 7 1 0301 14 12 2 0101 0401 701 1101

Each reference cited herein is incorporated by reference in its entirety for all that it teaches and for all purposes.

The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended as illustrations of individual aspects of the disclosure, and functionally equivalent methods and components form aspects of the disclosure. Indeed, various modifications of the disclosure, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. 

1. An isolated antigen binding protein that induces FGF21-mediated signaling.
 2. An isolated antigen binding protein that specifically binds to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.
 3. The antigen binding protein of claim 1, wherein the antigen binding protein comprises one or more of: (a) a light chain CDR3 comprising one or more of: (i) a light chain CDR3 sequence that differs by three, two or one amino acid additions, substitutions, deletions and combinations thereof from a CDR3 of one or more of CDRL3-1 to CDRL3-75 of Table 3B (SEQ ID NOs 947-1020, respectively, in order of appearance); (ii) (SEQ ID NO: 988) QQFGSSLT; (iii) (SEQ ID NO: 1443) QQSX₁SX₂X₃LT; (iv) (SEQ ID NO: 1447) LQX₄X₅SYPX₆T; (v) (SEQ ID NO: 1451) MQRX₇EFPX₈T; (vi) (SEQ ID NO: 1457) QX₉WDSX₁₀X₁₁VV; (vii) (SEQ ID NO: 1461) QQYNX₁₂WPX₁₃T; (viii) (SEQ ID NO: 1466) QVWDSSX₁₄DX₁₅VX₁₆; (ix) (SEQ ID NO: 1469) QQSS X₁₇IPWT; (x) (SEQ ID NO: 1470) QQTNSFPPWT; (xi) (SEQ ID NO: 1474) GTWDSSLSX₁₈X₁₉V; (xii) (SEQ ID NO: 1477) QQYDNLPX₂₀T; (xiii) (SEQ ID NO: 1480) QQYGSSX₂₁PWT; (xiv) (SEQ ID NO: 1483) QQYGX₂₂SX₂₃FT; (xv) (SEQ ID NO: 1488) QQYGSSX₂₄X₂₅X₂₆; (xvi) (SEQ ID NO: 1492) QAWDSSX₂₇TX₂₈V; (xvii) (SEQ ID NO: 1496) QAWDSX₂₉TVX_(30;) (xviii) (SEQ ID NO: 1499) QQX₃₁YSAX₃₂FT; (xix) (SEQ ID NO: 1502) QQYNX₃₃YPRT; (xx) (SEQ ID NO: 1505) HQX₃₄X₃₅DLPLT; (xxi) (SEQ ID NO: 1508) MQALQTX₃₆X₃₇T; (xxii) (SEQ ID NO: 1509) QQFGRSFT; (xxiii) (SEQ ID NO: 1512) YSTDSSX₃₈NHVV;

(b) a heavy chain CDR3 sequence comprising one or more of: (i) a heavy chain CDR3 that differs by eight, seven, six, five, four, three, two or one amino acid additions, substitutions, deletions and combinations thereof from a CDR3 of one or more of CDRH3-1 to CDRH3-81 of Table 3A (SEQ ID NOs 733-813, respectively, in order of appearance); (ii) (SEQ ID NO: 1669) MTX₁₁₀PYWYFX₁₁₁L; (iii) (SEQ ID NO: 1675) DX₁₁₂X₁₁₃X₁₁₄DFWX₁₁₅GYPX₁₁₆X₁₁₇X₁₁₈YYGX₁₁₉DV; (iv) (SEQ ID NO: 1676) VTGTDAFDF; (v) (SEQ ID NO: 1677) TVTKEDYYYYGMDV; (vi) (SEQ ID NO: 1678) DSSGSYYVEDYFDY; (vii) (SEQ ID NO: 1681) DX₁₁₉X₁₂₀IAVAGX₁₂₁FDY; (viii) (SEQ ID NO: 1682) EYYYGSGSYYP; (ix) (SEQ ID NO: 1683) ELGDYPFFDY; (x) (SEQ ID NO: 1684) EYVAEAGFDY; (xi) (SEQ ID NO: 1685) VAAVYWYFDL; (xii) (SEQ ID NO: 1686) YNWNYGAFDF; (xiii) (SEQ ID NO: 1689) RASRGYRX₁₂₂GLAFAI; (xiv) (SEQ ID NO: 1690) DGITMVRGVTHYYGMDV; (xv) (SEQ ID NO: 1693) DHX₁₂₃SCWYYYGMDV; (xvi) (SEQ ID NO: 1696) YX₁₂₄X₁₂₅WDYYYGX₁₂₆DV; (xvii) (SEQ ID NO: 1699) VLHYX₁₂₇DSX₁₂₈GYSYYX₁₂₉DX₁₃₀;

Or (c) the light chain CDR3 sequence of (a) and the heavy chain CDR3 sequence of (b); wherein, X₁ is Y or F; X₂ is T or S; X₃ is P or S; X₄ is H or R; X₅ is N or S; X₆ is L or R; X₇ is I or L; X₈ is I or L; X₉ is V or L; X₁₀ is S or N; X₁₁ is T, P or S; X₁₂ is N or T; X₁₃ is W or L; X₁₄ is S or C; X₁₅ is H, V or G; X₁₆ is V or absent; X₁₇ is S or T; X₁₈ is A or V; X₁₉ is V or M; X₂₀ is L or F; X₂₁ is P or absent; X₂₂ is R Or T; X₂₃ is L or P; X₂₄ is P or absent; X₂₅ is R or C; X₂₆ is S or T; X₂₇ is T or absent; X₂₈ is W or A; X₂₉ is G, T, A or absent; X₃₀ is V or I; X₃₁ is S or T; X₃₂ is T or P; X₃₃ is I or T; X₃₄ is S or Y; X₃₅ is S or D; X₃₆ is P or L; X₃₇ is F or I; X₃₈ is V or G; X₁₁₀ is T or S; X₁₁₁ is D or G; X₁₁₂ is R or Q; X₁₁₃ is Y, D or N; X₁₁₄ is Y or F; X₁₁₅ is S or N; X₁₁₆ is Y or F; X₁₁₇ is F or Y; X₁₁₈ is R, Y, F or H; X₁₁₉ is L or M; X₁₁₉ is W or L; X₁₂₀ is S or R; X₁₂₁ is T or S; X₁₂₂ is F or Y; X₁₂₃ is S or T; X₁₂₄ is S or R; X₁₂₅ is T or D; X₁₂₆ is V or M; X₁₂₇ is S or Y; X₁₂₈ is R or S; X₁₂₉ is S or F; and X₁₃₀ is F or Y.
 4. The antigen binding protein of claim 1, comprising one or more of: (a) a light chain CDR1 sequence comprising one or more of: (i) a light chain CDR1 that differs by seven, six, five, four, three, two or one amino acid additions, substitutions, deletions and combinations thereof from a CDR1 sequence of one or more of CDRL1-1 to CDRL1-81 of Table 3B (SEQ ID NOs 814-893, respectively, in order of appearance); (ii) (SEQ ID NO: 1591) RASX₆₂SX₆₃X₆₄X₆₅X₆₆X₆₇X₆₈A; (iii) (SEQ ID NO: 1602) RX₆₉SQX₇₀IX₇₁X₇₂YLN; (iv) (SEQ ID NO: 1612) GGNX₇₃IGSX₇₄X₇₅VX₇₆; (v) (SEQ ID NO: 1616) RASQX₇₇IRNDLX₇₈; (vi) (SEQ ID NO: 1622) RSSQSLX₇₉X₈₀X₈₁DX₈₂GX₈₃TYLD; (vii) (SEQ ID NO: 1629) SGX₈₄X₈₅LGDKYX₈₆X₈₇; viii) (SEQ ID NO: 1635) QASQX₈₈IX₈₉X₉₀X₉₁LN; (ix) (SEQ ID NO: 1640) RASQX₉₂IX₉₃X₉₄WL X₉₅; (x) (SEQ ID NO: 1645) SGSSSNIGX₉₆NYVX₉₇; (xi) (SEQ ID NO: 1648) RASX₉₈DISNYLA; (xii) (SEQ ID NO: 1652) RASQX₉₉VX₁₀₀SSYX₁₀₁V; (xiii) (SEQ ID NO: 1656) RSSQSLX₁₀₂HSNGX₁₀₃NYLD; (xiv) (SEQ ID NO: 1659) RASQTX₁₀₄RNX₁₀₅YLA; (xv) (SEQ ID NO: 1662) RSSX₁₀₆X₁₀₇LVYSDGNTYLN; and (xvi) (SEQ ID NO: 1665) SGDAX₁₀₈PKKYAX₁₀₉;

(b) a light chain CDR2 sequence comprising one or more of: (i) a light chain CDR2 that differs by three, two or one amino acid additions, substitutions, deletions and combinations thereof from a CDR2 sequence of one or more of CDRL2-1 to CDRL2-53 of Table 3B (SEQ ID NOs 894-946, respectively, in order of appearance); (ii) (SEQ ID NO: 1517) X₃₉ASSLX₄₀X₄₁; (iii) (SEQ ID NO: 1525) GX₄₂S X₄₃RX₄₄T; (iv) (SEQ ID NO: 1528) GAFSRAX₄₅; (v) (SEQ ID NO: 1533) X₄₆DX₄₇KRPS; (vi) (SEQ ID NO: 1536) TLSX₄₈RAS; (vii) (SEQ ID NO: 1539) AASNLQX₄₉; (viii) (SEQ ID NO: 1543) GX₅₀SNRAX₅₁; (ix) (SEQ ID NO: 1548) X₅₂ASX₅₃LQS; (x) (SEQ ID NO: 1551) DNX₅₃KRPS; (xi) (SEQ ID NO: 1554) DX₅₄SNLET; (xii) (SEQ ID NO: 1557) LX₅₅SNRAS; (xiii) (SEQ ID NO: 1561) QX₅₆NX₅₇RPS; (xiv) (SEQ ID NO: 1562) RDRNRPS; (xv) (SEQ ID NO: 1565) X₅₈DSNRPS; (xvi) (SEQ ID NO: 1566) DDSDRPS; (xvii) (SEQ ID NO: 1569) AX₅₉SSLQS; (xviii) (SEQ ID NO: 1572) TX₆₀SSLQS; and (xix) (SEQ ID NO: 1575) KX₆₁SNWDS;

(c) a heavy chain CDR1 sequence comprising one or more of: (i) a heavy chain CDR1 that differs by three, two or one amino acid additions, substitutions, deletions and combinations thereof from a CDR1 sequence of one or more of CDRH1-1 to CDRH1-53 of Table 3A (SEQ ID NOs 603-655, respectively, in order of appearance); (ii) (SEQ ID NO: 1775) SGX₁₇₀X₁₇₁TWX₁₇₂; (iii) (SEQ ID NO: 1781) X₁₇₃YYWX₁₇₄; (iv) (SEQ ID NO: 1786) X₁₇₅X₁₇₆GMS; (v) (SEQ ID NO: 1790) SYX₁₇₇MX₁₇₈; (vi) (SEQ ID NO: 1796) X₁₇₉YYX₁₈₀H; (vii) (SEQ ID NO: 1799) SYGX₁₈₁H; (viii) (SEQ ID NO: 1803) NYX₁₈₂MX₁₈₃; (ix) (SEQ ID NO: 1806) X₁₈₄YWIG; (x) (SEQ ID NO: 1809) GYX₁₈₅MH; (xi) (SEQ ID NO: 1813) SX₁₈₆DIX₁₈₇; (xii) (SEQ ID NO: 1816) X₁₈₈YAMS; (xiii) (SEQ ID NO: 1817) NAWMS; (xiv) (SEQ ID NO: 1818) SSSYYWG; (xv) (SEQ ID NO: 1821) X₁₈₉YYWN; (xvi) (SEQ ID NO: 1824) SNSAX₁₉₀WN; and (xvii) (SEQ ID NO: 1827) X₁₉₁YDMH;

(d) a heavy chain CDR2 sequence comprising one or more of (i) a heavy chain CDR2 that differs by nine, eight, seven, six, five, four, three, two or one amino acid additions, substitutions, deletions and combinations thereof from a CDR2 sequence of one or more of CDRH2-1 to CDRH2-77 of Table 3A (SEQ ID NOs 656-732, respectively, in order of appearance); (ii) (SEQ ID NO: 1716) X₁₃₁X₁₃₂X₁₃₃X₁₃₄X₁₃₅GX₁₃₆X₁₃₇X₁₃₈X₁₃₉NPSLKS; (iii) (SEQ ID NO: 1732) X₁₄₀IX₁₄₁X₁₄₂DGX₁₄₃NX₁₄₄X₁₄₅X₁₄₆ADSVKG; (iv) (SEQ ID NO: 1741) WX₁₄₇NPX₁₄₈SGX₁₄₉TX₁₅₀YAQKFX₁₅₁G; (v) (SEQ ID NO: 1744) EINHSX₁₅₂X₁₅₃TNYNPSLKS; (vi) (SEQ ID NO: 1747) IIYPGDSX₁₅₄TRYSPSFQG; (vii) (SEQ ID NO: 1751) SISSSSX₁₅₅YX₁₅₆YYX₁₅₇DSX₁₅₈KG; (viii) (SEQ ID NO: 1755) RIX₁₅₉X₁₆₀KTDGGTTX₁₆₁YAAPVKG; (ix) (SEQ ID NO: 1756) GISGSSAGTYYADSVGK; (x) (SEQ ID NO: 1759) VISX₁₆₂SGGX₁₆₃TYYADSVKG; (xi) (SEQ ID NO: 1760) RTYYRSKWYNDYAVSVKS; (xii) (SEQ ID NO: 1763) RIYX₁₆₄SGSTNYNPSLX₁₆₅X₁₆₆; and (xiii) (SEQ ID NO: 1766) WMNPYSGSTGX₁₆₇AQX₁₆₈FQX₁₆₉;

wherein X₃₉ is A or S; X₄₀ is Q or K; X₄₁ is S or F; X₄₂ is A or T; X₄₃ is S, T, A, R or N; X₄₄ is A or D; X₄₅ is S or T; X₄₆ is Q, R or E; X₄₇ is T or S; X₄₈ is Y or F; X₄₉ is R or S; X₅₀ is A or S; X₅₁ is I or T; X₅₂ is D or G; X₅₃ is S, T or N; X₅₃ is N or D; X₅₄ is A or V; X₅₅ is G or D; X₅₆ is D or N; X₅₇ is K or E; X₅₈ is S or C; X₅₉ is S or V; X₆₀ is A or T; X₆₁ is V or G; X₆₂ is P or Q; X₆₃ is V, I or F; X₆₄ is S, R or absent; X₆₅ is S, R or N; X₆₆ is D, S, N or M; X₆₇ is I, Y, H, Q, N or S; X₆₈ is L or V; X₆₉ is A Or T; X₇₀ is I, S, T or N; X₇₁ is R, S or N; X₇₂ is R, S, N, or I; X₇₃ is N, or D; X₇₄ is Y, I or K; X₇₅ is N, S, T or A; X₇₆ is H or Q; X₇₇ is D or G; X₇₈ is G or A; X₇₉ is L or F; X₈₀ is N or D; X₈₁ is S or N; X₈₂ is A or D; X₈₃ is T, D or N; X₈₄ is N or D; X₈₅ is K, E or N; X₈₆ is V or A; X₈₇ is C or F; X₈₈ is G or D; X₈₉ is S, K N or T; X₉₀ is N, K or I; X₉₁ is Y or F; X₉₂ is D or G; X₉₃ is D or S; X₉₄ is R or S; X₉₅ is V or A; X₉₆ is N, I or D; X₉₇ is A or S; X₉₈ is Q or H; X₉₉ is R or S; X₁₀₀ is P or A; X₁₀₁ is I or L; X₁₀₂ is L or Q; X₁₀₃ is Y or F. X₁₀₄ is V or I; X₁₀₅ is N or S; X₁₀₆ is Q or P; X₁₀₇ is R or S; X₁₀₈ is L or V; X₁₀₉ is Y or N; X₁₃₁ is N, F, Y, S or M; X₁₃₂ is I or L; X₁₃₃ is Y or F; X₁₃₄ is Y, H or D; X₁₃₅ is S or T; X₁₃₆ is T, G, S or T; X₁₃₇ is T or A; X₁₃₈ is Y, N or H; X₁₃₉ is F or Y; X₁₄₀ is L, G, I or V; X₁₄₁ is W or S; X₁₄₂ is Y, D or N; X₁₄₃ is S or D; X₁₄₄ is K Or N; X₁₄₅ is Y, N, D, or H; X₁₄₆ is Y or H; X₁₄₇ is I or M; X₁₄₈ is P, N, S or D; X₁₄₉ is A, G or D; X₁₅₀ is N, K, or D; X₁₅₁ is R, H or Q; X₁₅₂ is E Or G; X₁₅₃ is N or T; X₁₅₄ is D or E; X₁₅₅ is T or S; X₁₅₆ is I or E; X₁₅₇ is A or V; X₁₅₈ is V or L. X₁₅₉ is K or I; X₁₆₀ is S or G; X₁₆₁ is D or E; X₁₆₂ is D or G; X₁₆₃ is S or D; X₁₆₄ is I or T; X₁₆₅ is E or K; X₁₆₆ is N or S; X₁₆₇ is Y Or L; X₁₆₈ is N or R; X₁₆₉ is G or D; X₁₇₀ is V, G, N or D; X₁₇₁ is Y or N; X₁₇₂ is N, S or T; X₁₇₃ is T, S or G; X₁₇₄ is S or T; X₁₇₅ is S, T or F; X₁₇₆ is Y Or F; X₁₇₇ is A or S; X₁₇₈ is S, N or M; X₁₇₉ is Y or G; X₁₈₀ is I, L, K or T; X₁₈₁ is L or I; X₁₈₂ is G or N; X₁₈₃ is H, R or M; X₁₈₄ is S or G; X₁₈₅ is Y or F; X₁₈₆ is Y or H; X₁₈₇ is N or D; X₁₈₈ is N or H; X₁₈₉ is D or S; X₁₉₀ is T or A; X₁₉₁ is S or T; (e) the light chain CDR1 of (a) and the light chain CDR2 of (b); (f) the light chain CDR1 of (a) and the heavy chain CDR1 of (c); (g) the light chain CDR1 of (a) and the heavy chain CDR2 of (d); (h) the light chain CDR1 (a) and the heavy chain CDR1 of (c); (i) the heavy chain CDR1 of (c) and the heavy chain CDR2 of (d); (j) the light chain CDR2 of (b) and the heavy chain CDR2 of (d); (k) the light chain CDR1 of (a), the light chain CDR2 of (b), and the heavy chain CDR1 of (c); (l) the light chain CDR2 of (b), the heavy CDR1 of (c), and the heavy chain CDR2 of (d); (m) the light chain CDR1 of (a), the heavy chain CDR1 of (c), and the heavy chain CDR2 of (d); and (n) the light chain CDR1 of (a), the light chain CDR2 of (b), the heavy chain CDR2 of (c), and the heavy chain CDR2 of (d).
 5. The antigen binding protein of claim 1, comprising one or more of: (a) a light chain variable domain comprising one or more of; (i) a light chain CDR1 sequence selected from CDRL1-1 to CDRL1-81 of Table 3B (SEQ ID NOs 814-893, respectively, in order of appearance); (ii) a light chain CDR2 sequence selected from CDRL2-1 to CDRL2-53 of Table 3B (SEQ ID NOs 894-946, respectively, in order of appearance); (iii) a light chain CDR3 sequence selected from CDRL3-1 to CDRL3-75 of Table 3B (SEQ ID NOs 947-1020, respectively, in order of appearance); (b) a heavy chain variable domain comprising one or more of: (i) a heavy chain CDR1 sequence selected from CDRH1-1 to CDRH1-53 of Table 3A (SEQ ID NOs 603-655, respectively, in order of appearance); (ii) a heavy chain CDR2 sequence selected from CDRH2-1 to CDRH2-77 of Table 3A (SEQ ID NOs 656-732, respectively, in order of appearance); (iii) a heavy chain CDR3 sequence selected from CDRH3-1 to CDRH3-81 of Table 3A (SEQ ID NOs 733-813, respectively, in order of appearance); and (c) a combination comprising a light chain variable domain of (a) and a heavy chain variable domain of (b).
 6. The antigen binding protein of claim 1, wherein the antigen binding protein comprises one or more of: (a) a light chain variable domain sequence comprising one or more of: (i) amino acids having a sequence at least 80% identical to a light chain variable domain sequence comprising one or more of V_(L)1-V_(L)100 of Table 2A (SEQ ID NOs 217-315, respectively, in order of appearance); (ii) a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding the light chain variable domain sequence comprising one or more of V_(L)1-V_(L)100 of Table 2A (SEQ ID NOs 217-315, respectively, in order of appearance); (b) a heavy chain variable domain sequence comprising one or more of: (i) a sequence of amino acids that is at least 80% identical to a heavy chain variable domain sequence comprising one or more of V_(H)1-V_(H)94 of Table 2B 9SEQ ID NOs 316-409, respectively, in order of appearance); (ii) a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding the heavy chain variable domain sequence of V_(H)1-V_(H)94 of Table 2B (SEQ ID NOs 316-409, respectively, in order of appearance); and (c) a combination comprising a light chain variable domain of (a) and a heavy chain variable domain of (b).
 7. The antigen binding protein of claim 6, comprising one or more of: (a) a light chain variable domain sequence comprising one or more of: V_(L)1-V_(L)100 of Table 2A (SEQ ID NOs 217-315, respectively, in order of appearance); (b) a heavy chain variable domain sequence comprising one or more of: V_(H) 1-V_(H)94 of Table 2B (SEQ ID NOs 316-409, respectively, in order of appearance); and (c) a combination comprising a light chain variable domain of (a) and a heavy chain variable domain of (b).
 8. The antigen binding protein of claim 7, wherein the light chain variable domain and the heavy chain variable domain comprise one or more of: V_(L)1 and V_(H)1; V_(L)2 and V_(H)1; V_(L)3 and V_(H)2 or V_(H)3; V_(L)4 and V_(H)4; V_(L)5 and V_(H)5; V_(L)6 and V_(H)6; V_(L)7 and V_(H)6; V_(L)8 and V_(H)7 or V_(H)8; V_(L)9 and V_(H)9; V_(L)10 and V_(H)9; V_(L)11 and V_(H) 10; V_(L)12 and V_(H)11; V_(L)13 and V_(H)12; V_(L)13 and V_(H)14; V_(L)14 and V_(H)13; V_(L)15 and V_(H)14; V_(L)16 and V_(H)15; V_(L)17 and V_(H)16; V_(L)18 and V_(H)17; V_(L)19 and V_(H)18; V_(L)20 and V_(H)19; V_(L)21 and V_(H)20; V_(L)22 and V_(H)21; V_(L)23 and V_(H)22; V_(L)24 and V_(H)23; V_(L)25 and V_(H)24; V_(L)26 and V_(H)25; V_(L)27 and V_(H)26; V_(L)28 and V_(H)27; V_(L)29 and V_(H)28; V_(L)30 and V_(H)29; V_(L)31 and V_(H)30; V_(L)32 and V_(H)31; V_(L)33 and V_(H)32; V_(L)34 and V_(H)33; V_(L)35 and V_(H)34; V_(L)36 and V_(H)35; V_(L)37 and V_(H)36; V_(L)38 and V_(H)37; V_(L)39 and V_(H)38; V_(L)40 and V_(H)39; V_(L)41 and V_(H)40; V_(L)42 and V_(H)41; V_(L)43 and V_(H)42; V_(L)44 and V_(H)43; V_(L)45 and V_(H)44; V_(L)46 and V_(H)45; V_(L)47 and V_(H)46; V_(L)48 and V_(H)47; V_(L)49 and V_(H)48; V_(L)50 and V_(H)49; V_(L)51 and V_(H)50; V_(L) 52 and V_(H)51; V_(L)53 and V_(H)52; V_(L)54 and V_(H)53; V_(L)55 and V_(H)54; V_(L)56 and V_(H)54; V_(L)57 and V_(H)54; V_(L)58 and V_(H)55; V_(L)59 and V_(H)56; V_(L)60 and V_(H)57; V_(L)61 and V_(H)58; V_(L)62 and V_(H)59; V_(L)63 and V_(H)60; V_(L)64 and V_(H)1; V_(L)65 and V_(H)62; V_(L)66 and V_(H)63; V_(L)67 and V_(H)64; V_(L)68 and V_(H)65; V_(L)69 and V_(H)66; V_(L)70 and V_(H)67; V_(L)71 and V_(H)68; V_(L)72 and V_(H)69; V_(L)73 and V_(H)70; V_(L)74 and V_(H)70; V_(L)75 and V_(H)70; V_(L)76 and V_(H)71; V_(L)77 and V_(H)72; V_(L)78 and V_(H)73; V_(L)79 and V_(H)74; V_(L)80 and V_(H)75; V_(L)81 and V_(H)76; V_(L)82 and V_(H)77; V_(L)83 and V_(H)78; V_(L)84 and V_(H)79; V_(L)85 and V_(H)80; V_(L)86 and V_(H)81; V_(L)87 and V_(H)82; V_(L)88 and V_(H)86; V_(L)89 and V_(H)83; V_(L)90 and V_(H)84; V_(L)91 and V_(H)85; V_(L)92 and V_(H)87; V_(L)93 and V_(H)88; V_(L)94 and V_(H)88; V_(L)95 and V_(H)89; V_(L)96 and V_(H)90; V_(L)97 and V_(H)91; V_(L)98 and V_(H)92; V_(L)99 and V_(H)93; and V_(L)100 and V_(H)94.
 9. The antigen binding protein of claim 8, further comprising: (a) the kappa light chain constant sequence of SEQ ID NO: 12 (b) the lambda light chain constant sequence of SEQ ID NO: 13 (c) the heavy chain constant sequence of SEQ ID NO: 11; or (d) (i) the kappa light chain constant sequence of SEQ ID NO: 12 or the lambda light chain constant sequence of SEQ ID NO: 13, and (ii) the heavy chain constant sequence of SEQ ID NO:
 11. 10. The antigen binding protein of claim 1, wherein the antigen binding protein is a human antibody, a humanized antibody, chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an F(fab′)₂ fragment, a domain antibody, an IgD antibody, an IgE antibody, an IgM antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, an IgG4 antibody, or an IgG4 antibody having at least one mutation in the hinge region.
 11. The antigen binding protein of claim 1, that, when bound to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c: (a) binds to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4, with substantially the same Kd as a reference antibody; (b) induces FGF21-like signaling of 10% or greater than the signaling induced by a wild-type FGF21 standard comprising the mature form of SEQ ID NO: 2 as measured in an ELK-luciferase reporter assay; (c) exhibits an EC₅₀ of 10 nM or less of FGF21-like signaling in an assay comprising one of: (i) a FGFR1c/β-Klotho-mediated in vitro recombinant cell-based assay; and (ii) an in vitro human adipocyte functional assay; (d) exhibits an EC₅₀ of less than 10 nM of agonistic activity on FGFR1c in the presence of β-Klotho in an in vitro recombinant FGFR1c receptor mediated reporter assay; (e) exhibits an EC₅₀ of greater than 1 μM of agonistic activity on FGFR1c in the absence of β-Klotho in an in vitro recombinant FGFR1c receptor mediated reporter assay; (f) competes for binding with a reference antibody to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4, wherein the reference antibody comprises a combination of light chain and heavy chain variable domain sequences selected from the group consisting of V_(L)1 and V_(H)1; V_(L)2 and V_(H)1; V_(L)3 and V_(H)2 or V_(H)3; V_(L)4 and V_(H)4; V_(L)5 and V_(H)5; V_(L)6 and V_(H)6; V_(L)7 and V_(H)6; V_(L)8 and V_(H)7 or V_(H)8; V_(L)9 and V_(H)9; V_(L)10 and V_(H)9; V_(L)11 and V_(H) 10; V_(L)12 and V_(H)11; V_(L)13 and V_(H)12; V_(L)13 and V_(H)14; V_(L)14 and V_(H)13; V_(L)15 and V_(H)14; V_(L)16 and V_(H)15; V_(L)17 and V_(H)16; V_(L)18 and V_(H)17; V_(L)19 and V_(H)18; V_(L)20 and V_(H)19; V_(L)21 and V_(H)20; V_(L)22 and V_(H)21; V_(L)23 and V_(H)22; V_(L)24 and V_(H)23; V_(L)25 and V_(H)24; V_(L)26 and V_(H)25; V_(L)27 and V_(H)26; V_(L)28 and V_(H)27; V_(L)29 and V_(H)28; V_(L)30 and V_(H)29; V_(L)31 and V_(H)30; V_(L)32 and V_(H)31; V_(L)33 and V_(H)32; V_(L)34 and V_(H)33; V_(L)35 and V_(H)34; V_(L)36 and V_(H)35; V_(L)37 and V_(H)36; V_(L)38 and V_(H)37; V_(L)39 and V_(H)38; V_(L)40 and V_(H)39; V_(L)41 and V_(H)40; V_(L)42 and V_(H)41; V_(L)43 and V_(H)42; V_(L)44 and V_(H)43; V_(L)45 and V_(H)44; V_(L)46 and V_(H)45; V_(L)47 and V_(H)46; V_(L)48 and V_(H)47; V_(L)49 and V_(H)48; V_(L)50 and V_(H)49; V_(L)51 and V_(H)50; V_(L)52 and V_(H)51; V_(L)53 and V_(H)52; V_(L)54 and V_(H)53; V_(L)55 and V_(H)54; V_(L)56 and V_(H)54; V_(L)57 and V_(H)54; V_(L)58 and V_(H)55; V_(L)59 and V_(H)56; V_(L)60 and V_(H)57; V_(L)61 and V_(H)58; V_(L)62 and V_(H)59; V_(L)63 and V_(H)60; V_(L)64 and V_(H)1; V_(L)65 and V_(H)62; V_(L)66 and V_(H)63; V_(L)67 and V_(H)64; V_(L)68 and V_(H)65; V_(L)69 and V_(H)66; V_(L)70 and V_(H)67; V_(L)71 and V_(H)68; V_(L)72 and V_(H)69; V_(L)73 and V_(H)70; V_(L)74 and V_(H)70; V_(L)75 and V_(H)70; V_(L)76 and V_(H)71; V_(L)77 and V_(H)72; V_(L)78 and V_(H)73; V_(L)79 and V_(H)74; V_(L)80 and V_(H)75; V_(L)81 and V_(H)76; V_(L)82 and V_(H)77; V_(L)83 and V_(H)78; V_(L)84 and V_(H)79; V_(L)85 and V_(H)80; V_(L)86 and V_(H)81; V_(L)87 and V_(H)82; V_(L)88 and V_(H)86; V_(L)89 and V_(H)83; V_(L)90 and V_(H)84; V_(L)91 and V_(H)85; V_(L)92 and V_(H)87; V_(L)93 and V_(H)88; V_(L)94 and V_(H)88; V_(L)95 and V_(H)89; V_(L)96 and V_(H)90; V_(L)97 and V_(H)91; V_(L)98 and V_(H)92; V_(L)99 and V_(H)93; and V_(L)100 and V_(H)94; and (g) two or more of (a)-(f).
 12. The antigen binding protein of claim 11, that, when bound to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c and: (a) lowers blood glucose in an animal model; (b) lowers serum lipid levels in an animal model; (c) lowers insulin levels in an animal model; or (d) two or more of (a) and (b) and (c).
 13. The antigen binding protein of claim 1, wherein the antigen binding protein comprises one or more of: (a) a heavy chain comprising one of H1-H94; (b) a light chain comprising one of L1-L100; and (c) a combination comprising a heavy chain of (a) and a light chain of (b).
 14. A pharmaceutical composition comprising one or more antigen binding proteins of claims 1-13 in admixture with a pharmaceutically acceptable carrier thereof.
 15. An isolated nucleic acid comprising a polynucleotide sequence encoding the light chain variable domain amino acid sequence, the heavy chain variable domain amino acid sequence, or both amino acid sequences, of an antigen binding protein of claims 1-13.
 16. The isolated nucleic acid of claim 15, wherein the encoded amino acid sequence comprises one or more of: (a) V_(L)1-V_(L)100; (b) V_(H)1-V_(H)94; and (c) a combination comprising one or more sequences of (a) and one or more sequences of (b).
 17. An expression vector comprising the nucleic acid of claim
 16. 18. An isolated cell comprising the nucleic acid of claim
 17. 19. An isolated cell comprising the expression vector of claim
 18. 20. A method of producing an antigen binding protein comprising incubating the host cell of claim 19 under conditions that allow it to express the antigen binding protein.
 21. A method of preventing or treating a condition in a subject in need of such treatment comprising administering a therapeutically effective amount of the composition of claim 14 to the subject, wherein the condition is treatable by lowering one or more of blood glucose, insulin or serum lipid levels.
 22. The method of claim 21, wherein the condition is type 2 diabetes, obesity, dyslipidemia, NASH, cardiovascular disease or metabolic syndrome.
 23. The antigen binding protein of claim 1, wherein the antigen binding protein comprises one or more non-naturally occurring or encoded amino acids. 